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Human cytomegalovirus (HCMV) has the largest genome of the human 
herpesviruses, and its gene content is imperfectly understood. The gene content of 
HCMV strain AD 169 was recently re-evaluated, discounting 51 previously proposed 
protein-coding open reading frames (ORFs) because they have no counterparts in 
chimpanzee cytomegalovirus (CCMV) and lack any other convincing evidence for 
expression. Some of the discounted ORFs were located in blocks, and their omission 
left three large ‘empty’ regions in the AD 169 genome. One of these regions, located 
between genes RL1 and RL10, has been investigated previously leading to the 
discovery of a new gene. The other two regions are investigated in this study. The 
first, termed region X, is located between genes UL105 and UL112, which are firmly 
accepted as encoding proteins. The second, termed region O, is located between 
genes UL57 and UL69. Initial analysis of the AD 169 genome predicted six (UL106- 
UL111) and eleven (UL58-UL68) small ORFs in regions X and O, respectively, and 
subsequent analyses have predicted three further ORFs in each region (C-ORF16-C- 
ORF18 and ORF3-ORF5, respectively).
Sequence data were generated from seven HCMV strains by PCR amplification and 
cloning of region X (approximately 6 kbp) and region O (approximately 8 kbp). 
Sequence comparisons were used to identify which ORFs in these regions are 
conserved and which are disrupted by insertions, deletions or substitutions leading to 
in-frame termination codons. All o f the ORFs are frameshifted in certain strains, with 
the exception of UL108, C-ORF16 and C-ORF18 in region X, and UL66 in region O. 
The disrupted ORFs are unlikely to represent protein-coding genes. Moreover, the 
few ORFs unaffected by ffameshifts remain unlikely to encode proteins as they are 
predicted to encode very small proteins and lack counterparts in CCMV. 
Furthermore, in region X no transcripts corresponding to the cognate ORFs were 
detected by northern blotting, and in region O UL66 is completely overlapped by the 
previously identified pp67 transcript. This transcript, which is routinely detected by 
PCR assays, is disrupted in all the strains analysed and is therefore also unlikely to 
encode a protein.
Transcript mapping in region X detected a spliced 1.1 kb polyadenylated RNA and a
4.6 kb intron, which covers most of the region. 5’- and 3’-ends of the 1.1 kb RNA 
were identified, the former located 25 bp from a TATA box and the latter to two sites 
located 20 and 34 bp from a polyadenylation signal. These results consolidate the 
findings of two previous studies that had partially characterised the 5 kb and 1.1 kb 
RNAs, respectively. The splice sites, 3’-polyadenylation signal, and 5’-TATA box of 
the 1.1 kb RNA are conserved in the corresponding region o f CCMV, suggesting that 
a similar RNA with a large intron should be expressed in CCMV. However, this 
RNA is unlikely to encode a protein as no amino acid sequences are conserved 
between the two genomes.
A third region of the HCMV genome where coding potential was not clear was also 
investigated. Region G, at the end of the unique short (Us) sequence, is located 
between genes US32 and TRS1, which are firmly accepted as encoding proteins. On 
the basis of conservation in CCMV, three originally defined ORFs (US33, US35 and 
US36) had been discounted and a novel ORF (US34A) identified. Again, sequence 
data were generated from seven HCMV strains by PCR amplification and cloning. 
Comparisons showed that the sequence between US34A and TRS1 is highly variable, 
and that US35 and US36 are frameshifted in multiple strains. US33 is conserved 
between strains, but no relevant transcript was detected. However, a transcript from a 
small, novel ORF (US33A) was detected on the opposing strand. 5’- and 3’-ends 
were identified for this RNA, the 5’-end located 31 bp downstream from a TATA 
box. The US33A ORF and the TATA box are also conserved in CCMV, suggesting 
that US33A may constitute a novel HCMV gene. The US33A transcript was shown 
to be 3’-co-terminal with that of US34. Transcripts from US31 and US32, which are 
conserved ORFs immediately to the left o f region G, were also mapped. No 
convincing evidence was found for transcription of US34A.
This work extends the understanding of the genetic content of HCMV and has 
identified novel transcripts in HCMV, providing a basis on which to develop future 
experiments aimed at determining their function.
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1.1 The family Herpesviridae
The International Committee on Taxonomy of Viruses (ICTV) has divided the family 
Herpesviridae into three subfamilies (Davison et a i ,  2005a). The family 
Herpesviridae comprises over 120 large DNA viruses that infect vertebrates and at 
least one invertebrate, the oyster (Davison et al., 2005a). Members of the subfamily 
Alphaherpesvirinae (known colloquially as a-herpesviruses) infect epithelial cells in 
vivo and establish latency in the nervous system. Many cause evident epithelial 
lesions in their natural hosts. Members of the subfamily Betaherpesvirinae (13- 
herpesviruses) are often clinically silent in immunocompetent hosts. Many species 
show a restricted host range in vitro with a long productive cycle and are usually 
associated with enlarged (cytomegalic) cells. Members of the subfamily 
Gammaherpesvirinae (y-herpesviruses) establish latent infection in lymphocytes and 
infect lymphocytes in vitro, and are often associated with lymphoproliferative disease 
and carcinomas. Genera within the three subfamilies are shown in Table 1.1. A 
single fish herpesvirus has been classified into a genus (Ictalurivirus) separate from 
the three subfamilies.





Herpes simplex virus type 1 
Varicella-zoster virus 
Marek’s disease virus 
Infectious laryngotracheitis-like virus
Betaherpesvirinae Cytom egalov irus 









(Unassigned genus) Ictalurivirus Channel catfish virus
Table 1.1. Subfamilies and genera of the family Herpesviridae.
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1.2 Herpesvirus evolution, phylogeny and classification
The species that currently constitute the family Herpesviridae probably represent only 
a small fraction of the number in existence, as each herpesvirus is usually associated 
with a single host species in nature, and several distinct herpesviruses may infect a 
host (Davison, 2002). The host specificity displayed by herpesviruses implies that 
they have evolved with their hosts over long periods o f time and are well adapted to 
them. This also means that many herpeviruses are likely to have become extinct as 
their hosts became extinct, and that modem viruses represent only a small proportion 
of all the herpesviruses that have ever existed. In structuring the taxa within 
Herpesviridae, relationships between viral DNA and amino acid sequences have 
superseded comparisons o f viral antigenic and biological properties as the main 
criterion (McGeoch and Davison, 1999a). The phylogenetic trees shown in Figure 1.1 
illustrate the division of each of the three subfamilies and further into genera and 
species.
Genetic differences are readily identified between members of different genera within 
a subfamily, but the gene complements of these viruses are, for the most part, similar. 
For example, the a-herpesviruses herpes simplex vims type 1 (HSV-1, genus 
Simplexvirus) and varicella-zoster vims (VZV, genus Varicellovirus) share 64 genes 
(Davison, 2002). However, sublineages of a -  and p-herpesviruses show extensive 
speciation with host lineages, where the branching patterns and extent of divergence 
are similar. However, y-herpesvimses show a more complex picture, with higher and 
lower substitution rates in different sublineages (McGeoch et al., 2000).
Modem a-, P- and y-herpesvimses are thought to contain 43 genes contributed by an 
ancestral vims (Table 1.2) (Davison, 2002). These conserved, ‘core’ genes tend to be 
located in the central region of the genomes and can be arranged into seven blocks, 
which have different orders and orientations in each of the subfamilies. The functions 
of the core genes, which are involved in many vital aspects of the viral life cycle, such 
as cell entry, DNA replication, capsid formation and genome packaging, indicate that 
the ancestral vims was recognisably a herpesvirus (McGeoch and Davison, 1999a). 
Genes that are lineage-specific tend to be located towards the ends of the genome.
2
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Some of these genes may have arisen de novo, but many appear to have been captured 
from the cell. Gene duplication is also apparent, particularly in cytomegaloviruses ((3- 
herpesviruses), which contain large arrays of related genes (Davison, 2002). Original 
assessments of the timescale of herpesvirus evolution estimated that the three 
subfamilies arose approximately 180 to 220 million years ago (McGeoch et al., 1995). 
The root of the subfamilies is now thought to be around 400 million years ago 
(McGeoch and Gatherer, 2005). The major sublineages within the subfamilies 
probably arose before mammalian radiation of 60-80 million years ago, and 
speciations within the sublineages took place after this (McGeoch et al., 1995). A 
recent study of reptilian herpesvirus evolution has thrown up some new ideas about 
the evolution of the herpesviruses, particularly among the a-herpesviruses (McGeoch 
and Gatherer, 2005). Reptilian and mammalian viruses could have coevolved with 
their host lineages, but the two avian genera (Mar divirus and Iltovirus) would have 
arisen by a transfer mechanism. Alternatively, the reptilian and avian lineages could 
have coevolved with their host lineages, but the mammalian clade would have arisen 
by a transfer mechanism. Both scenarios are possible but mutually exclusive.
PLHV
0
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Figure 1.1. Phylogenetic tree of the a-, (3- and y-herpesviruses.
Phylogenetic tree for the Herpesviridae based on alignments of six sets of 
homologous proteins, obtained by a maximum likelihood evaluation, with molecular 
clock imposed. The dashed line, the branch for EIHV-1, was interpolated from a tree 
based on two available proteins. Unpublished data of A. Davison and D. McGeoch, 
MRC Virology Unit, Glasgow.
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Genome and Gene
Groun HSV-1 HCMV EBV Core sene function
Control and UL13 UL97 BGLF4 Serine-threonine protein-kinase
modulation UL54 UL69 BMLF1 Post-transcriptional regulator
DNA replication UL5 UL105 BBLF4 Helicase (DNA helicase-primase complex)
machinery UL8 UL102 BBLF2/3 Component of DNA helicase-primase complex
UL9 On-binding helicase
UL29 UL57 BALF2 Single-stranded DNA-binding protein
UL30 UL54 BALF5 Catalytic subunit of DNA polymerase
UL42 UL44 BMRF1 Processivity subunit o f DNA polymerase
UL52 UL70 BSLF1 Primase (DNA helicase-primase complex)
Peripheral UL2 UL114 BKRF3 Uracil-DNA glycosylase
enzymes UL23 BXLF1 Thymidine kinase
UL39 UL45 BORF2 Ribonucleotide reductase; large subunit
UL40 BaRFl Ribonucleotide reductase; small subunit
UL50 UL72 BLLF3 Deoxyuridine triphosphate
Processing and UL6 UL104 BBRF1 Portal protein
packaging of UL12 UL98 BGLF5 Deoxyribonuclease
DNA UL15 UL89 BGRF1 ATPase subunit o f terminase
UL17 UL93 BGLF1 Nuclear capsid localisation
UL25 UL77 BVRF1 Putative portal-capping protein
UL28 UL56 BALF3 Terminase subunit
UL32 UL52 BFLF1 Nuclear capsid localisation
UL33 UL51 BFRF1A Interacts with terminase
Capsid assembly UL18 UL85 BDLF1 Capsid triplex protein
and structure UL19 UL86 BcLFl Major capsid protein
UL26 UL80 BVRF2 Maturational protease
UL26.5 UL80.5 BdRFl Scaffolding protein
UL35 UL48A BFRF3 Capsid protein on hexon tips
UL38 UL46 BORF1 Capsid triplex protein
Egress o f capsid UL31 UL53 BFLF2 Nuclear matrix protein
from nucleus UL34 UL50 BFRF1 Inner nuclear membrane protein
Tegument UL7 UL103 BBRF2 Tegument protein
UL11 UL99 BBLF1 Myristylated tegument protein
UL14 UL96 BGLF3.5 Tegument protein
UL16 UL94 BGLF2 Tegument protein
UL36 UL48 BPLF1 Tegument protein
UL37 UL47 BOLF1 Tegument protein
UL51 UL71 BSRF1 Tegument protein
Surface and UL1 UL115 BKRF2 Virion glycoprotein L
Membrane UL10 UL100 BBRF3 Virion glycoprotein M
UL22 UL75 BXLF2 Virion glycoprotein H
UL27 UL55 BALF4 Virion glycoprotein B
UL49A UL73 BLRF1 Virion glycoprotein N
Unknown UL24 UL76 BXRF1 Nuclear protein
Table 1.2. Genes conserved in a-, (3- and y-herpesviruses.
Adapted from Davison (2002). Core genes are grouped according to function. HSV- 
1 is an a-herpesvirus, HCMV is a P-herpesvirus and EBV is a y-herpesvirus. Three 




Two other major herpesvirus lineages have been identified, one leading to the bony 
fish and amphibian viruses and the other to the only known herpesvirus that infects an 
invertebrate, oyster herpesvirus (OsHV-1) (Davison, 1992, 1998; Bernard and 
Mercier, 1993; Davison et al., 1999). However, these two lineages are extremely 
diverged and recent sequence comparisons have shown that OsHV-1 is, at best, 
tenuously related to the two classes of vertebrate herpesviruses (Davison et al., 
2005b). It is thought that the best method of taxonomic classification would be to 
establish three families, incorporating the three lineages described above, within an 
order, Herpesvirales (Davison et al., 2005b).
1.3 Herpesvirus genetic content
Herpesviruses have large, linear, double-stranded DNA genomes. Virus genomes 
range in size from 124 kbp to over 295 kbp; the smallest is simian varicella virus 
(SVV) (Gray et al., 2001), and the largest is koi herpesvirus (Waltzek et al., 2005). 
The largest mammalian herpesvirus genome, of 240 kbp, is chimpanzee 
cytomegalovirus (Davison et al., 2003a). The herpesvirus genomes are thought to 
contain between about 70 and 200 genes which are tightly packed and arranged in 
about equal numbers on each DNA strand. Most are expressed as single exons, and 
spliced genes, of which relatively few have been identified, are more common among 
the P- and y-herpesviruses than the a-herpesviruses (Davison and Clements, 1996). 
Overlaps between genes in different reading frames on the same strand or on the 
opposing strand are infrequent and usually not extensive. Families of genes tend to be 
arranged tandemly on the same strand and often share the same polyadenylation site.
A wide range of base compositions is also exhibited, ranging from 32-75% in G+C 
content (Honess, 1984). A characteristic feature of herpesvirus genome structure is 
the presence of terminal or internal repeated sequences, in direct or inverse 
orientations. Figure 1.2 shows the herpesvirus genome types, which differ in the 






Figure 1.2. Herpesvirus genome structures.
Black lines show unique sequences and coloured blocks show repeat elements in the 
genomes, which are not to scale. Arrows show orientations of the repeated regions. 
Adapted from Roizman and Pellett (2001).
(A) A long unique sequence flanked by large direct terminal repeats (Example 
genome: Human herpesvirus 6).
(B) A long unique sequence flanked by smaller tandem direct terminal repeats that are 
variable in number (Kaposi's sarcoma-associated herpesvirus).
(C) A long unique sequence flanked by smaller tandem direct terminal repeats, plus a 
different, internal sequence. The repeats are present in variable numbers (Epstein- 
Barr virus).
(D) A short unique sequence flanked by large inverted terminal repeats and a long 
unique sequence flanked by very small or no terminal repeats (Varicella-zoster virus).
(E) Long and short unique sequences, each flanked by large inverted terminal repeats, 
and a terminal direct repeat, the a sequence (green), which is found at the ends of the 
genome and in inverted orientation between the internal repeats (Human 
cytomegalovirus).





Herpesvirions are characteristic, but complex, spherical structures that comprise a 
core, capsid, tegument and envelope (Figure 1.3) (Wildy et al., 1960; Roizman and 
Pellett, 2001). In HSV-1, they can range in size from 160 to 230 nm, averaging 180 
nm (Szilagyi and Berriman, 1994). The core comprises the linear double-stranded 
DNA herpesvirus genome, packed in a liquid crystalline array that fills the entire 
volume of the preformed icosahedral capsid. The mature capsid is composed of 162 
capsomers: 12 pentavalent capsomers (pentons) at the vertices, 60 hexavalent 
capsomers (hexons) at the 20 faces and 90 hexavalent capsomers along the 30 edges 
(Wildy et al., 1960; Gibson, 1996). Between the nucleocapsid and envelope is a 
largely amorphous proteinaceous layer, the tegument, which consists of at least 18 
proteins (Zhou et al., 1999). Some of these proteins have functions related to 
morphogenesis, uncoating and regulation of gene expression, but the functions of 
many of the tegument proteins are not known. The envelope, a lipid bilayer enclosing 
the virion, is coated with glycoprotein spikes (Wildy et al., 1960).
Figure 1.3 Herpesvirion structure
(Left) A representation of a herpesvirion. (Right) A cryo-electron microscope image 
of an HSV-1 virion (courtesy of F. Rixon, MRC Virology Unit, Glasgow).
Glycoproteins 
Envelope -  
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1.5 Herpesvirus life cycle
The herpesvirus replicative life cycle, which consists of lytic and latent phases, is 
conveniently described in the case of HSV-1. The virus initially binds to 
glycosaminoglycans on cell surface proteoglycans via glycoproteins gB and/or gC 
(Shukla and Spear, 2001). This interaction, usually with heparan sulphate, is not 
thought to be essential for viral entry, but does greatly increase the efficiency of viral 
entry, thought to be due to concentrating virus on the cell surface so the appropriate 
entry receptor viral ligands find these receptors (Spear and Longnecker, 2003). Viral 
envelope glycoproteins are essential to virus entry, and mediate virus attachment and 
entry to the host cell. Three essential glycoproteins, gB, gH and gL, are conserved in 
other herpesviruses (Spear and Longnecker, 2003). HSV requires a fourth essential 
glycoprotein, gD, which acts as a ligand for several cell surface receptors. 
Consequently, all four essential glycoproteins are required to stimulate fusion of the 
viral envelope with a cell membrane. The capsid is then released into the cytoplasm.
On entry, the capsid migrates to the nucleus by binding to microtubules (Batterson et 
al., 1983; Sodeik et al., 1997). A microtubule-dependent motor, dynein, also attaches 
to the incoming capsids to drive them from the edge of the cell to the nucleus (Sodeik 
et al., 1997). At the nucleus, the nuclear pore complex spans the double membrane of 
the nuclear envelope. The capsid, essentially tegument-free at this stage, docks via 
importin p to cytoplasmic nuclear-pore-complex proteins (Greber and Fassati, 2003). 
It is thought that the cytosolic factors and energy are also recruited, and the capsid 
opens up at one side to eject the viral DNA into the nucleus (Dasgupta and Wilson, 
1999; Greber and Fassati, 2003). Within the nucleus, transcription, viral DNA 
replication, capsid formation and packaging of viral DNA take place.
Viral gene expression takes the form of a co-ordinated cascade that is regulated and 
sequentially ordered, with three main phases; immediate-early (IE), early (E) and late 
(L) (Honess and Roizman, 1974, 1975, Jones and Roizman, 1979; Sears and 
Roizman, 1990). Transcription takes place in the nucleus, but viral proteins are 
synthesised in the cytoplasm. IE genes are the first viral genes expressed after 
infection, and their transcription is enhanced by the virion structural protein VP 16.
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Most of the IE proteins expressed are trans-acting regulators which initiate the 
expression of E genes. E genes encode several enzymes involved in DNA replication 
and nucleotide metabolism, as well as a subset of glycoproteins. L gene expression 
follows production of E proteins, and is enhanced by viral DNA synthesis (Honess 
and Roizman, 1975).
Viral replication starts in the nucleus, near ND10 structures, with the circularisation of 
genomic DNA by direct ligation of the termini (Garber et al., 1993; Strang and Stow, 
2005). DNA synthesis is then initiated from the viral origins of lytic replication (oriS 
and oriL in HSV-1) to produce DNA in an endless conformation, probably as head-to- 
tail concatemers produced by a rolling circle mechanism (Jacob et al., 1979; 
Poffenberger and Roizman, 1985). Cleavage of these concatamers is site-specific, at 
unique sites (pac sites) within a sequences. The a sequences, which are present at the 
ends of the viral genome and at the internal repeated sequences, are necessary and 
sufficient for HSV-1 DNA cleavage and packaging. Unit-length molecules of viral 
DNA are now ready to be packaged in capsids. Seven HSV-1 proteins which have 
been identified which are involved in the processing and packaging of viral DNA: 
UL6, UL15, UL17, UL25, UL28, UL32 and UL33 (Brown et al., 2002). The 
functions of some of these genes have now been elucidated, and they are thought to 
have roles in introducing specific cuts in the DNA concatemer, forming the portal 
through which the virus DNA enters the capsid, assisting DNA translocation into the 
capsid, and sealing the capsid once it is filled.
Final capsid assembly occurs in the nucleus, although some capsid proteins can begin 
the initial stages of assembly in the cytoplasm (Rixon et al., 1996). Partial procapsids 
and procapsids are intermediates formed as the mature capsid is constructed. In 
understanding the process of capsid assembly, much of the work was carried out from 
studies o f herpesvirus proteins expressed by recombinant baculoviruses (Tatman et 
al., 1994; Thomsen et al., 1994). Partial procapsids are angular pieces of capsid shell 
which partially surround a portion of core. The shell contains the major capsid 
protein (VP5), the two triplex proteins (VP19C and VP23) and the core contains the 
scaffolding proteins (pre-VP22a and VP21) (Newcomb et al., 1996; Homa and 
Brown, 1997). The partial procapsid grows by progressive addition of shell and core 
proteins, in small increments. Once this structure is closed, the procapsid is formed.
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The procapsid is composed of capsomers, has the same diameter and the same 
symmetry (T= 16) as the mature capsid. However, at this stage the procapsid is 
spherical, unlike the mature capsid, and the morphology of the hexons is also 
different. In addition, the triplexes are thought to constitute the main links by which 
the capsomers are held together as the floor layer found in mature capsid is largely 
absent in the procapsid (Newcomb et al., 1996; Homa and Brown, 1997). The 
procapsid then undergoes extensive conformational changes, angularising to create 
the mature, icosahedral capsid. The scaffolding protein is cleaved and exits the capsid 
during this transformation. Although these changes generally do not involve the 
addition of further protein molecules, if  the small capsid protein is present, it is added 
only as a result o f angularisation (Chi and Wilson, 2000). The final capsid also has a 
much greater structural stability upon maturation (Newcomb et ah , 1996).
Viral DNA enters the capsid through the portal, a ring-shaped structure composed of 
12 UL6 protein molecules. Each mature capsid contains a single portal, as does each 
procapsid, indicating that it is incorporated during capsid assembly, into one of the 12 
capsid vertices (Sheaffer et al., 2001). It is thought, from electron microscopy o f 
HSV-1 capsids, that DNA packaging begins with the procapsid, and that procapsid 
angularisation may occur as the DNA is encapsidated (Brown et al., 2002).
Capsid egress from the nucleus begins at the nuclear membrane. The first budding 
process occurs here, in which the capsid acquires an envelope derived from the inner 
nuclear membrane (Mettenleiter, 2004). This process involves a complex of the 
UL31 and UL34 gene products (Chang et al., 1997; Roller et al., 2000). Consequent 
to this budding process is the formation of primary enveloped virions in the 
perinuclear space. At this stage, the primary virion is different both morphologically 
and biochemically from the secondary virion (Mettenleiter, 2004). This primary 
envelope then fuses with the outer nuclear membrane, releasing the nucleocapsid into 
the cytoplasm. It is thought that the UL34 protein, a component of primary virions, 
and the US3 protein of HSV-1 plays a role in this fusion process. However, these 
processes occur in the absence of other viral envelope and tegument proteins which 
are present in the mature virion (Mettenleiter, 2004).
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Once in the cytoplasm, the nucleocapsid must acquire more than 15 tegument proteins 
during the process of tegumentation, a complex network of protein-protein 
interactions. It is thought that the UL36 gene product interacts with the pentons of the 
capsid to form the first layer of tegument (McNabb & Courtney, 1992). This inner 
shell o f tegument shows icosahedral symmetry, with part o f it anchored at the vertices 
of the capsid (Zhou et al., 1999). A second layer of tegument is thought to be 
composed of the UL37 gene product (Mettenleiter, 2004). Subsequent tegumentation 
steps involving these other tegument proteins are not fully defined, however, a major 
structural role is predicted of UL48, which is critical for tegument formation. 
Secondary envelopment occurs at the Golgi apparatus, from where the vesicles into 
which budding occurs are derived. Although it is unclear how tegumented capsids are 
directed to this site and how viral glycoproteins are assembled, two viral proteins have 
been implicated. UL11 is thought to direct tegument components to the budding site, 
and gM is thought to aid accumulation of envelope glycoproteins at this site 
(Mettenleiter, 2004). This secondary envelopment process results in an enveloped 
virion within a secretory vesicle, which is then transported to the plasma membrane. 
These processes are not fully understood, however, the HSV-1 proteins UL20 and gK 
have been implicated (Baines et al., 1991; Foster and Kousoulas, 1999). The vesicle 
and plasma membranes fuse, and mature virions are released from the infected cell.
All the viruses are also able to establish life long infections in their host via various 
mechanisms. In the case of the human herpesviruses, HSV-1, HSV-2 and VZV are 
neurotropic, HHV-6, HHV-7 and EBV are lymphotropic, and HCMV establishes 
latency in the monocytic lineage (Roizman and Pellett, 2001). In its latent form, 
HSV-1 DNA is non-replicating, does not integrate into the host DNA and is present 
either as a circular molecule or as a concatemer (Rock and Fraser, 1983, 1985; 
Efstathiou et al., 1986; Mellerick and Fraser, 1987). During latency, expression from 
the HSV-1 genome is repressed, except for the latency-associated transcripts (LATs), 
which accumulate in the neurons and help to maintain latency in a process that is not 
fully understood (Stevens et al., 1988; Preston, 2000). Reactivation, which may occur 
in response to stress, fever or sunlight, causes lytic infection to proceed. It appears 
that ICP0, an initiator of lytic infection, plays an important role in reactivation in the 
neuronal nucleus, as ICPO-deficient viruses reactivate with reduced efficiency (Leib et 
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Figure 1.4 Herpesvirus life cycle.
Adapted from Davison and Clements (1996). After transport to the nucleus, the virus 
can either establish latency (the green box) or start productive infection (the red box).
1.6 Human herpesviruses
Eight human herpesviruses have been identified, representing all three subfamilies 
(Table 1.3). The effects of herpesvirus infection can range from asymptomatic to 
severe, depending on the virus and the host, but they are often disabling or fatal in the 
foetus, the very young and the immunosuppressed. A wide variety o f diseases may 





formal name Subfamily Genus
Genome 
Size Tvoe
HSV-1 HHV-1 Alphaherpesvirinae Simplexvirus 152 E
HSV-2 HHV-2 Alphaherpesvirinae Simplexvirus 155 E
VZV HHV-3 A Iphaherpesvirinae Varicellovirus 125 D
EBV HHV-4 Gammaherpesvirinae Lymphocryptovirus 172 C
HCMV HHV-5 Betaherpesvirinae Cytomegalovirus 236 E
HHV-6 HHV-6 Betaherpesvirinae Roseolovirus 159 A
HHV-7 HHV-7 Betaherpesvirinae Roseolovirus 153 A
KSHV HHV-8 Gammaherpesvirinae Rhadinovirus 165 B
Table 1.3. The eight human herpesviruses.
The formal names are those specified by the International Committee of Taxonomy of 
Viruses. The approximate genome size is in kbp and the genome type refers to the 
arrangements shown in Figure 1.2.
The clinical manifestations o f HSV-1 and HSV-2 overlap greatly, although each has 
different levels of prevalence. Oral lesions, or “cold sores”, are more commonly 
associated with HSV-1 (Whitley and Roizman, 1997), and genital lesions are more 
commonly associated with HSV-2 (Reeves et al., 1981; Corey et al., 1983). In rare 
cases, conjunctivitis, herpetic whitlow, keratitis or encephalitis may result. Primary 
infection and reactivation result in similar symptoms and neonatal infection is often 
life threatening (Whitley and Roizman, 1997). Primary infection with VZV causes 
chickenpox, with a rash appearing 14-15 days post-infection often accompanied by a 
fever (Gershon and Silverstein, 1997). The reactivated infection, “shingles”, later 
appears at the relevant dermatome, often causing severe pain and sometimes, and, if  
the ophthalmic branch of the trigeminal nerve is involved, corneal ulceration 
(Donahue et al., 1995). Primary HCMV infection often causes enlargement and 
fusion of macrophages, but is usually asymptomatic. However, infection can be 
problematic to the offspring of a mother infected during pregnancy, and in 
immunocompromised individuals, where symptoms commonly include retinitis and 
gastro-enteritis (Griffiths and Emery, 1997). HHV-6 and HHV-7 cause febrile illness 
and may act as opportunistic agents in immunosuppresed patients (Carrigan et al., 
1991; Cone et al., 1993). HHV-6 has two variants, HHV-6A and HHV-6B, which are
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known to cause exanthem subitum, pneumonia and encephalitis (Yamanishi et al., 
1988, 1997). EBV and KSHV are both associated with carcinomas. Primary EBV 
infection is often asymptomatic in young children but causes infectious 
mononucleosis in older children and adults. Infection is associated with Burkitt’s 
lymphoma, nasopharyngeal carcinoma and other lymphoproliferative disorders and 
carcinomas (Neri et al., 1991; Beaulieu and Sullivan, 1997). KSHV is associated 
with Kaposi’s sarcoma, a vasculated skin lesion, and Castleman’s disease (Renne et 
al., 1996; Moore and Chang, 1997).
Most of the human herpesviruses are highly prevalent in the developed and 
developing world. However, HHV-8 is common only in some populations in sub- 
Saharan Africa and southern Europe (Sarmati, 2004). HHV-8 is closely associated 
with HIV-1 populations, and can be identified in most patients with HIV-associated 
Kaposi’s sarcoma (KS), and a high incidence of KS is reported among HIV-infected 
homosexual men (Schulz, 1998).
1.7 General characteristics of HCMV
HCMV, which is formally designated HHV-5 (Table 1.3), was originally isolated by 
three groups in the 1950s (Smith, 1956; Rowe et al., 1956; Craig et al., 1957). The 
observations o f cytomegalic inclusions in the nuclei of infected salivary gland cells 
led Weller (1971) to coin the term “cytomegalovirus”, although “generalised 
cytomegalic inclusion disease” was used in a study by Wyatt et al. (1950) to describe 
specific infantile multi-organ disease. Although a variety of cell culture systems are 
permissive, the virus is propagated most efficiently in human fibroblasts (Pass, 2001). 
Virus growth in these cells is characteristically slow and causes cell enlargement and 
rounding (Figure 1.5). Cytopathic effect (CPE) can be well developed by 48 to 72 
hours post-infection, and it can take around 7 to 14 days to produce a generalised CPE 
involving the entire monolayer.
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Figure 1.5. HCMV CPE in a monolayer of hum an fibroblasts.
Courtesy of D. Dargan, MRC Virology Unit, Glasgow. The fibroblast monolayer, 
infected with HCMV strain AD 169, is shown at 10x magnification. Virus CPE and 
plaque formation can be seen as cells become enlarged and round.
HCMV has the ability to cause a lifelong subclinical infection in healthy adults, but 
uniquely among human herpesviruses establishes latency in monocytes (Kondo et al., 
1994; Hahn et al., 1998). Although the majority of infections are asymptomatic, 
HCMV can lead to significant morbidity and mortality in neonates and 
immunocompromised hosts. The significance of HCMV as a pathogen has increased 
in the past 20 years with the increased prominence of transplants and 
immunosuppressive post-transplant therapies, and AIDS. These conditions 
predispose individuals to primary HCMV infection or to reactivation of a latent 
infection, both of which can result in acute, life-threatening disease.
1.8 HCMV disease and epidemiology
In some cases, primary HCMV infection may manifest as a mononucleosis-like 
syndrome. Approximately 8% of all cases of mononucleosis are caused by HCMV,
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and show similar clinical symptoms to EBV-induced disease, including malaise, 
headaches, fatigue and fever (Klemola et al., 1970; Jordan et al., 1973). Congenital 
HCMV infection is clinically important because of the potential damage to the organs 
and the CNS in neonates. However, only 5-10% of neonates with congenital CMV 
infection exhibit clinical manifestations, the most common of these being petechiae, 
jaundice, hepatosplenomegaly, abnormal hearing and microcephaly (Bale et al., 1990; 
Ramsay et al., 1991; Boppana et al., 1992). Most symptomatic neonates exhibit a 
combination of these conditions. The involvement of multiple organ systems in utero 
corresponds to the range of symptoms exhibited (Boppana et al., 1992). In infants 
and young children, virus transmission via breast milk may cause symptoms, but only 
in rare cases. However, acquired HCMV infection is more likely to cause disease in 
infants with a low birth weight (Yeager, 1983).
In the immunocompromised host, primary infection or reactivation of latent HCMV 
can cause major complications (Hebart et al., 1998; Ljungman, 1996; Prentice and 
Kho, 1997). In transplant patients, the transplanted organ and transfusion can be a 
source of infection at a time when the patient is maximally immunosuppressed. 
Disease severity tends to correspond to the degree o f host immunosuppression, with 
symptoms ranging from febrile illness to life-threatening multisystem disease. The 
most common manifestations in transplant patients are fever, leukopenia, malaise, 
arthralgias and macular rash (Griffiths and Emery, 1997).
Life-threatening diseases such as pneumonitis (particularly in bone marrow 
transplantation), gastrointestinal ulceration and severe hepatic dysfunction may also 
result (Meyers et al., 1982). The majority of morbidity for HCMV disease occurs 
when the recipient is seronegative but the donor is seropositive (Ho et al., 1975; 
Smiley et al., 1985; Meyers et al., 1986; Apperley and Goldman, 1988; Winston et 
al., 1990). HCMV is also thought to be the leading opportunistic infection among 
adults with AIDS. Almost all adults and approximately 50% of children with HIV 
infection show serological evidence of HCMV infection, and the risk of developing 
HCMV disease in people with advanced AIDS is directly related to quantity of 
HCMV DNA in the plasma (Spector et al., 1998). In a study o f AIDS patients with 
HCMV disease, approximately 85% developed retinitis, and just under 10% 
developed oesophagitis or colitis (Cheung and Teich, 1999; Jacobson and Mills, 1988;
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Jabs et al., 1989; Gallant et al., 1992; Spector et al., 1993; Boppana et al., 1992). 
HCMV may also be a cofactor in the development of AIDS by enhancing HIV 
infection (Pass, 2001).
HCMV is universally distributed among human populations and antibody prevalence 
in normal adults ranges from 40-100% (Krech, 1973). In developing countries and in 
areas o f developed countries with lower socio-economic factors, HCMV is generally 
acquired earlier in life and is o f greater prevalence (Griffiths and Emery, 1997). 
Infection is not seasonal, but is endemic and present throughout the year (Gold et al., 
1990).
Transmission and infection via person to person contact can occur at any age and 
commonly takes place in settings where close contact with body fluids may occur. 
Infants and young children excrete HCMV in their respiratory tract and urine, and in 
settings such as day care centres the virus can be easily transmitted between children 
and adults (Stagno and Cloud, 1994). Transmission from mother to foetus occurs by 
three main routes: transplacental, intrapartum and breast milk. If the woman was 
infected long before pregnancy or acquires a primary infection during pregnancy, the 
virus may be transmitted across the placenta (Pass, 2001). Alternatively, local 
shedding o f the virus, which appears to increase closer to the time of delivery, may 
result in intrapartum transmission (Stagno et al., 1982).
Breast milk is the most common route of transmission from mother to neonate. With 
seropositive mothers, infants breast-fed for less than one month were extremely 
unlikely to be infected compared to a 39% rate of infection for infants breast-fed for 
more than one month (Dworsky et al., 1983). Furthermore, almost 70% of infants 
whose seropositive mothers have detectable HCMV in their breast milk become 
infected. These routes of transmission from the mother do not generally result in 
neonatal disease, but they are common, and are therefore important modes of vertical 
transmission for maintaining HCMV infection in the population.
Post puberty, the most important mode of transmission is sexual, particularly among 
homosexuals (Handsfield et al., 1985; Drew et al., 1981; Collier et al., 1987). 
Reinfection is also common in sexually active populations (Drew et al., 1984; Spector
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et al., 1984). The prevalence of HCMV infection is also higher among populations 
with other markers of sexual activity such as greater numbers of partners and sexually 
transmitted diseases (Chandler et al., 1985; Pereira et al., 1990; Sohn et al., 1991). 
Transmission of HCMV to immunocompromised hosts may occur via blood products 
or transplanted organs (Van der Meer et al., 1996). However, since this has been 
established as a source of infection, it is now routine to screen blood products and 
organs before transfusion and transplantation.
The quantity of viral load is directly related to the development o f HCMV disease. 
An initial study of congenital HCMV showed that children with congenital infection 
had approximately one log higher viral load in their urine if  they were asymptomatic 
when compared to children with asymptomatic perinatal infection (Stagno et al., 
1975). Significantly, symptomatic children had approximately two logs higher viral 
load in their urine. Subsequent studies have shown that high viral load, detected in 
urine and blood, is also the major determinant of HCMV disease in solid organ and 
bone marrow transplant populations (Cope et al., 1997a, 1997b; Gor et al., 1998). In 
the solid organ population, when peak viral load in urine for hosts was plotted against 
the presence of disease for the same individuals, the relationship between viral load 
and HCMV disease is clear (Griffiths et al., 1999). However, as high viral load 
coincides with HCMV disease, qualitative PCR and monitoring CMV viremia are 
recommended as a marker to initiate pre-emptive therapy (Griffiths et al., 1999).
1.9 The HCMV virion
The HCMV virion is generally typical o f herpesviruses, but the capsid, tegument and 
envelope each have unique features. The mature HCMV capsid is 130 nm in 
diameter, 5% larger than in HSV-1, to create an internal capsid volume 17% larger 
(Butcher et al., 1998; Chen et al., 1999). This accommodates the HCMV genome, 
which is approximately 37% longer than HSV-1 but is more densely packed (Bhella 
et al., 2000). Other differences include hexamer spacing, relative tilt, morphology of 
the tips of the hexons and the average diameter of the scaffold (Butcher et al., 1998). 
However, like HSV-1, the HCMV capsid is composed of 162 capsomers: 12 
pentavalent capsomers (pentons) at the vertices, and 150 hexavalent capsomers
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(hexons) at the faces and edges (Butcher et al., 1998). The 3D structure of the HCMV 
AD 169 capsid, determined by cryo-electron microscopy (cryo-EM) and image 
reconstruction, is shown in Figure 1.6.
The capsid contains at least six proteins: the minor capsid protein (mCP), the mCP- 
binding protein (mC-BP), both of which are triplex proteins, the major capsid protein 
(MCP), the small capsid protein (SCP), and two assembly proteins (Britt and 
Boppana, 2004; Mocarski and Tan Courcelle, 2001). The MCP (pUL86) constitutes 
approximately 90% of the capsid protein mass and comprises the pentamers and 
hexamers (Chen et al., 1999). The mCP (pUL85) and mC-BP (pUL46) are present in 
a 2:1 ratio and constitute the inter-capsomeric triplex that links adjacant capsomers 
(Chen et al., 1999). The SCP (pUL48A) is essential for the generation of infectious 
progeny in tissue culture cells and coats the tips of the hexons (Borst et al., 2001).
The assembly proteins are encoded by UL80 and UL80.5 (Oien et al., 1997; Butcher 
et al., 1998). The UL80.5 protein, ‘assembling forms a scaffold by self-interaction 
via N-terminal sequences, and interacts with the MCP via C-terminal sequences 
(Gibson, 1996; Irmiere and Gibson, 1983; Oien et al., 1997). Once nucleocapsids are 
assembled, the scaffolding proteins vacate the capsid following protease cleavage of a 
short C-terminal region, leaving space within the capsid to package the genome.
The tegument is an amorphous layer that lies between the nucleocapsid and envelope 
(Gibson, 1996; Zhou et al., 1999). The HCMV tegument consists of many 
phosphorylated proteins, o f which pp65 (UL83) and ppl50 (UL32) are the major 
ones. Other tegument proteins which have been identified have roles in regulating 
viral gene expression, modifying host cell responses, and capsid egress (Britt and 






Figure 1.6 The HCMV virion.
Courtesy of D. Bhella, MRC Virology Unit, Glasgow. (A, B) Reconstructions of the 
capsid and virion, respectively, from cryo-EM images. (C) A cryo-EM image of 
HCMV virions. A protrusion from the envelope of one of the virions is evident.
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The envelope, which encloses the virion, is a lipid bilayer derived from the host 
(Wildy et al., 1960). Glycoprotein spikes protrude from the envelope, a number of 
which have so far been identified. Three glycoprotein complexes are known to form: 
one comprising covalently linked dimers of gB, one comprising gM and gN, and the 
third comprising gH, gL and gO (Britt and Mach, 1996; Spaete et al., 1994). These 
glycoproteins (with the exception of gO) have homologues in other herpesviruses that 
form complexes in the virion envelope (Stinksi, 1976; Gibson, 1983; Pachl et al., 
1989; Britt and Mach, 1996).
The mature infectious virion is one of three types o f particle produced in HCMV- 
infected cells and released into the extracellular medium in culture (Mocarski and 
Stinski, 1979; Irmiere and Gibson, 1983). The other two, non-infectious enveloped 
particles (NIEPs) and dense bodies, can be distinguished by physical differences 
(Irmiere and Gibson, 1983; Sarov and Abady, 1975; Gibson, 1996). NIEPs, which 
resemble virions, lack the viral genome but retain one scaffolding protein; pUL80.5, 
the capsid assembly protein (Gibson, 1996; Irmiere and Gibson, 1983; Oien et ah, 
1997). Dense bodies are present only in the cytoplasm of infected cells, and lack both 
nucleocapsids and viral DNA (Irmiere and Gibson, 1983; Sarov and Abady, 1975). 
They are composed of tegument proteins, but principally of a single protein (pp65, 
encoded by UL83), and enclosed in a cytoplasmic membrane-derived envelope 
(Craighead et al., 1972; Sarov and Abady, 1975). In AD 169 virus preparations, they 
are found in approximately equal numbers to virions. It is thought that dense bodies 
may consist of surplus cellular and viral products, which accumulate in a storage 
vacuole that is subsequently voided into extracellular medium (Severi et al., 1992).
1.10 HCMV attachment and entry into host cells
When a herpesvirus initially associates with the host cell, viral glycoproteins on the 
surface of the envelope have important roles in adsorption and penetration o f virus 
into the cell, as has been shown for HSV-1 (Campadelli-Fiume, 1994). The most 
highly conserved herpesvirus glycoprotein, gB, is a multifunctional protein that has 
been shown to promote virion penetration into cells and transmission of infection 
from cell to cell (Compton et ah, 1992; Navarro et al., 1993; Bold et al., 1996).
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In HCMV, the virus envelope fuses with the host cell plasma membrane in a pH- 
independent process that probably involves the gH/gL complex (Compton et al., 
1992; Keay et al., 1991). Heparan sulphate interaction appears to play a role in this 
initial fusion event, as shown from studies of heparinase-treated cells, in which viral 
attachment was blocked (Neyts et al., 1992; Compton et al., 1993). The nucleocapsid 
is then released into the cytoplasm and migrates to the nucleus where DNA enters via 
nuclear pores. Tegument proteins, such as pp65 (UL83) also enter the nucleus, and 
can be detected within 30 minutes after virus inoculum exposure (Dal Monte et al., 
1996).
A different mechanism, that of endocytosis, has been proposed for HCMV entry into 
retinal pigmented epithelial (RPE) cells and endothelial (HUVEC) cells (Bodaghi et 
al., 1999). In contrast to fibroblasts, where nucleocapsids are released directly into 
the cytosol, the virus appears to enter endocytotic vesicles in RPEs and HUVECs. In 
addition, pp65 could only be detected in the nucleus 1 to 2 hours after virus-cell 
contact, much later than in fibroblasts.
1.11 Transcription and translation
As in other herpesviruses, HCMV transcription is temporally regulated. Genes are 
expressed in a cascade, in three kinetic classes. Genes expressed following viral 
entry, independent of any other viral gene expression, are termed immediate-early 
(IE). Early (E) gene expression is dependent on IE products, and late (L) gene 
expression occurs last. UL123 (IE1), UL122 (IE2), UL36-37, TRS1/IRS1 and US3 
are all IE genes, of which IE1, IE2 and US3 appear to be involved in subsequent gene 
regulation steps (Stenberg et al., 1985; Weston, 1988). Translation of IE mRNAs is a 
prerequisite for transcription of E genes, which are found throughout the genome and 
have roles in DNA replication, nucleotide metabolism and immune evasion 
(Demarchi, 1981). L genes are transcribed from about 24 h p.i., effectively after the 
inception of viral DNA replication (Stamminger and Fleckenstein, 1990). L gene 
expression is divided into two subclasses; E-L (leaky late) or L (true late). These can 
be classified quantitatively by the signal intensity from HCMV microarrays, as shown
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by Chambers et al. (1999). True L transcription is strictly dependent on DNA 
replication (Stasiak and Mocarski, 1992). Expression of L genes comes from 
throughout the genome and contributes proteins involved in virion assembly and 
morphogenesis. In cell culture, the different kinetic classes of transcripts can be 
separated using chemical inhibitors. Cycloheximide inhibits protein synthesis, 
stopping E transcription so that only IE transcripts are generated. Phosphonoacetic 
acid (PAA) or ganciclovir inhibit viral DNA replication, inhibiting L transcription so 
that only IE and E transcripts are generated.
Viral transcription trans-activators help to create a complex regulatory network that 
controls gene expression. The major HCMV trans-activators are the nuclear 
phosphoproteins IEHgiaa 72 kDa (UL123) and IE2s79aa 86 kDa (UL122). These IE 
proteins are expressed by differential splicing from the major immediate-early (MIE) 
gene locus (Figure 1.7). Expression from this locus generates differentially spliced 
polyadenylated transcripts. IE l49iaa shares an 85 residue N-terminal domain with 
IE2579aa, both of which have key roles in activating early and late gene expression. 
(Spector, 1996; Stenberg, 1996). IE2s79aa plays a key role in switching from IE to E 
gene expression. In addition to IE2579aa, IE2425aa is made from a transcript in which an 
additional intron is removed from UL122, and is less abundant. The most abundant 
IE2 gene product, yIE2338aa, is expressed exclusively from UL122 late in infection 
(Figure 1.7) (Stenberg, 1996; Jenkins et al., 1994). IE2338aa both represses IE gene 
expression and trans-activates E and L genes.
The MIE locus is under the control of a strong promoter-enhancer (MIEP), which is 
subject to positive and negative regulation. The MIEP contains a large number of 
binding sites for cellular transcription factors and specific viral proteins (Mocarski, 
1996). Similar enhancer elements control US3, another IE gene (Biegalke, 1999). 
IE l49iaa and IE2579aa autoregulate IE1/IE2 and US3 expression by activating via NF- 
k B  binding sites and repressing via IE2 cis-repression signals in these promoter- 
enhancers. The MIEP can be divided into three main regions; the enhancer region, 
the specific NF-1-binding region, and the modulator region. The complex array of 
binding sites in the enhancer and variety o f cellular factors binding to these allows the 
MIEP to respond to the intracellular environment in a range of cell types. Binding of
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transcription factors to the modulator region has been shown to repress transcription, 
but the role of this region is not fully understood.
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Figure 1.7 Differential splicing from the M IE gene locus.
Adapted from Mocarski (1996). The HCMV strain AD 169 genome is shown on the 
top line (the scale is in kbp). The principal spliced IE transcripts are shown with the 
coding regions as thick black lines. In the spliced transcripts, the two exons 
immediately after the AUG codon make up the 85 residue N-terminal domain shared 
by the IE1 and IE2 transcripts.
1.12 Evasion of host defences
Natural killer (NK) cells and specific cellular and humoral immunity all play 
important roles in controlling HCMV disease. Many studies of host defence utilised 
MCMV, which provides a tractable animal model for CMV infection. Beige mice, 
which are genetically deficient in functional NK cells, showed increased susceptibility 
to MCMV, and depletion of NK cells from non-beige mice leads to a more serious 
infection after challenge (Shellam et al., 1981; Bukowski et al., 1984). Furthermore, 
spleen cells with an NK cell phenotype were shown to confer protection from a lethal 
MCMV challenge (Bukowski et al., 1984, 1985). An in vitro study of NK responses 
to HCMV showed they were mediated by large granular lymphocytes, independent of 
interferon, and were manifest at the time early viral proteins were expressed 
(Borysiewicz et al., 1985).
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Severe HCMV disease (with the exception of congenital infection) is seen almost 
exclusively in patients with profoundly impaired cell-mediated immunity, such as 
bone-marrow transplant recipients or AIDS patients. Cytotoxic T-lymphocyte (CTL) 
responses to CMV in humans also appear to be noticeably suppressed after 
mononucleosis in infants and immunocompromised patients with HCMV disease 
(Levin et al., 1979; Pass et al., 1983; Pollard et al., 1978; Zanghellini et al., 1999). 
Consequently, important roles for CTL responses, and CD4+ helper T-lymphocytes in 
y-interferon production were suggested (Quinnan et al., 1978; Hengel et al., 1994). 
CD4+ helper T-lymphocyte responses to multiple structural and non-structural 
HCMV proteins have been demonstrated in humans with naturally acquired infection, 
and CTL response to HCMV was associated with clinical recovery from disease 
(Quinnan et al., 1982). Disease severity corresponds to the degree o f impairment o f 
T-lymphocyte responses. The humoral antibody response is important in settings 
such as neonatal disease and solid organ transplant (Yeager et al., 1981; Snydman and 
Falagas, 1996).
To avoid this variety of host defence mechanisms, HCMV has developed strategies to 
circumvent elimination of active infection, via gene products that can interfere with 
immune response (Huang et al., 1980; Wiertz et al., 1997). A number of related 
mechanisms are thought to assist HCMV escape from CTL response. 
Phosphorylation of an important CTL target, the 72 kD IE protein, by pp65 (UL83) 
prevents antigen processing (Gilbert et al., 1996). The US3 protein interferes with 
MHC class I complexes, either by destroying them or sequestering them in the 
endoplasmic reticulum (Jones et al., 1996). The US6 protein inhibits antigen 
presentation, and the US2 and US 11 proteins interact to re-import class I complexes 
from the endoplasmic reticulum to the cytosol where they are degraded in the 
proteosome (Wiertz et a l ,  1996; Ahn et al., 1996).
HCMV escape from NK cell attack is becoming better understood. One mechanism is 
the up-regulation of surface expression of HLA-E by the UL40-encoded glycoprotein, 
which is homologous to a class I MHC sequence. HLA-E expressed on the cell 
surface protects potential target from NK cell-mediated lysis by binding to inhibitory
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sensors on surface of NK cells (Tomasec et al., 2000). A protein encoded by UL18 
also has a similar function (Hassan-Walker et al., 1998). More recently, UL141 has 
been shown to block the surface expression of CD 155, a ligand for two NK cell- 
activating receptors (Tomasec et al., 2005). In addition, UL16 has been shown to 
sequester another ligand, NK62D, to assist virus escape from NK cell attack (Odeberg 
et al., 2003; Vales-Gomez et al., 2003).
Other mechanisms of HCMV immune evasion have been proposed. These include 
the binding and sequestering of (3-chemokines by US27, UL28 and UL33 (Bodaghi et 
al., 1998), down-regulating MHC class II expression on the surface of macrophages 
(Fish et al., 1996) and competing with the TNF receptor superfamily by UL144 
(Benedict et al., 1999).
HCMV can also prevent cell destruction, either by interfering with apoptosis or 
protecting infected cells from complement-mediated lysis (Zhu et al., 1995; Spear et 
al., 1995; Spiller et al., 1996). The UL36-UL38 IE gene locus encodes two anti- 
apoptotic genes: gpUL37 and pUL37xl (Colberg-Poley et al., 2000). These co- 
localise with Bax, which is involved in amplifying the apoptotic signal, in the 
mitochondria of the cell (Poncet et al., 2004). UL146 encodes a interleukin-8-like 
chemokine (vCXC-1) which influences the behaviour of leukocytes during infection 
(Penfold et al., 1999), and UL111A encodes an interleukin-10 homologue which 
possesses immunosuppressive properties, by inhibiting cytokine synthesis (Spencer et 
al., 2002).
1.13 Treating HCMV infection
There are several antiviral drugs used to treat the clinical manifestations of HCMV, 
but no vaccine is in use. In the USA there are currently only four approved antiviral 
therapies; ganciclovir, foscamet and cidofovir, all of which target the viral DNA 
polymerase, and fomivirsen, a novel antisense compound (De Clercq, 2004). 
Ganciclovir is a nucleoside analogue, a derivative of acyclovir, which is used to treat 
retinitis in immunocompromised patients (De Clercq, 2004). Ganciclovir is also
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available as a pro-drug (valganciclovir) with improved gastrointestinal absorption 
(Cvetkovic and Wellington, 2005). Foscamet, a pyrophosphate analogue, is 
effectively a second-line treatment for HCMV infection due to associated 
nephrotoxicity (Palestine et al., 1991). Cidofovir is also a nucleoside analogue, and 
an alternative to ganciclovir, that is used mainly to treat retinitis in AIDS patients and 
cutaneous disease, but is linked to neutropenia and nephrotoxicity (Lea and Bryson, 
1996). Fomivirsen is the latest HCMV antiviral drug to be approved, and the first 
novel antisense compound of any kind to be approved for therapeutic use (Galderisi et 
al., 1999). It is a 21-nucleotide phosphorothioate oligonucleotide that operates 
differently from other antiviral drugs by targeting mRNA from the MIE 
transcriptional unit (UL123) and inhibiting translation (de Smet et al., 1999; Jabs and 
Griffiths, 2002).
Use of anti-HCMV treatments has increased in the last 20 years with the increased 
prominence of transplants and immunosuppressive post-transplant therapies, and 
AIDS. The most common use of these drugs is the treatment of retinitis in AIDS 
patients. Intravenous treatment with ganciclovir, foscamet or cidofovir are the most 
common therapies for slowing the progression of retinitis or bringing acute retinitis 
into remission (Lalezari et al., 1998; Palestine et al., 1991; Spector et al., 1993). 
Antiviral treatment lengthens the progression of retinitis from two to three weeks (in 
untreated cases) to two to three months. Local treatment of retinitis via intravitreal 
injection with ganciclovir is an additional therapeutic approach (Masur et al., 1996). 
Fomivirsen is used exclusively for intravitreal injection. As fomivirsen cannot 
suppress HCMV infections elsewhere in the body, it is recommended that therapy is 
combined with oral ganciclovir treatment (Jabs and Griffiths, 2002). Combination 
therapy, generally of foscamet and ganciclovir, is widely used, and is specifically 
recommended for patients with CNS or neurological disease (Arribas et al., 1996). In 
addition to treating retinitis, intravenous ganciclovir and foscamet therapy has also 
been shown to be beneficial for other clinical manifestations; oesophagitis, 
enterocolitis, encephalitis, peripheral neuropathy and pneumonitis.
Antiviral treatment of bone marrow and solid organ transplant patients is largely 
similar. In the pre-antiviral era, mortality due to HCMV was much higher in bone 
marrow transplant patients than solid organ transplant patients. Ganciclovir treatment
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has been shown to reduce the incidence of HCMV disease in the first 100 days post­
transplant, but overall mortality and graft survival were not improved (Boeckh et al., 
1996). Detecting pp65 antigenemia in white blood cells and PCR detection o f HCMV 
in blood are two methods used to suggest pre-emptive antiviral therapy in transplant 
patients to help combat disease (Hebart et al., 1998). Antiviral therapy for congenital 
HCMV infection is not a common approach, but ganciclovir therapy has been shown 
to ameliorate some disease syndromes, and may help to limit neurodevelopment 
injury, particularly sensorineural hearing loss (Schleiss, 2004; Kimberlin et al., 2003).
The toxic side effects of ganciclovir (myelotoxicity), foscamet and cidofovir 
(nephrotoxicity) can create major obstacles when treating HCMV disease. Another 
major concern of long-term therapy is the emergence of resistant viral isolates (Drew 
et al, 1991; Baldanti et al., 2004). Resistance to ganciclovir is associated with a 
variety o f mutations in UL97 (protein kinase) and, in approximately 5% of cases, 
UL54 (DNA polymerase) (Perez, 1997; Erice, 1999). Resistance to foscamet is 
associated with mutations in UL54 (Chou et al., 2003). Therefore, the emergence of 
fomivirsen as a novel antiviral therapy is important when resistance to other antiviral 
dmgs emerges, particularly as it works by an alternative mechanism. The 
development of anti-HCMV therapies is necessary to combat the emergence of 
antiviral dmg resistance, with a priority of limiting the type of toxic side effects 
produced by the current therapies.
Currently, there is no vaccine available for HCMV. One major problem in developing 
a vaccine is the ability of HCMV to establish a persistent, latent infection. HCMV 
strain Towne, originally isolated from a child with congenital infection, was passaged 
more than 125 times in vitro to achieve attenuation, and did not produce a febrile 
illness in challenge studies (Plotkin et al., 1975). Immunisation with this strain as a 
vaccine does induce antibody response and lymphocyte proliferative responses (Starr 
et al., 1981). However, the Towne vaccine appears to induce only limited protection 
and does not confer the protection from reinfection that comes from naturally 
acquired infection (Adler et al., 1996). MCMV and GPCMV models have been used 
to show that immunisation with viral glycoproteins and virus mutants can provide 
protection from virus challenge (Rapp et al., 1992; Harrison et al., 1995; Gill et al.,
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2000; Morley et al., 2002). Some studies have focused on subunit vaccines, 
specifically directed against HCMV glycoprotein B (Speckner et al., 1999).
1.14 Cell tropism
HCMV is able to infect many organ systems, causing a variety of diseases including 
mental retardation, retinitis and vascular disorders. Consequently, HCMV is able to 
replicate in a variety of cell types: fibroblasts (Albrecht et al., 1980), macrophages 
(Ibanez et al., 1991), smooth muscle cells (Plachter et al., 1996), endothelial cells 
(Sinzger et al., 1995), leukocytes (Gema et al., 2003), epithelial cells (Heieren et al., 
1988; Waldman et al., 1991), astrocytes (Poland et al., 1990) and trophoblasts 
(Hemmings et al., 1998). However, the virus can normally be propagated efficiently 
in vitro only in human fibroblast cells such as HFL1 (human foetal lung) and HFFF2 
(human foetal foreskin fibroblasts), where CPE develops slowly and focally. Studies 
of HCMV cell tropism have subsequently shown that highly passaged laboratory 
strains, such as AD 169, Towne and Davis, have lost certain host range capabilities o f 
low passage strains and clinical isolates, and infection in other cell culture systems is 
often abortive (Sinzger and Jahn, 1996).
In contrast, low passage HCMV strains and clinical isolates have been shown to infect 
endothelial cells and leukocytes (Hahn et al., 2002). Accordingly, growth restrictions 
in cell culture appear to correspond with extensive passaging of laboratory stocks in 
fibroblasts (Brown et al., 1995; Sinzger et al., 2000). Furthermore, extensive 
passaging of the laboratory strains is associated with changes in the virus genome, 
including large-scale deletions (Cha et al., 1996).
Virus cell tropism is commonly determined during the initial stage o f the replicative 
cycle or at the initiation o f viral gene transcription (Tyler and Fields, 1996). 
However, the factor determining HCMV endothelial cell tropism, as suggested by 
differences between strains, appears to be transport of penetrated capsids toy/ards the 
nucleus o f endothelial cells (Sinzger et al., 2000).
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It seems likely that genes susceptible to ready mutation upon passage in cell culture 
have roles in tropism. UL128, UL130 and UL131A are genes that share a 
polyadenylation site, and are predicted to encode secreted proteins. UL128 and 
UL130 have sequence characteristics of a CC-chemokine (Akter et al., 2003; Novotny 
et al., 2001). Multiple strain analysis showed that many fibroblast-passaged strains 
have visibly disabling mutations in UL128, UL130 or UL131A (Akter et al., 2003; 
Hahn et al., 2004; Dolan et al., 2004) Adaptation of HCMV to fibroblasts is 
associated with disruption of any one of these genes, and each is required for growth 
in endothelial cells and transmission to leukocytes (Hahn et al., 2004). Furthermore, 
when these genes were supplied in /r<ms-complementation experiments, growth 
rescue was observed (Hahn et al., 2004). Other herpesviruses passaged in cell culture 
(CCMV and SCMV strain Colburn) also exhibit disruptions of UL128 (Davison et al., 
2003a). Most passaged HCMV strains also have mutations in at least one member of 
the RL11 gene family (usually RL13), which mostly encode glycoproteins and have 
also been suggested to have roles in tropism (Dunn et al., 2003; Davison et al., 
2003b). These studies suggest that fundamental biological properties may be lost in 
vitro according to cell culture system used. AD 169 may reacquire tropism for 
endothelial cells and leukocytes in vitro (Gema et al., 2003). As AD 169 lacks a 15 
kbp DNA segment in U l ,  this suggests that factors specifying tropism in these cells 
are encoded by viral genes elsewhere in the genome.
1.15 Latency
Like all herpesviruses, HCMV persists indefinitely within its host. Cells in bone 
marrow and peripheral blood are a key reservoir (Kondo et al., 1994). 
Myelomonocytic stem cells resident in bone marrow maintain the latent infection, and 
latently infected CD 14+ monocytes circulate in peripheral blood (Hahn et al., 1998). 
Differentiation o f these latently infected monocytes into macrophages then leads to 
reactivation and productive infection. Monocytes are the primary cell type infected in 
the blood during acute HCMV infection and are the predominant infiltrating cell type 
found in infected organs (Smith et al., 2004). Epithelial cells are also thought to play 
a part in this model of HCMV latency. Epithelial cells are infected by HCMV- 
containing bodily fluids, then the virus replicates and spreads to monocytes in the
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peripheral blood (Jarvis and Nelson, 2002; Smith et al., 2004). Latency could then be 
established by monocyte migration into bone marrow (Kondo et al., 1994; Smith et 
ah, 2004). It had been thought that vascular endothelial and smooth muscle cells may 
harbour latent HCMV virus. However, sensitive PCR assays by Reeves et al. (2004) 
could not detect viral sequences (specific to the MIE locus) in any of the individuals 
tested. Another site o f HCMV latency is myeloid dendritic cell progenitors (Hahn et 
al., 1998; Reeves et al., 2005). Differentiation o f these cells to mature dendritic cells 
leads to reactivation, leading to viral lytic gene expression and an increase in viral 
copy number (Reeves et al., 2005).
Induction of IE lytic gene expression appears to be preceded by chromatin 
remodelling of the MIE region of the viral genome. Latent HCMV in dendritic cell 
progenitors is thought to associate with a closed, transcriptionally silent chromatin 
conformation, as indicated by association with HP1, a silencing protein (Murphy et 
al., 2002; Reeves et al., 2005). On differentiation to mature dendritic cells, an 
association with acetylated histones was made which is consistent with an open, 
transcriptionally active chromatin conformation. Thus, viral lytic IE gene expression 
is reactivated. This mechanism is also linked to the down-regulation of HDAC1 
protein, a corepressor of other transcriptional repressors (Reeves et al., 2005).
In contrast to this model of transcriptional silencing, some HCMV transcripts appear 
to be expressed during latency. Although viral replication is not detectable during 
latency, viral transcripts from the major regulatory gene locus (IE1/IE2) have been 
detected in granulocyte-macrophage progenitors (Kondo et al., 1994, 1996). These 
viral transcripts have different structures from those transcribed during productive 
infection, and antibodies to the proteins encoded by these transcripts could be detected 
in the serum of seropositive individuals (Kondo et al., 1996). In addition, a vIL-10 
transcript that differed from that reported during productive infection has been 
detected using an experimental model o f latency in which human hematopoietic cells 
were latently infected with HCMV (Jenkins et al., 2004). An antisense transcript 
spanning the UL81-82 locus has also been identified, but in this study no IE genes 
were expressed (Bego et al., 2005). This creates a confusing picture of events during 
latency and much further work is required to elucidate a functional model.
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1.16 Genome analysis of HCMV strain AD169
The complete DNA sequence of HCMV strain AD 169 was determined by chain 
termination sequencing of M l3 clones generated from Hindlll fragments cloned in 
plasmids (Chee et al., 1990; Oram et al., 1982). Sequence analysis identified ORFs 
on the basis of three criteria: (1) an ORF size of 300 bp or greater, (2) overlap with 
other ORFs of not more than 60%, and (3) codon usage patterns. Consequently, 778 
ORFs were identified, o f which 581 were extensively overlapped by larger ORFs, 
leaving 197 candidate putative protein-coding ORFs. The gaps in the sequence were 
then examined for ORFs of less than 300 bp, for which additional criteria were 
employed: the presence of potential transcription signals and initiation codons, 
homology to other ORFs or known genes, the presence of protein structural or 
functional motifs in the amino acid sequence, and codon usage patterns. 
Consequently, a genome map of 189 ORFs was proposed (208 if diploid genes were 
counted twice). This map is shown in Figure 1.8.
The ORFs were numbered sequentially and prefixed to identify which segment of the 
genome they relate to: T R l  (11,247 bp; TRL1-14), U l  (166,972 bp; UL1-UL132), I R l  
(11,247 bp; IRL1-14), IRS (2,524 bp; IRS1), Us (35,418 bp; US1-US36) and TRS 
(2,524 bp; TRS1). The J ORFs (J1L, J1I and J1S), present in direct copies at the ends 
of the genome and an inverted copy between IR l and I R s ,  contain the a sequence 
which carries signals for cleavage and packaging of the viral genome (pac-1 and pac- 
2; Mocarski et al., 1987). The 229,354 bp genome has an average G+C content of 
57.2% and a class E structure (Figure 1.2). The ORFs, of which four were predicted 
to be spliced, were arranged about equally on both strands of the genome with little 
overlap. Further analysis revealed sets o f related genes that were grouped into nine 
families (Chee et al., 1990). Of the nine families identified, three were pairs o f genes 
(the UL25, UL82 and US2 families) and the others were groups of three to fourteen 
genes (the RL11, US6, US22, GCR, US1 and US12 families). Relatively few 
polyadenylation signals were postulated in the genome, and many genes, especially in 
gene families, were predicted to have coterminal 3’-ends.
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Figure 1.8. O riginal genome map of AD169.
The scale above the ORFs is in kbp. The thicker regions denote the inverted repeats 
and the thinner regions denote the unique long ( U l )  and unique short (Us) regions. 
Protein-coding regions are shown as open arrows above the gene nomenclature with 
prefixes omitted. The exons of spliced genes are connected by narrow horizontal 
bars. HCMV core genes and gene families are shown in different colours as 
indicated. Provided by A. Davison, MRC Virology Unit, Glasgow. Adapted from 
Chee et al. (1990).
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1.17 Errors and developments
The analysis of the AD 169 genome by Chee et al. (1990) was a landmark. 
Subsequent analyses o f this laboratory strain have identified a few errors in the 
sequence, leading to the reinterpretation of the affected ORFs. Two differences were 
identified in UL102, one extending the 5’-end and the other affecting the reading 
frame of the ORF (Smith and Pari, 1995). These changes effectively replaced UL101 
and UL102 with a single, larger ORF, also called UL102 (Figure 1.9). The 3’-end of 
US28 was also extended when an error in the original sequence was identified (Neote 
et al., 1993). Further differences were identified in AD 169 in the form of single 
residue insertions (Davison et al., 2003a). Two o f these disrupt UL15 and contribute 
to the emergence of an ORF on the other strand (UL15A, Figure 1.9), and one 
difference in US22 causes extension of the 5’-end. All o f these differences represent 
errors in the original AD 169 sequence.
Substantial differences between strains were identified in a comparative study of 
strains AD 169, Toledo and Towne (Cha et al., 1996). Southern blots indicated that 
Toledo and Towne contained additional sequence at the right end of Ul. The low- 
passage, virulent Toledo strain was found to contain a DNA segment absent from the 
high passage laboratory strains. Approximately 13 kbp of this additional U l sequence 
was not present in Towne and approximately 15 kbp was not present in AD 169. 
Using the same criteria employed by Chee et al. (1990), 19 additional ORFs in Toledo 
and four in Towne were identified, compared to AD 169. Most of the novel ORFs in 
Toledo were predicted to encode membrane proteins, and none was found to be 
homologous to ORFs in other p-herpesviruses (Cha et al., 1996). From these 
additional genes, three further HCMV gene families were identified (Davison et al., 
2003a).
Although Toledo contains an additional 15 kbp DNA segment, the genome is only 5 
kbp larger than AD 169 (approximately 235 kbp) since IR l is much shorter in Toledo 
than in AD 169 or Towne (Cha et al., 1996). This is because the diploid genes in 
AD 169 T R l / I R l  are haploid in Toledo. A subsequent study by Lurain et al. (1999) 
identified these 19 ORFs in a range of clinical isolates of HCMV, indicating that they
34
Introduction
are highly likely to be part of wild-type HCMV. It was speculated that part o f the 
additional DNA segment in Toledo is in an inverted orientation compared to the 
corresponding region in clinical isolates (Cha et al., 1996; Lurain et al., 1999). 
Analysis of the corresponding region in chimpanzee CMV (CCMV) supported the 
view that Toledo contains an inverted region (Davison et al., 2003a). An error in this 
extra segment in Toledo was also subsequently identified, as a single residue insertion 
in UL145 caused extension of the 5’-erid of this ORF (Davison et al., 2003a). Some 
stocks of A D I69, including that analysed by Chee et al. (1990), were also found to 
contain a 929 bp deletion affecting two genes: UL42 and UL43 (Dargan et al., 1997; 
Mocarski et al., 1997). This changes the reading frame at the 5’-end of UL42, 
expands UL43 from 187 to 423 codons and replaces UL41 with a new ORF, UL41A.
ORF Donor Acceptor Reference
UL22A 27,193 27,277 Rawlinson and Barrell, 1993
UL33 43,087 43,209 Margulies et ah, 1996





Kouzarides et al., 1988





Kotenko et al., 2000
UL112 161,345 161,503 Wright et al., 1988
UL119 167,563 167,474 Leatham et al., 1991












Akter et al., 2003
UL131A 176.589 176.480 Akter et al., 2003
Table 1.4. Spliced HCMV genes.
The splice donor and acceptor sites refer to strain AD 169.
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Although the original analysis of AD 169 identified only four spliced genes (Chee et 
al., 1990), a total o f 12 have now been characterised (Figure 1.9). The splice donor 
and acceptor sites within these genes are shown in Table 1.4. Other reports of spliced 
ORFs remain to be fully characterised (Rawlinson and Barrell, 1993). A number of 
additional ORFs were also characterised, such as UL48A (Gibson et al., 1996).
1.18 Reinterpreting the genome
Construction of an infectious bacterial artificial chromosome (BAC) clone of AD 169 
was reported by Yu et al. (2002). The authors used this clone in a subsequent study to 
introduce defined mutations by random or site-directed transposon mutagenesis, 
producing viral mutants for all ORFs deemed to have a high probability of encoding 
proteins (Yu et al., 2003). Mutants were selected and their growth assayed in cultured 
human fibroblasts to identify 41 essential, 88 non-essential and 27 augmenting ORFs 
in AD 169. A similar approach was used at the same time by Dunn et al. (2003), who 
generated a collection of viral mutants by deleting 162 ORFs from a BAC clone of 
Towne. In assessing the requirement for each ORF for replication in fibroblasts in 
vitro, 45 ORFs were identified as essential. O f these, 39 were also identified by Yu et 
a l  (2003).
The differences are in six ORFs which were identified as essential for Towne 
replication but as augmenting in AD 169 (UL48, UL71, UL76, UL90, UL94 and 
UL96), and two ORFs which were identified as essential for AD 169 replication but 
not Towne (UL61, which is probably non-protein coding and is located within or/Lyt, 
and UL80.5, a surprising result as it is completely overlapped by UL80, an essential 
ORF). Almost all the essential ORFs, for which no growth of the mutant was 
observed in fibroblasts, are core genes (conserved in herpesviruses) and are located in 
the central region of HCMV. Furthermore, genes UL64 and UL24 were required for 
replication in retinal pigment epithelial (RPE) cells and microvascular endothelial 
cells (HMVEC), respectively, but not in fibroblasts, indicating roles in viral tropism 
in different cell types (Dunn et al., 2003).
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A study by Murphy et al. (2003a) utilised a gene finder algorithm, the Bio- 
Dictionary-based Gene Finder, to identify potential new protein-coding ORFs based 
on matches to amino acid patterns derived from the large collection of proteins in the 
Swiss-Prot/TrEMBL database (Murphy et al., 2003a; Shibuya and Rigoutsos, 2002). 
Protein-coding ORFs were identified and then screened for orthologues in CCMV, 
RhCMV and MCMV. In total, 37 previously annotated ORFs were discarded, and 12 
ORFs with coding potential were added. This view was amended in a subsequent 
study by the same group, in which further strains o f HCMV were BAC-cloned 
(Murphy et al., 2003b). In addition to AD 169 and Towne, four low passage isolates 
(Toledo, PH, TR and FIX) were BAC-cloned and the genomes sequenced. The 
sequences were compared and a total of 252 ORFs were identified that were 
conserved in all four clinical isolates. ORFs were subsequently discounted if the 
ATG initiation codon was less than 80 codons from a termination signal, or if the 
ORF was overlapped by another ORF by more than 396 bp (the size of the largest 
overlap between recognised HCMV ORFs, involving UL76 and UL77). As a result, a 
list o f 29 newly recognised ORFs with the potential for coding proteins were 
identified (C-ORF1 to C-ORF29). Of the 12 new ORFs recognised in the previous 
study (Murphy et al., 2003a), two were discarded in the later work (ORF4 and 
ORF 12) to make a total of 39 newly recognised ORFs in the genome. However, most 
of these ORFs introduced by these analyses are small, overlap recognised HCMV 
genes and, most significantly, are not conserved in CCMV. In addition, assignment 
of these ORFs to HCMV is based on the predictions of a single algorithm.
At the same time as these studies, the sequence of CCMV, the closest known relative 
of HCMV, was compared with AD 169 and Toledo on the basis o f conservation of 
potential protein-coding regions and other sequence features, and the content of these 
genomes interpreted (Davison et al., 2003a). Of the previously proposed HCMV 
ORFs by Chee et al. (1990), 51 were discounted, modified interpretations were made 
for 24 (including the assignment of multiple exons), and 10 novel ORFs were 
proposed (Davison et al., 2003a). Within the additional region in Toledo, the genes 
recognised by Cha et al. (1996) were reinterpreted by redefining four, discounting five 
and introducing five novel ORFs. This region of Toledo is not collinear with CCMV 
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Figure 1.9. Genome map of Merlin.
The scale above the ORFs is in kbp. The thicker regions denote the inverted repeats 
and the thinner regions denote the unique long (U l)  and unique short (Us) regions. 
Protein-coding regions are shown as open arrows above the gene nomenclature with 
prefixes omitted. The exons of spliced genes are connected by narrow horizontal 
bars. HCMV core genes and gene families are shown in different colours as 
indicated. Provided by A. Davison, MRC Virology Unit, Glasgow.
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Consequently, the genetic content of HCMV was significantly altered from the 
original analysis of Chee et al. (1990), and a total of 164-167 genes predicted. 
Although the basis of this analysis was conservation of ORFs, virus-specific genes 
were recognised in each genome. CCMV lacks counterparts of HCMV genes UL1, a 
member of the RL11 glycoprotein family (Davison et al., 2003b) and UL111 A, which 
encodes an interleukin-10 homologue (Kotenko et al., 2000).
Sequencing of a low passage HCMV strain, Merlin, by the same group has further 
clarified the genetic content of wild-type HCMV (Dolan et al., 2004). The genome of 
Merlin is 235,645 bp, approximately 5 kbp larger than AD 169, and contains the extra 
DNA segment identified in Toledo without the inversion (Cha et al., 1996), and no 
internal repeat of ORFs RL1-RL13. Comparative analysis with AD 169 and Toledo 
identified a total of 165 genes, with Merlin containing no obvious mutations except a 
single nucleotide substitution that truncates UL128. The map of Merlin, shown in 
Figure 1.9, differs a great deal from the AD 169 genome described by Chee et al. 
(1990) (Figure 1.8), and presents a more conservative view of wild-type HCMV than 
the contemporaneous genome re-analyses (Murphy et al., 2003a, 2003b). The 
comparative analysis with CCMV contributes strongly to the Merlin genome map, 
containing the extra ORFs identified in the 19 kbp absent from AD 169, retaining the 
10 novel ORFs with counterparts in CCMV, and discounting a large number o f ORFs 
(Figure 1.10). Other new ORFs that have been well characterised since the original 
HCMV analysis (those discussed in Section 1.17), are also included. This map is 
thought to represent the most reliable account of the gene complement of wild-type 
HCMV, with a best estimate of 165 genes (Dolan et al., 2004).
1.19 HCMV strain variation
The most extensively used strains are also the most highly passaged strains. Davis 
was isolated via liver biopsy from a 3 month old girl with microencephaly (Weller et 
al., 1957). Towne, a vaccine candidate, was isolated from the urine of a congenital 
infection (Plotkin et al., 1975). AD 169, isolated via tonsillectomy-adenoidectomy 
from a 7-year-old girl (Rowe et a l , 1956), has become the most extensively used 
strain because it replicates so efficiently in cultured cells, and one form
39
Introduction
(AD169vflrUK) was used by Chee et al. (1990) in the original HCMV genome 
analysis. Low passage strains such as Toledo were subsequently used in HCMV 
analyses (Quinnan et al., 1984). Clinical isolates are not inclined to yield much 
extracellular virus unless they have been adapted to cell culture growth by serial 
passage, and can take much longer to achieve CPE than highly passaged laboratory 
strains. As discussed in sections 1.17 and 1.14, highly passaged strains have large 
scale deletions and gene disruptions or rearrangements associated with extensive 
passaging in cell culture.
In addition to large scale mutations that occur in vitro, many natural variations have 
been observed between strains. In a study of the genetic content of wild-type HCMV, 
a subset of genes showed unusually high variation between strains Merlin and AD 169 
or Toledo (Dolan et al., 2004). Ka values, a measure of nonsynonymous nucleotide 
substitution which results directly in amino acid sequence divergence, were computed 
for pairwise alignments of coding sequences. This approach identified a subset of 
genes displaying unusually high variation, comprising genes which are either known 
or predicted to encode secreted or membrane-associated proteins. All 25 genes with 
Ka values o f 0.03 or more are in this category (Figure 1.10). For example, analysis of 
the RL12 proteins encoded by the AD 169 and Merlin genomes show only 49% 
identity in their amino acid sequences.
As previously discussed, envelope glycoproteins form three complexes: gB, gM/gN 
and gH/gL/gO (Section 1.9). Each of UL55 (gB), UL73 (gN), UL75 (gH), UL115 
(gL) and UL74 (gO) is highly variable between HCMV strains. Sequence analysis 
has shown that each of these glycoproteins has four genotypes, with the exception of 
gH, which has two and gO, which has seven (Pignatelli et al., 2004). Genetic 
polymorphism has also been observed in other viral glycoproteins. US9 and UL4 
have four and three distinct groups, respectively (Rasmussen et al., 2003; Bar et al., 
2001). UL11, a transmembrane glycoprotein, and UL37, which encodes two anti- 
apoptotic proteins, both have highly variable extracellular domains (Hitomi et al., 
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Figure 1.10 Nonsynonymous 
divergence.
Nonsynonymous divergence (Ka) 
between Merlin and AD 169 genes 
(Dolan et al. , 2004). The gene 
order proceeds from the left end of 
the genome (top of the figure). 
Genes predicted to encode secreted 
or membrane-associated proteins 
are shown in red, and all other 
genes are shown in blue. The 
yellow bar indicates where Merlin 
was compared with Toledo as 
AD 169 lacks these genes. 
Comparisons of all other genes 
were carried out between Merlin 
and AD 169 genes.
UL146, which encodes a CXC-chemokine, is particularly variable. It has been 
sequenced in 40 strains, identifying 14 genotypes (Penfold et al., 1999; Prichard et al., 
2001; Dolan et al., 2004). US28, which encodes a p-chemokine receptor, has been 
sequenced in 25 strains to identify four genotypes (Rasmussen et al., 2003). UL144 
encodes a homologue of the tumour necrosis receptor superfamily (Arav-Boger et al.,
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2002; Bale et al., 2001; Lurain et al., 1999). In a study of 45 low-passage clinical 
isolates, an amino acid substitution rate of approximately 21% was found, most of the 
changes occurring in the 5’ half o f the gene (Lurain et al., 1999). The differences 
identified three genotpyes groups, with one group containing three subgroups.
The genetic polymorphism seen in numerous HCMV genes could have many different 
implications. For example, the polymorphism evident in the envelope glycoproteins 
could affect viral cell tropism. In particular, gB has important roles in virus 
penetration into the cell and in cell-to-cell fusion, and these functions could be 
affected. Other highly variable genes are known to have roles in immune evasion. 
UL146, US28 and UL144 could have developed genetic polymorphisms to help evade 
host immune surveillance (Pignatelli et al., 2004). Polymorphism also potentially 
increases the variety of ways in which HCMV is presented as an antigen, thus 
potentially helping to evade the host immune defence. There is also potential for 
polymorphism to affect viral replication efficiency and regulation, as some variation 
has also been observed in UL54, UL122 and UL123 (Zweygberg Wirgart et al., 1998; 
Sorg and Stamminger, 1998).
1.20 HCMV relationship to other herpesviruses
Comparing sequences to a close relative is one of the most significant ways of 
improving the interpretation of genetic content, on the basis that authentic protein- 
coding regions will have been conserved during evolution whereas spurious ORFs 
will not. The genetic content of CCMV, the closest known relative of HCMV, was 
reported by Davison et al. (2003a). The 241,087 bp genome was shown to be 
moderately diverged and essentially colinear with HCMV, with a similar genomic 
structure. CCMV is thought to contain only four genes that are not present in HCMV; 
UL146A and UL157, which are related to UL146 in HCMV (Penfold et al., 1999), 
UL155 and UL156. The comparative analysis used to modify the interpretation of the 
HCMV genome is discussed in Section 1.18.
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Host Species Name Reference Accession no. Genome size
Estimated 
gene no.
Human HCMV Chee et al. (1990) X I7403 229 208
Dolan et al. (2004) AY446894 236 165
Chimpanzee CCMV Davison et al. (2003a) AF480884 241 165
Rhesus RhCMV Hansen et al. (2003) AY186194 221 230
Murine MCMV Rawlinson et al. (1996) U68299 230 170
Rat RCMV Vink et al. (2000) AF232689 230 166
Tupaia TuHV-1 Bahr and Darai (2001) AF281817 196 158
HHV-6 HHV-6 Gompels et al. (1995) X683413 159 119
Dominguez et al. (1999) AF157706 162 119
Isegawa et al. (1999) AB021506 162 115
HHV-7 HHV-7 Nicholas (1996) U43400 144 109
Meeaw et al. ('1998') AF037218 153 84
Table 1.5. Sequenced Betaherpesvirus genomes.
Approximate genome sizes are in kbp.
The 221,469 bp genome of RhCMV strain 68-1 has been reported (Hansen et al., 
2003). This sequence provides another important tool for comparative analysis of 
HCMV as it is evolutionarily closer than most other p-herpesviruses. RhCMV 
appears to contain a single unique region with no large internal or terminal repeats 
like those in HCMV, but a virion packaging site (homologous to the a sequence in 
HCMV) separates the counterparts of the U l and Us regions of HCMV. Of the 230 
ORFs identified, 138 are homologous to known HCMV proteins, including almost all 
the HCMV gene families and all the /ra«s-activating factors required for HCMV lytic 
replication.
Several other P-herpesviruses more distantly related to HCMV have been completely 
sequenced (Table 1.5). The genomes of MCMV and RCMV are similar in size 
(230,278 bp and 229,896 bp, respectively) and both contain a core set of genes that 
have counterparts to those in HCMV. Analysis of the Smith strain of MCMV shows 
significant similarities to AD 169, particularly in 78 centrally located ORFs, including 
homologues of the UL25, UL82, US22 and GCR gene families (Rawlinson et al.,
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1996). The Maastricht strain of RCMV contains counterparts to all but one o f the 
ORFs conserved between MCMV and HCMV (Vink et al., 2000).
MCMV is the most studied CMV with the exception of HCMV. Analyses o f the 
MCMV genome subsequent to that o f Rawlinson et al. (1996) mirrors that of HCMV, 
as errors have been identified in the original sequence. Reannotation of the MCMV 
and RCMV genomes by Brocchieri et al. (2005) used a set of criteria that was 
significantly looser than that used in other genome analyses, but similar to that 
employed by the analyses o f Murphy et al. (2003a, 2003b) for HCMV. 
Consequently, over 100 new ORFs were assigned to each genome by Brocchieri et al. 
(2005) but only some (14 in MCMV and 20 in RCMV) were considered convincing 
as protein-coding genes.
The genome of TuHV-1 (195,857 bp) was sequenced by Bahr and Darai (2001). 
Reannotation of the genome by the same authors (Bahr and Darai, 2004) discounted 
23 of the original 158 protein-coding ORFs, leaving 76 centrally located ORFs 
showing significant homology to HCMV, and species-specific ORFs at the ends of 
the genome.
The U1102 strain of HHV-6 (159,321 bp) is predicted to encode 86 protein-coding 
ORFs, and lacks the RL11, US1, US2, US6 and US12 gene families (Megaw et al., 
1998; Zou et a l , 1999). HHV-7 (153,080 bp) is the closest relative of HHV-6, and 
has a total of 84 genes (Nicholas et al. 1996; Megaw et al., 1998).
1.21 Justification of study
Several analyses have led to reinterpretation of the HCMV genome. O f particular 
significance, comparative analysis with CCMV has discounted a substantial number 
of genes in the original analysis of Chee et al. (1990). This led to the appearance of 
three large regions in HCMV which apparently do not encode proteins; UL106- 
UL111, UL58-UL68, and RL2-RL9. The RL2-RL9 region has been investigated by 
Davison et al. (2003b), but the protein-coding potential of the other two regions 
require further evaluation. The region flanked by UL105 and UL112 has been termed
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Region X, and the region flanked by UL57 and UL69 has been termed Region O. A 
5 kb RNA in region X has been previously reported and requires further 
characterisation. Region O, which encompasses the HCMV origin o f lytic DNA 
replication, also harbours an RNA (pp67) previously reported to encode a protein. A 
third region investigated in the current study, which also contains ORFs not thought to 
encode proteins, is flanked by US32 and TRS1 and has been termed Region G. The 
protein-coding potential of ORFs predicted from the original work of Chee et al. 
(1990) and subsequent analyses (Murphy et al., 2003a, 2003b; Davison et al., 2003a; 
Dolan et al., 2004) are investigated in the current study by sequence comparisons of 






HCMV strain AD 169 (Chee et al., 1990) was provided by Dr. Derrick Dargan 
(Institute of Virology, Glasgow) and used for all low-multiplicity and high- 
multiplicity infections in cell culture. Infected cell DNA from strains AD 169 and 
Toledo were also obtained from Dr. Derrick Dargan. Low-passage strains 3157, 6397 
and Merlin were isolated from the urine of congenitally infected children, and DNA 
samples were obtained from Dr. Gavin Wilkinson (University of Cardiff). Strain 
3301, isolated directly from urine without passage, was also provided by Dr. Gavin 
Wilkinson. DNA from strain W was isolated, without passage, from the adrenal 
gland of an HCMV-infected AIDS patient, and was provided by Dr. Aycan Hassan- 
Walker and Prof. Paul Griffiths (University College Medical School).
2.1.2 PCR
Advantage 2 Polymerase Mix (50x): BD Clontech
Advan 2 PCR buffer 
dNTPs (10 mM each)
Primers Sigma Genosys
PCR Optimiser kit: Invitrogen
16 PCR buffers
2.5 mM dNTP mix 
DMSO
Control primers & template 
PCR-grade H2O
Advantage-GC 2 PCR kit: BD Clontech
50 x Advantage-GC 2 Polymerase Mix 
5 x Advantage-GC 2 PCR buffer 
GC-Melt (5 M) 
dNTPs (10 mM each)








DNA marker (2 log ladder)
Ethidium bromide
(10 mg/ml aqueous solution)





Catch tubes and spin filters
Turbo spin kit:
Turbo salt solution 
Wash concentrate 
Elution solution 
Catch tubes and spin filters
Sigma
109 g/1 Trizma 
55 g/1 boric acid
9.3 g/1 EDTA
37.2 g/1 EDTA 
100 g/1 Ficoll 400 
5 x TBE
1% (w/v) bromophenol blue 






One Shot TOP 10 Escherichia coli strain K12 competent cells (Invitrogen). 
Genotype: F" mcrA A(mrr-hdRMS-mcrBC) <})80/tfcZMA15 AlacXIA deoR recA\ 
anzD139 A(ara-leu)1691 galU galK rpsL (StrR) end A l nupG.
pGEM-T Vector System I: Promega
pGEM-T vector 
T4 DNA ligase 















Restriction endonucleases and buffers
2.1.5 Sequencing
Ethanol mix





1.5% (w/v) agar in L-broth 
autoclaved
Invitrogen
40 mg/ml 5-bromo-4-chloro-3-indoyl-P- 
D-galactopyranoside in N, N ’-dimethyl 
formamide
30 mg/ml isopropylthio-P-D-galactoside
85 mM NaCl 
1% (w/v) bactopeptone 
1% (w/v) yeast extract 
autoclaved
50 mM D-glucose 
25 mM Tris-HCl, pH 8 
10 mM EDTA
200 mM NaOH 
1% (w/v) SDS
3 M potassium acetate 
2 M acetic acid
20% (w/v) PEG 6000
2.5 M NaCl
phenol equilibrated with TE 
New England BioLabs
75% ethanol
40 pl/ml 3M sodium acetate pH 4.6
Amresco
0.48 g/ml urea 
12% (v/v) Page-plus 
10% (v/v) 10 x TBE
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Blue dextran 4 mg/ml blue dextran
EDTA
Loading buffer 70% (v/v) formamide
30% (v/v) blue dextran
2.1.6 Cells and media
Human foetal foreskin fibroblast (HFFF-2) cells were used in all cell culture 
experiments. Cells were initially supplied by Dr. Derrick Dargan (Institute of 
Virology). HFFF-2 cells were grown in Dulbecco’s Modified Eagle’s Medium with 
10% (v/v) foetal calf serum (FCS), 1% non-essential amino acids and 1% L-glutamine 
supplements. On occasion, 1% penicillin-streptomycin was also used as a 
supplement.
Versene (0.6 mM EDTA in PBS, 0.002% (w/v) phenol red) and trypsin (0.25% (w/v) 
in Tris-saline) were used for washing and removing cell monolayers.
Storage medium 90% (v/v) foetal calf serum (FCS)
10% (v/v) dimethylsulfoxide (DMSO)
Methylcellulose overlay 39% (v/v) carboxymethylcellulose
1.56% (v/v) tryptose phosphate
3.9% (v/v) FCS
24.3% (v/v) N aH C 03 (7.5%)
1.56% (v/v) penicillin/stremptomycin
0.08% (v/v) amphotericin B
7% (v/v) lOxGlasgow modified medium
Giemsa stain Sigma
Phosphate-buffered saline (PBS) 170 mM NaCl
3.4 mM KC1 
10 mM Na2H P04





2.1.7 RNA preparation and extraction
Cycloheximide 








Low salt wash buffer 
Elution buffer 
2 M Sodium Acetate 























4 mg/ml bromophenol blue 
4 mg/ml xylene cyanol 
0.25 g/ml Ficoll 400


















SP6 promoter adaptor 
T7 promoter adaptor 
10 x T4 DNA ligase 
10 x ligation buffer 
PCR adaptor primers 1 and 2 
Control template and primer 
Nuclease-free H2O
Maxi Script SP6/T7 kit: Ambion
SP6 enzyme mix 
T7 enzyme mix 
10 x transcription buffer 
ATP solution (10 mM)
CTP solution (10 mM)
GTP solution (10 mM)
UTP solution (10 mM)
DNase I
Nuclease-free H2O
Rapid hyb buffer Amersham
Gene-specific primers Sigma Genosys
[cc32P]CTP, [a32P]GTP, [a32P]UTP 
(3000 C i/mmol, 10 pCi/ml)
NEN Life Science
2.1.9 RT-PCR and RACE-PCR
RT-PCR Superscript III One-Step kit: Invitrogen
Superscript III RT/Taq enzyme mix 




GeneRacer amplification kit: Invitrogen
RNaseOut
Calf intestinal phosphatase (CIP)
10 x CIP buffer
Tobacco acid pyrophosphatase (TAP)
10 x TAP buffer
GeneRacer RNA Oligo
T4 RNA ligase




3 M Sodium acetate
GeneRacer 5’ primer and nested primer
GeneRacer 3’ primer and nested primer
Control total RNA and primers
SMARTRACE cDNA amplification kit: BD Clontech
SMART II oligonucleotide 
3’ RACE CDS primer 
5’ RACE CDS primer 
Powerscript reverse transcriptase 
5 x first-strand buffer 
DTT
Deionised H2O 
10 x universal primer mix 
Nested universal primer mix 
dNTP mix (10 mM each)
Tricine-EDTA buffer 
Control total RNA and primers
5 ’ -RACE amplification kit: Invitrogen
10 x PCR buffer 
25 mM MgCl2 
10 mM dNTP mix 
0.1 M DTT
Superscript II Reverse Transcriptase 
RNase mix 
5 x tailing buffer 
2 mM dCTP
Terminal deoxynucleotidyl transferase 
5’-RACE abridged anchor primer (10 pM)
2.1.10 Chemicals
All general chemicals were obtained from BDH or Sigma.
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2.1.11 Autoclaving and glassware sterilisation
Equipment and solutions were sterilised at 15 psi for 20 min by staff in the wash room 
of the Institute of Virology. Glassware was sterilised by baking in an oven at 180°C 
for at least 2 h.
CHAPTER 2.2: METHODS
2.2.1 PCR
PCR was performed in 50 pi reactions:
PCR buffer (10 x) 5 pi
dNTPs (10 mM each) 1 pi
Forward primer (10 pM) 1 pi
Reverse primer (10 pM) 1 pi
Template (genomic DNA) 1 pi 
H20  40 pi
Advantage II Polymerase 1 pi
Reactions were placed in a thermocycler and denatured at 94°C for 30 s. A standard 
PCR program was 35 cycles of 94°C/5 s (i.e. 94°C for 5 s), 68°C/30 s and 72°C/1 min 
per kb, followed by a final extension step of 72°C/7 min. Conditions were as 




Optimising PCR was performed in 45 pi reactions using an Invitrogen kit:
PCR buffer (5x) 10 pi
dNTPs (10 mM each) 1 pi
Forward primer (10 pM) 1 pi
Reverse primer (10 pM) 1 pi
Template (genomic DNA) 1 pi
h 2o 30 pi
Advantage II Polymerase 1 pi
Reactions were placed at 80°C and 5 pi of 2.5 mM dNTP mix was added (to make a 
total reaction volume of 50 pi) before proceeding directly to the thermocycler. For 
each set of primers, seven different PCR reactions were prepared using different 
buffers, each with a specific pH (ranging from 8.5 to 10) and Mg concentration 
(ranging from 1.5 to 3.5 mM). A standard PCR program was 94°C/2 min, 35 cycles 
of 94°C/1 min, 65°C/1 min and 72°C/1 min per kb, followed by a final extension step 
of 72°C/7 min. A series of optimiser PCRs is shown in Figure 2.1 (a).
2.2.3 High-GC PCR
High-GC PCR was performed in series of 50 pi reactions using a BD Clontech kit:
fina l GC-Melt concentration (M)
0 0 5  I L5
PCR buffer (5x) 10 10 10 10 pi
dNTPs (10 mM each) 1 1 1 1 pi
Forward primer (10 pM) 1 1 1 1 pi
Reverse primer (10 pM) 1 1 1 1 pi
Template (genomic DNA) 1 1 1 1 pi
GC-Melt 0 5 10 15 pi
h 2o 35 30 25 20 pi
Advantage-GC2 Polymerase 1 1 1 1 pi
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GC-Melt is a reagent, supplied in the kit, which further weakens base pairing in GC- 
rich sequences. Reactions were placed in a thermocycler and denatured at 94°C for 3 
min. A standard PCR program was 30 cycles of 94°C/30 s, 65°C/30 s and 68°C/1 min 
per kb, followed by a final extension step of 68°C/3 min. A series of high-GC PCRs 
is shown in Figure 2.1(B).
A B
A B C D F J N L 0 0.5 1 1.5
B uffer G C-M elt cone (M )
Figure 2.1: O ptim iser PCR and High-GC PCR
(A) A series of optimiser PCR reactions using seven different PCR buffers. In this 
series, primers worked optimally with buffer C. (B) A series of high-GC PCR 
reactions using different concentrations of GC-Melt reagent. In this series, primers 
work optimally with a GC-Melt concentration of 0.5 M. Lanes L are DNA markers.
2.2.4 Agarose gel electrophoresis
Unless otherwise stated, all agarose gels were at 1% (w/v) concentration. 1 g of 
agarose was melted in 100 ml of 1 x TBE and allowed to set at 4°C in a gel former. 
Gels were electrophoresed for approximately 2 h at 120 V, and then stained with 0.5 




2.2.5 Gel purification: low melting temperature agarose
1.5% (w/v) low-melting-temperature agarose gels electrophoresed overnight 
(approximately 16 h) at 30 V were stained with 0.5 pg/ml ethidium bromide for 1 h. 
Appropriate bands were cut out on a long-wave UV lightbox using a sterile scalpel, 
and placed in 1.5 ml microfuge tubes, each containing 20 pi of 10 x p-agarase buffer. 
Samples were heated at 65°C for 1 h, and then at 40°C for 5 min, 3 pi of p-agarase 
was added, and the tubes were left at 40°C for another 1 h. The samples were 
supplemented with 10 pi of 3M NaAc, incubated on ice for 15 min, and centrifuged at
12,000 x g for 10 min to pellet any remaining agarose. The supernatants were
transferred to fresh microfuge tubes, 200 pi of ethanol was added, and the tubes were
incubated at -20°C for 1 h. The samples were centrifuged at 12,000 x g for 10 min 
and the supernatants removed. The pellets were centrifuged in 100 pi of 70% ethanol, 
and the supernatants removed. The samples were dried at 37°C for 1 h, and the 
pellets were resuspended in 10 pi of sterile H2O and stored at -20°C. Sample 
recovery was checked by electrophoresis of 2 pi on a 1% (w/v) agarose gel.
2.2.6 Gel purification: GENECLEAN spin kit
1% (w/v) agarose gels electrophoresed for approximately 2 h at 120 V were stained 
with 0.5 pg/ml ethidium bromide for 30 min. Appropriate bands were cut out on a 
long-wave UV lightbox using a sterile scalpel, and transferred to 1.5 ml microfuge 
tubes. Gel samples were transferred to Spin Filter Tubes containing 400 pi of 
Glassmilk matrix solution, which is able to bind DNA. Samples were heated at 55°C 
for 10 min, and inverted every minute to prevent the matrix settling.
Samples were centrifuged at 12,000 x g for 1 min, and the flow-through discarded. 
Spin new wash was added (500 pi), samples were centrifuged at 12,000 x g for 1 min, 
and the flow-through was discarded. A further centrifugation step of 12,000 x g for 2 
min was carried out to dry the membrane. The filters were transferred to Elution 
Catch Tubes, and the Glassmilk resuspended in 20 pi of Spin Elution Solution
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(DNase-free H2O). The samples were centrifuged at 12,000 x g for 1 min, the filter 
was discarded, and the eluted DNA was stored at -20°C. Sample recovery was 
checked by the electrophoresis of 2 pi on a 1% (w/v) agarose gel.
2.2.7 Gel purification: GENECLEAN Turbo kit
1% (w/v) agarose gels electrophoresed for approximately 2 h at 120 V were stained 
with 0.5 pg/ml ethidium bromide for 30 min. Appropriate bands were cut out on a 
long-wave UV lightbox using a sterile scalpel, and transferred to 1.5 ml microfuge 
tubes. Turbo salt solution (150 pi) was added to each sample (more for bigger gel 
pieces) and incubated at 55°C for 10 min, inverting the samples every minute. Up to 
600 pi of each sample was then transferred to a Turbo cartridge in a catch tube.
The samples were centrifuged at 12,000 x g for 10 s and the flow-through discarded. 
Turbo Wash was added (500 pi), the samples were centrifuged at 12,000 x g for 10 s 
and the flow-through was discarded. A further centrifugation step of 12,000 x g for 4 
min was carried out to dry the membrane. The Turbo cartridges were transferred to 
new catch tubes and the Glassmilk was resuspended in 20 pi of elution solution 
(DNase-free H2O). The samples were centrifuged at 12,000 x g for 1 min, the Turbo 
cartridge was discarded and the eluted DNA was stored at -20°C. Sample recovery 
was checked by the electrophoresis of 2 pi on a 1% (w/v) agarose gel.
2.2.8 Ligations
Ligations were performed in 5 pi reactions using a Promega kit:
T4 DNA ligase buffer (2x) 2.5 pi
pGEM-T vector 0.25 pi
DNA insert 1.5 pi
H20  0.25 pi
T4 DNA ligase 0.5 pi
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Each set of ligation reactions included a positive control (a DNA sample supplied in 
the kit) and a negative control (no DNA insert). H2O was added to the controls to 
make a total volume of 5 pi. Reactions were incubated overnight at 4°C or at room 
temperature for 1 h.
2.2.9 Transformations
Competent cells were moved directly from -70°C to ice and allowed to thaw for 15 
min. Cells were divided into aliquots of 25 pi, and 1 pi ligation reaction was added, 
taking care not to damage the cells by pipetting. The samples were kept on ice for 30 
min, heat-shocked at 42°C for 30 s, then moved back to ice for 5 min. SOC medium 
(250 pi) was added to each sample, which was then incubated in a 37°C incubation 
shaking cabinet for 1 h. IPTG (10 pi) and X-gal (20 pi) were added to each tube, the 
sample mixed and the solution spread using a sterilised Pasteur pipette on an 
ampicillin plate pre-incubated at 37°C. The plates were allowed to stand at room 
temperature for 1 h, then incubated upside-down overnight at 37°C.
2.2.10 Plasmid purification: alkaline lysis
Bacterial colonies grown on ampicillin plates were picked using sterile cocktail sticks 
and grown overnight at 37°C in 2YT broth containing ampicillin. Each culture (1 ml) 
was transferred to a separate microfuge tube and centrifuged at 12,000 x g for 5 min. 
The supernatant was removed using a Pasteur pipette, and the pellet was resuspended 
in 100 pi GTE/lysosyme and left at room temperature for 5 min. NaOH/SDS (200 pi) 
was added to the vortexed mixture, and the tubes were inverted and left at 4°C for 5 
min. 3 M KAc pH5 (150 pi) was added, and the tubes were inverted immediately and 
left at 4°C for 5 min. The tubes were centrifuged at 12,000 x g for 10 min, and the 
supernatants transferred to fresh microfuge tubes. One volume o f phenol/chloroform 
was added to each tube, which was mixed by inversion for 1 min then centrifuged at
12,000 x g for 5 min. The upper phase was transferred to a fresh tube and 750 pi
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100% ethanol added. The samples were allowed to stand at room temperature for 30 
min, and then the tubes were centrifuged at 12,000 x g for 10 min. The supernatant 
was removed and the tubes were allowed to dry at 37°C for 20 min. The samples 
were resuspended in 50 pi TE and 100 pg/ml RNaseA, and incubated at 37°C for 30 
min. The tubes were inverted gently after addition of 60 pi PEG/NaCl, and allowed 
to stand at 4°C for 30 min. The samples were centrifuged at 12,000 x g for 7 min, 
and the supernatants removed. The DNA pellets were washed in 100 pi 70% ethanol. 
The samples were allowed to stand at 37°C for 30 min, and resuspended in 50 pi H2O 
and stored at -20°C.
2.2.11 Plasmid purification: QIAspin miniprep
Plasmid purification was also carried out using a Qiagen miniprep kit. Bacterial 
colonies grown on ampicillin plates were picked using sterile cocktail sticks and 
grown overnight at 37°C in 2YT broth containing ampicillin. Each culture (1 ml) was 
transferred to a separate microfuge tube and centrifuged at 12,000 x g for 5 min. The 
supernatant was removed using a Pasteur pipette, and the pellet was resuspended in 
250 pi buffer PI (containing RNaseA) and left at room temperature for 5 min. Lysis 
buffer P2 (250 pi) was added to the vortexed samples, which were mixed by inversion 
and allowed to stand no longer than 5 min. Neutralisation buffer N3 (350 pi) was 
added to the samples, which were immediately mixed by inversion. The samples 
were centrifuged at 12,000 x g for 10 min, and the supernatants were transferred to 
spin columns. The samples were centrifuged at 12,000 x g for 1 min and the flow­
through discarded. Wash buffer PE (750 pi) was added to each sample. The tubes 
were centrifuged at 12,000 x g for 1 min and the flow-through discarded. The empty 
columns were then centrifuged at 12,000 x g for 1 min, and the columns transferred to 
fresh microfuge tubes. H2O (60 pi) was added to each sample in the centre of the 
column and allowed to stand at room temperature for 2 min. The tubes were 
centrifuged at 12,000 x g for 1 min, the spin column discarded, and the recovered 
plasmid solution stored at -20°C.
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2.2.12 Restriction endonuclease digests
Each restriction endonuclease digest contained 0.4 pi of restriction enzyme, 2 pi of 
the appropriate buffer, made up to 20 pi with H2O. The reactions were incubated at 
37°C for 2 h, and the digest was checked by electrophoresis of 2 pi on a 1% (w/v) 
agarose gel.
2.2.13 Sequencing: Beckman 2000XL
Reactions were prepared in 96-well plastic plates. Each reaction contained 2 pi 
DTCS mix, 2 pi DNA and 1 pi primer (1 pM). Reactions were placed in a 
thermocycler. The PCR program used consisted of 30 cycles of 96°C/20 s, 50°C/20 s 
and 60°C/4 min. After thermocycling, the reactions were ethanol-precipitated by 
adding 62 pi ethanol mix to each well, then centrifuged immediately at 4,000 x g for 
30 min at 4°C. The plates were centrifuged briefly upside down, and the reactions 
were washed with 70% (v/v) ethanol by centrifuging at 4,000 x g for 15 min at 4°C. 
The plates were again centrifuged briefly upside down to dispel all ethanol and the 
pellets allowed to dry at room temperature. Sample (formamide-based) loading 
solution (20 pi) was added to each well, followed by a mineral oil overlay (500 pi), 
before the plate was loaded into the Beckman sequencer.
2.2.14 Sequencing: ABI 377
Reactions were performed in 96-well plastic plates. Each reaction contained:
10 x buffer 1 pi
BigDyes 2 pi
DNA 4 pi




The reactions were placed in a thermocycler. The PCR program consisted of a 
denaturation step of 94°C/2 min, then 30 cycles of 94°C/10 s, 50°C/5 s and 60°C/4 
min. After thermocycling, the reactions were ethanol-precipitated by adding 62 pi 
ethanol mix to each well, then immediately centrifuged at 4,000 x g for 30 min at 4°C. 
The plates were centrifuged briefly upside down, and the reactions were washed with 
70% (v/v) ethanol by centrifugation at 4,000 x g for 15 min at 4°C. The plates were 
again centrifuged briefly upside down to dispel all ethanol, and the pellets allowed to 
dry at room temperature.
Polyacrylamide gels were made using 50 ml acrylamide, 300 pi APS and 30 pi 
Temed, and allowed to set with a 96-well comb. The gels were pre-electrophoresed 
for 1 h before sample loading, using 1 x TBE as a buffer. A 3:1 mixture of 
formamide and blue dextran was made, and 3 pi added to each reaction. The plates 
were heated on a thermocycler at 96°C for 5 min, and then the samples were loaded 
into the wells and the gels electrophoresed for 7 h at 4800 V.
2.2.15 Cell culture
Monolayers o f human foetal foreskin fibroblast (HFFF-2) cells were grown in plastic 
flasks in a solution of Dulbecco’s modified eagle’s medium (DMEM) and 10% (v/v) 
foetal calf serum (FCS). Cells were grown at 37°C in a humidified atmosphere of 
95% (v/v) air and 5% (v/v) CO2 . Cells were harvested from roller bottles by pouring 
off the medium, washing the monolayer twice with 20 ml versene, then washing with 
20 ml trypsin/versene to detach the cells. The cells were then resuspended in fresh
n
medium and aliquots of approximately 10 cells were seeded into roller bottles 
containing 100 ml of medium. Aliquots of cells were also prepared for storage by 
harvesting, pelleting at 1000 x g and resuspending in storage medium. These aliquots 
were frozen to -70°C overnight then stored in liquid nitrogen. On recovery, the 





Virus stocks were prepared from HFFF-2 cells grown in roller bottles containing 100 
ml medium until 90% confluent. The medium was replaced with 30 ml fresh medium 
containing approximately 0.01 p.f.u./cell HCMV strain AD 169. The roller bottles 
were returned to 37°C, and the infected cells incubated until maximal CPE was 
observed (usually 10-15 days p.i.). The medium containing infected cells was 
decanted and cells pelleted by centrifugation for 15 min at 1000 x g at 4°C. The 
supematent was collected and stored at -70°C, and virus stocks were then titrated.
2.2.17 Titrations
Plaque assay on HFFF-2 cells was used to determine viral titres. HCMV stocks were 
serially diluted ten-fold using 900 pi of 1% PBS(A) in foetal calf serum. Tissue 
culture dishes containing HFFF-2 monolayers were infected with 100 pi of each virus 
dilution. The monolayers were allowed to adsorb virus for 1 h at 37°C, with rocking 
every 15 min. The inocula were removed and the cells overlaid with 2 ml per dish of 
cell overlay. The monolayers were incubated at 37°C for a few days until the plaques 
could be seen easily. The medium was removed, 2 ml fixing solution was added, and 
then approximately 1 ml Giemsa stain was applied to each dish. After 2 h, the stain 
was poured off, and the tissue culture dishes were washed and allowed to dry. The 
plaques were then counted under a light microscope.
2.2.18 Preparing RNA
All infections were carried out in 80cm tissue culture flasks with HFFF-2 cells at 
approximately 95% confluency. HCMV strain AD 169 was used for all infections.
Preparing M I RNA
The medium was replaced with fresh medium, and the flask was incubated at 37°C for 
1 h. The medium was then replaced with 10 ml of fresh medium and incubated at
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37°C. After 96 h, the medium was removed and the cells washed three times, all the 
medium was removed, and the flask was stored at -70°C.
Preparing IE RNA
The medium was replaced with fresh medium containing 200 pg/ml cycloheximide, 
and the flask was incubated at 37°C for 1 h. The medium was then removed and 
high-titre virus (approximately 5 p.f.u./cell) containing 200 pg/ml cycloheximide was 
added. The flask was incubated at 37°C for 1 h with gentle shaking every 15 min. 
The cells were then washed three times with medium containing 200 pg/ml 
cycloheximide, left and incubated in 10 ml of this medium at 37°C. After 24 h, the 
medium was removed and the cells were washed three times with medium containing 
200 pg/ml cycloheximide. All the medium was removed, and the flask was stored at - 
70°C.
Preparing E  RNA
The medium was replaced with fresh medium containing 300 pg/ml phosphonoacetic 
acid (PAA), and the flask was incubated at 37°C for 1 h. The medium was then 
removed and high-titre virus (approximately 5 p.f.u./cell) was added. The flask was 
incubated at 37°C for 1 h with gentle shaking every 15 min. The cells were then 
washed three times with medium containing 300 pg/ml PAA, and incubated in 10 ml 
of this medium at 37°C. After 24 h, the medium was removed and the cells were 
washed three times with medium containing 300 pg/ml PAA. All the medium was 
removed, and the flask was stored at -70°C.
Preparing L RNA
The medium was replaced with fresh medium, and the flask was incubated at 37°C for 
1 h. The medium was then removed and high-titre virus (approximately 5 p.f.u./cell) 
was added. The flask was incubated at 37°C for 1 h with gentle shaking every 15 
min. The cells were then washed three times with medium, and incubated in 10 ml of 
this medium at 37°C. After 24 h, the medium was removed and the cells were 




2.2.19 Extracting total cellular RNA
Infected cells were lysed in the flasks by adding 1.2 ml of TRIZOL and mixing with a 
pipette. The solutions were transferred to 1.5 ml microfuge tubes, and 200 pi of 
phenol/chloroform was added. The tubes were shaken, left at room temperature for 3 
min, and centrifuged at 12,000 x g for 15 min at 4°C. The upper phase containing the 
RNA was transferred to a fresh tube, a half-volume of propan-2-ol added, and the 
sample was left at room temperature for 10 min.
The samples were then centrifuged at 12,000 x g for 10 min at 4°C. The supernatant 
was removed, and 100 pi o f 75% ethanol was added to the RNA pellets. The samples 
were centrifuged again at 12,000 x g for 10 min at 4°C, the supernatant removed, and 
the pellets dried at room temperature. When dry, the samples were resuspended in 20 
pi TE, incubated at 55°C for 10 min, and stored at -70°C.
2.2.20 Extracting po!yA+ mRNA
For each RNA sample (IE, E, L and MI), 1 ml stock buffer and 20 pi Protein/RNase 
degrader was prepared and incubated at 45°C. The infected 80 cm flasks were 
defrosted in the presence of this solution and the cells were collected using a cell 
scraper and passed through a 19 gauge needle using a 2 ml syringe. The samples 
were incubated at 45°C for 20 min, and centrifuged at 4,000 x g for 5 min. The 
supernatant was transferred to a fresh microfuge tube, and 63 pi 5M NaCl was added 
to each. The DNA was sheared by passing the sample through a 19 gauge needle 
three or four times. The cell lysate was then transferred to a tube of oligo(dT) 
cellulose, and after 2 min was rotated for 20 min at room temperature to allow RNA 
to bind to the oligo(dT). The samples were centrifuged at 4,000 x g for 5 min, and the 
supernatants were removed carefully. At this point, the unbound RNA in the 
supernatant could be recovered by ethanol precipitation.
The oligo(dT) cellulose was resuspended in 1.3 ml binding buffer, centrifuged at
4,000 x g for 5 min, and the supernatant removed carefully. This washing step was
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repeated twice more. The oligo(dT) cellulose was resuspended in 300 pi washing 
buffer, and transferred to a spin column. The tubes were centrifuged at 4,000 x g for 
5 min and the flow-through discarded. This washing step was repeated thrice more. 
The samples were gently resuspended in 200 pi low salt wash buffer, centrifuged at
4.000 x g for 5 min and the flow-through discarded. This washing step was repeated 
once more.
The spin columns were transferred to fresh microfuge tubes. Elution buffer (100 pi) 
was used to resuspend the oligo(dT) cellulose, and the samples were centrifuged at
4.000 x g for 5 min and the flow-through retained. This elution step was repeated 
once more. 2M NaAc (30 pi), 2 mg/ml glycogen carrier (10 pi) and 100% (v/v) 
ethanol (600 pi) were added to each sample, which were frozen in dry ice until solid. 
The samples were then thawed and centrifuged at 13,000 x g for 15 min at 4°C. The 
supernatant was removed, the tubes centrifuged again briefly, and the last traces of 
supernatant removed. The samples were allowed to dry for 10 min, resuspended in 15 
pi of elution buffer and stored at -70°C.
2.2.21 Northern blot
A formaldehyde-agarose gel was made by mixing 1 g agarose and 85 ml H2O, 
boiling, then cooling to 55°C. A preheated mixture o f 5.8 ml formaldehyde and 10ml 
10 x MOPS (at 55°C) was added to the agarose, mixed well and set in a gel former 




10 X MOPS 1.5 pi
RNA 2 pi
Gels also included two lanes containing a marker RNA, containing 5 pi o f 0.24-9.5 kb 
RNA ladder (Invitrogen) and H2O adjusted to the required volume. Samples were
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incubated at 55°C for 15 min (the RNA marker at 65°C) and cooled on ice for 5 min. 
Sterile 10 x loading buffer (3 pi) was added. Samples were mixed and loaded onto 
the formaldehyde-agarose gel which had been electrophoresed for 15 min at 75 V. 
The gel was electrophoresed at 75 V for 4 h and stained with 0.05 pg/ml ethidium 
bromide for 45 min. The RNA ladder was visualised under short wave UV light with 
a ruler placed along one side of the gel. A picture was taken using the GelDoc system 
(BioRad) and used later for calculating transcript sizes.
RNA was transferred from the gel to a nylon membrane by capillary blotting. The gel 
was shaken gently at room temperature in H2O (twice for 5 min) then 10 x SSC (twice 
for 15 min). Nylon membrane was cut to size and pre-soaked in H2O (5 min) and 
then 20 x SSC (20 min). 3MM paper was also cut to size and pre-soaked in 2 x SSC 
for 20 min. The blot was set up by sitting the gel on top of a wick in a reservoir, then 
adding the nylon membrane, three sheets o f pre-soaked 3 MM paper, two sheets of dry 
3MM paper and a stack of absorbant towels. A weight was placed on top of the 
towels, and the reservoir filled with 20 x SSC. After overnight transfer of the RNA, 
the membrane was rinsed gently in 10 x SSC, dried for 15 min, and crosslinked using 
a Stratagene UV Crosslinker (12,000 Jem'2).
2.2.22 DNA probes
DNA was radiolabelled using a Qbiogene NonaPrimer kit. A mixture of plasmid 
DNA (4 pi) and H2O (3 pi) was denatured at 95 °C for 10 min, chilled on ice for 5 
min, and added to a 20 pi annealing reaction:
DNA/H2O mix 7 pi
L2 NonaPrimer mix 4 pi
L3 dATP 1 pi
L6 dTTP 1 pi
L5 dGTP 1 pi
a 32P -dCTP 5 pi
L7 Klenow enzyme 1 pi
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The reaction was incubated at 37°C for 30 min. Adsorb solution PI (60 pi) and 
DNAprep resin P2 (2 pi) were added to the sample, mixed, centrifuged briefly, and 
the supernatant discarded. The sample was resuspended in 100 pi wash buffer P3, 
centrifuged briefly, the supernatant discarded, and the washing step repeated. Eluting 
solution P4 (100 pi) was added, and the sample vortexed then incubated at 65°C for 
five min. The supernatant containing the purified DNA probe was recovered and 
added directly to the hybridisation mix at 68°C for overnight hybridisation.
2.2.23 RNA Probes
The Lig’n Scribe reaction (Ambion) is a two-step process, as illustrated in Figure 2.2. 
The first 5 pi reaction step ligates a phage T7 or SP6 promoter to a PCR fragment:
10 x ligation buffer 1 pi
T7/SP6 adaptor 1 pi
PCR product 1 pi
T4 DNA ligase 1 pi
h 2o 1 pi
The reaction was incubated at room temperature for 15 min. The second step is a 
PCR amplification that uses the ligation reaction, a gene-specific primer (one of the 
original PCR primers) and a T7/SP6 primer (supplied in the kit). The 50 pi reactions 
were prepared:
10 x PCR buffer 5 pi
dNTPs (10 mM) 1 pi
GSP (10 pM) 1 pi
Adapter primer 1 pi
T7/SP6 ligation reaction 1 pi







Lig’nScribe reaction: step 1
SP6 or T7 promoter adaptor 






A gene-specific primer (GSP) is chosen that will generate either a 
sense or antisense transcription template. A Lign’Scribe adaptor











Figure 2.2. L ign’Scribe reaction.
The LigrT Scribe reaction involves a ligation step and a PCR step to prepare a 
transcription template that can be radiolabelled.
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Purified Lig’n Scribe products were subsequently labelled radioactively in 20 pi 
reactions using the MaxiScript kit (Ambion):
10 x transcription buffer 2 pi
ATP (lOmM) 1 pi
CTP (lOmM) 1 pi
GTP (lOmM) 1 pi
Lig’n Scribe DNA product 1 pi
ct32P-dUTP 5 pi
T7/SP6 RNA polymerase 2 pi
h 2o 7 pi
The samples were incubated at 37°C for 20 min, 1 pi of DNase I was added, and 
incubation was continued at 37°C for a further 15 min. To separate the radiolabelled 
RNA probe from unincorporated nucleotides, a mixture of 3 M sodium acetate (5 pi), 
H2O (30 pi) and 100% (v/v) ethanol (150 pi) was added, and the sample was 
incubated at -20°C for 30 min. The sample was centrifuged at 12,000 x g for 15 min 
at 4°C, the supematent discarded and the pellet washed with (v/v) 70% ethanol. The 
pellets were allowed to dry, then were resuspended in H2O and added directly to the 
hybridisation bottles.
2.2.24 Hybridisation
Membranes containing RNA were prehybridised in 15 ml of hybridisation buffer at 
68°C in a Hybaid minioven. After 1 h, radioactive probe was added and the 
hybridisation continued overnight. The temperature was increased to 71°C when 
greater stringency was necessary. Hybridised membranes were washed once at room 
temperature with 2 x SSC/0.1% SDS for 20 min, then twice at 68°C with 0.1 x 
SSC/0.1% SDS for 20 min. The membranes were placed in a hybridisation bag, and 





RT-PCR was performed in 50 pi reactions using an Invitrogen kit:
2 x reaction mix 25 pi
Template RNA 2 pi
Sense primer 1 pi
Antisense primer 1 pi
RT/Taq Mix 1 pi
h 2o 20 pi
Samples were incubated at 55°C for 30 min (cDNA synthesis), then denatured at 
94°C for 2 min. PCR amplification was 40 cycles of 94°C for 15s, 62°C for 30s, 
68°C for 1 min/kbp, and a final extension step of 68°C for 5 min.
2.2.26 SMARTRACE
5’-and 3’-RACE reactions were carried out using the BD Clontech SMARTRACE 
kit. Two separate reactions for 5’-and 3’-RACE were prepared using polyA+ mRNA 
template and primers supplied in the kit:
fo r  5 ’-RACE fo r S'-RACE
RNA sample 1 pi RNA sample 1 pi
5’-CDS primer 1 pi 3’-CDS primer 1 pi
h 2o 2 pi H20 2 pi
SMART II A oligo 1 pi
The reactions were incubated at 70°C for 2 min, placed on ice for 2 min and 
centrifuged briefly. The following reagents were then added to each reaction tube:
5 x First-Strand buffer 2 pi
DTT (20 mM) 1 pi
dNTPs (10 mM each) 1 pi
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Figure 2.3. Mechanism of 5’-SMARTRACE reaction.
The 5’-CDS primer and SMART II oligonucleotide are used to synthesise the 5‘- 
RACE-ready cDNA. When reverse transcriptase (RT) reaches the end of the mRNA 
template, several dC residues are added. The SMART II oligonucleotide anneals to 
the tail of the cDNA and acts as an extended template for RT. The GeneRacer and 
5 'RACE methods used slightly different methods of polyA" mRNA modification and 
purification, as detailed in sections 2.2.27 and 2.2.28. For each PCR reaction, a kit- 




5 _ r | polyA -  3 ’ 
-T T T T T 26-
First-strand synthesis




|p o lyA  -  3 ’ 
IT T T T
SMART II oligo
IpolyA -  3 ’
kit p rim er
dsDNA 3’-RACE product
Figure 2.4. Mechanism of 3’-SMARTRACE reaction.
The 3’-CDS primer and SMART II oligonucleotide are used to synthesise the 3’- 
RACE-ready cDNA. The GeneRacer kit used a slightly different method to generate 
3’-RACE-ready cDNA, as detailed in section 2.2.27. For each PCR reaction, a kit- 
supplied primer and gene-specific primer (GSP) were used.
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The reactions were incubated at 42°C for 90 min in a thermocycler. First-strand 
reaction products were diluted in 200 pi Tricine-EDTA buffer and heated at 72°C for 
7 min. RACE-ready cDNA was used immediately for PCR or stored at -20°C.
The control template supplied in the kit was human placental total RNA. A standard 
SMARTRACE PCR program consisted of a 94°C/2 min denaturation step, 5 cycles of 
94°C/30 s, 72°C/3 min, 5 cycles of 94°C/30 s, 70°C/30s, 72°C/3 min, then 20 cycles of 
94°C/30 s, 68°C/30 s, 72°C/3 min. 5’- and 3’-RACE-PCR reactions were prepared in 
50 pi reactions:
UPM (lOx) 5 pi
GSP 1 pi
5’- or 3’-cDNA template 2.5 pi
10 x buffer 5 pi
dNTPs (10 mM each) 1 pi
Advantage II polymerase 1 pi
H20 34.5 pi
2.2.27 GeneRacer
The Invitrogen GeneRacer kit was used to make 5’- and 3’-RACE-ready cDNA from 
polyA+ mRNA. To dephosphorylate mRNA, 10 pi reactions were prepared:
RNA 1 pi
10 x CIP buffer 1 pi
RNaseOut 1 pi
CIP 1 pi
H20  6 pi
The samples were mixed, vortexed and centrifuged, and incubated at 50°C for 1 h. 
The GeneRacer ethanol precipitation step was then carried out. The samples were 
centrifuged, placed on ice, and 90 pi H20  and 100 pi phenol:chloroform were added. 
The samples were vortexed for 30 s, centrifuged for 13,000 x g for 5 min, and the
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upper layer was transferred to a fresh tube. The following 232 pi mixture was added 
to each sample;
10 mg/ml mussel glycogen 2 pi 
3 M sodium acetate pH 5.2 10 pi
95% (v/v) ethanol 220 pi
The samples were vortexed and freeze-dried for 10 min. The RNA was pelleted by 
centrifugation for 13,000 x g for 20 min at 4°C. The supernatant was carefully 
removed, 500 pi of (v/v) 70% ethanol was added, and the pellet centrifuged at 13,000 
x g for 2 min. The supernatant was removed carefully, the pellet was allowed to dry 
for 5 min and resuspended in 7 pi H2O. To remove the cap structure, the following 10
pi reaction was performed;
Dephosphorylated RNA 7 pi
lOx TAP buffer 1 pi
RNase Out 1 pi
TAP 1 pi
The samples were mixed, vortexed, centrifuged, and incubated at 37°C for 1 h. They 
were then subjected to the GeneRacer ethanol precipitation step described previously. 
The 7 pi of decapped mRNA was added to a vial o f GeneRacer RNA Oligo, mixed 
and centrifuged. To ligate the GeneRacer RNA Oligo to the decapped mRNA, the 
mixture was incubated at 65°C for 5 min to relax the secondary RNA structure, then 
placed on ice for 2 min. The following reagents were added, in order:
10 x Ligase buffer 1 pi
10 mM ATP 1 pi
RNaseOut 1 pi
T4 RNA ligase 1 pi
The samples were mixed, vortexed, centrifuged, and incubated at 37°C for 1 h. They 
were then subjected to the same ethanol precipitation step as described previously. 
The final resuspension in this step, however, was in 10 pi H2O. To reverse transcribe 
the mRNA, GSP (1 pi) and dNTAP mix (1 pi) were added to the reaction mix,
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incubated at 65°C for 5 min, on ice for 2 min, and centrifuged. The following
reagents were added, in order:
5 x RT buffer 4 jul
Cloned AMV RT 1 pi
H20  2 pi
RNaseOut 1 pi
The 20 jllI reaction was mixed thoroughly and incubated at 45°C for 1 h. A 15 min 
incubation at 85°C followed in order to inactivate the reverse transcriptase. The 
RACE-ready cDNA was then used immediately for PCR or stored at -20°C. The 
control template supplied in the kit was HeLa cell total RNA. A standard GeneRacer 
PCR program consisted of a 94°C/2 min denaturation step, 5 cycles o f 94°C/30 s, 
72°C/2 min, 5 cycles of 94°C/30 s, 70°C/2 min, 20 cycles of 94°C/30 s, 65°C/30 s, 
68°C/2 min, then a final extension step of 68°C/10 min. 5’- and 3’-RACE-PCR 
reactions were prepared in 50 pi reactions:
5’-or 3’-RACE primer 3 pi
GSP 1 pi
cDNA template 1 pi
10 x buffer 5 pi
dNTPs (10 mM each) 1 pi
Taq polymerase 1 pi
M gS04 2 pi
H20 36 pi
2.2.28 5’-RACE
The Invitrogen 5’-RACE kit was used to make 5’-RACE-ready cDNA from polyA+ 
mRNA. Wash buffer (1 ml wash buffer concentrate, 18 ml H20  and 21 ml 100% 




A mixture of template mRNA (1 pi), gene-specific primer (1 pi) and H2O (13.5 pi) 
was incubated at 70°C for 10 min and then on ice for 1 minute. The following
reagents were added, in order:
10 x PCR buffer 2.5 pi
25 mM MgC12 2.5 pi
lOm M dNTPs 1 pi
0 .1M D T T  2.5 pi
The reaction was incubated at 42°C for 1 min, and 1 pi Superscript II RT was added 
and incubation was continued at 42°C for a further 50 min. The reaction was 
terminated by incubation at 70°C for 15 min, and then 1 pi of RNase was added. The 
reaction was incubated at 37°C for a further 30 min and then placed on ice.
Binding solution (6 M Nal) was brought to room temperature, and 120 pi added to 
each reaction. The cDNA/Nal solution was transferred to a SNAP column and 
centrifuged at 13,000 x g for 20 s. The flow-through was retained for use as a control 
reaction. The SNAP column was washed with 0.4 ml cold Wash Buffer, centrifuged 
at 13,000 x g for 20 s, and the flow-through discarded. This step was repeated three 
more times. The SNAP column was then washed with 0.4 ml cold 70% (v/v) ethanol, 
centrifuged at 13,000 x g for 20 s, and the flow-through discarded. This step was 
repeated, then the empty tube centrifuged for 1 min. The cartridge was transferred to 
a recovery tube, 50 pi of H2O (preheated to 65 °C) was added, and the tube 
centrifuged at 13,000 x g for 20 s to elute the cDNA. The following reagents were 
added:
H 20  6.5 pi
5x tailing buffer 5 pi
2 m M  dCTP 2.5 pi
The cDNA sample was heated for 3 m in at 94°C, placed on ice and then 
centrifuged. TdT (1 pi) was added and the cDNA incubated at 37°C for 10 min. The 
TdT was heat inactivated by incubation at 65°C for 10 min. The RACE-ready cDNA 
was used immediately for PCR or stored at -20°C.
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Template RNA supplied in the kit was used as a control. A standard 5’-RACE PCR 
program consisted of a 94°C/2 min denaturation step, 35 cycles of 94°C/1 min, 
63°C/30 s, 72°C/2 min, then a final extension step of 72°C/10 min. 5’-RACE-PCR
was prepared on ice in 50 pi reactions:
Abridged anchor primer 2 pi
GSP 2 pi
dC-tailed cDNA 5 pi
1 Ox PCR buffer 5 pi
dNTPs (10 mM each) 1 pi
Taq polymerase 1 pi
25 mM MgC12 3 pi
H20  31 pi
2.2.28 Computer analysis
The sequence database was compiled from electropherograms using PreGap4 and 
Gap4 (Staden et al., 2000) and Phred (Ewing and Green, 1998; Ewing et al., 1998). 
Sequences were analysed using the GCG suite of programs by Accelrys.
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CHAPTER 3: REGION X
3.1 Protein-coding genes
A comparative analysis of the HCMV and CCMV genome (Davison et al., 2003) 
significantly altered the proposed gene complement of HCMV from that described in 
the original analysis of strain AD 169 (Chee et al., 1990). The study proposed ten 
novel genes, modified the interpretations of 24 genes and discounted 51 previously 
proposed ORFs because they had no counterparts in CCMV and lacked any other 
convincing evidence for expression. Some o f the discounted ORFs were located 
together in the genome, and their omission left ‘empty’ regions in the genome. One 
of these regions is located between ORFs UL105 and UL112, which are accepted as 
protein-coding genes (Figure 3.1). This is here termed region X.
Prior to and since the original analysis of the AD 169 genome (Chee et al., 1990), 
functions have been assigned to many HCMV genes. However, few have been 
mapped within region X. The original analysis of AD 169 predicted six ORFs in 
region X: UL106 to UL111 (Figure 3.1). There is no evidence for expression of 
proteins from these ORFs. However, a new protein-coding gene was identified in 
region X. A viral interleukin-10 homologue, vIL-10, is encoded by UL111A 
(Kotenko et al., 2000). UL111A retains the name and start site from the original 
analysis, but was subsequently shown to be spliced. Three further novel, protein- 
coding ORFs have been predicted in region X. A recent study of the coding content 
of the HCMV genome analysed six BAC-cloned strains for sequence comparisons, 
four of which were low-passage isolates (Murphy et al., 2003b). From a total o f 252 
ORFs that were conserved in all four clinical isolates, ORFs were subsequently 
discounted if they failed to meet specific criteria. This process is discussed in Section 
1.18. From the list of 29 newly recognised ORFs with the potential for coding 
proteins, three are in region X: C-ORF16, C-ORF17 and C-ORF18 (Figure 3.1).
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UL105 UL106 UL108 UL109 UL110 UL111 UL111A UL112
UL107 (viL-10)
Figure 3.1. M ap of the characterised genes and predicted genes in region X.
The scale at the top shows the genomic location (kbp) in the AD 169 genome. Dark 
green shows parts of ORFs of known functions. Introns in UL111A are shown as 
narrow black bars. Pink shows novel ORFs predicted by Murphy et al. (2003b). Red 
shows ORFs predicted by Chee et al. (1990) that have no known function and have 
been discounted because they have no counterparts in CCMV (Davison et al., 2003). 
This leaves a region of 4.9 kbp between UL105 and UL111A that appears to contain 
no protein-coding genes. The 3’-end of each ORF has a point to show its orientation, 
and the M shows the first in-frame ATG initiation codon in each red or pink ORF. 
Dark green ORFs start with ATG initiation codons. The blue line underneath the 
ORFs shows the 5 kb transcript and its orientation as described by Plachter et al. 
(1988).
The only confirmed gene in region X, the vIL-10 gene (UL111A), is composed of 
three exons and two introns (Kotenko et al., 2000). The splice junctions correspond 
to those between exons 1 and 2 and exons 3 and 4 in the human IL-10 gene, which is 
composed of five exons and four introns. In contrast, the first herpesvirus IL-10 
homologue that was identified, in EBV, contains no introns (Moore et al., 1990; Hsu 
et al., 1990). IL-10 gene homologues have also been identified in the corresponding 
region of the genomes of other primate CMVs (RhCMV, BCMV and SCMV), but not 
in CCMV (Lockridge et al., 2000; Davison et al., 2003a). vIL-10 can bind to the 
human IL-10 receptor and compete with human IL-10 for binding sites, despite the 
fact that there is only 27% amino-acid sequence identity between the two proteins 
(Kotenko et al., 2000). IL-10 is a potent suppressor of aspects of the cellular immune
79
Region X
response, and the presence of a virus-encoded homologue helps HCMV to circumvent 
detection and destruction by the host immune system. It has recently been shown that 
vIL-10 suppresses production of CXCL10 (a T-cell chemoattractant) during viral 
replication (Cheeran et al., 2003; Hu et al., 2002). Other studies have shown that vIL- 
10 is able to suppress lymphocyte proliferation, proinflammatory cytokine production 
and cell-surface expression of major histocompatability complex molecules (Spencer 
et al., 2002; Lockridge et al., 2000). Using an experimental model of latency in 
which human hematopoietic cells were latently infected with HCMV, a vIL-10 
transcript was detected that differed from that reported during productive infection. In 
this transcript the second intron was not excised from the mRNA (Jenkins et al., 
2004). The authors suggested that latent CMV might encode a functional, truncated 
vIL-10 that differs from that expressed during lytic infection.
At the left end of region X, UL105 specifies a 3.4 kb RNA, which was detected at 24 
h p.i. but not in the presence of cycloheximide (Smith et al., 1996). UL105 encodes 
the helicase activity of the HCMV helicase-primase complex, which associates with 
two other proteins encoded by UL70 (primase) and UL102 (primase-associated 
factor) (Smith et al., 1996). At the right end of region X, UL112 is a spliced gene 
which incorporates UL112 and UL113, originally predicted to be two separate 
overlapping ORFs (Chee et al., 1990; Rodems et al., 1988). Alternative splicing of 
UL112 specifies different 2.2 kb RNAs which encode four phosphorylated proteins 
expressed at early times p.i.: pp34, pp43, pp50 and pp84 (Staprans et al., 1988; 
Wright et al., 1988). The UL112 proteins appear to be required for efficient viral 
DNA replication, although they may not be essential, and they act as transactivators of 
the UL54 (DNA polymerase) promoter.
O f the other ORFs originally defined in region X, only UL106 and UL109 commence 
with ATG initiation codons. The other ORFs are preceded by termination codons, 
with UL107, UL108 and UL110 containing in-frame ATG codons internally and 
UL111 lacking such codons entirely (Figure 3.1). The three novel C-ORFs all 
commence with ATG initiation codons.
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3.2 The 5 kb RNA
A number of studies in the early 1980s identified and mapped the major HCMV 
transcripts. One of these was a 5 kb transcript mapping within region X (Figure 3.1). 
This transcript was first described in strains Towne (Wathen & Stinski, 1982) and 
Davis (DeMarchi et al., 1983), and subsequently in strain AD 169 (Nelson et al., 1984; 
Jahn et al., 1984). Plachter et al. (1988) mapped the 5 kb RNA, confirming its 
presence at high levels at IE and L times p.i., and at low levels at E times p.i. (in total 
RNA). The transcript was also found in equal abundance in cytoplasmic and nuclear 
RNA fractions, and evenly distributed between polyadenylated and 
nonpolyadenylated fractions in total infected cell RNA. To determine the size of the 
RNA, gels of a reduced agarose concentration were electrophoresed under a low 
voltage gradient. This led to the identification of two bands of approximately 5.0 and
4.6 kb. Northern blot, nuclease protection and primer extension experiments were 
used to map the 5’- and 3’-ends of the 5 kb transcript. The 5’-end was mapped to a G 
residue at nucleotide position 160,570 in A D I69, and the 3’-end to two sites 
downstream from a consensus polyadenylation signal at 155,759: A residues at 
155,750 and 155,737. SI analysis of a plasmid clone in the middle of the 5 kb RNA 
had previously indicated that splicing did not occur (Nelson et al., 1984), and no 
further indication of splicing at the ends o f the RNA was found by Plachter et al. 
(1988).
The 5 kb RNA was also identified as one of a number of viral RNAs specifically 
incorporated into virions (Bresnahan et al., 2000; Greijer et al., 2000). The RNAs 
were potentially delivered to the host cell on infection, suggesting that they could 
function immediately after virus entry, independent of transcription from the viral 
genome. However, a subsequent study found that RNAs were packaged into HCMV 
virions in proportion to their cellular concentration, independent of a cA-acting 
packaging element, and that viral and cellular RNAs were non-specifically 
incorporated into HCMV through interactions with several virion proteins (Terhune et 
al., 2004). The functional significance of virion-associated RNAs is therefore 
questionable. Northern blot analysis of the 5 kb RNA detected the transcript in 





UL105, UL111A and UL112 are well characterised protein-coding genes that would 
be expected to be conserved between HCMV strains. Other ORFs in region X, 
UL106-UL111 (Figure 3.1), are not considered to be protein-coding because they lack 
counterparts in CCMV. However, if  these, or any other previously unrecognised 
ORFs in the region, are protein-coding, they would also be expected to be conserved 
between HCMV strains. Sequence comparisons of multiple HCMV strains could be 
used to identify which of ORFs UL106-UL111 are conserved and which are disrupted 
by insertions or deletions. Sequence comparisons could also be used to investigate 
the 5 kb RNA (Figure 3.1).
Region X was sequenced in seven HCMV strains: high passage strain AD 169, low 
passage strains Toledo, Merlin, 3157 and 6397, and strains W and 3301 obtained 
directly from human tissue (Section 2.1.1). Initially, a single PCR product, 
originating from within UL105 and terminating in UL112, was amplified for each 
strain. However, very few plasmid clones were generated. Consequently, three 
overlapping PCR products were amplified (Figure 3.2) and cloned into plasmids, and 
at least four plasmids were sequenced for each product. Sequencing of multiple 
clones was performed to rule out PCR errors. Consensus sequences were compiled 
from the sequence data and PCR errors were identified where a single clone was 
different from the others at a specific position. When PCR fragments were not 
obtained from certain strains, alternative primers were used. The third fragment of 
strain 3301 was amplified using primers X30 and X I8, and the three fragments of 
strain W were amplified using primers X2 and X7, X6 and X I3, and X30 and X I8 
respectively (Appendix). Within the first PCR fragment (Figure 3.2), a 350 bp region 
failed to generate readable sequence. Therefore, PCR products were amplified for 
each strain using primers adjacent to this region (X I6 and X32, Appendix). These 
products were cloned and sequenced using dGTP Big Dye. The sequence database 
was compiled from electropherograms using PreGap4 and Gap4 (Staden et al., 2000) 
and Phred (Ewing and Green, 1998; Ewing et al., 1998).
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UL107 (viL-10)
Figure 3.2. PCR amplification of region X for sequence comparisons.
Blue bars show the three overlapping PCR fragments that were amplified using 
primers XI and X7, X6 and X9, and X8 and X5 respectively (Appendix). The grey 
box in the first PCR fragment is a 350 bp region that initially failed to generate 
readable sequence. This region was amplified using primers X I6 and X32 
(Appendix).
Figure 3.3. Sequence comparisons of seven HCMV strains in region X.
Alignments were made using ClustalW and displayed using Pretty. Yellow AD 169 
sequence shows all characterised and predicted ORFs in the region. The start and stop 
codons for each ORF are shown, the arrows indicating their orientation. Green shows 
the first ATG initiation codon for each ORF. Dark blue AD 169 sequence shows 
introns for UL111A. Purple shows insertions/deletions that cause frameshifts in 
comparison to AD 169. Sky blue shows variation in polynucleotide A:T tracts of eight 
or more residues that cause frameshifts in coding frames in comparison to AD 169. 
Grey shows in-frame insertions/deletions. Brown consensus residues show potential 
polyadenylation signals (AATAAA). Sequence for strain W is not complete at the 
ends because different primers were used for PCR amplification. The Figure is 
continued on the following pages.
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ADI 6 9  GTCTATCCCCAAAAAAA. CACACACCGTCAGGGAACACATCGCCTATAGATAGCGGCACTTTACATAAAACCACCGTACCTGCAjrCACGGTGGCTCGATA 
T o l e d o  GTCTATCCCCAAAAAAA. CACACACCGTCAGGGAACACATCGCCTATAGATAGCGGCACTTTACATAAAACCGCCGTACCTGCATCACGGTGGCTCGATA 
W GTCTATCTCCAAAAAAA. CACACACCGTCAGGGAACACATCGCCTATAGATAGCGGCACTTTACATAAAACCACCGTACCTGCATCACGGTGGCTCGATA 
3 1 5 7  GTCTATCCCCAAAAAAA§CACACACCGTCAGGGAACACATCGCCTATAGATAGCGGCACTTCACATAAAACCACCGTACCTGCATCACGGTGGCTCGATA 
3 3 0 1  GTCTATCCCCAAAAAAA. CACACACCGTCAGGGAACACATCGCCTATAGATAGCGGCACTTCACATAAAACCACCGTACCTGCATCACGGTGGCTCGATA
6 3 9 7  g t c t a t c c c c a a a a a a B c a c a c a c c g t c a g g g a a c a c a t c g c c t a t a g a t a g c g g c a c t t c a c a t a a a a c c a c c g t a c c t g c a t c a c g g t g g c t c g a t a  
Me r l i n  g t c t a t c c c c a a a a a a H c a c a c a c c g t c a g g g a a c a c a t c g c c t a t a g a t a g c g g c a c t t c a c a t a a a a c c a c c g t a c c t g c a t c a c g g t g g c t c g a t a  
c o n s e n s u s  g t c t a t c - c c a a a a a a - - c a c a c a c c g t c a g g g a a c a c a t c g c c t a t a g a t a g c g g c a c t t - a c a t a a a a c c - c c g t a c c t g c a t c a c g g t g g c t c g a t a
3 0 1
ADI 69  c a c t g g a a a t t c a a t a a a a a c c a c c g t g t c t c c g t g a c g g t a c t t a t c g g g t c a g c g t . . . 
T o l e d o  c a c t g g a a a t t c a a t a a a a a c c a c c g t g t c t c c g t t a c g g t a c t t a t c g g g t c a g c g t B e i  
w c a c t g g a a a t t c a a t a a a a a c c a c c g t g t c t c c g t g a c g g t a c t t a t c g g g t c a g c g t e t ' I  
3 1 5 7  c a c t g g a a a t t c a a t a a a a a c c a c c g t g t c t c c g t g a c g g t a c t t g c c g g g t c a g c g t e t i  
3 3 0 1  c a c t g g a a a t t c a a t a a a a a c a a c c g t g t c t c c g t g a c g g t a c t t c c c g g g t c a g c g t e t i  
6 3 9 7  c a c t g g a a a t t c a a t a a a a a c c a c c g t g t c t c c g t g a c g g t a c t t a t c g g g t c a g c a t C t i  
M e r l i n  CACTGGAAATTCAATAAAAACCACCGTGTCTCCGTGACGGTACTTATCGGGTCAGCATBQ 






I c t c t t g a g a t t t c t g t t c g t a a a c t t a t c c g t t t c c c c
■CTCTTGAGATTTTTGTTCGTAAACTTATCCGTTTCCCC
I c t c t t g a g a t t t t t g t t c g t a a a c t t a t c c g t t t c c c c
-CT-TTG -GA TTT-TGTTCGTAAACTTATCCGTTTCCC-
4 0 1  5 0 0
ADI 6 9  GGTCCGCGGTGTCTCCTCGCGAGGCTGACAGTCGACGGGTGGTACCTGCAAGAGAA. GAAACCCGGGTGGGAGCGACGCCGTCGCTGGGTATCAACCCCG
T o 1 e d o  GGTCCGCGGTGTCTCCTCGCGAGGCTGACAGTCTACGAGTGGTACCTGCAAGAGAA. GAAACCCGGGTGGGAGCGACGCCGTCGCTGGGTATCAACCCCG 
W GGTCCGCGGTGTCTCCTCGCGAGGCTGACAGTCTACGGGTGGTACCTGCAAGAGAA. GAAACCAGGGTGGGAGCGACGCCGTCGCTGGGTATCAACCCCG 
3 1 5 7  GGTCCGCGGTGTCTCTTCGCGAGGCTGACAGTCTACGAGTGGTATCTACAAGAGAA|GAAACCCGGGTGGGAGCGACGCCGTCGCTGGGTATCAACCCCG
3301  g g t c c g c g g t g t c t c c t c g c g a g g c t g a c a g t c t a c g a g t g g t a t c t a c a a g a g a a J g a a a c c c g g g t g g g a g c g a c g c c g t c g c t g g g t a t c a a c c c c g  
6 3 9 7  g g t c c g c g g t g t c t c c t c g t a a g g c t g a c a g t c t a c g a g t g g t a c c t g c a a g a g a a . g a a a c c c g g g t g g g a g c g a c g c c g t c g c t g g g t a t c a a c c c c g  
M e r l i n  g g t c c g c g g t g t c t c c t c g t a a g g c t g a c a g t c t a c g a g t g g t a c c t g c a a g a g a a . g a a a c c c g g g t g g g a g c g a c g c c g t c g c t g g g t a t c a a c c c c g  
c o n s e n s u s  g g t c c g c g g t g t c t c - t c g — a g g c t g a c a g t c - a c g - g t g g t a - c t - c a a g a g a a - g a a a c c - g g g t g g g a g c g a c g c c g t c g c t g g g t a t c a a c c c c g
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TTTTT . ATAATGAATACGCACTGATCCTATCCGTGACTGCGCGTGTGGCAGAGAGGATGCC TTATAACATGTATTTTGAAAAATTGCCAACAGCTATAAT 
TTTTi.ATAATGAATACGCACTGATCCTATCCGTGACTGCGCGTGTGGCAGAGAGGATGCCTTATAACATGTATTTTGAAAAATTGCCAACAGCTATAAT 
TTTT|.ATAATGAATACGCACTGATCCTATCCGTGACTGCGCGTGTGGCAGAGAGGATGCCTTATTACATGTATTTTGAAAAATTGCCAACAGCTATAAT 





8 0 1  9 0 0
ADI 6 9  TTCTCTCATGTAGCAGAATAGAGACCTTTTGTCGTCTTTTTGTTTGTCATTACTTGTTTTCCAGGGAATTAGAGAGAGGGAACCGCGCCTCCGGCGGCGG
T o l e d o  TTCTCTCATGTAGCAGAATAGAGACCTTTTGTCGTCTTTTTGTTTGTCATTACTTGTTTTCCAGGGAATTAGAGAGAGGGAACCGCGCCTCCGGCGGCGG 
W TTCTCTCATGTAGCAGAATAGAGACCTTTTGTCGTCTTTTTGTTTGTCATTACTTGTTTTCCAGGGAATTAGA^BGGGAACCGCGCCTCCGGCGGCGG 
3 1 5 7  TTCTCTCATGTAGCAGAATAGAGACCTTTTGTCGTCTTTTTGTTTGTCATTACTTGTTTTCCAGGGAATTAGAGAGAGGGAACCGCGCCTCCGGCGGCGG 
3 3 0 1  TTCTCTCATGTAGCAGAATAGAGACCTTTTGTCGTCTTTTTGTTTGTCATTACTTGTTTTCCAGGGAATTAGAGAGAGGGAACCGCGCCTCCGGCGGCGG 
6 3 9 7  TTCTCTCATGTAGCAGAATAGAGACCTTTTGTCGTCTTTTTGTTTGTCATTACTTGTTTTCCAGGGAATTAGAGAGAGGGAACCGCGCCTCCGGCGGCGG 
M e r l i n  TTCTCTCATGTAGCAGAATAGAGACCTTTTGTCGTCTTTTTGTTTGTCATTACTTGTTTTCCAGGGAATTAGAGAGAGGGAACCGCGCCTCCGGCGGCGG 
CONSENSUS TTCTCTCATGTAGCAGAATAGAGACCTTTTGTCGTCTTTTTGTTTGTCATTACTTGTTTTCCAGGGAATTAGA GGGAACCGCGCCTCCGGCGGCGG
9 0 1  1 0 0 0
ADI 6 9  TGCCCGCGGACCCCGGCCCCTTCTCGCGTGCGCGGTGTGACTGGTTGAGCGAATGAGCAGCTAGGCTTGGTGGTGCTCCGCGTGCGGGGGAGAAGACGAT
T o l e d o  TGCCCGCGGACCCCGGCCCCTTCTCGCGTGCGCGGTGTGACTGGTTGAGCGAATGAGCAGCTAGGCTTGGTGGTGCTCCGCGTGCGGGGGAGAAGACGAT 
W TGCCCGCGGACCCCGGCCCCTTCTCGCGTGCGCGGTGTGACTGGTTGAGC'GAATGAGCAGCTAGGCTTGGTGGTGCTCCGCGTGCGGGGGAGAAGACGAT 
3 1 5 7  TGCCCGCGGACCCCGGCCCCTTCTCGCGTGCGCGGTGTGACTAGTTGAGCGAATGAGCAGCTAGGCTTGGTGGTGCTCCGCGTGCGGGGGAGAAGACGAT 
3 3 0 1  TGCCCGCGGACCCCGGCCCCTTCTCGCGTGCGCGGTGTGACTGGTTGAGCGAATGAGCAGCTAGGCTTGGTGGTGCTCCGCGTGCGGGGGAGAAGACGAT 
6 3 9 7  TGCCCGCGGACCCCGGCCCCTTCTCGCGTGCGCGGTGTGACTGGTTGAGCGAATGAGCAGCTAGGCTTGGTGGTGCTCCGCGTGCGGGGGAGAAGACGAT 
M e r l i n  TGCCCGCGGACCCCGGCCCCTTCTCGCGTGCGCGGTGTGACTGGTTGAGCGAATGAGCAGCTAGGCTTGGTGGTGCTCCGCGTGCGGGGGAGAAGACGAT 
CONSENSUS TGCCCGCGGACCCCGGCCCCTTCTCGCGTGCGCGGTGTGACT-GTTGAGCGAATGAGCAGCTAGGCTTGGTGGTGCTCCGCGTGCGGGGGAGAAGACGAT
1001 1 1 00 
ADI 69  TAACAACAAAAAATAAGTGGAAGTGGCCGGTGGGTCTTTGTCCGCGTGCGCGCCCATCCGTCGCCGGGACCGAGCAGAAAGTGATGTGGTGGTAHBrGA
T o l e d o  TAACAACAAAAAATAAGTGGAAGTGGCCGGTGGGTCTTTGTCCGCGTGCGCGCCCATCCGTCGCCGGGACCGAGCAGAAAGTGATGTGGTGGTACATTGA 
W TAACAACAAAAAATAAGTGGAAGTGGCCGGTGGGTCTTTGTCCGCGTGCGCGCCCATCCGTCGCCGGGACCGAGCAGAAAGTGATGTGGTGGTACATTGA 
3 1 5 7  TAACAACAAAAAATAAGTGGAAGTGGCCGGTGGGTCTTTGTCCGCGTGCGCGCCCATCCGTCGCCGGGACCGAGCAGAAAGTGATGTGGTGGTACATTGA 
3 3 0 1  TAACAACAAAAAATAAGTGGAAGTGGCCGGTGGGTCTTTGTCCGCGTGCGCGCCCATCCGTCGCCGGGACCGAGCAGAAAGTGATGTGGTGGTACATTGA 
6 3 9 7  TAACAACAAAAAATAAGTGGAAGTGGCCGGTGGGTCTTTGTCCGCGTGCGCGCCCATCCGTCGCCGGGACCGAGCAGAAAGTGATGTGGTGGTACATTGA 
M e r l i n  TAACAACAAAAAATAAGTGGAAGTGGCCGGTGGGTCTTTGTCCGCGTGCGCGCCCATCCGTCGCCGGGACCGAGCAGAAAGTGATGTGGTGGTACATTGA 
CONSENSUS TAACAACAAAAAATAAGTGGAAGTGGCCGGTGGGTCTTTGTCCGCGTGCGCGCCCATCCGTCGCCGGGACCGAGCAGAAAGTGATGTGGTGGTACATTGA
1101  1200  
ADI 69  TTTTTTCCTTGACAGGAAAGAAAAAAAA. GAGTTTTGTTTTCCTATGTGAGAGGAGAAAGGTATGTGAGGAGATGTTCGATGATCGTATGTTACAGTTAT
T o l e d o  TTTTTTCCTTGACAGGAAAGAAAAAAAA^SAGTTTTGTTTTCCTATGTGAGAGGAGAAAGGTATGTGAGGAGATGTTCGATGATCGTATGTTACAGTTAT 
W TTTTTTCCTTGACAGGAAAGAAAAAAAA. GAGTTTTGTTTTCCTATGTGAGAGGAGAAAGGTATGTGAGGAGATGTTCGATGATCGTATGTTACAGTTAT 
3 1 5 7  TTTTTTCCTTGACAGGAAAGAAAAAAAA. GAGTTTTGTTTTCCTATGTGAGAGGAGAAAGGTATGTGAGGAGATGTTCGATGATCGTATGTTACAGTTAT 
3 3 0 1  TTTTTTCCTTGACAGGAAAGAAAAAAAA. GAGTTTTGTTTTCCTATGTGAGAGGAGAAAGGTATGTGAGGAGATGTTCGATGATCGTATGTTACAGTTAT 
6 3 9 7  TTTTTTCCTTGACAGGAAAGAAAAAAAAjfcAGTTTTGTTTTCCTATGTGAGAGGAGAAAGGTATGTGAGGAGATGTTCGATGATCGTATGTTACAGTTAT 
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1 4 0 1  1 5 0 0
ADI 69  TGTGATCATTGTGTCGAGCCAGAGAAAGCGCGCCTCGCACGACGTTTGCGGATCGGCTCGCGGGTGTGTGGAATTCCTAAGAACATAATCAGCTGGTCGT
T o l e d o  TGTGATCATTGTGTCGAGCCAGAGAAAGCGCGCCTCGCACGACGTTTGCGGATCGGCTCGCGGGTGTGTGGAATTCCTAAGAACATAATCAGCTGGTCGT 
W TGTGATCATTGTGTCGAGCCAGAGAAAGCGCGCCTCGCACGACGTTTGCGGATCGGCTCGCGGGTGTGTGGAATTCCTAAGAACATAATCAGCTGGTCGT 
3 1 5 7  TGTGATCATTGTGTCGAGCCAGAGAAAGCGCGCCTCGCACGACGTTTGCGGATCGGCTCGCGGGTGTGTGGAATTCCTAAGAACATAATCAGCTGGTCGT 
3 3 0 1  TGTGATCATTGTGTCGAGCCAGAGAAAGCGCGCCTCGCACGACGTTTGCGGATCGGCTCGCGGGTGTGTGGAATTCCTAAGAACATAATCAGCTGGTCGT 
6 3 9 7  TGTGATCATTGTGTCGAGCCAGAGAAAGCGCGCCTCGCACGACGTTTGCGGATCGGCTCGCGGGTGTGTGGAATTCCTAAGAACATAATCAGCTGGTCGT 
M e r l i n  TGTGATCATTGTGTCGAGCCAGAGAAAGCGCGCCTCGCACGACGTTTGCGGATCGGCTCGCGGGTGTGTGGAATTCCTAAGAACATAATCAGCTGGTCGT 
CONSENSUS TGTGATCATTGTGTCGAGCCAGAGAAAGCGCGCCTCGCACGACGTTTGCGGATCGGCTCGCGGGTGTGTGGAATTCCTAAGAACATAATCAGCTGGTCGT
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M e r l i n
CONSENSUS
A D I 69 
T o l e d o  
W
3 1 5 7
3 3 0 1
6 3 9 7
M e r l i n
CONSENSUS
ADI 69  
T o l e d o  W
3 1 5 7
3 3 0 1
6 3 9 7
M e r l i n
CONSENSUS
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GAATCCTATGGTGTCTTATTATCTCTAAAGTAG [









1 8 0 1  1 9 0 0
ADI 6 9  CATGAACAACAATATCCTTACTTACAGTCATCTTCGTGAGTTAATGAAGTATAATATCGGTCATCTATCAACTTATCTGCTATGTAACGTACCCTTTTAG 
T o l e d o  CATGAACAACAATATCCTTACTTACAGTCATCTTCGTGAGTTAATGAAGTATAATATCGGTCATCTATCAACTTATCTGCTATGTAACGTACCCTTTTAG 
W CATGAACAACAATATCCTTACTTACAGTCATCTTCGTGAGTTAATGAAGTATAATATCGGTCATCTATCAACTTATCTGCTATGTAACGTACCCTTTTAG 
3 1 5 7  CATGAACAACAATATCCTTACTTACAGTCATCTTCGTGAGTTAATGAAGTATAATATCGGTCATCTATCAACTTATCTGCTATGTAACGTACCCTTTTAG 
3 3 0 1  CATGAACAACAATATCCTTACTTACAGTCATCTTCGTGAGTTAATGAAGTATAATATCGGTCATCTATCAACTTATCTGCTATGTAACGTACCCTTTTAG 
6 3 9 7  CATGAACAACAATATCCTTACTTACAGTCATCTTCGTGAGTTAATGAAGTATAATATCGGTCATCTATCAACTTATCTGCTATGTAACGTACCCTTTTAG 
M e r l i n  CATGAACAACAATATCCTTACTTACAGTCATCTTCGTGAGTTAATGAAGTATAATATCGGTCATCTATCAACTTATCTGCTATGTAACGTACCCTTTTAG 
CONSENSUS CATGAACAACAATATCCTTACTTACAGTCATCTTCGTGAGTTAATGAAGTATAATATCGGTCATCTATCAACTTATCTGCTATGTAACGTACCCTTTTAG
1 9 0 1  2 0 0 0
ADI 6 9  GTATTTTGCGTTTCTTAACGAGTGTACCCGCCTGTGTGAGGCGAAACTCTGAGAAGTCTACCGAGTCGAGTTACAAGTCACTAAAACACTTACACGAGTT 
T o l e d o  GTATTTTGCGTTTCTTAACGAGTGTACCCGCCTGTGTGAGGCGAAACTCTGAGAAGTCTACCGAGTCGAGTTACAAGTCACTAAAACACTTACACGAGTT 
W GTATTTTGCGTTTCTTAACGAGTGTACCCGCCTGTGTGAGGCGAAACTCTGAGAAGTCTACCGAGTCGAGTTACAAGTCACTAAAACACTTACACGAGTT 
3 1 5 7  GTATTTTGCGTTTCTTAACGAGTGTACCCGCCTGTGTGAGGCGAAACTCTGAGAAGTCTACCGAGTCGAGTTACAAGTCACTAAAACACTTACACGAGTT 
3 3 0 1  GTATTTTGCGTTTCTTAACGAGTGTACCCGCCTGTGTGAGGCGAAACTCTGAGAAGTCTACCGAGTCGAGTTACAAGTCACTAAAACACTTACACGAGTT 
6 3 9 7  GTATTTTGCGTTTCTTAACGAGTGTACCCGCCTGTGTGAGGCGAAACTCTGAGAAGTCTACCGAGTCGAGTTACAAGTCACTAAAACACTTACACGAGTT 
M e r l i n  GTATTTTGCGTTTCTTAACGAGTGTACCCGCCTGTGTGAGGCGAAACTCTGAGAAGTCTACCGAGTCGAGTTACAAGTCACTAAAACACTTACACGAGTT 
CONSENSUS GTATTTTGCGTTTCTTAACGAGTGTACCCGCCTGTGTGAGGCGAAACTCTGAGAAGTCTACCGAGTCGAGTTACAAGTCACTAAAACACTTACACGAGTT
2001  2 1 0 0
ADI 69  ATCTATACTAAAATCACTATCTATGTTGTTTGCTTACCTAATTATTATCCTACATGACGAAGCTACCTCCCAACGTAAGGTAGGGGGAGAGGAGACAGAA 
T o l e d o  GTCTATACTAAAATCACTATCTATGTTGTTTGCTTACCTAATTATTATCCTACATGACGAAACTACCTCCCAACGTAAGGTAGGGGGAGAGGAGACAGAA 
W ATCTATACTAAAATCACTATCTATGTTGTTTGCTTACCTAATTATTATCCTACATGACGAAGCTACCTCCCAACGTAAGGTAGGGGGAGAGGAGACAGAA 
3 1 5 7  ATCTATACTAAAATCACTATCTATGTTGTTTGCTTACCTAATTATTATCCTACATGACGAAGCTACCTCCCAACGTAAGGTAGGGGGAGAGGAGACAGAA 
3 3 0 1  ATCTATACTAAAATCACTATCTATGTTGTTTGCTTACCTAATTATTATCCTACATGACGAAGCTACCTCCCAACGTAAGGTAGGGGGAGAGGAGACAGAA 
6 3 9 7  ATCTATACTAAAATCACTATCTATGTTGTTTGCTTACCTAATTATTATCCTACATGACGAAGCTACCTCCCAACGTAAGGTAGGGGGAGAGGAGACAGAA 
M e r l i n  ATCTATACTAAAATCACTATCTATGTTGTTTGCTTACCTAATTATTATCCTACATGACGAAGCTACCTCCCAACGTAAGGTAGGGGGAGAGGAGACAGAA 
CONSENSUS -TCTATACTAAAATCACTATCTATGTTGTTTGCTTACCTAATTATTATCCTACATGACGAA-CTACCTCCCAACGTAAGGTAGGGGGAGAGGAGACAGAA
210 1  2200  
AD I 6 9 CAATAAAAAGTAACTAATGTTTCTTAGAACTTACCCGCTAAGGACTTACCAAACTATATTCACCAAAAAACAACAGCTACGTGTTTCATTTGTTTTAATC 
T o l e d o  CAATAAAAAGTAACTAATGTTTCTTAGAACTTACCCGCTAAGGACTTACCAAACTATATTCACCAAAAAACAACAGCTACGTGTTTCATTTGTTTTAATC 
W CAATAAAAAGTAACTAATGTTTCTTAGAACTTACCCGCTAAGGACTTACCAAACTATATTCACCAAAAAACAACAGCTACGTGTTTCATTTGTTTTAATC 
3 1 5 7  CAATAAAAAGTAACTAATGTTTCTTAGAACTTACCCGCTAAGGACTTACCAAACTATATTCACCAAAAAACAACAGCTACGTGTTTCATTTGTTTTAATC 
3 3 0 1  CAATAAAAAGTAACTAATGTTTCTTAGAACTTACCCGCTAAGGACTTACCAAACTATATTCACCAAAAAACAACAGCTACGTGTTTCATTTGTTTTAATC 
6 3 9 7  CAATAAAAAGTAACTAATGTTTCTTAGAACTTACCCGCTAAGGACTTACCAAACTATATTCACCAAAATACAACAGCTACGTGTTTCATTTGTTTTAATC 
M e r l i n  CAATAAAAAGTAACTAATGTTTCTTAGAACTTACCCGCTAAGGACTTACCAAACTATATTCACCAAAAAACAACAGCTACGTGTTTCATTTGTTTTAATC
c o n s e n s u s  cH H H a a g t a a c t a a t g t t t c t t a g a a c t t a c c c g c t a a g g a c t t a c c a a a c t a t a t t c a c c a a a a - a c a a c a g c t a c g t g t t t c a t t t g t t t t a a t c
85
Region X
2 2 0 1  2 3 0 0
A D I69  TACCGAAGTAAAAAAAAAAA. . . GATGATTAGCTATCCAGAACCTACTTACTTCTTAATGTTTTAACTAAGGATGCCTATGGGATTGGAAAAAAAATCAC 
T o l e d o  TACCGAAGTAAAAAAAAAAAj. . GATGATTAGCTATCCAGAACCTACTTACTTCTTAATGTTTTAACTAAGGATGCCTATGGGATTGGAAAAAAAATCAC 
W TACCGAAGTAAAAAAAAAAAAAAGATGATTAGCTATCCAGAACCTACTTACTTCTTAATGTTTTAACTAAGGATGCCTATGGGATTGGAAAAAAAATCAC 
3 1 5 7  TACCGAAGTAAAAAAAAAAi. . . GATGATTAGCTATCCAGAACCTACTTACTTCTTAATGTTTTAACTAAGGATGCCTATGGGATTGGAAAAAAAATCAC 
3 3 0 1  TACCGAAGTAAAAAAAAAA|. . . GATGATTAGCTATCCAGAACCTACTTACTTCTTAATGTTTTAACTAAGGATGCCTATGGGATTGGAAAAAAAATCAC 
6 3 9 7  TACCGAAGTAAAAAAAAAAA. . . GATGATTAGCTATCCAGAACCTACTTACTTCTTAATGTTTTAACTAAGGATGCCTATGGGATTGGAAAAAAAATCAC 
M e r l i n  TACCGAAGTAAAAAAAAAA§. . . GATGATTAGCTATCCAGAACCTACTTACTTCTTAATGTTTTAACTAAGGATGCCTATGGGATTGGAAAAAAAATCAC 
CONSENSUS TACCGAAGTAAAAAAAAAA GATGATTAGCTATCCAGAACCTACTTACTTCTTAATGTTTTAACTAAGGATGCCTATGGGATTGGAAAAAAAATCAC
2 3 0 1  2 4 0 0
A D I 6 9  AGCAACTTGCTACTAATCAGTTGACAGCGAAGAGACTCATAACAAAGATTTCTGGGTAATACGGTTATAATAATGCTTATGGACTAAAGGATACTTGGAA 
T o l e d o  AGCAACTTGCTACTAATCAGTTGACAGCGAAGAGACTCATAACAAAGATTTCTGGGTAATACGGTTATAATAATGCTTATGGACTAAAGGATACTTGGAA 
W AGCAACTTGCTACTAATCAGTTGACAGCGAAGAGACTCATAACAAAGATTTCTGGGTAATACGGTTATAATAATGCTTATGGACTAAAGGATACTTGGAA 
3 1 5 7  AGCAACTTGCTACTAATCAGTTGACAGCGAAGAGACTCATAACAAAGATTTCTGGGTAATACGGTTATAATAATGCTTATGGACTAAAGGATACTTGGAA 
3 3 0 1  AGCAACTTGCTACTAATCAGTTGACAGCGAAGAGACTCATAACAAAGATTTCTGGGTAATACGGTTATAATAATGCTTATGGACTAAAGGATACTTGGAA 
6 3 9 7  AGCAACTTGCTACTAATCAGTTGACAGCGAAGAGACTCATAACAAAGATTTCTGGGTAATACGGTTATAATAATGCTTATGGACTAAAGGATACTTGGAA 
M e r l i n  AGCAACTTGCTACTAATCAGTTGACAGCGAAGAGACTCATAACAAAGATTTCTGGGTAATACGGTTATAATAATGCTTATGGACTAAAGGATACTTGGAA 
CONSENSUS AGCAACTTGCTACTAATCAGTTGACAGCGAAGAGACTCATAACAAAGATTTCTGGGTAATACGGTTATAATAATGCTTATGGACTAAAGGATACTTGGAA
2 4 0 1  2 5 0 0
A D 169 AAAAAGAACGGGCTATGACTATAGAGATTCGTCGAGATATCAAACTTCAAATAGGCGGCTATCATTCATGGTTGTGGTGACTATATCGTGGAGAAAAAAT 
T o l e d o  AAAAAGAACGGGCTATGACTATAGAGATTCGTCGAGATATCAAACTTCAAATAGGCGGCTATCATTCATGGTTGTGGTGACTATATCGTGGAGAAAAAAT 
W AAAAAGAACGGGCTATGACTATAGAGATTCGTCGAGATATCAAACTTCAAATAGGCGGCTATCATTCATGGTTGTGGTGACTATATCGTGGAGAAAAAAT 
3 1 5 7  AAAAAGAACGGGCTATGACTATAGAGATTCATCGAGATATCAAACTTCAAATAGGCGGCTATCATTCATGGTTGTGGTGACTATHc GTGGAGAAAAAAT 
3 3 0 1  AAAAAGAACGGGCTATGACTATAGAGATTCATCGAGATATCAAACTTCAAATAGGCGGCTATCATTCATGGTTGTGGTGACTATATCGTGGAGAAAAAAT 
6 3 9 7  AAAAAGAATGGGCTATGACTATAGAGATTCGTTGAGATATCAAACTTCAAATAGGCGGCTATCATTCATGGTTGTGGTGACTATATCGTGGAGAAAAAAT 
M e r l i n  AAAAAGAATGGGCTATGACTATAGAGATTCGTTGAGATATCAAACTTCAAATAGGCGGCTATCATTCATGGTTGTGGTGACTATATCGTGGAGAAAAAAT 
CONSENSUS AAAAAGAA-GGGCTATGACTATAGAGATTC-T-GAGATATCAAACTTCAAATAGGCGGCTATCATTCATGGTTGTGGTGACTAT— C G T G GAGAAAAAAT
2 5 0 1  2 6 0 0
ADI 69  GTGATCGTTAGTTAGCTAGGTGAGACTTACAGCTATCCATCCGTCTAGTTTTTCGTTGTAATGATGATAGTACGTCTATGGTGGTGATCGATTTTGGTTA 
T o l e d o  GTGATCGTTAGTTAGCTAGGTGAGACTTACAGCTATCCATCCGTCTAGTTTTTCGTTGTAATGATGATAGTACGTCTATGGTGGTGATCGATTTTGGTTA 
W GTGATCGTTAGTTAGCTAGGTGAGACTTACAGCTATCCATCCGTCTAGTTTTTCGTTGTAATGATGATAGTACGTCTATGGTGGTGATCGATTTTGGTTA 
3 1 5 7  GTGATCGTTAGTTAGCTAGGTGAGACTTACAGCTATCCATCCGTCTAGTTTTTCGTTGTAATGATGATAGTACGTCTATGGTGGTGATCGATTTTGGTTA 
3 3 0 1  GTGATCGTTAGTTAGCTAGGTGAGACTTACAGCTATCCATCCGTCTAGTTTTTCGTTGTAATGATGATAGTACGTCTATGGTGGTGATCGATTTTGGTTA 
6 3 9 7  GTGATCGTTAGTTAGCTAGGTGAGACTTACAGCTATCCATCCGTCTAGTTTTTCGTTGTAATGATGATAGTACGTCTATGGTGGTGATCGATTTTGGTTA 
M e r l i n  GTGATCGTTAGTTAGCTAGGTGAGACTTACAGCTATCCATCCGTCTAGTTTTTCGTTGTAATGATGATAGTACGTCTATGGTGGTGATCGATTTTGGTTA 
CONSENSUS GTGATCGTTAGTTAGCTAGGTGAGACTTACAGCTATCCATCCGTCTAGTTTTTCGTTGTAATGATGATAGTACGTCTATGGTGGTGATCGATTTTGGTTA
2 6 0 1  2 7 0 0
ADI 69  ACAATTTGTTCGTTTAAAGGCTTAATGTACTTATGCTACATGATGTATTATTCTTTGATTCATCGTTCCTCCTAAGGGGGTGTATGTATGTATGTACTAG 
T o l e d o  ACAATTTGTTCGTTTAAAGGCTTAATGTACTTATGCTACATGATGTATTATTCTTTGATTCATCGTTCCTCCTAAGGGGGTGTATGTATGTATGTACTAG 
W ACAATTTGTTCGTTTAAAGGCTTAATGTACTTATGCTACATGATGTATTATTCTTTGATTCATCGTTCCTCCTAAGGGGGTGTATGTATGTATGTACTAG 
3 1 5 7  GCAATTTGTTCGTTTAAAGGCTTAATGTACTTATGCTACATGATGTATTATTCTTTGATTCATCGTT'CCTCCTAAGGGGGTGTATGTATGTATGTATTAG 
3 3 0 1  GCAATTTGTTCGTTTAAAGGCTTAATGTACTTATGCTACATGATGTATTATTCTTTGATTCATCGTTCCTCCTAAGGGGGTGTATGTATGTATGTACTAG 
6 3 9 7  GCAATTTGTTCGTTTAAAGGCTTAATGTACTTATGCTACATGATGTATTATTCTTTGATTCATCGTTCCTCCTAAGGGGGTGTATGTATGTATGTACTAG 
M e r l i n  GCAATTTGTTCGTTTAAAGGCTTAATGTACTTATGCTACATGATGTATTATTCTTTGATTCATCGTTCCTCCTAAGGGGGTGTATGTATGTATGTACTAG 
CONSENSUS -CAATTTGTTCGTTTAAAGGCTTAATGTACTTATGCTACATGATGTATTATTCTTTGATTCATCGTTCCTCCTAAGGGGGTGTATGTATGTATGTA-TAG
ADI 69 
T o l e d o  W
3 1 5 7
3 3 0 1
6 3 9 7
M e r l i n
CONSENSUS
A D 169
T o l e d oW
3 1 5 7
3 3 0 1
6 3 9 7
M e r l i n
CONSENSUS









< ^ U L 1 0 9  stop | 2 9 0 0
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T o l e d oW
3 1 5 7
3 3 0 1
6 3 9 7
M e r l i n
CONSENSUS
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A D 169
T o l e d oW
3 1 5 7
3 3 0 1
6 3 9 7
M e r l i n
CONSENSUS
A D I 69 
T o l e d o  
W
3 1 5 7
3 3 0 1
6 3 9 7
M e r l i n
CONSENSUS
3 0 0 1  3 1 0 0
CAATGTTTGGTTGAGCGTTTTGTTTCATCGTCGTGGTG . . . GTTTTGTTGTTCTCTGTATATATCGTGTGGTGGCTTTATCGTCATCATTATTATCATCA
CAATGTTTGGTTGAGCGTTTTGTTTCATCGTCGTGGTG . . . GTTTTGTTGTTCTCTGTATATATCGTGTGGTGGCTTTATCGTCATCATTATTATCATCA 

















3 2 0 1  <^ U L 1 10 stop  |
t g c t c t t g c c t t c a t g g c g g t a t t t c t c t t c c t c c c c c c t a a c c c c a t t It t a a c t c g t g a g t g t c
ORF 17 s ta i l^ > 3 3 0 0
ADI 6 9  TGCTCTTGCCTTCATGGCGGTATTTCTCTTCCTCCCCCCTAACCCCATflTTAACTCGTGAGTGTqBBpTTAGAGTGGCTGCTTGTTTTTTTTTTCTTTT 
T o l e d o  TGCTCTTGCCTTCATGGCGGTATTTCTCTTCCTCCCCCCTAACCCCATATTAACTCGTGAGTGTGATGGTTAGAGTGGCTGCTTGTTTTTTTTTTCTTTT
w t g c t c t t g c c t t c a t g g c g g t a t t t c t c t t c c t c c c c c c t a a c c c c a t a t t a a c t c g t g a g t g t g a t g g t t a g a g t g g c t g c t t g t t t t t t t t t | c t t t t  
3 1 5 7  t g c t c t t g c c t t c a t g g c g g t a t t t c t c t t c c t c c c c c c t a a c c c c a t a t t a a c t c g t g a g t g t g a t g g t t a g a g t g g c t g c t t g t t t t t t t t t t c t t t t  
3 3 0 1  t g c t c t t g c c t t c a t g g c g g t a t t t c t c t t c c t c c c c c c t a a c c c c a t a t t a a c t c g t g a g t g t g a t g g t t a g a g t g g c t g c t t g t t t t t t t t t  
6 3 9 7  t g c t c t t g c c t t c a t g g c g g t a t t t c t c t t c c t c c c c c c t a a c c c c a t a t t a a c t c g t g a g t g t g a t g g t t a g a g t g g c t g c t t g t t t t t t t t t ! 
M e r l i n  TGCTCTTGCCTTCATGGCGGTATTTCTCTTCCTCCCCCCTAACCCCATATTAACTCGTGAGTGTGATGGTTAGAGTGGCTGCTTGTTTTTTTTTTCTTTT 
CONSENSUS TGCTCTTGCCTTCATGGCGGTATTTCTCTTCCTCCCCCCTAACCCCATATTAACTCGTGAGTGTGATGGTTAGAGTGGCTGCTTGTTTTTTTTT-CTTTT
r |cr|cTTTTTTTT
3 3 0 1  3 4 0 0
ADI 6 9  CTCTTTGGAACAACAAAAGAGGATAAAGATGGTCGGTGAATGTATTATTATTAT . . . CATCATTATGATACGGTCGCGGTCTTCTTCTCCGATGACGAAA
T o l e d o  CTCTTTGGAACAACAAAAGAGGATAAAGATGGTCGGTGAATGTATTATTATTAT . . . CATCATTATGATACGGTCGCGGTCTTCTTCTCCGATGACGAAA 
W CTCTTTGGAACAACAAAAGAGGATAAAGATGGTCGGTGAATGTATTATTATTAT.
3 1 5 7  CTCTTTGGAACAACAAAAGAGGATAAAGATGGTCGGTGGATGTATTATTATTAT.
3 3 0 1  CTCTTTGGAACAACAAAAGAGGATAAAGATGGTCGGTGGATGTATTATTATTATTATCATCATTATGATACGGTCGCGGTCTTCTTCTCCGATGACGAAA 
6 3 9 7  CTCTTTGGAACAACAAAAGAGGATAAAGATGGTCGGTGAATGTATTATTATTAT . . . CATCATTATGATACGGTCGCGGTCTTCTTCTCCGATGACGAAA 
M e r l i n  CTCTTTGGAACAACAAAAGAGGATAAAGATGGTCGGTGAATGTATTATTATTATCATCATCATTATGATACGGTCGCGGTCTTCTTCTCCGATGACGAAA 




T o l e d o  
W
3 1 5 7
3 3 0 1
6 3 9 7
M e r l i n
CONSENSUS
ADI 6 9 
T o l e d o  
W
3 1 5 7
3 3 0 1
6 3 9 7
M e r l i n
CONSENSUS
ADI 69 
T o l e d o  W
3 1 5 7
3 3 0 1
6 3 9 7
M e r l i n
CONSENSUS
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: g t t c t c a t g a t c g c g g a g a c c a c a c a g a c g t g
CGTTCTCATGATCGCGGAGACCACACAGACGTG
3 7 0 1  3 8 0 0
ADI 6 9  CGCGTCTCCCAATGGCTAGGCGTTCTTTTTAGGTAGTAATTTTTTGATCTTTTTTTTTTCTTAACAAGTCTGGCTTGATTTCTTTTATCTATGATCGATT 
T o l e d o  CGCGTCTCCCAATGGCTAGGCGTTCTTTTTAGGTAGTAATTTTTTGATCTTTTTTTTTTCTTAACAAGTCTGGCTTGATTTCTTTTATCTATGATCGATT 
W CGCGTCTCCCAATGGCTAGGCGTTCTTTTTAGGTAGTAATTTTTTGATCTTTTTTTTTTCTTAACAAGTCTGGCTTGATTTCTTTTATCTATGATCGATT 
3 1 5 7  CGCGTCTCCCAATGGCTAGGCGTTCTTTTTAGGTAGTAATTTTTTGATCTTTTTTTTTTCTTAACAAGTCTGGCTTGATTTCTTTTATCTATGATCGATT 
3 3 0 1  CGCGTCTCCCAATGGCTAGGCGTTCTTTTTAGGTAGTAATTTTTTGATCTTTTTTTTTTCTTAACAAGTCTGGCTTGATTTCTTTTATCTATGATCGATT 
6 3 9 7  CGCGTCTCCCAATGGCTAGGCGTTCTTTTTAGGTAGTAATTTTTTGATCTTTTTTTTT|CTTAACAAGTCTGGCTTGATTTCTTTTATCTATGATCGATT 
M e r l i n  CGCGTCTCCCAATGGCTAGGCGTTCTTTTTAGGTAGTAATTTTTTGATCTTTTTTTTTTCTTAACAAGTCTGGCTTGATTTCTTTTATCTATGATCGATT 
CONSENSUS CGCGTCTCCCAATGGCTAGGCGTTCTTTTTAGGTAGTAATTTTTTGATCTTTTTTTTT-CTTAACAAGTCTGGCTTGATTTCTTTTATCTATGATCGATT
3 8 0 1  3 9 0 0
ADI 6 9  CTTCTTTTTCTCGGGGGTTGCATCTTCCGTGAAAGTAAAGTGACACTACTCTAAATGGTAACCATATTATCTGTTGATTAGGAGAAAAAATAATTTTTTC 
T o l e d o  CTTCTTTTTCTCGGGGGTTGCATCTTCCGTGAAAGTAAAGTGACACTACTCTAAATGGTAACCATATTATCTGTTGATTAGGAGAAAAAATAATTTTTTC 
W CTTCTTTTTCTCGGGGGTTGCATCTTCCGTGAAAGTAAAGTGACACTACTCTAAATGGTAACCATATTATCTGTTGATTAGGAGAAAAAATAATTTTTTC 
3 1 5 7  CTTCTTTTTCTCGGGGGTTGCATCTTCCGTGAAAGTAAAGTGACACTACTCTAAATGGTAACCATATTATCTGTTGATTAGGAGAAAAAATAATTTTTTC 
3 3 0 1  CTTCTTTTTCTCGGGGGTTGCATCTTCCGTGAAAGTAAAGTGACACTACTCTAAATGGTAACCATATTATCTGTTGATTAGGAGAAAAAATAATTTTTTC 
6 3 9 7  CTTCTTTTTCTCGGGGGTTGCATCTTCCGTGAAAGTAAAGTGACACTACTCTAAATGGTAACCATATTATCTGTTGATTAGGAGAAAAAATAATTTTTTC 
M e r l i n  CTTCTTTTTCTCGGGGGTTGCATCTTCCGTGAAAGTAAAGTGACACTACTCTAAATGGTAACCATATTATCTGTTGATTAGGAGAAAAAATAATTTTTTC 
CONSENSUS CTTCTTTTTCTCGGGGGTTGCATCTTCCGTGAAAGTAAAGTGACACTACTCTAAATGGTAACCATATTATCTGTTGATTAGGAGAAAAAATAATTTTTTC
3 9 0 1  4 0 0 0
ADI 6 9  GCACGAAATCGATCCTAAGTGAGGTGATTTACTTGCTATCACACGAAATGATTATCTTTTGCTGCTAACGTACTGAATTTTTTAACAGAATTGCTTCTCC 
T o l e d o  GCACGAAATCGATCCTAAGTGAGGTGATTTACTTGCTATCACACGAAATGATTATCTTTTGCTGCTAACGTACTGAATTTTGTAACAGAATTGCTTCTCC 
W GCACGAAATCGATCCTAAGTGAGGTGATTTACTTGCTATCACACGAAATGATTATCTTTTGCTGCTAACGTACTGAATTTTTTAACAGAATTGCTTCTCC 
3 1 5 7  GCACGAAATCGATCCTAAGTGAGGTGATTTACTTGCTATCACACGAAATGATTATCTTTTGCTGCTAACGTACTGAATTTTTTAACAGAATTGCTTCTCC 
3 3 0 1  GCACGAAATCGATCCTAAGTGAGGTGATTTACTTGCTATCACACGAAATGATTATCTTTTGCTGCTAACGTACTGAATTTTTTAACAGAATTGCTTCTCC 
6 3 9 7  GCACGAAATCGATCCTAAGTGAGGTGATTTACTTGCTATCACACGAAATGATTATCTTTTGCTGCTAACGTACTGAATTTTTTAACAGAATTGCTTCTCC 
M e r l i n  GCACGAAATCGATCCTAAGTGAGGTGATTTACTTGCTATCACACGAAATGATTATCTTTTGCTGCTAACGTACTGAATTTTTTAACAGAATTGCTTCTCC 
CONSENSUS GCACGAAATCGATCCTAAGTGAGGTGATTTACTTGCTATCACACGAAATGATTATCTTTTGCTGCTAACGTACTGAATTTT-TAACAGAATTGCTTCTCC
4 0 0 1  4 1 0 0
ADI 6 9  GTAACTATTTCCGCAGATTCAGACAGATTGTCAAAAAAGAA. TACGGCACAGAAATAGTGGGTCTGTGGCTTTTGGTTCGTGTACATTCGCGTTTGCGTG 
T o l e d o  GTAACTATTTCCGCAGATTCAGACAGATTGTCAAAAAAAAA. TACGGCACAGAAATAGTGGGTCTGTGGCTTTTGGTTCGTGTACATTCGCGTTTGCGTG 
W GTAACTATTTCCGCAGATTCAGACAGATTGTCAAAAAAAAA. TACGGCACAGAAATAGTGGGTCTGTGGCTTTTGGTTCGTGTACATTCGCGTTTGCGTG 
3 1 5 7  GTAACTATTTCCGCAGATTCAGACAGATTGTCAAAAAAAAA. TACGGCACAGAAATAGTGGGTCTGTGGCTTTTGGTTCGTGTACATTCGCGTTTGCGTG 
3 3 0 1  GTAACTATTTCCGCAGATTCAGACAGATTGTCAAAAAAAAA. TACGGCACAGAAATAGTGGGTCTGTGGCTTTTGGTTCGTGTACATTCGCGTTTGCGTG 
6 3 9 7  GTAACTATTTCCGCAGATTCAGACAGATTGTCAAAAAAAA|.TACGGCACAGAAATAGTGGGTCTGTGGCTTTTGGTTCGTGTACATTCGCGTTTGCGTG 
M e r l i n  GTAACTATTTCCGCAGATTCAGACAGATTGTCAAAAAAAAA§TACGGCACAGAAATAGTGGGTCTGTGGCTTTTGGTTCGTGTACATTCGCGTTTGCGTG 
CONSENSUS GTAACTATTTCCGCAGATTCAGACAGATTGTCAAAAAA-A--TACGGCACAGAAATAGTGGGTCTGTGGCTTTTGGTTCGTGTACATTCGCGTTTGCGTG
4 1 0 1  4 2 0 0
ADI 6 9  TCGAGATTTCTACGGTATGTTTATTCTTCCTGCGATGATGTAGGGTCCTTGGTGTAAGTAGGATTTCGAGTATCTCTCTTAGAGCGAACAAAATAATCAA 
T o l e d o  TCGAGATTTCTACGGTATGTTTATTCTTCCTGCGATGATGTAGGGTCCTTGGTGTAAGTAGGATTTCGAGTATCTCTCTTAGAGCGAACAAAATAATCAA 
W TCGAGATTTCTACGGTATGTTTATTCTTCCTGCGATGATGTAGGGTCCTTGGTGTAAGTAGGATTTCGAGTATCTCTCTTAGAGCGAACAAAATAATCAA 
3 1 5 7  TCGAGATTTCTACGGTATGTTTATTCTTCCTGCGATGATGTAGGGTCCTTGGTGTAAGTAGGATTTCGAGTATCTCTCTTAGAGCGAACAAAATAATCAA 
3 3 0 1  TCGAGATTTCTACGGTATGTTTATTCTTCCTGCGATGATGTAGGGTCCTTGGTGTAAGTAGGATTTCGAGTATCTCTCTTAGAGCGAACAAAATAATCAA 
6 3 9 7  TCGAGATTTCTACGGTATGTTTATTCTTCCTGCGATGATGTAGGGTCCTTGGTGTAAGTAGGATTTCGAGTATCTCTCTTAGAGCGAACAAAATAATCAA 




4 2 0 1  4 3 0 0
A D I 6 9  AAAACAACAGCTAGGAAATCGAGGGTTACTCTACGATAAAGTGTCTCTACAAAGTGAAGAATGTTACGTTGTGGTGGAATAATAAGACTCGCGTGATCGA 
T o l e d o  AAAACAACAGCTAGGAAATCGAGGGTTACTCTACGATAAAGTGTCTCTACAAAGTGAAGAATGTTACGTTGTGGTGGAATAATAAGACTCGCGTGATCGA 
W AAAACAACAGCTAGGAAATCGAGGGTTACTCTACGATAAAGTGTCTCTACAAAGTGAAGAATGTTACGTTGTGGTGGAATAATAAGACTCGCGTGATCGA 
3 1 5 7  AAAACAACAGCTAGGAAATCGAGGGTTACTCTACGATAGAGTGTCTCTACAAAGTGAAGAATGTTACGTTGTGGTGGAATAATAAGACTCGCGTGATCGA 
3 3 0 1  AAAACAACAGCTAGGAAATCGAGGGTTACTCTACGATAAAGTGTCTCTACAAAGTGAAGAATGTTACGTTGTGGTGGAATAATAAGACTCGCGTGATCGA 
6 3 9 7  AAAACAACAGCTAGGAAATCGAGGGTTACTCTACGATAAAGTGTCTCTACAAAGTGAAGAATGTTACGTTGTGGTGGAATAATAAGACTCGCGTGATCGA 
M e r l i n  AAAACAACAGCTAGGAAATCGAGGGTTACTCTACGATAAAGTGTCTCTACAAAGTGAAGAATGTTACGTTGTGGTGGAATAATAAGACTCGCGTGATCGA 
CONSENSUS AAAACAACAGCTAGGAAATCGAGGGTTACTCTACGATA-AGTGTCTCTACAAAGTGAAGAATGTTACGTTGTGGTGGAATAATAAGACTCGCGTGATCGA
4 3 0 1  4 4 0 0
ADI 6 9  TGAGTGATCGAGAGCGGCTCGAACCTTCTTTAAGAGCTTTGTTTAGTGCAACTTTAAATTACAAGGAGTAGAAAGCTGAAATGAATCTATGAAGGTGCTA 
T o l e d o  TGAGTGATCGAGAGCGGCTCGAACCTTCTTTAAGAGCTTTGTTTAGTGCAACTTTAAATTACAAGGAGTAGAAAGCTGAAATGAATCTATGAAGGTGCTA 
W TGAGTGATCGAGAGCGGCTCGAACCTTCTTTAAGAGCTTTGTTTAGTGCAACTTTAAATTACAAGGAGTAGAAAGCTGAAATGAATCTATGAAGGTGCTA 
3 1 5 7  TGAGTGATCGAGAGCGGCTCGAACCTTCTTTAAGAGCTTTGTTTAGTGCAACTTTAAATTACAAGGAGTAGAAAGCTGAAATGAATCTATGAAGGTGCTA 
3 3 0 1  TGAGTGATCGAGAGCGGCTCGAACCTTCTTTAAGAGCTTTGTTTAGTGCAACTTTAAATTACAAGGAGTAGAAAGCTGAAATGAATCTATGAAGGTGCTA 
6 3 9 7  TGAGTGATCGAGAGCGGCTCGAACCTTCTTTAAGAGCTTTGTTTAGTGCAACTTTAAATTACAAGGAGTAGAAAGCTGAAATGAATCTATGAAGGTGCTA 
M e r l i n  TGAGTGATCGAGAGCGGCTCGAACCTTCTTTAAGAGCTTTGTTTAGTGCAACTTTAAATTACAAGGAGTAGAAAGCTGAAATGAATCTATGAAGGTGCTA 
CONSENSUS TGAGTGATCGAGAGCGGCTCGAACCTTCTTTAAGAGCTTTGTTTAGTGCAACTTTAAATTACAAGGAGTAGAAAGCTGAAATGAATCTATGAAGGTGCTA
4 4 0 1  4 5 0 0
ADI 6 9  TTCTTTGAATATCTTACTTTGTACGCTTCACATTCGTTATTTGGATAGAGAGTTGTCTAGAGAAAATCTGTGATTCTCTATGAGTGTTATTTTTATTATC 
T o l e d o  TTCTTTGAATATCTTACTTTGTACGCTTCACATTCGTTATTTGGATAGAGAGTTGTCTAGAGAAAATCTGTGATTCTCTATGAGTGTTATTTTTATTATC 
W TTCTTTGAATATCTTACTTTGTACGCTTCACATTCGTTATTTGGATAGAGAGTTGTCTAGAGAAAATCTGTGATTCTCTATGAGTGTTATTTTTATTATC 
3 1 5 7  TTCTTTGAATATCTTACTTTGTACGCTTCACATTCGTTATTTGGATAGAGAGTTGTCTAGAGAAAATCTGTGATTCTCTATGAGTGTTATTTTTATTATC 
3 3 0 1  TTCTTTGAATATCTTACTTTGTACGCTTCACATTCGTTATTTGGATAGAGAGTTGTCTAGAGAAAATCTGTGATTCTCTATGAGTGTTATTTTTATTATC 
6 3 9 7  TTCTTTGAATATCTTACTTTGTACGCTTCACATTCGTTATTTGGATAGAGAGTTGTCTAGAGAAAATCTGTGATTCTCTATGAGTGTTATTTTTATTATC 
M e r l i n  TTCTTTGAATATCTTACTTTGTACGCTTCACATTCGTTATTTGGATAGAGAGTTGTCTAGAGAAAATCTGTGATTCTCTATGAGTGTTATTTTTATTATC 
CONSENSUS t t c t t t g a a t a t c t t a c t t t g t a c g c t t c a c a t t c g t t a t t t g g a t a g a g a g t t g t c t a g a g a a a a t c t g t g a t t c t c t a t g a g t g t t a t t B e h M a t c
4 5 0 1
A D I 69  c t t t t g g g g a c t a c g a t t t t t c t t c t t g t t c t a c a t a c c a c t a c t a c t c g t a a t c a c a t a c a t g g a c g a a a a a a a a a  . 
T o l e d o  c t t t t g g g g a c t a c g a t t t t t c t t c t t g t t c t a c a t a c c a c t a c t a c t c g t a a t c a c a t a c a t g g a c g a a a a a a a a a M t
W CTTTTGGGGACTACGATTTTTCTTCTTGTTCTACATACCACTACTACTCGTAATCACATACATGGACGAAAAAAAAA^ T 
3 1 5 7  CTTTTGGGGACTACGATTTTTCTTCTTGTTCTACATACCACTACTACTCGTAATCACATACATGGACGAAAAAAAAA.
3 3 0 1  c t t t t g g g g a c t a c g a t t t t t c t t c t t g t t c t a c a t a c c a c t a c t a c t c g t a a t c a c a t a c a t g g a c g a a a a a a a a a J
6 3 9 7  CTTTTGGGGACTACGATTTTTCTTCTTGTTCTACATACCACTACTACTCGTAATCACATACATGGACGAAAAAAAAA. 
M e r l i n  CTTTTGGGGACTACGATTTTTCTTCTTGTTCTACATACCACTACTACTCGTAATCACATACATGGACGAAAAAAAAA. 
CONSENSUS CTTTTGGGGACTACGATTTTTCTTCTTGTTCTACATACCACTACTACTCGTAATCACATACATGGACGAAAAAAAAA--









4 6 0 1 4 7 0 0
A D I 69  
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W
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M e r l i n
CONSENSUS
TTGCACACAGTTTATTCAGTATAGTTTTTCTTCTTGCCATGATCAATTAAGCCCACCACCTTTTTTTTT . AGAGAGGAGGAATTTCGTCTTGATCTCCAG 


























. C GGGAGAG AC T T CAAGGCAAT GAAAAAAAAA 
. CGGGAGAGAC T T CAAGGCAAT GAAAAAAAAA
-CGGGAGAGACTTCAAGGCAATGAAAAAAAAA-TTTCGTTTTGCCATCAAGTGGTGACGATAACCCG
ADI 69  
T o l e d o  
W
3 1 5 7
3 3 0 1
6 3 9 7
M e r l i n
CONSENSUS
ADI 69  
T o l e d o  
W
3 1 5 7
3 3 0 1
6 3 9 7
M e r l i n
CONSENSUS
ADI 69  
T o l e d o  W
3 1 5 7
3 3 0 1
6 3 9 7
M e r l i n
CONSENSUS
4 9 0 1  5 0 0 0
TCAGATTGATAATTGGTTCCTACAGAAACTATTCTAACCGCGGAAGAAAGAAATTGAAAAAAAAAA. . TTGACAAAAACATCATAACATAAAGGACCACC
t c a g a t t g a t a a t t g g t t c c t a c a g a a a c t a t t c t a a c c g c g g a a g a a a g a a a t t g a a a a a a a a a a M t t g a c a a a a a c a t c a t a a c a t a a a g g a c c a c c
t c a g a t t g a t a a t t g g t t c c t a c a g a a a c t a t t c t a a c c g c g g a a g a a a g a a a t t g a a a a a a a a a a I ^ t t g a c a a a a a c a t c a t a a c a t a a a g g a c c a c c
TCAGATTGATAATTGGTTCCTACAGAAACTATTCTAACCGCGGAAGAAAGAAATTGAAAAAAAAAA. . T . GACAAAAACATCATAACATAAAGGACCACC 
TCAGATTGATAATTGGTTCCTACAGAAACTATTCTAACCGCGGAAGAAAGAAATTGAAAAAAAAAA. . TTGACAAAAACATCATAACATAAAGGACCACC 
TCAGATTGATAATTGGTTCCTACAGAAACTATTCTAACCGCGGAAGAAAGAAATTGAAAAAAAa H  - • TTGACAAAAACATCATAACATAAAGGACCACC 
TCAGATTGATAATTGGTTCCTACAGAAACTATTCTAACCGCGGAAGAAAGAAATTGAAAAAAAAAA. . TTGACAAAAACATCATAACATAAAGGACCACC 
TCAGATTGATAATTGGTTCCTACAGAAACTATTCTAACCGCGGAAGAAAGAAATTGAAAAAAAA-------- T-GACAAAAACATCATAACATAAAGGACCACC









5 1 0 1 < ^ U L 1 1 1  start 5 2 0 0
GGCGCTTCCGAGGAGGCGAAGCCGGCGAC . . .GACGA. . . CGATAAAGAATACAAAGCCGCAGTGTCGTCCAGAGGATTACGCGACCAGATTGCAAGATC
GGCGCTTCCGAGGAGGCGAAGCCGGCGAC . . .GACGA. . . CGATAAAGAATACAAAGCCGCAGTGTCGTCCAGAGGATTACGCGACCAGATTGCAAGATC 
GGCGCTTCCGAGGAGGCGAAGCCGGCGACAACGACGA. . . CGATAAAGAATACAAAGCCGCAGTGTCGTCCAGAGGATTACGCGACCAGATTGCAAGATC 
GGCGCTTCCGAGGAGGCGAAGCCGGCAACGACGACGACGACGATAAAGAATACAAAGCCGCAGTGTCGTCCAGAGGATTACGCGACCAGATTGCAAGATC
GGCGCTTCCGAGGAGGCGAAGCCGGCAACGACGAC................ GATAAAGAATACAAAGCCGCAGTGTCGTCCGGAGGATTACGCGACCAGATTGCAAGATC
GGCGCTTCCGAGGAGGCGAAGCCGGCGAC. . .GACGA. . . CGATAAAGAATACAAAGCCGCAGTGTCGTCCGGAGGATTACGCGACCAGATTGCAAGATC 




5 2 0 1 ________________________________________________________________________________________5 3 0 0
a d i  69  t c c g c g t c a c c t t t c a t c g a g t a a a a c c t a c g t t g H H I ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H ^ H H
T o l e d o  TCCGCGTCACCTTTCATCGAGTAAAACCTACGTTGGTAGGTCACGTAGGTACGGTTTATTGTGACGGTCTTTCTTTTCCGCGTGTCGGGTGACGTAGTTT 
W TCCGCGTCACCTTTCATCGAGTAAAACCTACGTTGGTAGGTCACGTAGGTACGGTTTATTGTGACGGTCTTTCTTTTCCGCGTGTCGGGTGACGTAGTTT 
3 1 5 7  TCCGCGTCACCTTTCATCGAGTAAAACCTACGTTGGTAGGTCACGTAGGTACGGTTTATTGCGACGGTCTTTATTTTCCGCGTGTCGGGTGACGTAGTTT 
3 3 0 1  TCCGCGTCACCTTTCATCGAGTAAAACCTACGTTGGTAGGTCACGTAGGTACGGTTTATTGCGACGGTCTTTCTTTTCCGCGTGTCGGGTGACGTAGTTT 
6 3 9 7  TCCGCGTTACCTTTCATCGAGTAAAACCTACGTTGGTAGGTCACGTAGGTACGGTTTATTGCGACGGTCTTTCTTTTCCGCGTGTCGGGTGACGTAGTTT 
M e r l i n  TCCGCGTCACCTTTCATCGAGTAAAACCTACGTTGGTAGGTCACGTAGGTACGGTTTATTGCGACGGTCTTTCTTTTCCGCGTGTCGGGTGACGTAGTTT
c o n s e n s u s  t c c g c g t - a c c t t t c a t c g a g t a a a a c c t a c g t t g g t a g g t c a c g t a g g t a c g g M ^ B g - g a c g g t c t t t - t t t t c c g c g t g t c g g g t g a c g t a g t t t
5 3 0 1  5 4 0 0
ADI 6 9  ^JdB^CAACGTGAGGACGACTACTCCGTGTGGCTCGACGGTACGGTGGTCAAAGGCTGTTGGGGATGCAGCGTCATGGACTGGTTGTTGAGGCG
T o l e d o  TCCTCTTGTAGCAACGTGAGGACGACTACTCCGTGTGGCTCGACGGTACGGTGGTCAAAGGCTGTTGGGGATGCAGCGTCATGGACTGGTTGTTAAGGCG 
W TCCTCTTGTAGCAACGTGAGGACGACTACTCCGTGTGGCTCGACGGTACGGTGGTCAAAGGCTGTTGGGGATGCAGCGTCATGGACTGGTTGTTGAGGCG 
3 1 5 7  TCCTCTTGTAGCAACGTGAGGACGACTACTCCGTGTGGCTCGACGGTACGGTGGTCAAAGGCTGTTGGGGATGCAGCGTCATGGACTGGTTGTTGAGGCG 
3 3 0 1  TCCTCTCGTAGCAACGTGAGGACGACTACTCCGTGTGGCTCGACGGTACGGTGGTCAAAGGCTGTTGGGGATGCAGCGTCATGGACTGGTTGTTGAGGCG 
6 3 9 7  TCCTCTTGTAGCAACGTGAGGACGACTACTCCGTGTGGCTCGACGGTACGGTGGTCAAAGGCTGTTGGGGATGCAGCGTCATGGATTGGTTGTTGAGGCG 
M e r l i n  TCCTCTTGTAGCAACGTGAGGACGACTACTCCGTGTGGCTCGACGGTACGGTGGTCAAAGGCTGTTGGGGATGCAGCGTCATGGACTGGTTGTTGAGGCG 
CONSENSUS TCCTCT-GTAGCAACGTGAGGACGACTACTCCGTGTGGCTCGACGGTACGGTGGTCAAAGGCTGTTGGGGATGCAGCGTCATGGA-TGGTTGTT-AGGCG
5 4 0 1  5 5 0 0
ADI 69  GTATCTGGAGATCGTGTTTCCCGCAGGCGACCACGTCTATCCCGGACTCAAGACGGAATTGCATAGTATGCGCTCGACGCTAGAATCCATCTACAAAGAC
T o l e d o  GTATCTGGAGATCGTGTTCCCCGCAGGCGACCACGTCTATCCCGGACTCAAGACGGAATTGCATAGTATGCGCTCGACGCTAGAATCCATCTACAAAGAC 
W GTATCTGGAGATCTTGTTCCCCGCAGGCGACCACGTCTATCCTGGACTCAAGACGGAATTGCATAGTATGCGCTCGACGCTAGAATCCATCTACAAAGAC 
3 1 5 7  GTATCTGGAGATCGTGTTCCCCGCAGGCGACCACGTCTATCCCGGACTTAAGACGGAATTGCATAGTATGCGCTCGACGCTAGAATCCATCTACAAAGAC 
3 3 0 1  GTATCTGGAGATCGTGTTCCCCGCAGGCGACCACGTCTATCCCGGACTTAAGACGGAATTGCATAGTATGCGCTCGACGCTAGAATCCATCTACAAAGAC 
6 3 9 7  GTATCTGGAGATCGTGTTCCCCGCAGGCGACCACGTCTATCCCGGACTTAAGACGGAATTGCATAGTATGCGCTCGACGCTAGAATCCATCTACAAAGAC 
M e r l i n  GTATCTGGAGATCGTGTTCCCCGCAGGCGACCACGTCTATCCTGGACTTAAGACGGAATTGCATAGTATGCGCTCGACGCTAGAATCCATCTACAAAGAC 
CONSENSUS GTATCTGGAGATC-TGTT-CCCGCAGGCGACCACGTCTATCC-GGACT-AAGACGGAATTGCATAGTATGCGCTCGACGCTAGAATCCATCTACAAAGAC
5 5 0 1  5 6 0 0
ADI 6 9  A T G C G G C A A T G T m H ^ ^ H
T o l e d o  ATGCGGCAATGCGTAAGTGTCTCTGTGGCGGCGCTGTCCGCGCAGAGGTAACAACGTGTTCATAGCACGCTGTTTTACTTTTGTCGGGCTCCCAGCCTCT 
W ATGCGGCAATGCGTAAGTGTCTCTGTGGCGGCGCTGTCCGCGCAGAGGTAACAACGTGTTCATAGCACGCTGTTTTACTTTTGTCGGGCTCCCAGCCTCT 
3 1 5 7  ATGCGGCAATGCGTAAGTGTCTCTGTGGCGGCGCTGTCCGCGCAGAGGTAACAACGTGTTCATAGCACGCTGTTTTACTTTTGTCGGGCTCCCAGCCTCT 
3 3 0 1  ATGCGGCAATGCGTAAGTGTCTCTGTGGCGGCGCTGTCCGCGCAGAGGTAACAACGTGTTCATAGCACGCTGTTTTACTTTTGTCGGGCCCCCAGCCTCT 
6 3 9 7  ATGCGGCAATGCGTAAGTGTCTCTGTGGCGGCGCTGTCCGCGCAGAGGTAACAACGTGTTCATAGCACGCTGTTTTACTTTTGTCGGGCTCCCAGCCTCT 
M e r l i n  ATGCGGCAATGCGTAAGTGTCTCTGTGGCGGCGCTGTCCGCGCAGAGGTAACAACGTGTTCATAGCACGCTGTTTTACTTTTGTCGGGCTCCCAGCCTCT 
CONSENSUS ATGCGGCAATG-GTAAGTGTCTCTGTGGCGGCGCTGTCCGC-CAGAGGTAACAACGTGTTCATAGCACGCTGTTTTACTTTTGTCGGGC-CCCAGCCTCT
ADI 65  
T o l e d o  W
3 1 5 7
3 3 0 1
6 3 9 7
M e r l i n
CONSENSUS
ADI 69  
T o l e d o  W
3 1 5 7
3 3 0 1
6 3 9 7
M e r l i n
CONSENSUS
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6 1 0 1  6 1 5 4
A D I 69  GGACGGCGATGGCAAGGTGCTGCACCTCAACAAGGGCTGGCTCTGCGCTACCAT
T o l e d o  GGACGGCGATGGCAAGGTGCTGCACCTCAACAAGGGCTGGCTCTGCGCTACCAT
W GGACGGCGATGGCAAGGTGCTGC.......................................................................................
3 1 5 7  GGACGGCGATGGCAAGGTGTTGCACCTCAACAAGGGCTGGCTCTGCGCTACCAT
3 3 0 1  GGACGGCGATGGCAAGGTGCTGC.......................................................................................
6 3 9 7  GGACGGCGATGGCAAGGTGCTGCACCTCAACAAGGGCTGGCTCTGCGCTACCAT 




Region X is well conserved, with over 99% identity between strains. The data for 
AD 169 confirmed the previously published sequence in this region (Chee et al., 
1990). Data for Merlin confirmed the recently published sequence for this strain 
(Dolan et al., 2004) with the exception of three differences, all found in the length of 
polynucleotide A:T tracts. Variation in the length of A:T tracts can be an artefact of 
PCR amplification, as the fidelity of DNA synthesis is affected by factors including 
the polymerase and 3’-5’ exonuclease activity (Hite et al., 1996). The variation 
occurs due to slipped strand extension by Taq DNA polymerase (Shinde et a l , 2001). 
During amplification, insertion/deletion events can produce ‘stutter’ products that 
differ from the original template by multiples of the repeat unit length (in this case, 
one nucleotide). The mutation rate of (A)n repeats was estimated at 1.5 x 10' per 
repeat per PCR cycle with contractions outnumbering expansions by more than five­
fold (Shinde et al., 2001). The type of polymerase used for PCR amplification in the 
current study was a mixture of Taq polymerases (Section 2.1.2) and could be expected 
to have a higher fidelity than other Taq polymerases, but PCR errors and variation in 
the length of A:T tracts between clones were nonetheless observed. The threshold for 
detecting stutter products was found to be eight repeat units (Shinde et al., 2001), and 
sequence analysis of the HCMV strains in region X showed that only A:T tracts of 
eight residues or more showed repeat length variation between clones. These 
differences could not be considered a reliable indicator of sequence variation between 
strains. Polynucleotide A:T tracts of eight or more residues are very rare in protein- 
coding regions in HCMV (discussed in Chapter 6), and are found at a much higher 
frequency in region X than in the rest of the genome (Table 3.1). Similar patterns are 
observed in the corresponding regions o f other CMV genomes (Table 3.1).
During the course of this work, an analysis of the coding content of the HCMV 
genome was carried out sequencing six strains that had been cloned as infectious 
bacterial artificial chromosomes (BACs) (Murphy et al., 2003b). Two of these strains 
were extensively passaged laboratory strains (AD 169 and Towne) and four were low- 
passage isolates (Toledo, FIX, PH and TR). Each BAC DNA was sequenced using a 
shotgun cloning method, thus avoiding PCR-generated length variation in A:T tracts. 
The corresponding sequences of the four strains not utilised for comparison in the 
current study (Towne, FIX, PH and TR) were subsequently compared to the seven
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strains analysed in the present study in order to investigate variation in the A:T tracts 
and other differences between strains that would cause ffameshifts.
Number of A:T tracts of > 8 residues/kbp







Table 3.1. The distribution of A:T tracts in different CMV genomes.
* Region O, the area between UL57 and UL69, which is discussed in Chapter 4, also 
contains several A:T tracts and is excluded.
Despite the high level of sequence identity between the strains in the present study, 
each of UL106-UL111, with the exception of UL108 (and C-ORFs 16 and 18), were 
disrupted in certain strains by nucleotide insertions or deletions that shift the reading 
frame in comparison with AD 169. UL108, which was not disrupted by a frameshift, 
contains a single nucleotide substitution that introduces an in-frame termination 
codon. As expected of recognised genes, no frameshifts were registered in UL105, 
UL111A or UL112. The data in Table 3.2 shows all the frameshifts in each ORF 
caused by insertions or deletions. The Table also specifies which o f these are caused 
by differences in A:T tract length, where strains differ from each other in the number 
of A or T residues. As explained above, variation in A:T tract length within strains 
could be due to PCR amplification artefacts, and these differences were an unreliable 
indicator of real variation between strains. However, data from the four strains of 




In addition to the frameshifts identified in UL106-UL111, a total of nine differences 
that would cause frameshifts were also found in the regions between the ORFs 
(Figure 3.4). Further analysis of region X not affected by ffameshift mutations 
revealed no novel ORFs potentially encoding proteins. All ORFs in strains AD 169 
and Merlin are shown in Figure 3.5. The potential of region X to contain protein- 
coding ORFs is limited by the high frequency of stop codons in all six coding frames 
and by frameshifts in the few ORFs conserved in the HCMV strains. Consequently, it 
is unlikely that ORFs UL106-UL111, or any other ORFs in region X, code for 
proteins.
Number of frameshift Number of these frameshifts
mutations affecting caused by variation in A:T








C-ORF 17 1 1
UL111 2 2
UL111A 0 0
C-ORF 18 0 0
UL112 0 0
Table 3.2. Frameshift mutations in the ORFs of region X, identified by 
sequence comparisons.
The central column concerns all frameshift mutations which affect the ORF. The 
right column concerns the number of these frameshift mutations caused by differences 














UL109 UL110 UL111 UL111A UL112
(vlL-10)
Figure 3.4. Frameshifts between HCMV strains in region X.
Navy blue lines show insertions/deletions that cause frameshifts in comparison to 
AD 169. Gold lines show A:T tracts of variable length that cause frameshifts in 
comparison to AD 169. Green lines show single base substitutions that introduce an 
in-frame stop codon. Red arrows show potential polyadenylation signals (AATAAA) 
and the M shows the first in-frame ATG codon of each ORF. No frameshifts were 




■ > i i i i i i i i i
i =»—n im immiih win— n n»- d— • =
i n i— i n i i n n  mu n \ n mi n i— vun
q — tq h n nun inh m u n n - - - - - - t = i t i — *
• i i i i i i i > i i
----------------1~ i r i H — (m — U—dd— fi d  HfiPil--------i=W — f=
-idmiififHi ftitfw—nn m i ii run 1----- 1-----m i—i
i m n n m - i  ( f i n > m  . n d - d i -a d — w n m
• i , i i i i i < * i
1 5 5 , 0 0 0  1 6 0 , 0 0 0
Merlin
i ~i i nm m rnmnn nmi n—num nn i— =i
i-------- h i—in— n m iiill i >i inn i n i— n  n  i-
q — t q - - - - - - - - - - - h  n  n i i n i n m m n — t u - - - - - i = i t q — n _
 1—in irid  n— m------ u-jwi----- du—1=
d d d lPd fH I itWH-l M l I II i nn mu 1 in i— i
i-------------- d-ddd—I dl l  rdd----- nPii rt~i 1 Id d
• i i i i > i i i i ■
1 5 5 , 0 0 0  1 6 0 , 0 0 0
Figure 3.5. ORFs in region X.
ORFs for the six translation frames of the DNA sequences of AD 169 and Merlin have 
been computed using Frames. Start codons are shown as short lines extending above 
the box, and stop codons are shown as short lines extending below the box. The 
region shown is larger than that shown in Figures 3.1 to 3.4, to include ORFs UL105 
and UL112/UL113, which are highlighted in green.
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3.4 Transcripts in region X: northern blot and RT-PCR analysis
Northern blots were carried out to determine the expression kinetics and sizes of 
transcripts from region X. Equal amounts o f polyA+ AD 169 mRNA were 
electrophoresed in agarose-formaldehyde gels, blotted to membranes overnight, and 
fixed by UV irradiation. A polyA+ RNA marker ladder was electrophoresed alongside 
the mRNA samples to aid estimation of transcript sizes (Section 2.1.8).
The three overlapping PCR products which were used to sequence region X (Figure 
3.2) were used to make dsDNA probes (section 2.2.22). The 5 kb RNA characterised 
by Plachter et al. (1988) was detected by each, and sized at approximately 4.6 kb. 
Detection of this in L RNA at high levels, in much lower levels in IE RNA, and not at 
all in E RNA (Figure 3.6), is consistent with previously published data (Plachter et al., 
88). A heterogeneous transcript of approximately 1.1 kb was also detected in L RNA 
by probe A, possibly by probe C and not by probe B (Figure 3.6).
Probe ORF Strand F primer R nrimer Size (bn)
D UL106 - X16 X40 321
E UL108 + X25 X7 566
F UL109/110 - X20 X21 720
G UL111A + X57 X59 457
H UL111 - X57 X59 457
I C-ORF 18 _ X53 X54 149
Table 3.3. ssRNA probes used for northern blots in region X.
Each probe was amplified by Lign’Scribe PCR reaction (Section 2.2.23) using the 
primers listed in Appendix. The positions of the probes within the region are shown 
in Figure 3.7. For each of probes D-I, the primer in bold was used in the MaxiScript 
radiolabelling reaction to make the ssRNA probe (Section 2.2.23).
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UL105 UL106 UL107 UL108 UL109 UL110 UL111 VlL-10 UL112
V v --------------7
Figure 3.6. N orthern blot analysis of region X using dsDNA probes.
The locations of the DNA probes are shown. Each blot included IE, E and L AD 169 
polyA" mRNA, and a negative control of MI polyAT mRNA. The results obtained 
using a GAPDH probe are shown at the bottom of each blot.
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H
Ml IE E L
4.6 kb 4.6 kb
1.1 kb §
1.1 kb
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Figure 3.7. N orthern blot analysis of region X using ssRNA probes.
The locations of the ssRNA probes are shown (not to scale, see Table 3.3 for accurate 
sizes), the arrows indicating the direction of any RNAs they would detect. Each blot 
included IE, E and L AD 169 polyA+ mRNA, and a negative control of MI polyAT 




Strand-specific ssRNA probes were also used in northern blots to investigate the 
transcripts in region X. The primers used for generating the ssRNA probes are listed 
in Table 3.3. PCR products generated by the Lign’Scribe reaction (Section 2.2.23) 
were radiolabelled using the MaxiScript reaction. When hybridised to northern blots, 
ssRNA probes create RNA-RNA hybrids that are more stable than the DNA-RNA 
hybrids. Their strand-specificity also avoids the depletion of available probe by 
hybridisation to the complementary strand that occurs with dsDNA probes. All blots 
were performed twice to ensure their reproducibility and accuracy. Probe D 
(corresponding to UL106) detected the 4.6 kb RNA in IE and L RNA and the 1.1 kb 
RNA in L RNA, which was also detected by dsDNA probe A (Figures 3.7 and 3.6, 
respectively). Probe E (UL108) did not detect any transcripts, but the 4.6 kb RNA 
was detected by probe F (UL109/110). Probe H (UL111) also detected a 1.1 kb RNA 
in the same orientation as the other transcripts, which was not detected by probe I. 
Probe G (UL111 A) did not appear to detect the UL111A RNA (of approximately 0.7 
kb). Previous studies of this gene also did not detect the transcript by northern blot, 
possibly because it is present in low abundance during lytic infection (Jenkins et al., 
2004; Cheeran et al., 2003; Kotenko et al., 2000).
The 4.6 kb RNA was detected in the middle of region X, between UL106 and 
UL111 A, and ssRNA probes at the ends of the region detected a 1.1 kb RNA in the 
same orientation as the larger transcript. Although two different 1.1 kb RNAs may 
have been detected, it is possible that this transcript is spliced, with the probes at the 
ends of the region (probes D and H, Figure 3.7) detecting the exons flanking the 4.6 
kb intron.
Plachter et al. (1988) described the 5 kb RNA as being evenly distributed between 
polyA+ and poly A' fractions of total infected cellular RNA. However, transcript 
mapping in the present study suggested that the 4.6 kb RNA detected was the intron 
derived during maturation of a 1.1 kb transcript. To check the polyadenylation status 
of both transcripts, total cellular RNA was prepared at late times from a high m.o.i. 
HCMV infection, and equal amounts were separated into polyA+ and polyA" fractions 
(Section 2.2.20). Probe A detected the 4.6 kb RNA as a strong signal in the total 
RNA and poly A' RNA samples, but as a very faint signal in the polyA+ sample 
(Figure 3.8). The small amount of 4.6 kb RNA in the polyA+ fraction may be a result
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of binding of the RNA to the oligo(dT) matrix via the many poly(A) tracts found 
throughout the sequence. The 1.1 kb message was detected as a strong signal in the 
total RNA and polyA+ mRNA samples, but as a very weak signal in the polyA" 
samples. The small amount of 1.1 kb RNA in the polyA' sequence is likely to be 
contamination from when the polyA+ and polyA' fractions were separated. Therefore, 
the 4.6 kb RNA is not polyadenylated, consistent with it being an intron spliced 
during maturation of the 1.1 kb RNA, which has exons at the ends of region X.
T A+ A  Ml
4.6 kb 
1.1 kb
Figure 3.8. Polyadenylation of RNAs in region X.
Lane T contains late total cellular RNA, lane A^ contains the polyA+ fraction of the 
total RNA sample and lane A" contains the polyA' fraction of the total RNA sample. 
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Figure 3.9. Splicing in region X.
(A) Positions of the splice donor and acceptor sites in region X. The blue bars show 
the approximate sizes of the PCR and RT-PCR products amplified using primers X I6 
and X46 (Appendix). (B) PCR and RT-PCR across region X. Lane 1 shows the PCR 
product generated from a genomic DNA template. Lanes 2 to 5 show the RT-PCR 
products generated from a polyA' RNA template (MI, IE, E and L respectively). (C) 
The conserved splice sites in HCMV and CCMV, donor and acceptor respectively, 
where y is a pyrimidine residue, r is a purine residue and n is any residue. The strand 
corresponding to the transcript is shown.
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Comparative studies have shown that UL106-UL111 do not have counterparts in 
CCMV (Davison et al., 2003), and that there is limited sequence identity between the 
two genomes in region X. However, splice donor and splice acceptor sites in UL111 
and UL106, respectively, are conserved between HCMV and CCMV (Figure 3.9), and 
in all of the sequenced HCMV strains. These splice sites are potentially involved in 
production of the 4.6 kb and 1.1 kb RNAs identified by northern blotting. Primers 
X I6 and X23 (Appendix) were designed in the predicted exons of the transcript for 
PCR amplification across the region, and across the predicted intron. Using these 
primers and AD 169 DNA as a template, a product of approximately 5.1 kbp was 
amplified (Figure 3.9). RT-PCR reactions also used the same set of primers, with a 
template of AD 169 IE, E or L polyA+ mRNA, and a negative control of MI polyA+ 
mRNA. RT-PCR products of approximately 600 bp were amplified using the IE, E 
and L templates (Figure 3.9). The amplification of a smaller product from polyA+ 
mRNA than from genomic DNA suggested that a processed transcript had been 
detected, minus an intron removed by splicing. Sequencing of the RT-PCR products 
confirmed that the transcript detected was spliced, with a large intron of 4528 bp 
excised from the splice sites postulated from the sequence comparisons.
On identification of this novel spliced RNA, a detailed literature search of previously 
identified HCMV spliced RNAs was carried out. Consequently, it was found that a 
study by Rawlinson et al. (1993) had sequenced a single clone derived from L RNA, 
identifying a 1.1 kb RNA with a large intron of 4528 nt. This RNA was termed 
R160461. The splice junction identified by Rawlinson et al. (1993) is congruent with 
that in the present study. The ends o f the 1.1 kb RNA were subsequently determined 
in the present study by RACE analysis to verify if these were also congruent with the 
ends ofR160461 (Section 3.5).
RT-PCR was also used to confirm splicing of the UL111A (vIL-10) transcript. 
Amplification reactions employed a primer at the start of the UL111A transcript (X57, 
Appendix) and a primer from the SMARTRACE kit (Section 2.1.9) that anneals to the 
poly(A) tail at the 3’-end of the transcript. Sequencing o f the RT-PCR products 
identified fully spliced UL111A transcripts, in agreement with the results previously 
reported by Kotenko et al. (2000), partially spliced transcripts (in which only the first 
intron was excised) and unprocessed transcripts (in which no splicing had occurred).
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3.5 Transcripts in region X: RACE analysis of 3’- and 5’-ends
To characterise the transcripts in region X identified by northern blotting and RT- 
PCR, RACE was performed using a combination of two different kits to identify the 
3’- and 5’-ends: SMARTRACE and GeneRacer (Sections 2.2.26 and 2.2.27, 
respectively). RACE reactions used a template of polyA+ L mRNA harvested from 
total infected cell RNA (Section 2.2.20). The primers used to map the ends of the 1.1 
kb transcript are shown in Figure 3.10. 3’-RACE products of approximately 450 bp 
were amplified using primer X48 (Figure 3.10). To map the 5’-end of the transcript, 
RACE products were amplified using five different primers. Using primers X57, X66 
and X28, 5’-RACE products of approximately 850, 710 and 300 bp were amplified 
(Figure 3.10). No products were amplified using primers X53 and X50, suggesting 
that these primers were either directly adjacent to or upstream from the 5’-end. Each 
RACE-PCR product was gel purified and cloned, and approximately 10 clones were 
sequenced for each to ensure that an accurate 3’- or 5’-end was obtained.





Figure 3.10. 3’- and 5’-RACE amplification of the ends of the 1.1 kb RNA.
Lanes 1 to 5 are 5’-RACE products amplified using primers X57, X66, X28, X53 and 
X50 respectively. Lane 6 is a 3’-RACE product for the 1.1 kb RNA, using primer 
X48. Lanes L are DNA markers.
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Figure 3.11. Three-fram e translation of the spliced 1.1 kb RNA in AD169.
Yellow shows exon sequence of the 1.1 kb RNA. The splice donor and acceptor sites 
are separated by a 4528 nt intron. Green shows a 27 aa protein starting on the first 
ATG codon and purple shows the 78 aa protein (the largest coding region starting on 
an ATG). At the 3'-end, red shows the poly(A) signal (AATAAA) and the two 
downstream RNA cleavage sites. At the 5’-end, blue shows the T residue mapped at 
the 5?-end and the upstream TATA box (TATTTATA). Lines indicate the UL111A 
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Figure 3.12. Signals for the 1.1 kb HCMV RNA are conserved in CCMV.
An alignment of AD 169 and CCMV sequences. Yellow shows the exons of the 
AD 169 1.1 kb RNA. Red shows the mapped 3’-ends of the RNA and the consensus 
poly(A) signal (AATAAA) conserved in CCMV. Blue shows the mapped 5'-end of 
the RNA and the TATA box (TATTTAT) conserved in CCMV.
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The 3’-end o f the 1.1 kb transcript mapped to two sites: a T residue at nucleotide 
position 155,740 in AD169, and a G residue at 155,726. These cleavage sites were 20 
bp and 34 bp, respectively, downstream from a consensus poly(A) signal AATAAA 
(Figure 3.11). The 3’-end identified by Rawlinson et al. (1993) corresponds to the 
second of these two RNA cleavage sites. The 5’-end mapped to a T residue at 
161,392, 830 bp upstream of the splice donor site, the same as the end mapped by 
Rawlinson et al. (1993) (Figure 3.11). A TATA box was identified 25 bp upstream 
from the 5’-end of the transcript. The two exons combine to make a transcript of 
approximately 1.14 kb. Potential translation products o f the transcript in strain 
AD 169 in the three reading frames are shown in Figure 3.11.
On characterising the 1.1 kb RNA, Rawlinson et al. (1993) identified a 31 aa protein, 
crossing the splice site, as the likely product encoded by the mRNA. However, this 
does not use an in-frame ATG initiation codon. The first ATG initiation codon in the 
mRNA specifies a 27 aa protein (highlighted in green in Figure 3.11) and the largest 
product would be a 78 aa protein (highlighted in purple in Figure 3.11). Two 
frameshifts, potentially affecting any protein coding region, were found towards the 
3’-end of the mRNA. Neither of these frameshifts affect the 27 aa or the 78 aa coding 
regions, but the 31 aa region is disrupted. None of these three amino acid sequences 
is significantly similar to any proteins in the NCBI database.
Sequence comparisons show that the poly(A) signal at the 3’-end, the splice site, and 
the TATA box at the 5’-end of the 1.1 kb RNA are also conserved in CCMV (Figure 
3.12). This suggests that a similar RNA, o f approximately 0.5 kb with a 5 kb intron, 
would be transcribed from the corresponding region in CCMV. However, within this 
putative CCMV RNA, there are no ATG codons (Figure 3.12).
3.6 Discussion
It is unlikely that ORFs UL106-UL111, assigned to region X in the original analysis 
of HCMV strain AD 169 (Chee et al., 1990), actually encode proteins. Only UL106 
and UL109 commence with ATG codons. The other ORFs are preceded by
105
Region X
termination codons, with UL107, UL108 and UL110 containing initiation codons 
internally and UL111 lacking such codons (Figure 3.1). Sequence comparisons of 
seven HCMV strains in region X showed that these ORFs, with the exception of 
UL108, are not intact in all HCMV strains, being disrupted by frameshifts in 
comparison with AD 169 (Figure 3.4). At many of the frameshifts, differences 
between the two clinical (unpassaged) samples, W and 3301, were observed. 
Moreover, no RNAs specified by these ORFs were detected in previous transcript 
mapping studies of the region, and none were detected in the present study. O f the 
three ORFs identified by Murphy et al. (2003b), only C-ORF 17 is frameshifted, in 
strains 3301, W, 6397 and BAC-cloned strain TR. C-ORF 16 and C-ORF 18 remain 
intact, although neither has a counterpart in CCMV. Furthermore, ssRNA probes D 
and I, used for northern blot analysis in the present analysis, did not detect transcripts 
corresponding to these ORFs (Figure 3.7). Probes D and I should detect transcripts C- 
ORF16 and C-ORF 18 respectively, based on the positions of poly(A) signals in 
region X. The three ORFs in region X unaffected by frameshifts (UL108, C-ORF16 
and C-ORF 18) are small compared to other HCMV protein-coding ORFs, potentially 
encoding proteins of only 46 aa, 90 aa and 84 aa, respectively, and none of these are 
similar to other proteins in the NCBI database. In addition to the frameshifts 
identified in UL106-UL111, other frameshifts occurred throughout the region and no 
novel ORFs emerged as potentially encoding proteins from the sequence 
comparisons. The known functional ORFs (UL105, UL111A and UL112) were 
conserved.
Region X has a distinct nucleotide composition, consisting of local regions of high 
G+C content embedded in sequences of low G+C content (Figure 3.13). The regions 
of high G+C content (and therefore where termination codons are rarer) tend to 
coincide with UL106-UL111. Overall, the G+C content of the region falls well below 
the average level for the rest of the genome. Similar patterns of unusual nucleotide 
composition are exhibited in the corresponding regions o f other CMV genomes, and 
to a lesser extent in HHV-6 and HHV-7 (Figure 3.13). In addition, polynucleotide 
A:T tracts o f eight or more residues are more common in region X than in the rest of 
the genome (Table 3.1).
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Figure 3.13. The nucleotide composition of region X and corresponding regions 
in other CMVs.
The plots were computed using Window (100 nucleotides shifted by 3 nucleotide 
increments) and displayed using Statplot. Known genes UL105, UL111A (present 






Figure 3.14. Sequence comparisons of region X between HCMV 
and other CMVs.
Comparisons were computed using Compare (window of 21 nucleotides with 
minimum match of 17 nucleotides) and displayed using Dotplot.
Region X
Sequences corresponding to region X are present in other CMVs, where they are 
similar in size and position in the genome. DNA sequence comparisons between 
HCMV and other CMV sequences are shown as matrix plots in Figure 3.14. The 
genomes of HCMV and CCMV (the closest known relative of HCMV) are only 
moderately diverged and are essentially collinear (Davison et al., 2003; discussed in 
Section 1.20). None of the ORFs predicted to be in region X (UL106-UL111 and C- 
ORFs 16-18) are conserved in CCMV, and the regions share limited sequence 
similarity. In addition, a distinct discontinuity is apparent near the right end of the 
region, where CCMV lacks a homologue of HCMV UL111A (vIL-10). Sequences 
corresponding to region X can also be identified in the more distantly related genomes 
of RhCMV (approximately 3.4 kbp), MCMV (9.2 kbp), RCMV (11.5 kbp) and 
TuHVl (6.7 kbp) (Figure 3.13). When compared with HCMV, these genomes are 
extremely divergent in region X, much more so than in the flanking genes (UL105 
and U L112).
Transcript analysis identified a spliced 1.1 kb RNA and its 4.6 kb intron as the only 
RNAs detected from region X (Figure 3.15). The splice sites, 3’-poly(A) signal, and 
5’-TATA box of the 1.1 kb RNA are conserved in the corresponding region in 
CCMV, suggesting that a similar RNA with a large intron should be expressed in 
CCMV. However, it is unlikely that the RNA encodes a functional protein, either in 
HCMV or in CCMV. In HCMV, the RNA has the potential to encode proteins of 27 
aa (utilising the first in-frame ATG initiation codon) or 78 aa (utilising the third in­
frame ATG codon). However, neither o f these are conserved in the potential CCMV 
reading frame, which contains no ATG initiation codons.
The 4.6 kb transcript identified by northern blot analysis in the present study 
corresponds to the 5 kb RNA originally characterised by Plachter et al. (1988). The 
5’-end of the 5 kb RNA was mapped to a residue four bases from the splice donor site 
identified in the current study (Figure 3.11). The 3’-end was mapped to two sites 
downstream from a poly(A) signal at nucleotide position 155,759 in AD169. This is 
the same poly(A) signal subsequently identified at the 3’-end of the 1.1 kb RNA 
(Figure 3.11). The nucleotide sequence published by Plachter et al. (1988) was 
compared to that of AD 169 in region X from the present study. The comparison 
identified a 211 bp deletion in the strain originally used to map the 5 kb RNA, from
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156,008 to 156,219. This deletion included the splice acceptor site, and thus would 
compromise processing of the 1.1 kb RNA. This explains why some of the 







UL105 UL106 UL108 UL109 UL110 UL111 UL111A UL112
UL107 (viL-10)
Figure 3.15. A model of the spliced 1.1 kb RNA and its 4.6 kb intron in region X.
The exons, at either end of the region, are joined via the splice sites shown in the 
figure to create a 1.1 kb RNA, and the 4.6 kb intron is consequently excised.
A study of the 5 kb RNA was recently published, investigating its role as an intron 
(Kulesza and Shenk, 2004). The authors showed that the transcript was an intron, 
derived from the processing of a precursor RNA. In transfection experiments, the 5 
kb RNA was shown to be spliced from a heterologous reporter gene in transfection. 
Northern blot analysis confirmed that the majority of the 5 kb RNA is found in the 
polyA' fraction of IE and L RNA. A viable mutant was constructed with a mutation 
in the splice donor site of the RNA, compromising processing of the 1.1 kb RNA. 
Total RNA prepared from cells infected with this viral mutant did not express the 4.6 
kb or the 1.1 kb RNA (Kulesza and Shenk, 2004).
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It is unlikely that there are protein-coding ORFs in region X, and the only RNAs 
identified in the region, a 1.1 kb spliced RNA with a 4.6 kb intron, are also unlikely to 
encode functional proteins. However, corresponding regions are found in other 
CMVs, and one study has noted that the expression of a large transcript can be 
detected in RhCMV and MCMV (Kulesza and Shenk, 2004). Also, sequence 
comparisons in the present study suggest that a similar RNA with a large intron is 
expressed from the corresponding region of CCMV. It seems likely that the RNAs 




CHAPTER 4: REGION O
4.1 Protein-coding genes
The second large region in HCMV not thought to contain protein-coding genes is 
located between ORFs UL57 and UL69. This region is here termed region O. The 
analysis o f AD169 predicted 11 ORFs in region O, UL58-UL68 (Chee et al., 1990). 
The ORFs flanking region O, UL57 and UL69, have been characterised, and a 
transcript related to UL65 has been identified, but there is no evidence for expression 
of proteins by UL58-UL64 and UL66-UL68. Three further novel, protein-coding 
ORFs have been predicted in region O by the analyses of Murphy et a l  (2003a; 
2003b), which are discussed in Section 1.18. From the list of 39 newly recognised 
ORFs with the potential for coding proteins, three are in region O: ORF3, ORF4 and 
ORF5. Part of region O has been shown to have an essential viral ds-acting function 
as the origin of lytic replication (orz'Lyt). Features of the origin region and its 
boundaries are discussed in Section 4.2.
At the left end of region O, UL57 specifies transcripts of 10 and 14 kb in infected cell 
RNA, and a 17 kb RNA of low abundance (Pari and Anders, 1993; Smuda et al., 
1997; Kiehl et a l,  2003). The 10 kb transcript was detected in cycloheximide-treated 
infected cells, but not in the presence of anisomycin, a more effective inhibitor (Kiehl 
et al., 2003). Accordingly, the RNA transcribed is consistent with early kinetics of 
expression. Three distinct 5’-ends were identified, spread over 800 bp (Kiehl et al., 
2003). Two of these sites contain upstream sequences which function as promoters, 
responsive to HCMV infection in transient assays. The third promoter was predicted, 
by sequence homology, to be regulated by specific promoter elements often present in 
cellular, usually TATA-less promoters, but not previously found in HCMV (Burke 
and Kadonaga, 1997; Kiehl et al., 2003). These sites constitute a large, complex 
promoter region with novel features which control UL57 expression. Sequences have 
also been identified which regulate UL57 transcription and oriLyt activation (Kiehl et 
al., 2003). UL57 encodes an early, nuclear, single-stranded DNA-binding protein of 
about 140 kDa, which is one of 11 trans-acting factors required for transient 
complementation of on'Lyt-dependent DNA replication (Pari and Anders, 1993).
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At the right end of region O, UL69 specifies a complex pattern of transcripts that 
changes during the HCMV replicative cycle. Two transcripts, o f 2.7 and 3.5 kb, 
classified as E-L genes, could be detected as early as 7 h p.i. but not in the presence of 
CHX (Winkler et al., 1994). UL69 encodes a regulatory protein which exerts a broad 
stimulatory effect on gene expression and is required for efficient HCMV replication 
(Hayashi et al., 2000). The UL69 protein, which is present in dense bodies, was not 
detected within the membrane fraction of purified virions after treatment with 
detergent, suggesting that the protein is a tegument constituent (Winkler and 
Stamminger, 1996). A phosphorylated form of the protein also contained in the virion 
has been identified by Western blot (Winkler and Stamminger, 1996). In cell culture, 
UL69 is able to arrest cell cycle progression by causing different cell types, including 
HFFF cells, to accumulate within the G1 compartment of the cell cycle (Lu and 
Shenk, 1999; Hayashi et al., 2000). In the presence o f UL69, even the introduction of 
serum fails to induce progression of quiescent HFFF cells into S phase.
A transcript outwith the core oriLyX region is also known to be expressed from region 
O. The late RNA pp67 is routinely detected in nucleic acid sequence-based 
amplification (NASBA) assays used to monitor the progression of HCMV infection 
and the effect of antiviral therapy on viral activity (Blok et al., 1998; Gema et al., 
1999). The initial study by Davis et al. (1984) also detected an associated 67 kDa 
protein in strain Towne. Although the pp67 RNA is routinely detected in NASBA 
assays, the study by Davis et al. (1984) remains the only one to characterise this 
protein. The potential for this RNA to encoded a protein will also be investigated in 
the present study by sequence comparisons of seven HCMV strains.
O f the other ORFs originally defined in region O, only UL59, UL67 and UL68 
commence with ATG initiation codons. The other ORFs are preceded by termination 
codons, with UL60-UL62 and UL64-UL66 containing in-frame ATG codons 
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Figure 4.1. Map of the characterised genes and predicted genes in region O.
The scale at the top shows the genomic location (kbp) in the AD 169 genome. Dark 
green shows parts of ORFs of known functions. Red shows ORFs predicted by Chee 
et al., 1990 that have no known function and have been discounted because they have 
no counterparts in CCMV (Davison et al., 2003a). Pink shows novel ORFs predicted 
by Murphy et al. (2003a, 2003b). The 3’-end of each ORF has a point to show its 
orientation, and the M shows the first in-frame ATG initiation codon in each red ORF. 
ORFs 3,4 and 5 all commence on ATG initiation codons. Dark green and pink ORFs 
all start with ATG initiation codons. The core region of the HCMV origin of lytic 
replication (oriLyt) is shown as a grey bar and the three characterised RNAs in the 
origin are shown as blue arrows (Zhu et al., 1998; Huang et al., 1996; Prichard et al., 
1998). A fourth transcript in the region, pp67, has also been previously mapped in 
AD 169 (Scott et al., 2002).
4.2 Origin of lytic DNA replication (or/Lyt)
After the original HCMV analysis of Chee et al. (1990), a candidate origin of lytic 
replication was identified in SCMV and HCMV by assessing the ability of cloned 
restriction fragments to mediate DNA replication after transfection into HFFFs when 
required trans-acting factors were supplied by infection (Anders and Punturieri, 1991; 
Hamzeh et al., 1990). In SCMV strain Colburn, sequence analysis identified four 
distinct domains containing different repeat elements. Clustered sets of repeat 
elements, similar to those in SCMV, were also identified in HCMV oriLyX (Anders et 
al., 1992). Masse et al. (1992) identified a region between nucleotide positions 
93,000 and 94,400 in AD 169, residing within oriLyX, which contains the greatest
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content of inverted and direct repeats in HCMV. Various studies, using transient 
replication assays, identified a core region of oriLyt that contains elements required 
for oriLyt function, including multiple copies of elements similar to known 
transcription factor binding sites, but requires flanking sequences for full activity 
(Masse et al., 1992; Anders et al., 1992; Zhu et al., 1998). The core region o f oriLyt 
shown in Figure 4.1 was determined to be between 92,682 and 94,230 from the most 
recent analysis (Zhu et al., 1998). Cotransfection assays of oriLyt replication in 
HCMV cosmids identified eleven ORFs which encode trans-acting factors sufficient 
for transient complementation of orz'Lyt-dependent DNA replication (Pari and Anders, 
1993). UL57, which is to the left o f region O, is one of these essential ORFs in which 
engineered ffameshift mutations prevent complementation of DNA replication.
Transcript analysis studies identified at least four transcripts that cross or originate 
within oriLyt, but only one of these has been characterised (Huang et al., 1996). The 
smallest replicator transcript (SRT) is an RNA of approximately 0.25 kb, localised to 
approximately the centre of the core region of oriLyt by northern blot analysis. The 
RNA was detected as early as 2 h p.i. but not in the presence of CHX. A single 5’- 
end was identified, and sequence immediately upstream of SRT was shown to 
function as a promoter, responsive to HCMV infection in transfection assays (Huang 
et al., 1996). SRT is not polyadenylated and was shown to have heterogeneous 3’- 
ends which overlap an oligopyrimidine sequence shown by mutation analysis to be 
essential to oriLyt replicator function (Huang et al., 1996). SRT is likely to play a 
role in initiating or regulating HCMV lytic-phase DNA synthesis. Two more RNAs, 
of approximately 300 and 500 bp, were identified in on'Lyt by Prichard et al. (1998). 
These were termed vRNAs (virus-associated RNAs) from their association with 
packaged virion DNA. They were mapped to positions within the origin region, as 
shown on Figure 4.1. One of these, vRNA-2, was identified as a RNA-DNA hybrid 
and mapped within the core oriLyt, on the same strand as SRT (Prichard et al., 1998).
4.3 Sequence comparisons
As discussed in Section 3.3, sequence comparisons of multiple HCMV strains can be 
used to identify ORFs that are conserved or disrupted by insertions or deletions.
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Region O was sequenced in seven HCMV strains: high passage strain AD 169, low 
passage strains Toledo, Merlin, 3157 and 6397, and strains obtained directly from 
human tissue: W and 3301 (Section 2.1.1). Initially, six different PCR product were 
amplified for each strain (PCR products 1,2 and 4-7, Table 4.1 and Figure 4.2). 
Larger PCR products proved difficult to amplify and clone, most likely because of the 
unusual nucleotide composition of the region and the presence of various repeat 
elements associated with oriLyt.
PCR
product F prim er R prim er Size (kbp) Strains amplified
1 07 013 1.4 A, T, M, 31,63, 33, W
2 054 060 1 A, T, M, 31,63, 33, W
3a 078 084 0.3 A, T, M, 31,63, 33, W
3b 03 072 0.3 A, T, M, 31,63, 33, W
3c 086 073 0.2 A, T, M, 63
3d 076 096 0.2 A
3e 088 093 0.25 A
3f 096R O101R 0.3 A
3g 090 0 9 1R 0.2 A
3h 083 095 0.55 A, T, M, 31,63,33
4 021 020 1 A, T, M, 31,63,33
5 019 018 1.4 A, T, M, 31 ,63 ,33 , W
6 017 016 1.4 A, T, M, 31 ,63 ,33 , W
7 028 06 1.3 A, T. M, 31 .63 ,33 . W
Table 4.1. PCR amplification of region O for sequence comparisons.
Each PCR amplification product was amplified by the primers shown (Appendix). 
The approximate size of each PCR fragment and the strains amplified for each set of 
primers is also shown: A is AD 169, T is Toledo, M is Merlin, 31 is 3157, 63 is 6397, 
33 is 3301, W is W. PCR products 3a-3h required a high-GC PCR kit for 
amplification (Section 2.2.3). The positions of these overlapping PCR fragments are 
shown in Figure 4.2.
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PCR products 3a-3h (Table 4.1), which largely correspond to the core orz'Lyt region, 
were especially difficult to obtain and could not be amplified for all the strains. 
Where products were obtained, they were amplified using a high G+C kit (Section 
2.2.3) and sequenced using dGTP Big Dye, a sequencing reagent for high G+C 
templates. Sequence data across the entire region could only be generated for strain 
AD 169, the rest of the strains containing gaps of approximately 500 bp (strains 
Merlin, Toledo and 6397), 600 bp (strains 3301 and 3157) or 1 kbp (strain W) in 
UL61 (Figures 4.2 and 4.3). Each PCR product was cloned into plasmids, and at least 
four plasmids were sequenced for each product. The sequence database was compiled 
from electropherograms using PreGap4 and Gap4 (Staden et al., 2000) and Phred 
(Ewing and Green, 1998; Ewing et al., 1998).
I  i i i i i i i r
91 92 93 94 95 96 97 98 99
a c m
ort-yt UL66UL57 UL58 UL59 UL60 UL61 UL62 UL63 UL64 UL65 UL67 UL68 UL69
Figure 4.2. PCR amplification of region O for sequence comparisons.
Blue bars show the overlapping PCR fragments, amplified using the primers shown in 
Table 4.1. Fragment 3 corresponds to the region of high G+C content that was 
amplified in even smaller fragments (Table 4.1), and not in all strains. The dark grey 
box over UL61, which corresponds to the core region of oriLyt, shows where 
complete sequence was only generated for AD 169.
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< ^ U L 5 7  start 100
ADI 6 9  CGTTCAACCTGCTGAAGTAGAGAAAAGCCGCGGGCCCCACCGGCGCTAGCGCGGTTAGTTCCTCGTGGCT§^jGGTGGATGAACGGAAGACAATGGCTAC
3 1 5 7  CGTTCAACCTGCTGAAGTAGAGAAAAGCCGCGGGCCCCACCGGCGCTAGCGCGGTTAGTTCCTCGTGGCTCATGGTGGATGAACGGAAGACAATGGCTAC 
6 3 9 7  CGTTCAACCTGCTGAAGTAGAGAAAAGCCGCGGGCCCCACCGGCGCTAGCGCGGTTAGTTCCTCGTGGCTCATGGTGGATGAACGGAAGACAATGGCTAC 
3 3 0 1  CGTTCAACCTGCTGAAGTAGAGAAAAGCCGCGGGCCCCACCGGCGCTAGCGCGGTTAGTTCCTCGTGGCTCATGGTGGATGAACGGAAGACAATGGCTAC 
W CGTTCAACCTGCTGAAGTAGAGAAAAGCCGCGGGCCCCACCGGCGCTAGCGCGGTTAGTTCCTCGTGGCTCATGGTGGATGAACGGAAGACAATGGCTAC 
M e r l i n  CGTTCAACCTGCTGAAGTAGAGAAAAGCCGCGGGCCCCACCGGCGCTAGCGCGGTTAGTTCCTCGTGGCTCATGGTGGATGAACGGAAGACAATGGCTAC 
T o l e d o  CGTTCAACCTGCTGAAGTAGAGAAAAGCCGCGGGCCCCACCGGCGCTAGCGCGGTTAGTTCCTCGTGGCTCATGGTGGATGAACGGAAGACAATGGCTAC 
CONSENSUS CGTTCAACCTGCTGAAGTAGAGAAAAGCCGCGGGCCCCACCGGCGCTAGCGCGGTTAGTTCCTCGTGGCTCATGGTGGATGAACGGAAGACAATGGCTAC
101  200  
ADI 6 9  GCCGCCACTGAGTGAATTTTATACCAAGGAAAAGTTCAGCACGTCATGTTTGACGCACGACGTCTGAGACACCACCGTGGCCACCACTGCGGTCTGGCTG 
3 1 5 7  GCCGCCACTGAGTGAATTTTATACCAAGGAAAAGTTCAGCACGTCATGTTTGACGCACGACGTCTGATACACCACCGTGGCCACCACTGCGGTCTGGCTG 
6 3 9 7  GCCGCCACTGAGTGAATTTTATACCAAGGAAAAGTTCAGCACGTCATGTTTGACGCACGACGTCTGATACACCACCGTGGCCACCACTACGGTCTGGCTG 
3 3 0 1  GCCGCCACTGAGTGAATTTTATACCAAGGAAAAGTTCAGCACGTCATGTTTGACGCACGACGTCTGATACACCACCGTGGCCACCACTGCGGTCTGGCTG 
W GCCGCCACTGAGTGAATTTTATACCAAGGAAAAGTTCAGCACGTCATGTTTGACGCACGACGTCTGATACACCACCGTGGCCACCACTGCGGTCTGGCTG 
M e r l i n  GCCGCCACTGAGTGAATTTTATACCAAGGAAAAGTTCAGCACGTCATGTTTGACGCACGACGTCTGAGACACCACCGTGGCCACCACTGCGGTCTGGCTG 
T o l e d o  GCCGCCACTGAGTGAATTTTATACCAAGGAAAAGTTCAGCACGTCATGTTTGACGCACGACGTCTGAGACACCACCGTGGCCACCACTGCGGTCTGGCTG 
CONSENSUS GCCGCCACTGAGTGAATTTTATACCAAGGAAAAGTTCAGCACGTCATGTTTGACGCACGACGTCTGA-ACACCACCGTGGCCACCACT-CGGTCTGGCTG
ADI 69  
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4 0 1  5 0 0
ADI 69  CGTCCGATCACAATCCGTTTTCCCACTCAGTCGCACAAGCAGCACATAAAAACCCCACACAGGGCACGTGAAAACACCGTCCCTAGAAAACGGCGTTTTC 
3 1 5 7  CGTCCGATCACAACCCGTTTTCCCACTCAGTCGCACAAGCAGCACATAAAAACCCCACACAGAGCACGTGAAAACAACGTCCCTAGAAAACGGTGTTTTC 
6 3 9 7  CGTCCGATCACAACCCGTTTTCCCACTCAGTCGCACAAGCAGCACATAAAAACCCCACACAGGGCACGTGAAAACAACGTCCCTAGAAAACGGTGTTTTC 
3 3 0 1  CGTCCGATCACAACCCGTTTTCCCACTCAGTCGCACAAGCAGCACATAAAAACCCCACACAGAGCACGTGAAAACAACGTCCCTAGAAAACGGTGTTTTC 
W CGTCCGATCACAACCCGTTTTCCCACTCAGTCGCACAAGCAGCACATAAAAACCCCACACAGGGCACGTGAAAACAACGTCCCTAGAAAACGGTGTTTTC 
M e r l i n  CGTCCGATCACAATCCGTTTTCCCACTCAGTCGCACAAGCAGCACATAAAAACCCCACACAGGGCACGTGAAAACACCGTCCCTAGAAAACGGTGTTTTC 
T o l e d o  CGTCCGGTCACAACCCGTTTTCCCACTCAGTCGCACAAGCAGCACATAAAAACCCCACACAGGGCACGTGAAAACACCGTCCCTAGAAAACGGTGTTTTC 
CONSENSUS CGTCCG-TCACAA-CCGTTTTCCCACTCAGTCGCACAAGCAGCACATAAAAACCCCACACAG-GCACGTGAAAACA-CGTCCCTAGAAAACGG-GTTTTC
ADI 69 
3 1 5 7  
6 3 9 7  
3 3 0 1  
W
M e r l i n
T o l e d o
CONSENSUS
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7 0 1  8 0 0
ADI 6 9  GAATCTGGTCTCGCAACCTCAATCGCCGCTATCACCACCGATTTTCGCTGCGCTCCGCCGACAAAACGCCGTACAAGCTACACACCCCAAAAACCCGCGC
3 1 5 7  GGATCTGGTCTCGCAACCTCAATCGCCGCTATCACCACCGACTTTCGCTGCGCTCCGCCGACAAAACGCCGTACAAGTTACACACCCCAAAAACCTGCGC 
6 3 9 7  GGATCTGGTCTCGCAACCTCAATCGCCGCTATCACCACCGACTTTCGCTGCGCTCCGCCGACAAAACGCCGTACAAGTTACACACCCCAAAAACCTGCGC 
3 3 0 1  GGATCTGGTCTCGCAACCTCAATCGCCGCTATCACCACCGACTTTCGCTGCGCTCCGCCGACAAAACGCCGTACAAGTTACACACCCCAAAAACCTGCGC 
W GGATCTGGTCTCGCAACCTCAATCGCCGCTATCACCACCGACTTTCGCTGCGCTCCGCCGACAAAACGCCGTACAAGCTACACACCCCAAAAACCTGCGC 
M e r l i n  GAATCTGGTCTCGCAACCTCAATCGCCGCTATCACCACCGATTTTCGCTGCGCTCCGCCGACAAAACGTCGTACAAGCTACACACCCCAAAAACCCGCGC 
T o l e d o  GGATCTGATCTCGCAACCTCAATCACCGCTATCACCACCAATTTTCGCTGCGCTCCGCCGACAAAACGCCGTACAAGCTACACACCCCAAAAACCCGCGC 
CONSENSUS G-ATCTG-TCTCGCAACCTCAATC-CCGCTATCACCACC-A-TTTCGCTGCGCTCCGCCGACAAAACG-CGTACAAG-TACACACCCCAAAAACC-GCGC
Figure 4.3. Sequence comparisons of seven HCMV strains in region O.
Alignments were made using ClustalW and displayed using Pretty. Yellow AD 169 
sequence shows all characterised and predicted ORFs in the region. The start and stop 
codons for each ORF are shown, the arrows indicating their orientation. Purple shows 
insertions/deletions that cause frameshifts in comparison to AD 169. Sky blue shows 
variation in polynucleotide A:T or G:C tracts of eight or more residues that cause 
frameshifts in comparison to AD 169. Grey shows in-frame insertions/deletions. 
Brown consensus residues show conserved potential polyadenylation signals 
(AATAAA). The figure is continued on the following pages.
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C G TA C TC G A A G A C C TTA C A G TTTA C G A G TC A A TA A A A CA G G A A A A G A TCCG A A CTTTA A A A TTG TG TA TTTTTA TTTTCCCA TCCCCCTC. . T T T T T A C C  
C G TA C TC G A A G A C C TTA C A G TTTA C G A G TC A A TA A A A CA G G A A A A G A TCCG A A CTTTA A A A TTG TG TA TTTTTA TTTTCCCA TCCCCCTC. . T T T T T A C C  
C G TA C TC G A A G A C C TTA C A G TTTA C G A G TC A A TA A A A CA G G A A A A G A TCCG A A CTTTA A A A TTG TG TA TTTTTA TTTTCCCA TCCCCCTC. . T T T T T A C C  
C G TA C TC G A A G A C C TTA C A G TTTA C G A G TC A A TA A A A C A G G A A A A G A TCCG A A CTTTA A A A TTG TG TA TTTTTA TTTTCCCA TCCCCCTC. . T T T T T A C C  
C G TA C TC G A A G A C C TTA C A G TTTA C G A G TC A A TA A A A C A G G A A A A G A TCCG A A CTTTA A A A TTG TG TA TTTTTA TTTTCCCA TCCCCCTC. . T T T T T A C C  
CGTACTCGAA G A CCTTA CA G TTTA CG A G TCAATAAAACA GGAAAAGATCCGAACTTTAAAATTGTGTATTT T T A T T T C C C C A TC C C C C C T J T T T T T A C C
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AA A A A A C ACATTTTTCGTCTTGTAAAAAGTAACTTTCGCCCATTGCCATGAAACACCGTGATGGGGAACGGTGTTGTGTGTCGACTGACGTCACTACGGC
A A A A AACACATTTTTCGTCTTGTAAAAAGTAACTTTCGCCCATTGCCATGAAACACCGTGATGGGGAACGGTGTTGTGTGTCGACTGACGTCACTACGGC
A A A A AACACATTTTTCGTCTTGTAAAAAGTAACTTTCGCCCATTGCCATGAAACACCGTGATGGGGAACGGTGTTGTGTGTCGACTGACGTCACTACGGC
A A A A AACACATTTTTCGTCTTGTAAAAAGTAACTTTCGCCCATTGCCATGAAACACCGTGATGGGGAACGGTGTTGTGTGTCGACTGACGTCACTACGGC
A A A A A A C ACATTTTTCGTCTTGTAAAAAGTAACTTTCGCCCATTGCCATGAAACACCGTGATGGGGAACGGTGTTGTGTGTCGACTGACGTCACTACGGC
A AAAAACACATTTTTCGTCTTGTAAAAAGTAACTCTCGCCCATTGCCATGAAACACCGTGATGGGGAACGGTGTTGTGTGTCAACTGACGTCACTACGGC
A A A A A A C A C A TTTTTC G TC TTG TA A A A A G TA A CT-TCG CCCA TTG CCA TG A A A CA CCG TG A TG G G G A A CG G TG TTG TG TG TC-A CTG A CG TCA CTA CG G C
1101  1200  
A D I 69  GATCAGTATCGACGTCGTGTATACATAACGGTGCCCGGTGTTTTTATTCGGGGCGTTGTCGCGTCTTGATGTAATGTAACCTGAAACCGCCGTGCCCAAG
3 1 5 7  GATCAGTATCG A CG TCG TG TA TA CA TA A CG G TG CCCG G TG TTTTTA TTCG G G G CG TTG TCG CG TCTTG A TG TA A TG TA A CCTG A A A CCG CCG TG CCTA A G  
6 3 9 7  GATCAGTATCGACG TCG TG TA TA CA TA A CG G TG CCCG G TG TTTTTA TTCG G G G CG TTG TCG CG TCTTG A TG TA A TG TA A CCTG A A A CCG CCG TG CCTA A G  
3 3 0 1  GATCAGTATCGACG TCG TG TA TA CA TA A CG G TG CCCG G TG TTTTTA TTCG G G G CG TTG TCG CG TCTTG A TG TA A TG TA A CCTG A A A CCG CCG TG CCTA A G  
W GATCAGTATCGACG TCG TG TA TA CA TA A CG G TG CCCG G TG TTTTTA TTCG G G G CG TTG TCG CG TCTTG A TG TA A TG TA A CCTG A A A CCG CCG TG CCTA A G  
M e r l i n  GATCAGTATCGACGTCG TG TA TA CA TA A CG G TG CCCG G TG TTTTTA TTCG G G G CG TTG TCG CG TCTTG A TG TA G TG TA A CCTG A A A CCG CCG TG CCCA A G  
T o l e d o  GATCAGTATCGACGTCGTGTA TA CA TA A CG G TG CCCG G TG TTTTTG TTCG G G G CG TTG TCG CG G CTTG A TG TA A TG TA A CCTG A A A CCG CCG TG TCCA A G  
C O N SE N SU S G A TC A G TA TC G A C G TC G TG TA TA C A TA A C G G T G C C C G G T G T T T T T -T T C G G G G C G T T G T C G C G -C T T G A T G T A -T G T A A C C T G A A A C C G C C G T G -C -A A G
A D 169
3 1 5 7
6 3 9 7
3 3 0 1W
M e r l i n
T o l e d o
C O N SEN SU S
ADI 69  
3 1 5 7  
6 3 9 7  
3 3 0 1  W
M e r l i n
T o l e d o
CO N SEN SU S
1 2 0 1  1 3 0 0
AATGCGGAAGCCAGCGTGTAATCATAACGGGGTTTTGGGTACAATCTGACGACATCTGGCGGCGAGCGTACACCATCGAATGTGGCGATCGCCGGCTCTA
A A TG CG G AAGCCAGCGTGTAATCATAACGGGGTTTTGGGTACAATCTGACGACATCTGGCGGCGAGCGTACACCATCGAATGTGGCGATCGCCGGCTCTA
A A TG CG G AAGCCAGCGTGTAATCATAACGGGGTTTTGGGTACAATCTGACGACATCTGGCGGCGAGCGTACACCATCGAATGTGGCGATCGCCGGCTCTA
A A TG CG G AAGCCAGCGTGTAATCATAACGGGGTTTTGGGTACAATCTGACGACATCTGGCGGCGAGCGTACACCATCGAATGTGGCGATCGCCGGCTCTA
A A TGCGGAAGCCAGCGTGTAATCATAACGGGGTTTTGGGTACAATCTGACGACATCTGGCGGCGAGCGTACACCATCGAATGTGGCGATCGCCGGCTCTA
A A TG CG G AAGCCAGCGTGTAATCATAACGGGGTTTTGGGTACAATCTGACGACATCTGGCGGCGAGCGTACACCATCGAATGTGGCGATCGCCGGCTCTA
A A TG CG G AAGCCAGCGTGTAATCATAACGGGGTTTTGGGTACAACCTGACGACATCTGGCGGCGAGCGTACACCATCGAATGTGGCGATCGTCGGCTCTA
AATGCGGAAGCCAGCGTGTAATCATAACG G G G TTTTG G G TA CA A -CTG A CG A CA TCTG G CG G CG A G CG TA CA CCA TCG A A TG TG G CG A TCG -CG G CTCTA
1 3 0 1  <^ U L 5 9  start | 14Q0
CGTCACAATGACGCAAAAACACACTGTAAAACCCGCGTAGACAGCTTTCCTGGTCAACGAGCGcjjcTGGTGTCGGCATAAGAACAGGCATCAACCCCG






CG TCA CAATGACGCAAAAA-AC — TG T A A A A C -C G C G T A G A C A G C T T T C C -G -T C A A -G A G C G C C A T C T G G T G T C -G C A T A A G A A C A G G C A T -A A C C C C G
1 4 0 1  1 5 0 0
A D I 6 9  TGGCCGGCGAGGCGGTGAGCACTTTTGTTGGTCACGTGACCATCAGCGCAGGAAGCGAGGCCCGTAGAACCGCCCAAGAGGCGGTGCCAGATGCCAACGT 
3 1 5 7  TGGCCGGCGAGGCGGTGAGCACTTTTGTTGGTCACGTGACCATCTGCGCAGGAAGCGAGGCCCGTAGAACCGCCCAAGAGGCGGTGCCAGATGCCAACGT 
6 3 9 7  TGGCCGGCGAGGCGGTGAGCACTTTTGTTGGTCACGTGACCATCCGCGCAGGAAGCGAGGCCCGTAGAACCGCCCAAGAGGCGGTGCCAGATGCCAACGT 
3 3 0 1  TGGCCGGCGAGGCGGTGAGCACTTTTGTTGGTCACGTGACCATCAGCGCAGGAAGCGAGGCCCGTAGAACCGCCCAAGAGGCGGTGCCAGATGCCAACGT 
W TGGCCGGCGAGGCGGTGAGCACTTTTGTTGGTCACGTGACCATCCGCGCAGGAAGCGAGGCCCGTAGAACCGCCCAAGAGGCGGTGCCAGATGCCAACGT 
M e r l i n  TGGCCGGCGAGGCGGTGAGCACTTTTCCTGGTCACGTGACCATCAGTGCAGGAAGCGAGGCCCGTAGAACCGCCCAAGAGGCGGTGCCAGATGCCAACGT 
T o l e d o  TGGCCGGCGAGGCGGTGAGCACTTTTGTTGGTCACGTGACCATCGGCGCAGGAAGCGAGACCCGTAGAACCGCCCAAGAGGCGGTGCCAGATGCCAACGT 
CO N SE N SU S TG G C C G G C G A G G C G G TG A G C A C TTTT--TG G TC A C G TG A CCA TC-G -G CA G G A A G CG A G -CCCG TA G A A CCG CCCA A G A G G CG G TG CCA G A TG CCA A CG T
1 5 0 1  1 6 0 0
A D I 6 9 CA T A A T CA CA A G G TG A TTTG TTA CG TCA CG CG ...................................................CGCGCACGCACGCGCGCGGTAGAATACAGCGATCCCTAGTGAAGCCACACCC
3 1 5 7  C A T A A T CA CA A G G TG A TTTG TTA CG TCA CG CG . . . . CACACGCACGCGCGCGCACGCACGCGCGCGGTAGAATACAGCGATCCCTAGTGAAGCCACACCC 
6 3 9 7  C A T A A T CA CA A G G TG A TTTG TTA CG TCA CG CG . . . . CACACGCACGCGCGCGCACGCACGCGCGCGGTAGAATACAGCGATCCCTAGTGAAGCCACACCC
3 3 0 1  C A T A A T CA CA A G G TG A TTTG TTA CG TCA CG CG   ...............................H CGCACGCACGCGCGCGGTAGAATACAGCGATCCCTAGTGAAGCCACACCC
W C A C A A T C A C A A G G TG A TT|G TG A C G TC A C G C G ...................................................CGCGCACGTGCGCGCGCGGTAGAATATAGCGATCCCTAGTGAAGCCACACCC
M e r l i n  CATAATCACAAGGTGATTTGTTACGTCACGCGfrGTGCGCACACGCGCACGCGCGCACACGCGCGCGGTAGAATACAGCGATCCCTAGTGAAGCCACACCC
T o l e d o  C A T A A T CA CA A G G TG A TTTG TTA CG TCA CG CG ............................................ JC G C A C G C A C G C G C G C G C G G TA G A A TA CA G CG A TCCCTA G TG A A G CCA CA CCC
CO N SE N SU S C A -A A T C A C A A G G T G A T T -G T -A C G T C A C G C --------------------------------------------G C - C - C -------CG CG CG CG GTAGAATA-AGCGATCCCTAGTGAAGCCACACCC
1 6 0 1  1 7 0 0
A D I 6 9  ATTACGTGTAGCCATATCCGCTTA CG TA TA CA G CCA CA CCCCTA G G TA CG CCA CCTTA TCTA CCA A TCA CA G A A A CG G A TA TA CA A TG A CCCCTCCCTA G  
3 1 5 7  ATTACGTGTAGCCATATCCGCTTACGTATACA G CCA CA CCCCTA G G TA CG CCA CCTTA TCTA CCA A TCA CA G A A A CG G A TA TA A A A TG A CCCCTCCCTA G  
6 3 9 7  ATTA CGTGTAGCCATATCCGCTTACGTATACAGCCACACCCCTAGGTACGCCACCTTATCTACCAATCACAGAAACGGATATAAAATGACCC . TCCCTAG 
3 3 0 1  A TTACGTGTAGCCATA TCCG CTTA CG TA TA CA G CCA CA CCCCTA G G TA CG CTA CCTTA TCTA CCA A TCA CA G A A A CG A A TA TA CA A TG A CCCCTCCCTA G  
W A TTA TG TG TA G CCA TA TCCG CTTA CG TA TA CA TCCA CA CCCCTA G G TA CG CTA CCTTA TCTA CCA A TCA CA G A A A CG A A TA TA CA A TG A CCCCTCCCTA G  
M e r l i n  ATTACGTGTAGCCATATCCGCTTACGTA TA CA A CCA CA CCCCTA G G TA CG CCA CCTTA TCTA CCA A TCA CA G A A A CG G A TA TA CA A TG A G CCCTCCCTA G  
T o l e d o  ATTACGTGTAGCTATATCCGCTTA CG TA TA CA G CCA CA CCCCTA G G TA CG CCA CCTTA TCTA CCA A TCA CA G A A A CG G A TA TA CA A TG A G CCCTCCCTA G  
C O N SE N SU S A T T A -G T G T A G C -A T A T C C G C T T A C G T A T A C A -C C A C A C C C C T A G G T A C G C -A C C T T A T C T A C C A A T C A C A G A A A C G -A T A T A -A A T G A -C C -T C C C T A G
1 7 0 1  1 8 0 0
A D I 6 9  A CTCCACCCCTTGTA CG G A A A TTTCA G A TA G G TG G A A CCCG TTA G G G TTCCA CCG TCCTCG G TG TA CG TA CA G G CTTCTCCG TCTA CCG G A A A TA TA CA C 
3 1 5 7  A CTCCACCCCTTG TA CG G A A A TTTCA G A TA G G TG G A A CCCG TTA G G G TTCCA CCG TCCTCG G TG TA CG TA CA G G CTTCTCCG TCTA CTG G A A A TA TA CA C 
6 3 9 7  ACTCCACCCCTTGTA CG G A A A TTTCA G A TA G G TG G A A CCCG TTA G G G TTCCA CCG TCCTCG G TG TA CG TA CA G G CTTCTCCG TCTA CCG G A A A TA TA CA C 
3 3 0 1  A CTCCACCCCTTG TA CG G A A A TTTCA G A TA G G TG G A A CCCG TTA G G G TTCCA CCG TCCTCG G TG TA CG TG CA G G CTTCTCCG TTTA CCG G A A A TA TA CA C 
W A CTCCA CCCCTTG TA CG G A A A TTTCA G A TA G G TG G A A CCCG TTA G G G TTCCA CCG TCCTCG G TG TA CG TA CA G G CTTCTCCG TTTA CCG G A A A TA TA CA C 
M e r l i n  ACTCCACCCCTTG TA CG G A A A TTTCA G A TA G G TG G A A CCCG TTA G G G TTCCA CCG TCCTCG G TG TA CG TA CA G G CTTCTCCG TCTA CCG G A A A TA TA CA C 
T o l e d o  ACTCCACCCCTTG TA CG G A A A TTTCA G A TA G G TG G A A CCCG TTA G G G TTCCA CCG TCCTCG G TG TA CG TA CA G G CTTCTCCG TCTA CCG G A A A TA TA CA C 
C O N SE N SU S A CTC C A C C C C TTG TA C G G A A A TTTC A G A TA G G TG G A A C C C G TTA G G G TTC C A C C G TC C TC G G TG TA C G T-C A G G C TTC TC C G T-TA C -G G A A A TA TA C A C
119
Kegion U
1 8 0 1  1 9 0 0
A D 169 CTGCTGACGTAGACGCTACTCCCGGATACGCGTCATAAGCTACTGGACCCTAGGGGGGAGTGTCTACAGGGCTACGTGCACGCCCCCTTACCTAGGGTAT 
3 1 5 7  CTGCTGACGTAGACGCTACTCCCGGATACGCGTCATAAGCTACTGGACCCTAGGGGGGAGTGTCTACAGGGCTACGTGCACGCCCCCTTACTTAGGGTAT 
6 3 9 7  CTGCTGACGTAGACGCTACTCCCGGATACGCGTCATAAGCTACTGGACCCTAGGGGGGAGTGTCTACAGGGCTACGTGCACGCCCCCTTACCTAGGGTAT 
3 3 0 1  CTGCTGACGTAGACGCTACTCCCGGATACGCGTCATAAGCTACTGGACCCTAGGGGGGAGTGTCTACAGGGCTACGTGCACGCCCCCTTACTTAGGGTAT 
W CTGCTGACGTAGACGCTACTCCCGGATACGCGTCATAAGATACTGGACCCTAGGGGGGAGTGTCTACAGGGCTACGTGCACGCCCCCTTACTTAGGGTAT 
M e r l i n  CTGCTGACGTAGACGCTACTCCCGGATACGCGTCATAAGCTACTGGACCCTAGGGGGGAGTGTCTACAGGGCTACGTGCACGTCCCCTTACCTAGGGTAT 
T o l e d o  CTGCTGACGTAGACGCTACTCCCGGATACGCGTCATAAGCTACTGGACCCTAGGGGGGAGTGTCTACAGGGCTACGTGCACGCCCCCTTACCTAGGGTAT 
CONSENSUS CTGCTGACGTAGACGCTACTCCCGGATACGCGTCATAAG-TACTGGACCCTAGGGGGGAGTGTCTACAGGGCTACGTGCACG-CCCCTTAC-TAGGGTAT
1 9 0 1  2 0 0 0
ADI 69  CCGCCCCCTTCCTCTGTTTTGGCCTAGTAAACTTAACGCCGCCGCTTCTCACGTGACCCCTGACAAGCCTACGTCACACTCGCGTGACCACACCCACTCC 
3 1 5 7  CCGCCCCTTTCCTCTGTTTTGGCCTAATAAACTTAACGCCGCCGCTTCTCACGTGACCCCTGACAAGCCTACGTCACACTCGCGTGACCACACCCACTCC 
6 3 9 7  CCGCCCCCTTCCTCTGTTTTGGCCTAGTAAACTTAACGCCGCCGCTTCTCACGTGACCCCTGACAAGCCTACGTCACACTCGCGTAGCCACACCCACTCC 
3 3 0 1  CCGCCCCCTTCCTCTGTTTTGGCCTAGTAAACTTAACGCCGCCGCTTCTCACGTGACCCCTGACAAGCCTACGTCACACTCGCGTGACCACACCCACTCC 
W CCGCCCCCTTCCTCTGTTTTGGCCTAGTAAACTTAACGCCGCCGCTTCTCACGTGACCCCTGACAAGCCTACGTCACACTCGCGTGACCACACCCACTCC 
M e r l i n  CCGCCCCCTTCCGCTGTTTTGGCCTAGTAAACTTAACGCCGCCGCTTCTCACGTGACCCCTGACAAGCCCACGTCACACTCGCGTAGCCACACCCACTCC 
T o l e d o  CCGCCCCCTTCCTCTGTTTTGGCCTAGTAAACTTAACGCCGCCGCTTCTCACGTGACCCCTGGCAAGCTCACGTCACACTCGCGTGACCACACCCACTCC 
CONSENSUS CCGCCCC-TTCC-CTGTTTTGGCCTA-TAAACTTAACGCCGCCGCTTCTCACGTGACCCCTG-CAAGC— ACGTCACACTCGCGT— CCACACCCACTCC
ADI 69  
3 1 5 7  
6 3 9 7  
3 3 0 1  W
M e r l i n
T o l e d o
CONSENSUS
ADI 6 9  
3 1 5 7  
6 3 9 7  
3 3 0 1  
W
M e r l i n
T o l e d o
CONSENSUS
2001  2100  

















2 2 0 1  2 3 0 0
ADI 69  TAGGATGCATACCCTATATAGCATAATTCTTCTAACGAAACGTTCTACGAAAACGGACTGGCGGAACGGGAACCACCGTAACCCCCCCCCCTCACCCCCC
3 1 5 7  TAGGATGCATACCCTATATAGCATAATTCTTCTAACGAAACGTTCTACGAAAACGGACTGGCGGAACGGGAACCACCGTAACCCCCCCCCCTCACCCCCC 
6 3 9 7  TAGGATGCATACCCTATATAGCATAATTCTTCTAACGAAACGTTCTACGAAAACGGACTGGCGGAACGGGAACCACCGTAACCCCCCCCCCTCACCCCCC 
3 3 0 1  TAGAATGCATACCCTATATAGCATAATTCTTCTAACGAAACGTTCTACGAAAACGGACTGGCGGAACGGGAACCACCGTAACCCCCCCCCCTCACCCCCC 
W TAGGATGCATACCCTATATAGCATAATTCTTCTAACGAAACGTTCTACGAAAACGGACTGGCGGAACGGGAACCACCGTAACCCCCCCCCCTCACCCCCC 
M e r l i n  TAGGATGCATACCCTATATAGCATAATTCTTCTAACGAAACGTTCTACGAAAACGGACTGGCGGAACGGGAACCACCGTAACCCCCCCCCCTCACCCCCC 
T o l e d o  TAGGATGCATACCCTATATAGCATAATTCTTCTAACGAAACGTTCTACGAAAACGGACTGGCGGAACGGGAACCACCGTAACCCCCCCCCCTCACCCCCC 
CONSENSUS TAG-ATGCATACCCTATATAGCATAATTCTTCTAACGAAACGTTCTACGAAAACGGACTGGCGGAACGGGAACCACCGTAACCCCCCCCCCTCACCCCCC
ADI 69  
3 1 5 7  
6 3 9 7  
3 3 0 1  
W
M e r l i n
T o l e d o
CONSENSUS









2 4 0 1  2 5 0 0
ADI 6 9  AGTTTTTGGTTGTCAGGGCGTTGCCACGCGGATTATGGGATGGTGACTCGAGTGCGCATGCGCCGGGGATGCCGCATGGAAAACCTATATATAAGGAGGG
3 1 5 7  AATTTTCGGTTGCCAGGGCGTTACCACGCGGATTATGGGATGGGTACTCGAGTGCGCATGCGCCAGGGATGTCGTATGGAAAGCCTATATATAAAGAGGG 
6 3 9 7  AGTTTTTGGTTGTCAGGGCGTTGCCACGCGGATTATGGGATGGTGACTCGAGTGCGCATGCGCCGGGGATGCCGCATGGAAAGCCTATATATAAGGAGGG 
3 3 0 1  AATTTTCGGTTGTCAGGGCGTTGCCACGCGGATTATGGGATGGGGGCTTGAGTGCGCATGCGCCGGGAATGCCGCATGGAAAACCTATATATAAGGAGGG 
W AGTTTTTGGTTGTCAGGGCGTTGCCACGCGGATTATGGGATGGTGACTCGAGTGCGCATGCGCCGGGGATGCCGCATGGAAAACCTATATATAATGAGGG 
M e r l i n  AATTTTCGGTTGTTAGGGCGTTGCCACGCGGATTATGGGATGTGGCCTCGAGTGCGCATGCGCCGGGGATGTCGTATAAAAAGCCTATATATAAAGAGGG 
T o l e d o  AATTTTCGGTTGTTAGGGCGTTGCCACGCGGATTATGGGATGTGGCCTCGAGTGCGCATGCGCCGGGGATGTCGTATGGAAAGCCTATATATAAAGAGGG 
CONSENSUS A -T T T T -G G T T G — AGGGCGTT-CCACGCGGATTATGGGATG-------- CT-GAGTGCGCATGCGCC-GG-ATG-CG-AT— AAA- CC TATAT AT A A - GAGGG
A DI 6 9  
3 1 5 7  
6 3 9 7  
3 3 0 1  
W
M e r l i n
T o l e d o
CONSENSUS
A DI 6 9  
3 1 5 7  
6 3 9 7  
3 3 0 1  W
M e r l i n
T o l e d o
CONSENSUS
2 5 0 1
g t g a a c c a g g g g c c c c g g g g c g c a t g c g c g g g c c a g g g c c c g c g g g a g g g t c g c c c t g c g ( H g c g c c g g t a a a a t t c c a c t .
g t g a a c c a g g g g c c c c g g t g c g c a t g c g c g g g t c c t g g c c c g c g g g a g g g t c a t c c t g c g c a t g c g c c g g t a a a a t t c c a c t I
g c g a a t c a g g g g c c c c g g t g c g c a t g c g c g g g c c a g g g c c c g c a g g a g g g t c g c c c t g c g c a t g c g c c g g t a a a a t t c c a c c
g t g a a c c a g g g g c c c c g g t g c g c a t g c g c g g g c c c t g g t c c g c g g g a g g a t c a c c c t g c g c a t g c g c c g g t a a a a t t c c a c t |
g t g a a c c a g g g g c c c c g g t g c g c a t g c g c g g g c c c t g g c c c g c g g g a g g g t c g c c c t g c g c a t g c g c c g g t a a a a t t c c a c |
g t g a a c c a g g g g a c c c g g t g c g c a t g c g c g g g c c a g g a c c c g c g g g a g g c g c g c c c t g c g c a t g c g c c g g t a a a a t t c c a c
t t a a a c c a g g g g a c c c g g t g c g c a t g c g c g g g c c a g g a c c c g c g g g a g g c g c g c c c t g c g c a t g c g c c g g t a a a a t t c c a c t |
 AA-CAGGGG-CCCGG-GCGCATGCGCGGG-C— G— CCGC-GGAGG— C— CCTGCGCATGCGCCGGTAAAATTCCAC—









< ^ U L 6 0  start < C UL61 sl°P I 2 7 0 0
AGATGTGCGCCGTGCGCATGCGCCGGTATTTTTCCACTGGGC









ADI 69  
3 1 5 7  
6 3 9 7  
3 3 0 1  W
M e r l i n
T o l e d o
CONSENSUS







ADI 69  
3 1 5 7  
6 3 9 7  
3 3 0 1  
W
M e r l i n
T o l e d o
CONSENSUS
ADI 69  
3 1 5 7  
6 3 9 7  
3 3 0 1  
W
M e r l i n
T o l e d o
CONSENSUS
ADI 69  
3 1 5 7  
6 3 9 7  
3 3 0 1  
W
M e r l i n
T o l e d o
CONSENSUS
ADI 69  
3 1 5 7  
6 3 9 7  
3 3 0 1  W
M e r l i n
T o l e d o
CONSENSUS
ADI 69  
3 1 5 7  
6 3 9 7  
3 3 0 1  
W
M e r l i n
T o l e d o
CONSENSUS
A DI 69  
3 1 5 7  
6 3 9 7  
3 3 0 1  
W
M e r l i n
T o l e d o
CONSENSUS
A D 169
3 1 5 7
6 3 9 7
3 3 0 1
W
M e r l i n
T o l e d o
CONSENSUS
ADI 6 9  
3 1 5 7  
6 3 9 7  
3 3 0 1  W
M e r l i n
T o l e d o
CONSENSUS
ADI 69  
3 1 5 7  
6 3 9 7  
3 3 0 1  
W
M e r l i n
T o l e d o
CONSENSUS
ADI 69  
3 1 5 7  
6 3 9 7  
3 3 0 1  
W
M e r l i n
T o l e d o
CONSENSUS
2 8 0 1  2 9 0 0
ACCCGGCGTGCCCGCCGCCCCCCGGCGCAGTCCGCGGCAGGGTTCCGGCCGTGCTGCGGTCCGCACGCTGCGCCCGCTCCCGCCTGCCTCCCGCCCTACC
2 9 0 1    3 0 0 0
CCCCACCCTCCCCGGCCGAGGCCCGGCGCCGGTCCGTCCGCGGGCCCGTCCCACCGCCCTGGAGCACBfcCGGGGCCGTGGGCCGGGCACCGGGCGCGG
3 0 0 1  3 1 0 0
CCCGCTCCGGACCTCGGCCGGGGGTCCCTCCCCTCCCCCCGCTCGACCCCCCCATCCGACGGCCCGGCCGGGCTGGGACCCCCGCACCGGGGTCCCGGTT
3 1 0 1  3 2 0 0
CCCGTCCGTGGCCCGGGGGGACCCGAGCGGGGGCTTCCCACCCCCACCCCGCTCCTCCCCGGGCTCCGGCCCGGGATCCCTCGCTGCTCCCGGCGACCTC
3 2 0 1  3 3 0 0
CGCCGGCTTCCCGGTCCACCCGCCGCGGAATGGACGGGACCCGGGGTCCGCGCCCTTCCCCTCCCCCCACGGGGGGCTGGGTCGCGGACCCCGGTTCCTA
................................................................................................ I g g g a c c c g g g g t c I g c g c c c t t c c c c t c c c c H a c g g g g g g c t g g g t c g c g g a c c c c g a g t c c t a
................................................................................................ | g g g a c c c g g g g t c c g c g c c c t t c c c c t c c c c c c a c g g g g g g c t g g g t c g c g g a c c c c g g t t c c t a
.......................................................................| g g g a c c c g g g g t c c g c g c c c t t c c c c t c c c c c c c c c c c c c a c g g g g g g g g c t g g g t c g c g g a c c c c g g t t c c t a
■ g g g a c c c g g g g t c c g c g c c c t t c c c c t c c c c c c a c g g g g g g c t g g g t c g c g g a c c c c g g t t c c t a
J g g g a c c c g g g g t c c g c g c . c c t t c c c c t c c c c c a c g g g g g g c t g g g t c g c g g a c c c c g g t t c c t a
3 3 0 1  3 4 0 0
g g c t c g t t c c g c g g t g g g c g a c c g g g g a t c c c c c a c c c a g c t c c c c t t c c c g g c c c g c c t t g c t g g c t t t t g g g c c c c t g c g g g c t t t t t t t t t c c g g c t
g g c t c g t t c c g c g g t g g g c g a c c g g g g a t c c c c c a c c c a g c t c c c c t t c t c g g c c c g c c c c g c t g g c t t t t g g g c c c c t c c g g g c t t t t t t ^ B c c g g c t
g g c t c g t t c c g c g g t g g g c g a c c g g g g a t c c c c c a c c c a g c t c c c c t t c c c g g c c c g c c c c g c t g g c t t t t g g g c c c c t c c g g g c t t t t t t t H c c g g c t
g g c t c g t t c c g c g g t g g g c g a c c g g g g a c c c c c c a c c c a g c t c c c c t t c c c g g c t c g c c c c g c t g g c t t t t g g g c c c c t c c g g g c t t t t t t H ( c c g g c t
g g c t c g t t c c g c g g t g g g c g a c c g g g g a t c c c c c a c c c a g c t c c c c t t c c c g g c c c g c c c c g c t g g c t t t t g g g c c c c t c c g g g c t t t t t t t t t c c g g c t
g g c t c g t t c c g c g g t g g g c g a c c g g g g a t c c c c c a c c c a g c t c c c c t t c c c g g c t c g c c c c g c t g g c t t t t g g g t c c c t c c g g g c t c t t t t t J § : c g g c t
3 4 0 1  3 5 0 0
GGGGGTCGCGGCGGTCGGCCGACGACGACGGTAGGTGGGCCGGGTGGACGGTGGTGGGGACGGGCGACGCCCCGGCTCGACGGCAATCGGTCCCGGAAGG





















3 7 0 1  3 8 0 0
CGTGACGCTCCCCTCCCCCGCTGCTCCCCAAAAAAA. . CTCCGCCCGAACCGTCGCGGCTTGCTGGCCCTGGGCGTGGTCCCCC . ACTCCCCTCCCCCCA
CGTGACGCTCCCTTCCCCCGCTGCTCCCCAAAAAAi. . GTCCGCCCGAACCGTCGCGGCTTGCTGGCCCTGGGCGTGGTCCCCC . ACTCCCCTCCCCCCA 
CGTGACGCTCCCCTCCCCCACTGCTCCCCAAAAAA1.. CTCCGCCCGAACCGTCGCGGCTTGCTGGCCCTGGGCGTGGTCCCCC. ACTCCCCTCCCCCCA 
CGTGACGCTCCCTTCCCCCGCTGCTCCCCAAAAAa | .  . GTCCGCCCGAACCGTCGCGGCTTGCTGGCCCTGGGCGTGGTCCCCC . ACTCCCCTCCCCCCA 
CGTGACGCTCCCCTCCCCCACTGCTCCCCAAAAAAAJJ;TCCGCCCGAACCGTCGCGGCTTGCTGGCCCTGGGCGTGGTCCCCC . ACTCCCCTCCCCCCA 





A D I 69 
3 1 5 7  
6 3 9 7  
3 3 0 1  
W
M e r l i n
T o l e d o
CONSENSUS
A D I 69 
3 1 5 7  
6 3 9 7  
3 3 0 1  N
M e r l i n
T o l e d o
CONSENSUS









3 9 0 1
GGTCGACGGTGGGCCGC









ADI 69  
3 1 5 7  
6 3 9 7  
3 3 0 1  W
M e r l i n
T o l e d o
CONSENSUS















ADI 69  
3 1 5 7  
6 3 9 7  
3 3 0 1  
W
M e r l i n
T o l e d o
CONSENSUS









4 2 0 1
ADI 69 ......(
3 1 5 7 TT .
6 3 9 7 TTTTC
3 3 0 1
W m  ■'
M e r l i n ...... t
T o l e d o ! ■ • • • <
CONSENSUS
|O R F3 s t o r >  |O R F4 stop~ ^>
CCCTTCTCCGATTTTGCCGTGGAAAA. CCCGTG? ACCGATACGGGTGCAGACGGCCGAAAAAAAT . CGAGACGACAATATGJ
4 3 0 0  
CGGCAGGGCGCGA
: c c t t c t c c g a t t t | g c c g t g g a a a a | c c c g t g a a c c g a t a c g g g t g c a g a c g g c c g a a a a a a t t . c g a g a c g a c a a t a c g a c g a c a g g g c g t g a  
x c t t c t c c g a t t t I g c c g t g g a a a a . c c c g t g a a c c g a t a c g g g t a c a g a c g g c c g a a a a a a a t | c g a g a c . . . a a t a c g a c g g c a g g g c g t g a
rCCTTCTCCGATTT|GCCGTGGAAAA.CCCGTGAACCGATACGGGTACAGACGGCCGAAAAAAAT|CGAGACGACAATACGACGGCAGGGCGTGA 
CCCTTCTCCGATTTTGCCGTGGAAAA. CCCGTGAACCGATACGGGTGCAGACGGCCGAAAAAAAT . CGAGACGACAATATGACGGCAGGGCGCGA 
CCTTCTCCGATTT|GCCGTGGAAAA. CCCGTGAACCGATACGGGTGCAGACGGCCGAAAAAATT . CGTGACGGCAATACGACGACAGGGCGTGA 
CCTTCTCCGATTt | g CCGTGGAAAA-CCCGTGAACCGATACGGGT-CAGACGGCCGAAAAAA-T-CG-GAC AATA-GACG-CA-GGCG-GA
4 3 0 1  4 4 0 0
ADI 6 9 TCTTCTCCCCCATCCGACAAAACCGTGTCCCTTAAAATT . CCCCACCTTTCTCTGTTCAAATGGCCCCGAAACTGTAAAACACCGTTTGACCGCACCCCA
3 1 5 7  TTTTTTCCCCCATCCGACAAAACCGTGTCCCTTAAAATT . CCCCACCTTTCTCTGTTCAAATGGCCCCGAAACTGTAAAACACCGTTTGACCGCACCCCA 
6 3 9 7  TTTTCTCCCCCATCCGACAAAACCGTGTCCCTCAAAATT|CCCCACCTTTCTCTGTTCAAATGGCCCCGAAACTGTAAAACACCGTTTGACCGCACCCCA 
3 3 0 1  TTTTCTCCCCCATCCGACAAAACCGTGTCCCTTAAAATT. CCCCACCTTTCTCTGTTCAAATGGCCCCGAAACTGTAAAACACCGTTTGACCGCACCCCA 
W TTTTCTCCCCCATCCGACAAAAACGTGTCCCTTAAAATT . CCCCACCTTTCTCTGTTCAAATGGCCCCGAAACTGTAAAACACCGTTTGACCGCACCCCA 
M e r l i n  TCTTCTCCCCCATCCGACAAAACCGTGTCCCTTAAAATT. CCCCACCTTTCTCTGTTCAAATGGGCCCGAAACTGTAAAACACCGTTTGACCGCACCCCA 
T o l e d o  TTTTATCCCCCATCCGACAAAACCGTGTCCCTCAAAATT. CCCCACCTTTCTCTGTTCAAATGGCCCCGAAACTGTAAAACACCGTTTGACCGCACCCCA 
CONSENSUS T-TT-TCCCCCATCCGACAAAA-CGTGTCCCT-AAAATT-CCCCACCTTTCTCTGTTCAAATGG-CCCGAAACTGTAAAACACCGTTTGACCGCACCCCA
ADI 69  
3 1 5 7  
6 3 9 7  
3 3 0 1  
W
M e r l i n
T o l e d o
CONSENSUS
ADI 69 
3 1 5 7  
6 3 9 7  
3 3 0 1  
W
M e r l i n
T o l e d o
CONSENSUS









4 5 0 1 < ^ U L 6 2  start 4 6 0 0
GAGCGTTTTTGCTCCAGGCGGGTAAAAAAATAGCACGATAACTTTTCTGTGCTTTTTTTTGAGACGTTTTAGAAGAGCTTTTTT. . CTGCTCAGAGCGAA 
GAGCGTTTTCGCTCCAGGCGGGTAAAAAAATAGCACGATAACTTTTCTGTGCTTTHHBgAGACGTTTTAGAAGAGCTTTTTT . . CTGCTCAGAGCGAA 
GAGCGTTTTCGCTCCAGGCGGGTAAAAAAATAGCACGATAACTTTTCTGTGCTTTTTTT|GAGACGTTTTAGAAGAGCTTTTTT|.CTGCTCGGAGCGAA 
GAGCGTTTTCGCTCCAGGCGGGTAAAAAAATAGCACGATAACTTTTCTGTGCTTTTTTt I gAGACGTTTTAGAAGAGCTTTTTT . . CTGCTCAGAGCGAA 
GAGCGTTTTCGCTCCAGGCGGGTAAAAAA.TAGCACGATAACTTTTCTGTGCTTTTTTBGAGACGTTTTTGAAGAGCTTTTTTg|CTGCTCAGAGCGAA 
GAGCGTTTTCGCTCCAGGCGGGTAAAAAAATAGCACGATAACTTTTCTGTGCTTTTTTTTGAGACGTTTTAGAAGAGCTTTTTT. . CTGCTCAGAGCGAA 
GAGCGTTTTCGCTCCAGGCGGGTAAAAAAATAGCACGATAACTTTTCTGTGCTTTTTTBGAGACGTTTTTGAAGAGCTTTTTT|. CTGCTCAGAGCGAA 
GAGCGTTTT-GCTCCAGGCGGGTAAAAAA-TAGCACGATAACTTTTCTGTGCTTT GAGACGTTTT-GAAGAGCTTTTTT--CTGCTC-GAGCGAA
4 6 0 1  4 7 0 0
ADI 69  AAAATGATAGCCCTGAAAATCTCGACGAGTCTGGCCGAGCGGCGCCATCTTGGAGGAGGGGCGAGTCGCGGGCACCGCCTCGGTACCCCCTGGCCGAGGC 
3 1 5 7  AAAATGATAGCCCTGAAAATCTCGACGAGTCTGGCCGAGCGGCGCCATCTTGGAGGAGGGGCGAGTCGCGGGCACCGCCTCGGTACCCCCTGGCCGAGGC 
6 3 9 7  AAAATGATAGCCCTGAAAATCTCGACGAGTCTGGCCGAGCGGCGCCATCTTGGAGGAGGGGCGAGTCGTGGGCACCGCCTCGGTACCCCCTGGCCGAGGC 
3 3 0 1  AAAATGATAGTCCTGAAAATCTCGACGAGTCTGGCCGAGCGGCGCCATCTTGGAGGAGGGGCGAGTCGCGGGCACCGCCTCGGTACCCCCTGGCCGAGGC 
W AAAATGATAGCCCTGAAAATCTCGACGAGTCTGGCCGAGCGGCGCCATCTTGGAGGAGGGGCGAGTCGCGGGCACCGCCTCGGTACCCCCTGGCCGAGGC 
M e r l i n  AAAATGATAGCCCTGAAAATCTCGACGAGTCTGGCCGAGCGGCGCCATCTTGGAGGAGGGGCGAGTCGCGGGCACCGCCTCGGTACCCCCTGGCCGAGGC 
T o l e d o  AAAATGATAGCCCTGAAAATCTCGACGAGTCTGGCCGAGCGGCGCCATCTTGGAGGAGGGGCGAGTCGCGGGCACCCCCTCGGTACCCCCTGGCCGAGGC 
CONSENSUS AAAATGATAG-CCTGAAAATCTCGACGAGTCTGGCCGAGCGGCGCCATCTTGGAGGAGGGGCGAGTCG-GGGCACC-CCTCGGTACCCCCTGGCCGAGGC
4 7 0 1  4 8 0 0
ADI 6 9  GAGTCCGCGGTCGCCGCCTGTTCCGTGATGCTACCTAGAGGGCGCTGTCGAGGCGACTCTTCCTGTTTTCGCCCTGAGGGCTAACGGTCGCTGACGTCAA 
3 1 5 7  GAGTCCGCGGTCGCCGCCTGTTCCGTGATGCTACCTAGAGGGCGCTGTCGAGGCGACTCTTCCTGTTTTCGCCCTGAGGGCTAACGGTCGCTGACGTCAA 
6 3 9 7  GAGTCCGCGGTCGCCGCCTGTTCCATGATGCTACCTAGAGGGCGCTGTCGAGGCGACTCTTCCTGTTTTCGCCCTGAGGGCTAACGGTCGCTGACGTCAA 
3 3 0 1  GAGTCCGCGGTCGCCGCCTGTTCCGTGATGCTACCTAGAGGGCGTTGTCGAGGCGACTCTTCCTGTTTTCGCCCTGAGGGCTAACGGTCGCTGACGTCAA 
W GAGTCCGCGGTCGCCGCCTGTTCCGTGATGCTACCTAGAGGGCGCTGTCGAGGCGACTCTTCCTGTTTTCGCCCTGAGGGCTAACGGTCGCTGACGTCAA 
M e r l i n  GAGTCCGCGGTCGCCGCCTGTTCCGTGATGCTACCTAGAGGGCGCTGTCGAGGCGACTCTTCCTGTTTTCGCCCTGAGGGCTAACGGTCGCTGACGTCAA 




4 8 0 1  4 9 0 0
AD I 6 9  ACCATCTCGTGCTCGCTGAGTCACATCCGGTTGTTGACAAGCGATGGAGGACCGCACCCAAAGTGCGCCCTCTAGTCATCGCGCCTGACCCCTTTTATAA 
3 1 5 7  ACCATCTCGTGCTCGCTGAGTCACATCCGGTTGTTGACAAGCGATGGAGGACCGCACCCAAAGTGCGCCCTCTAGTCATCGCGCCTGACCCCTTTTATAA 
6 3 9 7  ACCATCTCGTGCTCGCTGAGTCACATCCGGTTGTTGACAAGCGATGGAGGACCGCACCCAAAGTGCGCCCTCTAGTCATCGCGCCTGACCCCTTTTATAA 
3 3 0 1  ACCATCTCGTGCTCGCTGAGTCACATCCGGTTGTTGACAAGCGATGGAGGACCGCACCCAAAGTGCGCCCTCTAGTCATCGCGCCTGACCCCTTTTATAA 
W ACCATCTCGTGCTCGCTGAGTCACATCCGGTTGTTGACAAGCGATGGAGGACCGCACCCAAAGTGCGCCCTCTAGTCATCGCGCCTGACCCCTTTTATAA 
M e r l i n  ACCATCTCGTGCTCGCTGAGTCACATCCGGTTGTTGACAAGCGATGGAGGACCGCACCCAAAGTGCGCCCTCTAGTCATCGCGCCTGACCCCTTTTATAA 
T o l e d o  ACCATCTCGTGCTCGCTGAGTCACATCCGGTTGTTGACAAGCGATGGAGGACCGCACCCAAAGTGCGCCCTCTAGTCATCGCGCCTGACCCCTTTTATAA 
CONSENSUS ACCATCTCGTGCTCGCTGAGTCACATCCGGTTGTTGACAAGCGATGGAGGACCGCACCCAAAGTGCGCCCTCTAGTCATCGCGCCTGACCCCTTTTATAA
4 9 0 1  5 0 0 0
ADI 6 9  ACTGCTCGAAGAAAAGAACACCTTATGTGAAAAAA. TACAGAATGATGACAAGTTCATCCAACACAACCGCTCAACAACGCCATATCTATCAGTGTCCAA 
3 1 5 7  ACTGCTCGAAGAAAAGAACACCTTATGTGAAAAAA. TACAGAATGATGACAAGTTCATCCAACACAACCGCTCAACAACGCCATATCTATCAGTGTCCAA 
6 3 9 7  ACTGCTCGAAGAAAAGAACACCTTATGTGAAAAAA§TACAGAATGATGACAAGTTCATCCAACACAACCGCTCAACAACGCCATATCTATCAGTGTCCAA 
3 3 0 1  ACTGCTCGAAGAAAAGAACACCTTATGTGAAAAAA. TACAGAATGATGACAAGTTCATCCAACACAACCGCTCAACAACGCCATATCTATCAGTGTCCAA 
W ACTGCTCGAAGAAAAGAACACCTTATGTGAAAAAA. TACAGAATGATGACAAGTTCATCCAACACAACCGCTCAACAACGCCATATCTATCAGTGTCCAA 
M e r l i n  ACTGCTCGAAGAAAAGAACACCTTATGTGAAAAAA. TACAGAATGATGACAAGTTCATCCAACACAACCGCTCAACAACGCCATATCTATCAGTGTCCAA 
T o l e d o  ACTGCTCGAAGAAAAGAACACCTTATGTGAAAAAA. TACAGAATGATGACAAGTTCATCCAACACAACCGCTCAACAACGCCATATCTATCAGTGTCCAA 
CONSENSUS ACTGCTCGAAGAAAAGAACACCTTATGTGAAAAAA-TACAGAATGATGACAAGTTCATCCAACACAACCGCTCAACAACGCCATATCTATCAGTGTCCAA
ADI 69  
3 1 5 7  
6 3 9 7  
3 3 0 1  W
M e r l i n
T o l e d o
CONSENSUS
ADI 69 
3 1 5 7  
6 3 9 7  
3 3 0 1  W
M e r l i n
T o l e d o
CONSENSUS


















ADI 69  
3 1 5 7  
6 3 9 7  
3 3 0 1  
W
M e r l i n
T o l e d o
CONSENSUS
ADI 69 
3 1 5 7  
6 3 9 7  
3 3 0 1  
W
M e r l i n
T o l e d o
CONSENSUS









5 3 0 1
TCTGTTTGGTAAAAAGCTCATAAGTCTGTATGTGACCTATATATA. . TTATACGCT
ORF5 s t a r t j > 5 4 0 0
 TACACCGAACTGTCGCTGTTGTATAAGAAGAAAAAACTCTC
TcTGTTTGGTAAAAAGCTCATAAGTCTGTATGTGACCTATATATAjJlTTATACGCTATGTACACCGAACTGTCGCTGTTGTATAAGAAGAAAAAACTCTC 
TCTGTTTGGTAAAAAGCTCATAAGTCTGTATGTGACCTATATATA . ■ TTATACGCTATGTACACCGAACTGTCGCTGTTGTATAAGAAGAAAAAACTCTC
TCTGTTTGGTAAAAAGCTCATAAGTCTGTATGTGACCTATATAT^HTATACGCTATGTACACCGAACTGTCGCTGTTGTATAAGAAGAAAAAACTCTC
TCTGTTTGGTAAAAAGCTCATAAGTCTGTATGTGACCTATATATA. . TTATACGCTATGTACACCGAACTGTCGCTGTTGTATAAGAAGAAAAAACTCTC 
t c t g t t t g g t a a a a a g c t c a t a a g t c t g t a t g t g a c c t a t a t a t a H t t a t a c g c t a t g t a c a c c g a a c t g t c g c t g t t g t a t a a g a a g a a a a a a c t c t c  
TCTGTTTGGTAAAAAGCTCATAAGTCTGTATGTGACCTATATATA. . TTATACGCTATGTACACCGAACTGTCGCTGTTGTATAAGAAGAAAAAACTCTC 
TCTGTTTGGTAAAAAGCTCATAAGTCTGTATGTGACCTATATAT TATACGCTATGTACACCGAACTGTCGCTGTTGTATAAGAAGAAAAAACTCTC
ADI 69  
3 1 5 7  
6 3 9 7  
3 3 0 1  W
M e r l i n
T o l e d o
CONSENSUS
ADI 69 
3 1 5 7  
6 3 9 7  
3 3 0 1  W
M e r l i n
T o l e d o
CONSENSUS


















5 6 0 1
ADI 69 T T T T T .
3 1 5 7 T T T T T ,
6 3 9 7 T T T | . .
3 3 0 1 TTTTTl
W t t t t t )
M e r l i n t t t | .
T o l e d o t t t t t |
CONSENSUS TTT-----
5 7 0 1
|O R F5 s t o p j > 5 7 0 0
TGAACCAAGAATAAAACTCTAGCTCTCGTCTATTTTTAATATGCTCTACTTAGAACCTTTTTAATGA
JRCAAAATATATGATGAACCAAGAATAAAACTCTAGCTCTCGTCTATTTTTAATATGCTCTACTTAGAACCTTTTTAATGA 




• - a c a a a a t a t a t g a t g a a c c a a g M H B a c t c t a g c t c t c g t c t a t t t t t a a t a t g c t c t a c t t a - a a c c t t t t t a a t g a
ADI 69 
3 1 5 7  
6 3 9 7  
3 3 0 1  W
M e r l i n















5 8 0 1  5 9 0 0
ADI 6 9  TGATGACCTGATATCCCTCCATATATATGATCGGATATTATTCCGTTAGACTTGTCCTCCTTTTTTTT . CCTCATCTCCTGTATCTGGAGATATATGTTG
3 1 5 7  TGATGACCTGATATCCCTCCATATATATGATCGGATATTATTCCGTTAGACTTGTCCTCCTTTTTTTT. CCTCATCTCCTATATCTGGAGATATATGTTG 
6 3 9 7  TGATGACCTGATATCCCTCCATATATATGATCGGATATTATTCCGTTAGACTTGTCCTCCTTTTTTTT. CCTCATCTCCTGTATCTGGAGATATATGTTG 
3 3 0 1  TGATGACCTGATATCCCTCCATATATATGATCGGATATTATTCCGTTAGACTTGTCCTCCTTTTTTTT. CCTCATCTCCTGTATCTGGAGATATATGTTG 
W TGATGACCTGATATCCCTCCATATATATGATCGGATATTATTCCGTTAGACTTGTCCTCCTTTTTTTT. CCTCATCTCCTGTATCTGGAGATATATGTTG 
M e r l i n  TGATGACCTGATATCCCTCCATATATATGATCGGATATTATTCCGTTAGACTTGTCCTCCTTTTTTTT . CCTCATCTCCTATATCTGGAGATATATGTTG 
T o l e d o  TGATGACCTGATATCCCTCCATATATATGATCGGATATTATTCCGTTAGACTTGTCCTCCTTTTTTTTgCCTCATCTCCTGTATCTGGAGATATATGTTG 
CONSENSUS TGATGACCTGATATCCCTCCATATATATGATCGGATATTATTCCGTTAGACTTGTCCTCCTTTTTTTT-CCTCATCTCCT-TATCTGGAGATATATGTTG
ADI 69  
3 1 5 7  
6 3 9 7  
3 3 0 1  W
M e r l i n
T o l e d o
CONSENSUS
ADI 69  
3 1 5 7  
6 3 9 7  
3 3 0 1  
W
M e r l i n
T o l e d o
CONSENSUS
ADI 69  
3 1 5 7  
6 3 9 7  
3 3 0 1  
W
M e r l i n
T o l e d o
CONSENSUS
5 9 0 1  6 0 0 0
ACCACCACCGCH^ACCACCAAAAAGCTAGCCGTCACGACTAGAAATGTGTAGGATTCGGACTTTCCGTTCGAGAAGAAAAAGAGACCGCGTCTCTGGA












6 0 0 1 < ^ U L 6 4  start 6 1 0 0
CGCTCTTTTT . GTCAGTCTGAATCGACCCGGGATACGTAAGAGAGCGGCQCTACATCGGGGGGCGCTCGAGACCGACGACGTTCCATCTGACCAGAAAAA 
CGCTCTTTTT . GTCGGTCTGAATCGACCCGGGATACGTAAGAGAGCGGCCCTACATCGGGGGGCGCTCGAGACCGACGACGTTCCATCTGACCAGAAAAA 
CGCTCTTTTT|GTCGGTCTGAATCGACCCGGGATACGTAAGAGAGCGGCCCTACATCGGGGGGCGCTCGAGACCGACGACGTTCCATCTGACCAGAAAAA 
CGCTCTTTTT . GTCGGTCTGAATCGACCCGGGATACGTAAGAGAGCGGCCCTACATCGGGGGGCGCTCGAGACCGACGACGTTCCATCTGACCAGAAAAA 
CGCTCTTTTT . GTCAGTCTGAATCGACCCGGGATACGTAAGAGAGCGGCCCTACATCGGGGGGCGCTCGAGACCGACGACGTTCCATCTGACCAGAAAAA 
CGCTCTTTTT . GTCGGTCTGAATCGACCCGGGATACGTAAGAGAGCGGCCCTACATCGGGGGGCGCTCGAGACCGACGACGTTCCATCTGACCAGAAAAA 
CGCTCTTTTT . GTCGGTCTGAATCGACCCGGGATACGTAAGAGAGCGGCCCTACATCGGGGGGCGCTCGAGACCGACGACGTTCCATCTGACCAGAAAAA 
CGCTCTTTTT-GTC-GTCTGAATCGACCCGGGATACGTAAGAGAGCGGCCCTACATCGGGGGGCGCTCGAGACCGACGACGTTCCATCTGACCAGAAAAA




A A A i. GGCACCCCTCGGTAGCGACCTCTTACCATCGTTTGCCCGTCCGCCCGTCCTTCGTAGCCATCATCATCAT . . . CTCAGGCTCTATCGGTACCATC 
AAaB . GGCACCCCTCGGTGGCGACCTCTCACCATCGTTTGCCCGTCCGCCCGTCCTTCGCAGCCATCATCATCAT. . . CTCAGGCTCTATCGGTACCATC 
A A |J .  GGCACCCCTCGGTAGCGACCTCTCACCATCGTTTGCCCGTCCGCCCGTCCTTCGTAGCCATCATCATCAT . . . CTCAGGCTCTATCGGTACCATC
AAAAfGGCACCCCTCGGTGGCGACCTCTCACCATCGTTTGCCCGTCCGCCCGTCCTTCGTAGCCATCATCAT................CTCAGGCTCTATCGGTACCATC
AA GGCACCCCTCGGT-GCGACCTCT-ACCATCGTTTGCCCGTCCGCCCGTCCTTCG-AGCCATCATCAT-------------CTCAGGCTCTATCGGTACCATC
AD I 6 9 
3 1 5 7  
6 3 9 7  
3 3 0 1  W
M e r l i n
T o l e d o
CONSENSUS
ADI 6 9 
3 1 5 7  
6 3 9 7  
3 3 0 1  
W
M e r l i n
T o l e d o
CONSENSUS
ADI 6 9  
3 1 5 7  
6 3 9 7  
3 3 0 1  
W
M e r l i n
T o l e d o
CONSENSUS


















6 3 0 1 UL66 stop  | 6400
AAAAA. . . CGCACCATCGACACCACACC<}TC»AGCACCACCTGTCGGTGTTGGTCGTCCTCCATCGTTCTCTACGAACATCTCGACGCCCGGGTGACG




AAA AAl. .CGCACCATCGACACCACACCCTCATGAGCACCACCTGTCGGTGTTGGTCGTCCTCCATCGTTCTCTACGAACATCTCGACGCCCGGGTGACG 
AAAAa J .  .CGCACCATCGACACCACACCCTCATGAGCACCACCTGTCGGTGTTGGTCGTCCTCCATCGTTCTCTACGAACATCTCGACGCCCGGGTGACG 
AAAA CGCACCATCGACACCACACCCTCATGAGCACCACCTGTCGGTGTTGGTCGTCCTCCATCGTTCTCT-CGAACATCTCGACGCCCGGGTGACG
6 5 0 0
ACGAGACTGTGAGTACGAC









AD I 69  
3 1 5 7  
6 3 9 7  
3 3 0 1  
W
M e r l i n
T o l e d o
CONSENSUS
JU0169
3 1 5 7
6 3 9 7
3 3 0 1
W
M e r l i n
T o l e d o
CONSENSUS


















6 7 0 1  6 8 0 0
ADI 69  CACAATCGTATAACGCTCTATTCATGGAACGAACTTGGAATAAAAAAA. CCATCGCAGGCCAGAGGCTAAGCCGAAACCGTCCGGGGJ1AGCGGGCGCGAG 
3 1 5 7  CACAATCGTATAACGCTCTATTCATGGAACGAACTTGGAATAAAJ1AAA. CCATCGCAGGCCAGAGGCTAAGCCGAAACCGTCCGGGGAAGCGGGCGCGAG 
6 3 9 7  CACAATCGTATAACGCTCTATTCATGGAACGAACTTGGAATAAAAJ1AA.CCATCGCAGGCCAGAGGCTAAGCCGAAACCGTCCGGGGJ1AGCGGGCGCGAG 
3 3 0 1  CACAATCGTATAACGCTCTATTCATGGAACGAACTTGGAATAAAAAAA. CCATCGCAGGCCAGAGGCTAAGCTGAAACCGTCCGGGGAAGCGGGCGCGAG 
W CACAATCGTATAACGCTCTATTCATGGAACGAACTTGGAATAAAAAAA. CCATCGCAGGCCAGAGGCTAAGCCGAAACCGTCCGGGGAAGCGGGCGCGAG 
M e r l i n  CACAATCGTATAACGCTCTATTCATGGAACGAACTTGGAATAAAJlAAAfCCATCGCAGGCCAGAGGCTAAGCCGAAACCGTCCGGGGAAGCGGGCGCGAG 
T o l e d o  CACAATCGTATAACGCTCTATTCATGGAACGAACTTGGAATAAAAAAA.CCATCGCAGGCCAGAGGCTAAGCCGJIAACCGTCCGGGGJiAGCGGGCGCGAG 




3 1 5 7  
6 3 9 7  
3 3 0 1  
W
M e r l i n
T o l e d o
CONSENSUS
A D 169
3 1 5 7
6 3 9 7
3 3 0 1
W
M e r l i n
T o l e d o
CONSENSUS
6 8 0 1  6 9 0 0
TTTTCCGACTTAGCCTTTGGTGCTCGTTGAGCCTCTTTTTTTTTT. . CTGATTCTCTGAAGAATCACCGTCACAGCCCTATGACGCGAAATCAATTGCTA 
TTTTCCGACTTAGTCTCTGGTGCTCGTTGAGCCTCTTTTTTTTTTffCTGATTCTCTGAAGAATCACCGTCACAGCCCTATGACGCGAAATCAATTGCTA 
TTTTCCGACTTAGTCTCTGGTGCTCGTTGAGCCTCTTTTTTTTTT . . CTGATTCTCTGAAGAATCACCGTCACAGCCCTATGACGCGAAATCAATTGCTA 
TTTTCCGACTTAGTCTCTGGTGCTCGTTGAGCCTCTTTTTTTHI. .CTGATTCTCTGAAGAATCACCGTCACAGCCCTATGACGCGAAATCAATTGCTA 




UL67 stop |6 9 0 1  UL' "  I 7 0 0 0
GAACATAAACGTTCTCAACAGGTATGAAATGAACAAACTAGATGATGCTATAAC(Jt TATATTGTGTGTATATAGATAGGTGTGAAATTT . GTAGGATAAA 
GAACATAAACGTTCTCAACAGGTATGAAATGAACAAACTAGATGATGCTATAACCTTATATTGTGTGTATATAGATAGGTGTGAAATTT. GTAGGATAAA 
GAACATAAACGTTCTCAACAGGTATGAAATGAACAAACTAGATGATGCTATAACCTTATATTGTGTGTATATAGATAGGTGTGAAATTT . GTAGGATAAA
g a a c a t a a a c g t t c t c a a c a g g t a t g a a a t g a a c a a a c t a g a t g a t g c t a t a a c c t t a t a t t g t g t g t a t a t a g a t a g g t g t g a a a t t t | g t a g g a t a a a
GAACATAAACGTTCTCAACAGGTATGAAATGAACAAACTAGATGATGCTATAACCTTATATTGTGTGTATATAGATAGGTGTGAAATTT . GTAGGATAAA 
GAACATAAACGTTCTCAACAGGTATGAAATGAACAAACTAGATGATGCTATAACCTTATATTGTGTGTATATAGATAGGTGTGAAATTT . GTAGGATAAA 
GAACATAAACGTTCTCAACAGGTATGAAATGAACAAACTAGATGATGCTATAACCTTATATTGTGTGTATATAGATAGGTGTGAAATTT. GTAGGATAAA 
GAACATAAACGTTCTCAACAGGTATGAAATGAACAAACTAGATGATGCTATAACCTTATATTGTGTGTATATAGATAGGTGTGAAATTT-GTAGGATAAA
ADI 69  
3 1 5 7  
6 3 9 7  
3 3 0 1  W
M e r l i n
T o l e d o
CONSENSUS










3 1 5 7
6 3 9 7
3 3 0 1
W
M e r l i n
T o l e d o
CONSENSUS
A D 169
3 1 5 7
6 3 9 7
3 3 0 1W
M e r l i n
T o l e d o
CONSENSUS


















7 3 0 1  7 4 0 0
A D I 6 9  CCACCAATTCGCATCACTTAAGAAAGTAGTAGCAACCGCGGCGGCGGCGACCGGCCGGTCGTCGTCTCCTCGTCCTCAAATGTTGTACATGTGCAGAAAA 
3 1 5 7  CCACCAATTCGCATCACTTAAGAAAGTAGTAGCAACCGCGGCGGCGGCGACCGGCCGGTCGCCGTCTCCTCGTCCTCAAATGTTGTACATGTGCAGAAAA 
6 3 9 7  CCACCAATTCGCATCACTTAAGAAAGTAGTAGCAACCGCGGCGGCGGCGACCGGCCGGTCGTCGTCTCCTCGTCCTCAAATGTTGTACATGTGCAGAAAA 
3 3 0 1  CCACCAATTCGCATCACTTAAGAAAGTAGTAGCAACCGCGGCGGCGGCGACCGGCCGGTCGTCGTCTCCTCGTCCTCAAATGTTGTACATGTGCAGAAAA 
W CCACCAATTCGCATCACTTAAGAAAGTAGTAGCAACCGCGGCGGCGGCGACCGGCCGGTCGTCGTCTCCTCGTCCTCAAATGTTGTACATGTGCAGAAAA 
M e r l i n  CCACCAATTCGCATCACTTAAGAAAGTAGTAGCAACCGCGGCGGCGGCGACCGGCCGGTCGTCGTCTCCTCGTCCTCAAATGTTGTACATGTGCAGAAAA 
T o l e d o  CCACCAATTCGCATCACTTAAGAAAGTAGTAGCAACCGCGGCGGCGGCGACCGGCCGGTCGTCGTCTCCTCGTCCTCAAATGTTGTACATGTGCAGAAAA 
CONSENSUS CCACCAATTCGCATCACTTAAGAAAGTAGTAGCAACCGCGGCGGCGGCGACCGGCCGGTCG-CGTCTCCTCGTCCTCAAATGTTGTACATGTGCAGAAAA
7 4 0 1  7 5 0 0
ADI 6 9  ATGTGTAAATACGTGTTATTTATCCCATGCGTCTTGTACATAGATATATGTTTTTATATACGCTATTTATACTTTATATATCCTTTTGCATAACCATAGA 
3 1 5 7  ATGTGTAAATACGTGTTATTTATCCCATGCGTCTTGTACATAGATATATGTTTTTATATACGCTATTTATACTTTATATATCCTTTTGCATAACCATAGA 
6 3 9 7  ATGTGTAAATACGTGTTATTTATCCCATGCGTCTTGTACATAGATATATGTTTTTATATACGCTATTTATACTTTATATATCCTTTTGCATAACCATAGA 
3 3 0 1  ATGTGTAAATACGTGTTATTTATCCCATGCGTCTTGTACATAGATATATGTTTTTATATACGCTATTTATACTTTATATATCCTTTTGCATAACCATAGA 
W ATGTGTAAATACGTGTTATTTATCCCATGCGTCTTGTACATAGATATATGTTTTTATATACGCTATTTATACTTTATATATCCTTTTGCATAACCATAGA 
M e r l i n  ATGTGTAAATACGTGTTATTTATCCCATGCGTCTTGTACATAGATATATGTTTTTATATACGCTATTTATACTTTATATATCCTTTTGCATAACCATAGA 
T o l e d o  ATGTGTAAATACGTGTTATTTATCCCATGCGTCTTGTACATAGATATATGTTTTTATATACGCTATTTATACTTTATATATCCTTTTGCATAACCATAGA 
CONSENSUS ATGTGTAAATACGTGTTATTTATCCCATGCGTCTTGTACATAGATATATGTTTTTATATACGCTATTTATACTTTATATATCCTTTTGCATAACCATAGA
A D 169
3 1 5 7
6 3 9 7
3 3 0 1
W
M e r l i n
T o l e d o
CONSENSUS
ADI 69  
3 1 5 7  
6 3 9 7  
3 3 0 1  
W
M e r l i n
T o l e d o
CONSENSUS









7 6 0 1  
CCCTTGT71
<C U L68 s t° P  I 77  00
.CTACCACCCCGATAAAAACCACATCATCATCGTCACCACGACCTGGAAACGACACACGTTCCCCCCCAATCTTGGGCATGT. . GTATATATA
CCCTTGTACTACCACCCCGATAAAAACCACATCATCATCGTCACCACGACCTGGAAACGACACACGTTCCCCCCCAATCTTGGGCATGT . .ATATATATA 
CCCTTGTACTACCACCCCGATAAAAACCACATCATCATCGTCACCACGACCTGGAAACGACACACGTTCTCCCCCAATCTTGGGCATGT^.TATATATA 





7 7 0 1  7 8 0 0
A D I 6 9  AAAAGAATGGGAGGGAGAGGACGTGGGGCTCGAGAAGAAATAAACGCCAAGCTCGATTCGAACCAAAAAACCACATGTGTATTGTGCTTTGTTTTTTTTT
3 1 5 7  AAAAGAATGGGAGGGAGAGGACGTGGGGCTCGAGAAGAAATAAACGCCAAGCTCGATTCGAACCAAAAAACCACATGTGTATTGTGCTTTGTTTTTTTTl 
6 3 9 7  TAAAGAATGGGAGGGAGAGGACGTGGGGCTCGAGAAGAAATAAACGCCAAGCTCGATTCGAACCAAAAAACCACATGTGTATTGTGCTTTGTTTTTTTTT 
3 3 0 1  AAAAGAATGGGAGGGAGAGGACGTGGGGCTCGAGAAGAAATAAACGCCAAGCTCGATTCGAACCAAAAAACCACATGTGTATTGTGCTTTGTTTTTTTTT
w t a a a g a a t g g g a g g g a g a g g a c g t g g g g c t c g a g a a g a a a t a a a c g c c a a g c t c g a t t c g a a c c a a a a a a c c a c a t g t g t a t t g t g c t t t g t t t t t t t H  
M e r l i n  t a a a g a a t g g g a g g g a g a g g a c g t g g g g c t c g a g a a g a a a t a a a c g c c a a g c t c g a t t c g a a c c a a a a a a c c a c a t g t g t a t t g t g c t t t g t t t t t t t t t
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. . ACGGTGGGGGAAAAGGAGGGGGCCGTCATTAACAGAAACCGTGTATGGGGTCCGGACACGAACAGTACACAGCTTATGGGGAAAAAAGCTCACA 
. . ACGGTG. GGGAAAAGGAGGGGGCCGTCATTAACGGAAACCGTGTATGGGGTCCGGACACGAACAGTACACAGCTTATGGGGAAAAAAGCTCACA 
. . ACGGTGGGGGAAAAGGAGGGGGCCGTCATTAACGAAAACCGTGTATGGGGTCCGGACACGAACAGTACACAGCTTATGGGGAAAAAAGCTCACA 
--ACGGTG-GGGAAAAGGAGGGGGCCGTCATTAAC--AAACCGTGTATGGGGTC-GGACACGAACAGTACACAGCTTATGGGGAAAAAAGCTCACA
7 9 0 1  < ^U L 68  start | g000
GAGAGAAAAAA. . . CACCAAGCTCAGGCACGCGTACATCATTATTAT^^ATCGGATATCTCACCACGGGTCATAGTAGTACCAAGGAGTGTGT. .AAC 
GAGAGAAAAAA. . . CACCAAGCTCAGGCACGCGTACATCATTAT . . .  CATCATCGGATATCTCACCACGGGTCATAGTAGTACCAAGGAGTGTGT . .AAC 
GAGAGAAAAAAMBc ACCAAGCTCAGGCACGCGTACATCATTAT. » . CATCATCGGATATCTCACCACGAGTCATAGTAGTACCAAGGAGTGTGT . .AAC 
GAGAGAAAAAA^BcACCAAGCTCAGGCACGCGTACATCATTAT . . . CATCATCGGATATCTCACCACGAGTCATAGTAGTACCAAGGAGTGTGT . .AAC 
GAGAGAAAAAA^FCACCAAGCTCAGGCACGCGTACATCATTAT . . .  CATCATCGGATATCTCACCACGGGTCATAGTAGTACCAAGGAGTGTGlH-AAC 
GAGAGAAAAAAM^ACCAAGCTCAGGCACGCGTACATCATTAT. . .  CATCATCGGATATCTCACCACGAGTCATAGTAGTACCAAGGAGTGTGT . .AAC 
GAGAGAAAAAAj. . CACCAAGCTCAGGCACGCGTACATCATTAT . . . CATCATCGGATATCTCACCACGGGTCATAGTAGTACCAAGGAGTGTGT . .AAC 
GAGAGAAAAAA CACCAAGCTCAGGCACGCGTACATCATTAT------CATCATCGGATATCTCACCACG-GTCATAGTAGTACCAAGGAGTGTGT— AAC
8 0 0 1 K
r^T T A
UL69 stop 8 1 0 0
ACCATTTTTTC . . TTTTCTTTGTAACGGGATAAGGGACAGCAATCATCACGCACAACACCCTTCACTCTC . . TT'j GTCATCCATATCATCGCTGTAA 
A C C A T T T T T T |. . TTTTCTTTGTAACGGGATAAGGGACAGCAATCATCACGCACAACACCCTTCACTCTC . . TTTTTAGTCATCCATATCATCGCTGTAA 
ACCATTTTTTCHTTTTCTTTGTAACGGGATAAGGGACAGCAATCATCACGCACAACACCCCTCACTCTC. .TTTTTAGTCATCCATATCATCGCTGTAA 
ACCATTTTTTcBTTTTCTTTGTAACGGGATAAGGGACAGCAATCA.j; i;iiCGCACAACACCCCTCACTCTC. .TTTTTAGTCATCCATATCATCGCTGTAA 
ACCATTTTTTC. . TTTTCTTTGTAACGGGATAAGGGACAGCAATCATCACGCACAACACCCTTCACTTTT|®TTTTTAGTCATCCATATCATCGCTGTAA 
ACCATTTTTTCB T T T T CTTTGTAACGGGATAAGGGACAGCAATCATCACGCACAACACCCTTCACTCTC. . TTTTTAGTCATCCATATCATCGCTGTAA 
A C C A T T T T T T |. .^BCTTTGTAACGGGATAAGGGACAGCAATCATCACGCACAACACCCTTCACTCTC. .TTTTTAGTCATCCATATCATCGCTGTAA 
ACCATTTTTT---------------CTTTGTAACGGGATAAGGGACAGCAATCA------CGCACAACACCC-TCACT-T------TTTTTAGTCATCCATATCATCGCTGTAA
8 1 0 1  8 2 0 0
ADI 6 9 CACAGCATGTCCTCGTAATCGGGCGTCTGGCAGCGCATTACCACCGAGTCGTCTTCTTGCGGTACCGGTGGTGGTGG...............TGGTGGCGGCGGCGGCT
3 1 5 7  CACAGCATGTCCTCGTAATCGGGCGTCTGGCAGCGCATTACCACCGAGTCGTCTTCTTGCGGTGCTGGTGGTGG*.....................CGGCGGCGGCGGCTGCT
6 3 9 7  CACAGCATGTCCTCGTAATCGGGCGTCTGGCAGCGCATTACCACCGAGTCGTCTTCTTGCGGTACCGGTGGTGGTGGCGGCGGCGGCGGCGGCGGCGGCT
3 3 0 1  CACAGCATGTCCTCGTAATCGGGCGTCTGGCAGCGCATTACCACCGAGTCGTCTTCTTGCGGTACCGGTGGTGG*............................. TGGCGGCGGCGGCT
W CACAGCATGTCCTCGTAATCGGGCGTCTGGCAACGCATTACCACCGAGTCGTCTTCTTGCGGTACCGGTGGTGG^......................................TGGCGGCGGCG
M e r l i n  CACAGCATGTCCTCGTAATCGGGCGTCTGGCAGCGCATTACCACCGAGTCGTCTTCTTGCGGTACCGGTGGTGG...................................... . CGGCGGCGGCT
T o l e d o  CACAGCATGTCCTCGTAATCGGGCGTCTGGCAGCGCATTACCACCGAGTCGTCTTCTTGCGGTACCGGTGGTGG.......................................................... CGGCG
CONSENSUS CACAGCATGTCCTCGTAATCGGGCGTCTGGCA-CGCATTACCACCGAGTCGTCTTCTTGCGGT-C-GGTGGTGG-------------------------------------------- C -G C -
8 2 0 1  8 2 9 8
ADI 6 9  GCTGCTGCTGGGTTGCCGTCGTACTGTGATTACCGTTGGCGGACTGCACCGGGATGATGGGCTGCTTGTGGGGAACCTGGGGTGGACTGCCGCCGTGA
3 1 5 7  GCTGCTGCTGGGTTGCCGTCGTACTGTGATTACCGTTGGCGGACTGCACCGGGATGATGGGCTGCTTGTGGGGAACCTGGGGTGGACTGCCGCCGTGA 
6 3 9 7  GCTGCTGCTGGATTGCCGTCGTACTGTGATTACCGTTGGCGGACTGCACCGGGATGATGGGCTGCTTGTGGGGAACCTGGGGTGGACTGCCGCCGTGA 
3 3 0 1  GCTGCTGCTGGGTTGCCGTCGTACTGTGATTACCGTTGGCGGACTGCACCGGGATGATGGGCTGCTTGTGGGGAACCTGGGGTGGACTGCCGCCGTGA 
W GCTGCTGCTGGGTTGCCGTCGTACTGTGATTACCGTTGGCGGACTGCACCGGGATGATGGGCTGCTTGTGGGGAACCTGGGGTGGACTGCCGCCGTGA 
M e r l i n  GCTGCTGTTGGGTTGCCGTCGTACTGTGATTACCGTTGGCGGACTGCACCGGGATGATGGGCTGCTTGTGGGGAACCTGGGGTGGACTGCCGCCGTGA 
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Figure 4.4. Fram eshifts between HCMV strains in region O.
Navy blue lines show insertions/deletions that cause frameshifts in comparison to 
AD 169. Gold lines show A:T tracts of variable length that cause frameshifts in 
comparison to AD 169. Red arrows show polyadenylation signals and the first in­
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Table 4.2. Frameshift mutations in the ORFs of region O, identified by 
sequence comparisons.
The central column concerns all frameshift mutations which affect the ORF. The 
right column concerns the number of these frameshift mutations caused by differences 
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Figure 4.5. ORFs in region O.
ORFs for the six translation frames of the DNA sequences of AD 169 and Merlin have 
been computed using Frames. Start codons are shown as short lines extending above 
the box, and stop codons are shown as short lines extending below the box. The 
region shown is larger than that shown in Figures 4.1 to 4.4, to include ORFs UL57 
and UL69, which are highlighted in green.
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Region O is well conserved, with a very high level of identity between strains. The 
data for AD 169 and Merlin confirmed the previously published sequence for these 
strains in this region (Chee et al., 1990; Dolan et al., 2004). Like region X, region O 
contains a number of polynucleotide A:T tracts, in which length variation was 
observed between clones. As previously discussed in Section 3.3, variation in these 
tracts (of eight repeat units or more) appears to be an artefact of PCR amplification. 
Consequently, the corresponding sequences of four strains (Towne, FIX, PH and TR) 
sequenced by Murphy et al. (2003b) from cloned BACs were compared to the seven 
strains in the sequence comparisons in region O to more reliably investigate variation 
in these tracts.
Each of UL58-UL68, with the exception of UL66, was disrupted in certain strains by 
nucleotide insertions or deletions that shift the reading frame, in comparison with 
AD 169. Although approximately 600 bp of sequence for six of the seven strains 
sequenced in the present study is missing from UL61, four frameshifts were registered 
in other regions of this ORF UL61. This part of region O is of particularly high G+C 
content and contains numerous inverted and direct repeats within the core region of 
oriLyt (Section 4.2).
The data in Table 4.2 shows all the frameshifts in each ORF caused by insertions or 
deletions, also specifying which frameshifts are caused by differences in A:T tract 
length. In addition to the frameshifts identified in UL58-UL68, a total of nine 
differences that would cause frameshifts were also found in the areas between the 
predicted ORFs (Figure 4.4). Analysis of the areas of region O not affected by 
frameshift mutations concluded that no novel ORFs emerged as potentially encoding 
proteins from the sequence comparisons. All ORFs in strains AD 169 and Merlin are 
shown in Figure 4.5. The potential o f region O to contain protein-coding ORFs is 
limited by the high frequency o f stop codons in all six coding frames and by 
frameshifts in the few ORFs conserved in the HCMV strains. Consequently, it is 
unlikely that ORFs UL58-UL68, or any other ORFs in region O, code for proteins. 




It seems unlikely that UL58-UL68, which were assigned to region O in the original 
analysis of HCMV strain AD 169 (Chee et al., 1990), actually encode proteins. Only 
UL59, UL67 and UL68 commence with ATG codons. The other ORFs are preceded 
by termination codons, with UL60-UL62 and UL64-UL66 containing in-frame ATG 
codons internally and UL58 and UL63 lacking such codons (Figure 4.1). Sequence 
comparisons of seven HCMV strains in region O showed that each of these ORFs, 
with the exception of UL66, is not intact in all HCMV strains and is disrupted by 
frameshifts, in comparison with AD 169 (Figure 3.4). In addition, the three ORFs 
defined by Murphy et al. (2003a) are all disrupted by frameshifts. Using an internal 
ATG initiation codon, UL66 would be predicted to encode a protein o f 78 aa, which is 
not similar to other proteins in the NCBI database, and UL66 is completely 
overlapped by pp67, a transcript originating from region O (Figure 4.1).
Sequence comparisons show that frameshifts also affect pp67, a late RNA associated 
with UL65. This RNA was originally sequenced and mapped in strain Towne by 
Davis et al. (1984, 1985), then later in strain AD 169 by Scott et al. (2002). The pp67 
RNA is routinely detected in nucleic acid sequence-based amplification (NASBA) 
assays to monitor the progression of HCMV infections and the effect of antiviral 
therapy on viral activity (Blok et al., 1998; Gema et al., 1999). The initial study by 
Davis et al. (1984) reported that this RNA encodes a 67 kDa protein, which could be 
detected by monoclonal antibodies in total protein preparations from Towne-infected 
cells. Although the pp67 RNA is routinely detected in NASBA assays, the work by 
Davis et al. (1984) remains the only study suggesting that a protein is encoded, and 
the authors did not describe the process by which monoclonal antibodies were 
prepared. A more recent study by Scott et al. (2002) characterised pp67 transcripts in 
AD 169, identifying multiple 5’-ends. The authors noted that multiple strain analysis 
would be required to confirm initial differences observed between the Towne and 
AD 169 ORFs. Sequence comparisons of seven strains in the present study suggest 
that pp67 does not encode a protein.
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Figure 4.6. Sequence comparisons of region O in HCMV and other CMVs.
Comparisons are displayed in a matrix plot computed using Compare (window of 21 
nucleotides with a minimum match of 17 nucleotides) and displayed using Dotplot.
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Figure 4.7. The nucleotide composition of region O and corresponding regions 
in other CMVs.
The plots were computed using Window (100 nucleotides shifted by 3 nucleotide 




Sequence comparisons did not identify any novel ORFs emerging as potentially 
encoding proteins because of other frameshifts which were identified throughout the 
region, and the number of stop codons. The lack of protein-coding ORFs in region O 
leaves a large region of 7.9 kbp that contains oriLyt, a region of unusual nucleotide 
composition and possibly the highest content o f inverted and direct repeats in HCMV 
(Masse et al., 1992). Corresponding regions are present in other CMVs, where they 
are similar in size and position in the genome (Table 4.3). DNA sequence 
comparisons between HCMV and other CMV sequences are shown as two- 
dimensional comparisons on matrix plots in Figure 4.6. The corresponding region in 
CCMV, the closest relative of HCMV, is similar in size and position but the genomes 
show little collinearity in UL58-UL68, in contrast to the sequence similarity evident 
in the flanking genes UL57 and UL69 (Figure 4.6). Regions corresponding to region 
O can also be identified in the more distantly related CMV genomes of RhCMV (4.4 
kb), MCMV (3.3 kb), RCMV (4.9 kbp) and TuHV-1 (6.1 kbp) (Table 4.3, Figure 4.6). 
When compared with HCMV, these genomes are extremely divergent in region O, 
much more so than in the flanking genes (UL57 and UL69).
Region O in HCMV has an asymmetrical nucleotide composition, with high G+C 
content in the core oriLyt region and lower G+C content elsewhere (Figure 4.7). 
Similar patterns of unusual nucleotide composition are exhibited in the corresponding 
regions of other CMV genomes. Even in distant relatives such as TuHV-1, which has 
little sequence similarity to HCMV, a similar pattern can be seen (Figure 4.7). 
Polynucleotide A:T tracts of eight or more residues are a common feature in the low 
G+C part of region O, as in region X (Chapter 3). In contrast, such tracts are not 
common in recognised HCMV genes.
Located in the left half o f region O, oriLyt functions as an essential ds-acting factor 
required for lytic-phase DNA replication, as previously described (Section 4.2). The 
origin regions in the other CMVs, where they have been identified, map to the 
corresponding region. The core region of oriLyt is flanked by sequences that are 
required for full activity but are not essential. Each of UL58-UL62, sequences 
essential to or augmenting oriLyt function are disrupted by frameshift mutations. In 
the right half of region O, UL63-UL68 and ORF3-ORF5 do not encode proteins as
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they are disrupted by frameshift mutations. The only ORF in this half o f region O 
reported to encode a transcript, pp67, is also disrupted by frameshift mutations and is 
therefore unlikely to be protein-coding. Transcript mapping would be required to 
further investigate the possibility of other RNAs originating from this region, 
although none would be expected to be protein-coding.
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CHAPTER 5: REGION G
5.1 Protein-coding genes
In addition to regions X and O, which are investigated in chapters 3 and 4, the 
proposed gene content o f a region at the end of the Us sequence of the viral genome 
was affected by the comparative analysis with CCMV (Davison et al., 2003a). This 
region, US33-US36, is here termed region G. ORFs US33, US35 and US36 have 
been discounted as they have no counterparts in CCMV, and a novel ORF, US34A, 
has been identified as having a counterpart in CCMV (Davison et al., 2003a). The 
region is flanked by ORFs US32 and TRS1, and contains US34 internally (Figure
5.1).
TRS1 extends from TRs into Us, and has a counterpart gene, IRS1, which extends 
from IRs into the Us (Chee et al., 1990). Transcription is controlled by identical 
promoters, and both genes are expressed at IE times p.i., although their mRNAs and 
encoded proteins could be detected during all phases of the viral replication cycle 
(Romanowski and Shenk, 1997).
TRS1 and IRS1 encode proteins with identical N-terminal domains (549 aa) and 
different C-terminal regions (240 aa and 298 aa, respectively). TRS1 encodes a 789 
aa, 84 kDa protein, which is present in the nucleus and cytoplasm IE and E times p.i., 
but mostly in the cytoplasm at L times p.i. (Romanowski and Shenk, 1997). Both the 
TRS1 and IRS1 proteins are associated with HCMV virions, and were not degraded 
when intact virions were treated with trypsin (Romanowski et al., 1997). As IE 
proteins, pIRSl and pTRSl are transcriptional trans-activators that co-operate with 
the major IE1 and IE2 proteins to create a complex regulatory network that controls 
gene expression (Pari and Anders, 1993; Pari et al., 1993). However, TRS1- 
expressing plasmids were shown to produce several-fold-higher levels of activity than 
IRS 1-expressing plasmids, as shown using reporter genes (Kerry et al., 1996).
135
Keg ion (J
"i— i— i-------------- 1------------ 1— i-------------- 1 r224 225 226 227
-►M M^1
» □ > 1___ 7 m ] <
US31 US32 US33 US34 US34A US35 US36 TRS1
G T *   - .* G 3 R
Figure 5.1. M ap of the characterised genes and predicted genes in region G 
and flanking sequences.
The scale at the top shows the location (kbp) in the AD 169 genome. Dark green 
shows ORFs thought to encode proteins. Red shows ORFs predicted by Chee et al. 
(1990) that have no known function and have been discounted because they lack 
counterparts in CCMV (Davison et al., 2003). Purple shows a novel ORF that has a 
counterpart in CCMV. Blue bars show the two overlapping PCR products amplified 
using the primers shown in Appendix. The 3'-end of each ORF has a point to show 
its orientation, and the M shows the first in-frame ATG initiation codon in each ORF.
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An IE gene product encoded within IRS1 gene, termed pIRSl , was identified by 
Romanowski and Shenk (1997). This new protein was encoded within the 3’-end of 
the IRS1 gene in same reading frame as the large pIRSl protein. Expression of the 
smaller protein was controlled by a promoter residing within IRS1, in the Us region. 
The protein pIRSl , maximally expressed at early times p.i. and residing in the 
nucleus, can antagonise the transcriptional activating capabilities o f pTRSl 
(Romanowski and Shenk, 1997).
Deletion mutants which failed to produce pIRSl and pIRSl proteins were shown to 
replicate in HFFF cells with normal growth kinetics (Jones and Muzithras, 1992; 
Blankenship and Shenk, 2002). A TRS1 C-terminal deletion mutant, however, 
produced ~200-fold less virus than wild-type HCMV, apparently due to a packaging 
defect (Blankenship and Shenk, 2002). On infection of this mutant, viral DNA 
accumulated normally but two tegument proteins were abnormally localised and 
infectious viral particles did not accumulate to normal levels. It was concluded that 
the structure of the mutant particles was aberrant, indicating that the TRS1 protein 
was required, either directly or indirectly, for efficient assembly o f virus particles 
(Blankenship and Shenk, 2002). More recent studies have shown that TRS1 and 
IRS1 are also able to counteract critical host cell antiviral responses, indicating that 
TRS1 is a complex gene with multiple distinct functions (Child et al., 2002; Child et 
a l , 2004).
US32, which flanks the left end of region G, is a member of the HCMV US1 gene 
family, with US1 and US31 (Chee et al., 1990). US31 was one o f 24 HCMV ORFs 
revised by the analysis of Davison et al. (2003a) in which a simple correction was 
made at the start of the reading frame to reduce the size to 486 bp, allowing the 
putative protein (revised to 162 aa) to commence on an ATG initiation codon. US34 
has been partially characterised in a study by Scott et al. (2002). The transcript, 
sequenced from a late cDNA library, was found to be mostly congruent with the 
US34 ORF predicted by Chee et al. (1990), although a definitive 5’-end was not 
determined. US34A was introduced to region G as one of four new AD 169 genes 
predicted from the comparative study with CCMV (Davison et al., 2003a).
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All of these characterised or partially characterised genes within or flanking region G 
commence with ATG codons (Figure 5.1). Only US33, US35 and US36, which were 
discounted by the comparative analysis with CCMV, do not commence with ATG 
initiation codons. These ORFs are preceded by termination codons, and contain in­
frame ATG codons internally (Figure 5.1).
5.2 Sequence comparisons
Sequence comparisons of this region were used to investigate the protein-coding 
potential o f the three ORFs discounted by comparative analysis with CCMV (US33, 
US35 and US36), and the novel ORF introduced (US34A) (Davison et al., 2003a). 
Sequence data were also obtained for flanking ORFs. Two overlapping PCR products 
were amplified for each strain (Figure 5.1), one originating from US31 and 
terminating in US34A, and the other originating from US34A and terminating in 
TRS1. The seven HCMV strains sequenced were high passage strain AD 169, low 
passage strains Toledo, Merlin, 3157 and 6397, and strains obtained directly from 
human tissue, W and 3301 (Section 2.1.1). The PCR products for each strain were 
cloned into plasmids and at least four plasmids were sequenced for each PCR product, 
as described previously (Section 3.3). Electrophoresis of the PCR products identified 
one distinct difference between strains, where the amplification product of strain 6397 
(using primers G4R and G2; Figure 5.1) was approximately 350 bp larger than the 
corresponding product for all the other strains.
The sequence is very well conserved between strains in US31-US34A and TRS1 
(Figure 5.2). Data for AD 169 confirmed the previously published sequence for this 
strain (Chee et al., 1990). Data for Merlin also confirmed the recently published 
sequence for this strain with the exception of two differences, both found in 
polynucleotide G:C tracts (Dolan et al., 2004). Three G:C tracts were identified in the 
region, all o f variable length between strains, and all located in US35 or US36 (Figure
5.2). Sequence comparisons in regions X and O (Chapters 3 and 4, respectively) 
showed higher frequencies of A:T tracts in apparently non-protein-coding regions. 
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2 0 1  3 0 0
ADI 6 9  GCGTCGTGTAATCCACGACTCGCACGGCCTGTGGTGCGACTGCGGCGACTGGCGAGAGCACCTCTATTGTGTGTACGACAGCCATTTTCAGCGACGACCC
3 3 0 1  GCGTCGTGTAATCCACGACTCGCATGGCCTGTGGTGCGACTGCGGCGACTGGCGAGAGCACCTCTATTGTGTGTACGACAGCCATTTTCAGCGACGACCC 
T o l e d o  GCGTCGTGTAATCCACGACTCGCACGGCCTGTGGTGCGACTGCGGCGACTGGCGAGAGCACCTCTATTGTGTGTACGACAGCCATTTTCAGCGACGACCC 
W GCGTCGTGTAATCCACGACTCGCACGGCCTGTGGTGCGACTGCGGCGACTGGCGAGAGCACCTCTATTGTGTGTACGACAGCCATTTTCAGCGACGACCC 
M e r l i n  GCGTCGTGTAATCCACGACTCGCACGGCCTGTGGTGCGATTGCGGCGACTGGCGAGAGCACCTCTATTGTGTGTACGACAGCCATTTTCAGCGACGACCC 
3 1 5 7  GCGTCGTGTAATCCACGACTCGCACGGCTTGTGGTGCGACTGCGGCGACTGGCGAGAGCACCTCTATTGTGTGTACGACAGCCATTTTCAGCGACGACCC 
6 3 9 7  GCGTCGTGTAATCCACGACTCGCACGGCCTGTGGTGCGATTGCGGCGACTGGCGAGAGCACCTCTATTGTGTGTACGACAGCCATTTTCAGCGACGACCC 
CONSENSUS GCGTCGTGTAATCCACGACTCGCA-GGC-TGTGGTGCGA-TGCGGCGACTGGCGAGAGCACCTCTATTGTGTGTACGACAGCCATTTTCAGCGACGACCC
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5 0 1  6 0 0
ADI 6 9  CTTCTCGCGGGCCTACCACCACCGCATTAACCGGGGTCTGCGGGGCACGCCCCCACCGCGCAACTTGCCGGGATACGAGCACGCCTCCGAGGGCTGGCGG
3 3 0 1  CTTCTCGCGGGCCTACCACCACCGCATTAACCGGGGTCTGCGGGGCACGCCCCCACCGCGCAACTTGCCGGGATACGAGCACGCCTCCGAGGGCTGGCGG 
T o l e d o  CTTCTCGCGGGCCTACCATCACCGCATTAACCGGGGTCTGCGGGGCACGCCCCCACCGCGCAACTTGCCGGGATACGAGCACGCCTCCGAGGGCTGGCGG 
W CTTCTCGCGGGCCTACCACCACCGCATTAACCGGGGTCTGCGGGGCACGCCCCCACCGCGCAACTTGCCGGGATACGAGCACGCCTCCGAGGGCTGGCGG 
M e r l i n  CTTCTCGCGGGCCTACCACCACCGCATTAACCGGGGTCTGCGGGGCACGCCCCCACCGCGCAACTTGCCGGGATACGAGCACGCTTCCGAGGGCTGGCGG 
3 1 5 7  CTTCTCGCGGGCCTACCATCACCGCATCAACCGGGGTTTGCGGGGCACGCCCCCACCACGCAACTTGCCGGGATACGAGCACGCCTCCGAGGGCTGGCGG 
6 3 9 7  CTTCTCGCGGGCCTACCACCACCGCATTAACCGGGGTCTGCGGGGCACGCCCCCACCGCGCAACTTGCCGGGATACGAGCACGCCTCCGAGGGCTGGCGG 
CONSENSUS CTTCTCGCGGGCCTACCA-CACCGCAT-AACCGGGGT-TGCGGGGCACGCCCCCACC-CGCAACTTGCCGGGATACGAGCACGC-TCCGAGGGCTGGCGG
6 0 1  7 0 0
ADI 6 9  TTTTGCAGTCGACGGGAACGGCGAGAGGACGATCTTCGCACGCGGGCTGAGCCGGACCGCGTGGTGTTCCAGTTAGGGGGAGTACCCCCTCGCCGTCACC
3 3 0 1  TTTTGCAGTCGACGGGAACGGCGAGAGGACGATCTTCGCACGCGGGCTGAGCCGGACCGCGTGGTGTTCCAGTTAGGGGGAGTACCTCCTCGCCGTCACC 
T o l e d o  TTTTGCAGTCGACGGGAACGGCGAGAGGACGATCTTCGCACGCGGGCTGAGCCGGACCGCGTGGTGTTCCAGTTAGGGGGAGTGCCGCCTCGCCGTCACC 
W TTTTGCAGTCGACGGGAACGGCGAGAGGACGATCTTCGCACGCGGGCTGAGCCGGACCGCGTGGTGTTCCAGTTAGGGGGAGTACCTCCTCGCCGTCACC 
M e r l i n  TTTTGCAATCGACGGGAACGGCGAGAGGACGATCTTCGCACGCGGGCTGAGCCGGACCGCGTGGTGTTCCAGTTAGGGGGAGTACCTCCTCGCCGTCACC 
3 1 5 7  TTTTGCAATCGACGGGAACGGCGAGAGGACGATCTTCGCACGCGGGCTGAGCCGGATCGCGTGGTGTTCCAGTTAGGGGGAGTACCGCCTCGCCGTCACC 
6 3 9 7  TTTTGCAATCGACGGGAACGGCGAGAGGACGATCTTCGCACGCGGGCTGAGCCGGACCGCGTGGTGTTCCAGTTAGGGGGAGTACCTCCTCGCCGTCACC 
CONSENSUS TTTTGCA-TCGACGGGAACGGCGAGAGGACGATCTTCGCACGCGGGCTGAGCCGGA-CGCGTGGTGTTCCAGTTAGGGGGAGT-CC-CCTCGCCGTCACC
Figure 5.2. Sequence comparisons of seven HCMV strains in region G.
Alignments were made using ClustalW and displayed using Pretty. Yellow AD 169 
sequence shows all characterised and predicted ORFs in the region. The start and stop 
codons for each ORF are shown, the arrows indicating their orientation. Purple shows 
insertions/deletions that cause frameshifts relative to AD 169. Sky blue shows length 
variation in polynucleotide A:T or G:C tracts of eight or more residues that cause 
frameshifts in comparison to AD 169. Grey shows in-frame insertions/deletions. 
Brown consensus residues show conserved potential poly(A) signals (AATAAA). 
Green shows the internal ATG initiation codon in ORFs US33, US35 and US36. The 
Figure is continued on the following pages.
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1 9 0 1  | US34A stop^>
ACGGAAAAACCGCGCACGGCGTCGGCAGTCTTTTCCGTGi .CTTGGGGCGATGGGTCCGAGCTGCGGTATGGGTCACGGCGGCGTGTGT1








-C -G A A A -A -C — GCACGGCGTCGGCA------ TTTTCCGTGACTTGGGGCG-TGGGTCCGAGCTGCGGTATGGGTCACGGC-GCGTG-GT-TT--T-AC-AA
200 1  2100  
GATGCCGATGTGTGACTAAAAA.CGTCCCAGCCCCAGAGCGATATGTTTCAATAAAAAAAATATGTAGTATlHATTATGCGTGTCCTGGTTTTTCATTT
GATGCCTATGTGTGACTAGAAA. CGTCCCAGCCCTAGAGCGATATGTTTGAATAAAAAAABTATATAGTATCATATTATGCGTGTCCTGGTTTTTCATTT
g a t g c c g a t g t a t g a c t a a a a a . c g t c c c a g c c c c a g a g c g a t g t g t t t c a a t a a a a a a a I t a t g t a g t a t c a t a t t a t g c g t g t c c t g g t t t t t c a t t t  
g a t g c c g a t g t g t g a c t a a a a a . c g t c c c a g c c c c a g a g c g a t g t g t t t c a a t a a a a a a a Mt a t g t a g t a t c a t a t t a t g c g t g t c c t g g t t t t t c a t t t  
GATGCCGATGTGTGACTAAAAA§CGTCCCAGCCCCAGAGCGATGTGTTTCAATAAAAATHt a t g t a g t a t c a t a t t a t g c g t g t c c t g g t t t t t c a t t t  
g a t g c c g a t g t g t g a c t a a a a a . c g t c c c a g c c c c a g a g c g a t a t g t t t c a a t a a a a a a a a t a t g t a g t a t c a t a t c a t g c g t g t c c t g g t t t t t c a t t t  
g a t g c c g a t g t g t g a c t a a a a a | c g t c c c a g c c c c a g a g c g a t g t g t t t c a a t a a a a a t M t a t g t a g t a t c a t a t t a t g c g t g t c c t g g t t t t t c a t t t  
GATGCC-ATGT-TGACTA-AAA-CGTCCCAGCCC-AGAGCGAT-TGTTT-f iE S B lA A  TAT-TAGTATCATAT-ATGCGTGTCCTGGTTTTTCATTT
2 10 1  2200  
T T . GGATGTATGTATCGCATAAAGGGTGGCGAGGTGTGAGGATGAAACATATGCAGATACGCAGTGTTGTTATCCGAACGAAACCCGTGTAATGCGTACA
T T . GGATGTATTTGTCGCATAAAAGGCGGTGAGATGTGGGGATGAAACATATCTAGATACGCAGTTTTGTTATCCGAACAAAGCTCGTGTGATGCGAAAA 
C T . GGATGTATTTGTTACATAAAAGGCGGTGGGATATGGGGATGAAACATATGTAGATACGCAGTTTTATTATCCGAACAAAGCTCGTGTGATGCGAAAA 
C T . GGATGTATTTGTTACATAAAAGGCGGTGGGATATGGGGATGAAACATATGTAGATACGCAGTTTTATTATCCGAACAAAGCTCGTGTGATGCGAAAA 
TT|GGATGTATTTGTCGCATAAAAGGCGGTGGGATGTGGGGATGAAATATATCCAGATACGCAGTTTTGTTATCCTAACAAAACCCGTGTCATGCTAAAA 
T T . GGATATATGTATCGCATAAAGGGTGGCGAGGTGTGAGGATGAAACATATGCAGATACGCAGTTTTGTTATCCGAACGAAACCCGTGTAATGCGTACA 
TT|GGATGTATTTGTCGCATAAAAGGCGGTGGGATGTGGGGATGAAATATATCCAGATACGCAGTTTTGTTATCCTAACAAAACCCGTGTCATGCTAAAA 
-T -G G A T -T A T -T -T — CATAAA -G G -G G -G -G -T-TG -G G A TG A A A -A TA T— A G A TA CG CA G T-TT-TTATCC-AAC-A A-C-CGTGT-ATGC— A -A
2 2 0 1  < C US36 stop | 2 3 0 0
ACGGTACTjrCAGTATGAAAGTCCCGTGTGTGGGGGGGGGGGGCA. • ■ AATAGTTGCGTTTGCCGTTGGGCGTACGCTACGTTTGTATTTCTGGCTATAAT
ACGGTACTGCAGGATGAAAGTCCCGTTGTTGGGGGGGGGGGGCAGATAGTAGTCGCTGTTGCCGCTGGGCGTACGCTATGCTTGTATTTGTGACTATAAT 
ACGGTACTGCAGGATGAAAGTCCCGTTG.. , GGGGGGGGGG|CAGAGAGTAGTCGCTTTTGCCGCTGGGCATACGCTATGCTTGTATTTGTGACTATACT 
ACGGTACTGCAGGATGAAAGTCCCGTTG. . . GGGGGGGGGGGCAGAGAGTAGTCGCTTTTGCCGCTGGGCATACGCTATGCTTGTATTTGTGACTATACT 
ACGGTAATGCAGGATGAAAGTCCCGTGT . . .  GGGGGGGGGGGCATATAGTAGTCGCTTTTACCGCTGGGCATACGCTATGCTTGTATTTGTGACTATACT 
ACGGTACTTCAGTATGAAAGTCCCGTGG.. . GGGGGGGGGGGCA. . . AATAGTCGCGTTTGCCGTTGGGCGTACGCTGCGTTTGTATTTCTGGCTATAAT 
ACGGTAATGCAGGATGAAAGTCCCGTGGGGGGGGGGGGGAGGCAGACAGTAGTCGTTTTTGCCGCTGGGCGTACGCTATGCTTGTATTTATGACTATAAT 
ACGGTA-T-CAG-ATGAAAGTCCCGT GGGGGGGG-G-CA A -T A G T -G  T T -C C G -T G G G C -T A C G C T --G -T T G T A T T T -T G -C T A T A -T
2 3 0 1 < ^ U S 3 5  start
ATGTGCGGTCATGTGTCGATGTTC








A T G T -C — TC-TGTGTCGATGTTCCTATTGGGAAGGGTGTGA-TGTA-G--GTATAAAG-A-GGTGGGA-GC-G------G -C A T -G -T A G A -A C A G -T — A -
2 4 0 1
CGCTGTACGAGTTTCACACGCTGAATCGGCGCCAAGAATAAAACAGTGGTTATTCGTAAAAGTAT
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GGGGGGGGG. .  
. . GGGGGGGGGG. .  
. GGGGGGGGGG. .  
GGGGGGGGGGCGCTGTACGAGTTTCACACGCTGATTCGGCGCCAAGAATAAAACAGTGGTTATTCGTAAAAGTAT .
CGTTGTGCTAGCCCCACCTG^MAGCAGCGTCATGAATAAAGCGGTGATTAAGCGTGAAAACAcM g l . . GGGGGGGGGG . . ________
 T G T -C -A G  C -C -------------------------G C G -CA -G — T A A A -C -G T G -T -A — CGT-AAA— A------------- GGGGGGGG--------------------------G— TG-TG
2 5 0 0
G.ATGTTGT
Ig c t t g g t g g
pCTTGGTGG
b c T T G G T G G
Ig c t t g g t g g
G G A T G T T G T
Ig c t t g g t g g
2 5 0 1 < ^ U S 3 6  start 2 6 0 0
t t a t t g t g a c g t a g c a a t t a t c g t a t t g t g c a t g t g t c g t tc g a c g g t t g t t a g a t g c a t t g c g t a t c t g t a t t a g t a g t t t t g c a a g c c g t g g t g c g t q ';
c a g t g g c c g t t a g a t a c a t t a c g t g t c t g t a t t g g t a c a t t t g c a a a c t g c c g g g c g t g t c g g t a t a g t t t a g c g a t g a t a a t a t c a t g t a t g t g c c g t a  
c g g t g t t c a t t a a a t g c a t t a t g t g t a t t t a t t g t t a c a t t t g c a a a t c g c c g a g t a t a c c g g t a t a a t g t a g c a a t a a t c g t a t t a t g t g t g t a c t a t a  
c g g t g t t c a t t a a a t g c a t t a c g t g t a t t t a t t g t t a c a t t t g c a a a t c g c c g a g t a t a c c g g t a t a a t g t g g c a a t a a t c g t a t t a t g t g t g t a c t a t a  
c g g t g t t c a t t a a a t g c a t t c t g t g t a t t t a t t g g t a c a t t t g c a a a t c g c c g a g t a t a c c g g t a t a a t g t g g c a a t a a t c g t a t t B g t g t g t a c t a t g  
c g a c g g t t g t t a g a t g c a t t g c g t a t c t g t a t t a g t a g t t t t g c a a g c c g t g g t g c g t g t t a t t g t g a c g t a g c a a t t a t c g t a t t g t g c a t g t g t c g t t  
c a g t g g c c g t t g g a t a c c t t a c g t g t c t g t a t t g g t a c a t t t g c a a a t c g t c g g g t g c g a c g g t a t a g t t t a a c g a t a a t t a t a t t a t g t a t g c g c a g t a  
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2 7 0 1  2 8 0 0
A DI 6 9 ......... .............................................................................................................................................................................................................................................................................................
3 3 0 1  ..............................................................................................................................................................................................................................................................................................
T o l e d o  ..............................................................................................................................................................................................................................................................................................
W ..............................................................................................................................................
M e r l i n  ..............................................................................................................................................................................................................................................................................................
3 1 5 7  ..............................................................................................................................................................................................................................................................................................
6 3 9 7  AGTTACACGTTTGTCTATGTGCGAGTTCAAGGACACTTGTATAATGCATATGACGGCAAAAGGCCGCAGAAACGACGGGGGGGGGGGGGTAGTAACTGTA 
CONSENSUS -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
2 8 0 1  2 9 0 0
ADI 6 9 ......... ..............................................................................................................................................................................................................................................................................................
3 3 0 1   : ........................................................................
T o l e d o  ..............................................................................................................................................................................................................................................................................................
w .............................................................................................................................................................................................................................................................................................
M e r l i n  ............................................................................................................................................................ ......................................................... ........................................................................
3 1 5 7  ..............................................................................................................................................................................................................................................................................................
6 3 9 7  TTAATTATACGTCTTGTAGTACACGTTACCGTGTACTGGTGCGCGTATTACGACACAAACTACATAGCGCTATAACCGGATGTATGGTATTTATATGTGC 
CONSENSUS -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
2 9 0 1  3 0 0 0
AD I 6 9 ......... ..............................................................................................................................................................................................................................................................................................
3 3 0 1  ..............................................................................................................................................................................................................................................................................................
T o l e d o   GCAA. .GTGTGGGA
W ...................................................................................................................................................................................................................................................... GCAA. .GTGTGGGA
M e r l i n  ................................................................................................................................................................. GCAA. .GTGTGGGA
3 1 5 7  ..............................................................................................................................................................................................................................................................................................
6 3 9 7  GTCTAGCATCCTTGTGAGATTCTGAGAGTCTTCTTGTAAGCGTAATGACAACGGTGTATGTTCTGCGTAAAGTGCATGCAAACAATGTAACAGTATGGGA 
CONSENSUS -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
3 0 0 1  3 1 0 0
ADI 6 9 ......... ................................ ACTAATATG. AAGCGTCGCGAGTAT . . . TAAAGCAATTGGTG.................................. TCTCTGTGCTAGTCTAACAACACCTGTGTAATGC
3 3 0 1  . GAA. ACGTTACAATTACATATAAAAGCGAGAAGTATACATATAAGGGTTGCTAGACACAGGTTTGTTTCTGTGCTAGCCCAATGGCACTTGTACAATCC
T o l e d o  ACAATGCCAGTGAAGAATATATAAAAGGCAGAAACATACATAAATGAATTGCTAGATACAGGGTTCTTTGTGTACTAGCCCAATCATGTCAATACAATGT 
W ACAATGCCAGTGAAGAATATATAAAAGGCAGAAACATACATAAATGAATTGCTAGATACAGGGTTCTTTGTGTACTAGCCCAATCATGTCAATACAATGT 
M e r l i n  ACAATGCCAGTGAAGAATATATAAAAGCCAGAAACATACATAAATGAATTGCTAGATACAGGGTTCTTTGTGTACTAGCCCAATCATGTCAATACAATGT
3 1 5 7  ................................ ACTAATATG. AAGCGTCGCGAGTAT . . . TAAAGCAATTGGTG.................................. TCTCTGTGCTAGTCTAACAACACCTGTGTAATGC
6 3 9 7  TGAATGCCAATAAATAACATATAAAAGCCAGAAGTATACATACAAGAGTTGCTAGACACAGGTTTGTTTCTGTGCTAGCCCAACGGCACTGGTACAATCC 
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3 1 5 7  GTACAACCAGAAAAAAGACGCGAAAG. 
6 3 9 7  ATGCAACCAGAAAAAGGATGCGAAAC| 
CONSENSUS -T - C A  AAA AA-GA-GC-A--------
3 2 0 0
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 GAC — C TG C A A -A -A -A A -C — ®TTAXfr-AGCATTGTAATG-TA-TG-GTGGCTA— TTAGAAAACGTGACGCGTCGCATGTCGCGGCACAATCTGG
3 4 0 1  3 5 0 0
ADI 6 9  CAGCGGGGTCGGGGTAGGGTACGGTGGGAGGCATGTACACAGATGGAACAAAAGCAGAAGTAACGTGAGAAGGAGCATACAGTCCAGTATCCAGCGGTTC
3 3 0 1  CAGCGGGGTCGGGGTAGGGTACGGTGGGAGGCATGTACACAGATGGAACAAAAGCAGAAGTAACGTGAGACGGAGCATATAGTCCAGTATCCAGCGGTTC 
T o l e d o  CAGCGGGGTCGGGGTAGGGTACGGTGGGAGGCATGTACACAGATGGAACAAAAGCAGAAGTAACGTGAGACGGAGCATATAGCCCAGTATCCAGCGGTTC 
W CAGCGGGGTCGGGGTAGGGTACGGTGGGAGGCATGTACACAGATGGAACAAAAGCAGAAGTAACGTGAGACGGAGCATATAGCCCAGTATCCAGCGGTTC 
M e r l i n  CAGCGGGGTCGGGGTAGGGTACGGTGGGAGGCATGTACACAGATGGAACAAAAGCAGAAGTAACGTGAGACGGAGCATATAGTCCAGTATCCAGCGGTTC 
3 1 5 7  CAGCGGGGTCGGGGTAGGGTACGGTGGGAGGCATGTACACAGATGGAACAAAAGCAGAAGTAACGTGAGACGGAGCATATAGTCCAGTATCCAGCGGTTC 
6 3 9 7  CAGCGGGGTCGGGGTAGGGTACGGTGGGAGGCATGTACACAGATGGAACAAAAGCAGAAGTAACGTGAGACGGAGCATATAGTCCAGTATCCGGCGGTTC 
CONSENSUS CAGCGGGGTCGGGGTAGGGTACGGTGGGAGGCATGTACACAGATGGAACAAAAGCAGAAGTAACGTGAGA-GGAGCATA-AG-CCAGTATCC-GCGGTTC
3 5 0 1  3 6 0 0
ADI 6 9  CTGAGTAGCACCACCCATCAACTGAATGCCCTCATGAGTAAAAGTCTGCGGGCGACAGCCCTTGGGGACCGTTGGCATGGGACGATCAATCTCCAAACCA
3 3 0 1  CTGAGTAGCACCACCCATCAACTGAATGCCCTCATGAGTAAAAGTCTGCGGGCGGCAGCCCTTGGGGACCGTTGGCATGGGACGATCGATCTCCAAACCA 
T o l e d o  CTGAGTAGCACCACCCATCAACTGAACGCCCTCATGAGTAAAAGTCTGCGGGCGGCAGCCCTTGGGGACCGTTGGCATGGGACGATCAATCTCCAAACCA 
W CTGAGTAGCACCAACCATCAACTGAACGCCCTCATGAGTAAAAGTCTGCGGGTGGCAGCCCTTGGGGACCGTTGGCATGGGACGATCAATCTCCAAACCA 
M e r l i n  CTGAGTAGCACCACCCATCAACTGAATGCCCTCATGAGTAAAAGTCTGCGGGCGGCAGCCCTTGGGGACCGTTGGCATGGGACGATCAATCTCCAAACCA 
3 1 5 7  CTGAGTAGCACCACCCATCAACTGAATGCCCTCATGAGTAAAAGTCTGCGGGCGGCAGCCCTTGGGGACCGTTGGCATGGGACGATCAATCTCCAAACCA 
6 3 9 7  CTGAGTAGCACCACCCATCAACTGAATGCCCTCATGAGTAAAAGTCTGCGGGCGACAGCCCTTGGGGACCGTTGGCATGGGACGATCAATCTCCAAACCA 
CONSENSUS CTGAGTAGCACCA-CCATCAACTGAA-GCCCTCATGAGTAAAAGTCTGCGGG-G-CAGCCCTTGGGGACCGTTGGCATGGGACGATC-ATCTCCAAACCA
ADI 69 
3 3 0 1  
T o l e d o  
W
M e r l i n
3 1 5 7
6 3 9 7
CONSENSUS




















US31 US32 US33 US34 US34A US35 US36 TRS1
+ 350 bp
Figure 5.3. Fram eshifts between HCMV strains in region G.
Navy blue lines show insertions/deletions that cause frameshifts in comparison to 
AD 169. Gold lines show A:T tracts of variable length that cause frameshifts in 
comparison to AD 169. Red arrows show poly(A) signals and the first in-frame ATG 
codon of each ORF is shown by the yellow M. No frameshifts were detected in 
US31-US34A, or in TRS1. In strain 6397, the location of the additional sequence (of 
approximately 350 bp) is shown.
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Figure 5.4. ORFs in region G.
ORFs for the six translation frames of the DNA sequences of AD 169 and Merlin have 
been computed using Frames. Start codons are shown as short lines extending above 
the box, and stop codons are shown as short lines extending below the box. The 
region shown is larger than that shown in Figures 3.1 to 3.4, to include ORFs UL31 
and TRS1, which are highlighted in green. In addition, US32 and US34 are 




Sequence data confirmed previous observations from gel electrophoresis of the PCR 
products across region G that strain 6397 harboured extra sequence. An insertion of 
approximately 350 bp was identified in 6397, between the end of TRS1 and the start 
o f ORF US36 (Figure 5.3). A recent analysis of the coding content of the HCMV 
genome sequenced six strains of HCMV which had been cloned as infectious bacterial 
artificial chromosomes (Murphy et al., 2003b). BAC DNA was subcloned and 
sequenced using a shotgun cloning method so the length o f polynucleotide tracts was 
not affected by the fidelity o f a PCR amplification reaction, as described in Section 
3.3. The corresponding sequences of four of the strains (Towne, FIX, PH and TR) 
were subsequently compared to the seven strains sequenced in the current study to 
investigate variation in the polynucleotide tracts and other differences between strains 
that would cause frameshifts.
In comparison with AD 169, one or more strains exhibit frameshifts in US35 and 
US36. These ORFs are disrupted in certain strains by nucleotide insertions or 
deletions that shift the reading frame in comparison with AD 169 (Figures 5.2 and 
5.3). As expected, a number of in-frame insertions/deletions which do not cause 
frameshifts were identified. Strain 6397, which contains additional sequence between 
US36 and TRS1, is distinctly different from the other strains in this area of region G. 
However, this strain alone did not account for the frameshifts observed, since 
variation was found in all strains. Data for BACs Towne and TR were mostly 
congruent with that of strain 6397, containing the additional -350 bp in region G 
compared to the other strains. Although similar in size, the additional sequence in 
these three strains is also quite variable. As each of US35-US36 exhibits frameshifts 
in comparison with AD 169, it is very unlikely that these ORFs actually encode 
proteins since they are not intact in all HCMV strains. Frameshifts were also 
identified in the sequence between US36 and TRS1. Furthermore, the presence of 
three G:C tracts of eight or more residues would be unusual for HCMV protein- 
coding regions. The only other G:C tracts o f eight or more residues in the genome are 
grouped within the non-coding, highly repetitive oriLyi (Section 4.3). Consequently, 
analysis o f the region found no novel ORFs emerging as potentially encoding proteins 
from the sequence comparisons. All ORFs in strains AD 169 and Merlin are shown in 
Figure 5.4. The sequence between US34A and TRS1 was highly variable between 
strains, and no novel ORFs were found to be conserved in all the HCMV strains. Nor
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were any novel ORFs identified in the additional sequence of strain 6397. 
Significantly, no frameshifts were registered in US31-US34A or in TRS1, as expected 
of protein-coding genes.
In addition to US35 and US36, US33 also has no counterpart in CCMV. In contrast 
to US35 and US36, this ORF was well conserved between strains and not 
frameshifted (Figure 5.2). The ORF as defined by Chee et al. (1990) is preceded by a 
stop codon and contains an in-frame ATG initiation codon internally, 66 bp 
downstream from the predicted start site. Transcript analysis was undertaken to 
evaluate US 3 3 further.
5.3 Transcript analysis in region G and flanking ORFs:
northern blot analysis
Northern blots were carried out to determine the expression kinetics and sizes of 
transcripts from the sequence containing region G. Equal amounts o f polyA+ AD 169 
mRNA were electrophoresed in agarose-formaldehyde gels, blotted to membranes 
overnight, and fixed by UV irradiation. A polyA+ RNA ladder was electrophoresed 
alongside the mRNA samples to aid estimations of transcript sizes (Section 2.1.8).
The two overlapping PCR products which were used to sequence region G, shown in 
Figure 5.1, were used to make dsDNA probes (section 2.2.22). The TRS1 RNA, 
characterised by Romanowski et al. (1997), was detected by probe K (Figure 5.5). 
The kinetics of expression were consistent with the published data, detecting an IE 
RNA of approximately 2.8 kb. A smear, also detected by probe K, appears to 
correspond to transcripts in E and L RNA of between approximately 0.7 kb and ~1.2 
kb. Although not well defined by the dsDNA probe, the RNAs detected might 
correspond to US34 and US34A. Probe J also detected transcripts similar in size and 
kinetics of expression to the smear detected by probe K (Figure 5.5). An RNA of 
approximately 1.2 kb was detected in E and L RNA. In L RNA, this RNA was more 
abundant, and a smaller, L transcript of approximately 0.8 kb was also detected. The 
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Figure 5.5. N orthern blot analysis of region G using dsDNA probes.
The locations of the DNA probes are shown. Each blot included IE, E and L AD 169 
polyA" mRNA, and a negative control of MI polyA+ mRNA. The results obtained 
using a GAPDH probe are shown at the bottom of each blot.
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Figure 5.6. N orthern blot analysis of region G using ssRNA probes.
The locations of the ssRNA probes are shown (not to scale, see Table 3.3 for accurate 
sizes), the arrows indicating the direction of any RNAs they would detect. Each blot 
included IE, E and L AD 169 polyA+ mRNA, and a negative control of MI polyA+ 
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Figure 5.7. F u rther northern  blot analysis of region G using ssRNA probes.
The locations of the ssRNA probes are shown (not to scale, see Table 3.3 for accurate 
sizes), the arrows indicating the direction of any RNAs they would detect. Each blot 
included IE, E and L AD 169 polyAT mRNA, and a negative control of MI polyA* 




Probe ORF strand F nrimer R nrimer size (bn)
L US33 + G10 G24 337
M US33 - G10 G24 337
N US34 + G14 G7 194
O US34 - G14 G7 194
P US34A + G4R G21 213
Q US34A - G4R G21 213
R US31 + G23 G1R 234
S US32 + G6 G15 176
T US35/US36 + G12 G22 270
U US35/US36 - G12 G22 270
Table 5.1. ssRNA probes used for northern blot in region G and flanking ORFs.
Each probe was amplified by Lign’Scribe PCR reaction (Section 2.2.23) using the 
primers listed in Appendix. The positions of the probes within the region are shown 
in Figure 3.8. For each of probes L-U, the primer in bold was used in the MaxiScript 
radiolabelling reaction to make the probe single-stranded and therefore strand-specific 
(Section 2.2.23).
Sequence comparisons identified only three consensus poly(A) signals (A AT AAA) in 
region G that were conserved in all the strains, as shown in Figure 5.3. From the 
positions of the poly(A) signals, it was predicted that US31 and US32 would express 
3’-co-terminal transcripts utilising the poly(A) signal at nucleotide position 224,884 
in ADI 69, and producing RNAs of approximately 1.3 and 0.7 kb, respectively. US34 
and US34A were also predicted to express co-terminal transcripts, utilising a poly(A) 
signal at position 226,202, and producing RNAs of approximately 0.9 and 0.4 kb, 
respectively.
Strand-specific ssRNA probes were then used in northern blots to investigate further 
the transcripts in region G. All blots were performed twice to ensure their 
reproducibility and accuracy. Probe M, which corresponds to the US33 ORF 
predicted by Chee et al., (1990), did not detect any transcripts. However, probe L 
(corresponding to the opposite strand o f US33) detected an RNA of approximately 1.2
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kb in E RNA, accumulating to a higher level in L RNA (Figure 5.6). Probe N (US34) 
detected a band of approximately 2 kb in all the polyA+ mRNA samples (Figure 5.6), 
which probably is the 18S ribosomal RNA (1.9 kb). Probe N also detected two other 
transcripts, of approximately 1.2 and 0.8 kb. The size and kinetics of expression of 
the 1.2 kb RNA were the same as the RNA detected by probe L. The 0.8 kb RNA 
was detected in L RNA, and at low levels in E RNA. Probe P (US34A) also detected 
the 1.2 and 0.8 kb RNAs. Probes O and Q, corresponding to the opposite strands of 
US34 and US34A, respectively, did not detect any transcripts.
Probes R and S were specific to US31 and US32, which were predicted to be 3’-co- 
terminal genes (Figure 5.7). Probe R (US31) detected a transcript of approximately
1.3 kb in E and L RNA. Probe S (US32) detected the same RNA, with the same 
kinetics of expression, and a smaller transcript o f approximately 0.7 kb in L RNA. 
Both probes also detected a number of additional RNAs. Two of these were present 
in all RNA samples, and probably correspond to cellular ribosomal RNAs 18S (1.9 
kb) and 28S (5 kb) RNAs. RNAs of approximately 2.4 and 3.8 kb were also detected 
in L RNA by both probes. These could correspond to US29 and US30, upstream of 
US31 and in the same orientation, if these ORFs utilise the poly(A) site downstream 
of US32 and not a poly(A) site 2 bp downstream of the end of US30. Probes T and U, 
covering ORFs US35 and US36 and corresponding to the two strands, did not detect 
any transcripts (Figure 5.7).
Northern blot analysis identified strong candidates for the RNAs of US31, US32 and 
US34, each corresponding to the size predicted from the sequence. RNAs from 
US33, US35 and US36 were not detected. A transcript from US34A was not clearly 
detected. A novel RNA was mapped to the region occupied by US33, but on the 
opposite strand. This 1.2 kb E RNA, identified by probe L (Figure 5.6), is in the same 
orientation as US34, and consequently was detected by probes N and P, located 
downstream. The detection of this RNA by all three probes, and the sequence 
comparison data, suggested the transcript shared the same poly(A) signal as US34, 
making them co-terminal. RACE analysis was required to map accurately the ends of 
this novel transcript and those of the other RNAs identified in the region.
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5.4 Transcript analysis in region G and flanking ORFs:
3’- and 5’-RACE
RACE was performed using a combination of three different kits to identify 3’- and 
5’-ends: SMARTRACE, GeneRacer and 5’RACE (Sections 2.2.26, 2.2.27 and 2.2.28, 
respectively). RACE reactions utilised a template of L polyA+ mRNA harvested from 
total infected cell RNA (Section 2.2.20). The primers used to map the ends of region 
G RNAs are shown in Table 5.2.
The 1.2 kb transcript, mapping to the opposite strand from US33, was termed US33A. 
This has not been previously recognised as an ORF. Sequence and northern blot 
analyses suggested that the US33A, US34 and possibly the US34A RNAs are 
expressed as co-terminal transcripts. Primers G29, G14 and G4R were used to 
amplify 3’-RACE products, and primers G28, G7 and G27 were used to amplify 5’- 
RACE products for these three ORFs, respectively (Table 5.2 and Figure 5.8). Each 
RACE-PCR product was gel purified and cloned, and approximately 10 clones were 
sequenced. All three 3’-RACE amplification products mapped to an A residue at 
nucleotide position 226,222 in AD 169, 20 bp downstream from a consensus poly(A) 
signal (AATAAA). However, as US33A and US34 utilise the same poly(A) signal 
downstream from US34A, the presence of a US34A RNA could not be confirmed.
The 5’-end of US34 mapped to an A residue at position 225,383 and the 5’-end of 
novel ORF US33A mapped to an A residue at position 225,048. Two potential non­
consensus TATA elements were identified upstream of the 5’-ends of the genes: 
CATAA motifs 31 bp and 33 bp upstream of the transcription start sites of US33A 
and US34, respectively (Figure 5.10). Using primer G27, 5’-RACE products of 
approximately 700 bp and 1050 bp were amplified that corresponded to US34 and 
US33A, respectively. From the same reaction, a 5’-RACE product o f approximately 
350 bp was amplified that corresponded to the predicted start o f novel ORF US34A. 
This 5’-RACE product, which could only be identified using SMARTRACE reactions 
(Section 2.2.26), were gel purified and cloned. Each sequenced clone identified a 
different 5’-end. None of the potential 5’-ends was associated closely with an 
upstream consensus or non-consensus TATA box (Figure 5.10).
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Figure 5.8. 3’- and S’-RACE amplification of the ends of RNAs in region G
and flanking ORFs.
(A) 5’-RACE amplification products. Lanes 1-5 show RACE products amplified 
using primers specific to US33A, US34, US34A, US31 and US32 respectively (Table
5.2). (B) 3’-RACE amplification products. Lanes 6-10 show RACE products
amplified using primers specific to US33A, US34, US34A, US31 and US32, 
respectively (Table 5.2). Lanes L are DNA markers. Sequencing of additional bands 




ORF prim er product sizes (bp) prim er product sizes (bp)
US31 G1R 550 G23 1100
US32 G15 450, 1100 G6 600
US33A G28 400 G29 1200
US34 G7 300, 700 G14 850
US34A G27 350. 700. 1050 G4R 400
Table 5.2. 3’- and S’-RACE amplification of the ends of RNAs in region G
and flanking ORFs.
The primers used for RACE amplification are detailed in Appendix. The approximate 
product sizes refer to the bands detected in the agarose gels that correspond to the 
predicted 5’- and 3’-ends of the ORFs. Multiple product sizes indicate the primer 
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Figure 5.9. Summ ary of RACE transcrip t m apping in region G and flanking 
ORFs.
RACE transcript mapping identified two sets of 3’-co-terminal ORFs: US33A, US34 
and US34A in region G, and US31 and US32 flanking region G. Blue bars show the 
5’-ends of the ORFs and red bars show the 3’-ends of the ORFs. We were unable to 




Q R H N - R G L V T D V Q D V T R V R E S H K N G V V S G F P Q E  
S A S Q L T W V G H - R A G C Y A S Q R I A - E R G G E R V P T G V  
S V T T D V G W S L T C R M L R E S E N  R  I  R  T G W - A G S H R S  
C A G C G T C A C A A C T G A C G T G G G T T G G T C A C T G A C G T G C A G G A T G T T A C G C G A G T C A G A G A A T C G flj|gg jgG A A C G G G G T G G T G A G C G G G T T C C C A cfG G A G T  US33A 5’-end
S L A Q K H H E P Q V P R E G G L R E T G I P P A C Q T R V G A - P  
S  G A  K A  P  -  A S G S  P R G R V T R N W D T A R M P N A C G C M T
l  h  r  k  s  t
CTCTGGCGCAAAAGCACCATGAGCCTCAGGTTCCCCGAGAGGGCGGGTTACGAGAAACTGGGATACCGCCCGCATGCCAAACGCGTGTGGGTGCATGACCG29^ '
V G  I  D A V Y H E A T H D V P A G V A V H  F S V L R A A V L A R Q  
R W D - R G L S - G N S - C T R W C C R S L F R F T C R G P S  T S  
^ ■ Q E H Q H 9 E B B K H 3 B H ^ H 9 B 9 0 B 9 E H B Q H 9 E K H 9 B I B E B i f l Q H 3 Q E H S  H v  s
CGTTGGGATTGACGCGGTTTATCATGAGGCAACTCATGATGTACCCGCTGGTGTTGCCGTTCACTTTTCCGTTTTACGTGCCGCGGTCCTAGCACGTCAG
W - R - - L Q H G P - R T R L G R T S I P R Q T A V T W L N V E T  
V V T L I I A T W P M T N P L G T N V N T T S N R R D L A E R - N I  
G D A D N C N M A H D E P A W D E R Q Y H V K P P - L G - T L K H  
TGGTGACGCTGATAATTGCAACATGGCCCATGACGAACCCGCTTGGGACGAACGTCAATACCACGTCAAACCGCCGTGACTTGGCTGAACGTTGAAAjjj|| US34 5 ’-end
- S Q S A V G T W L Q S S A S G R C D G D E L R A T H Q R P W S A R  
K P K R R R H L A S E Q R L G A M R R R  -  T -  S N S S T S L V C S  
K A K A P S A L G F R A A P R G D A T A  9 D E H 9 B 9 D H I B H H 9 I B B B  
MtAGCCAAAGCGCCGTCGG^ACTTGGCTTCgGAGCAGCGCCTCGGGGCGATGCGAGGGGGATGAAGTTAGAf.CAACTCATCAAGGTGCTTGGTCTGCTCG
L D C R S C C Q P R W S A W L R T R L S -  
S G L P L V L S A A L V R M A P D S  F I V
A S - F L R V S A A G P
S F M I S T G I C S W T
TCTGGATTGCCGCTCGTGCTGTCAGCCGCGTTGGTCCGCATGGCTCCGGACTCGTTTATCGTGAGCTTCATGATTTCTACGGGTATCTGCAGCTGGACCT
S G T S G G G E S L S P D L E R A G G P S Q R D L R S A F R P - Y
F W D Q W W R G I A Q S G P G E S R R T E P E G P S F G V Q A L I L
TCTGGGACCAGTGGTGGCGGGGAATCGCTCAGTCCGGACCTGGAGAGAGCAGGCGGACCGAGCCAGAGGGACCTTCGTTCGGCGTTCAGGCCTTAATACT■^ G7
L R Y L T R R P V S S R R R G V P P
S  -  T A
AGCCACATCTTACCTGTCGGCGGCCTGTCTGGGGGCTCCGGTACCTTACCCGCCGGCCTGTATCGTCCCGAAGAAGAGGTGTTCCTCCTCTTGAACCGCT
P W A T V N A E K R L S G - G W C R - C Q F F I S L Q C R - F S R
A M G H C Q R R K A L V W L R L V S L M P V F Y L A S M S V I F T
GCCATGGGCCACTGTCAACGCCGAAAAGCGCTTGTCTGGCTGAGGTTGGTGMCGCTMATGCCAGTTTTTTATCTCGETTCAATGTCGGTGATTTTCACGG U S 3 4 A 5 -e n d s
S V M G K R Y R S R W R A R G
I L L K I T - T T S S S F  
N S S - N Y V N D V V Q S L C R  
ACGGTSCCGCTCCCGATGGAGAGCCCGGGGTATGCTGAAATTCTTCTTAAAATTACGTAAACGACGTCGTCCAGTCGTTGTGCCGC
I R T V H R L R R F V H R R C A T R E T R A - C A P S A V - R T I
D S Y G S S S T S F C S P S L C N A - N K S V M R T F G G M K N D
GATTCGTACGGTTCATCGTCTACGTCGTTTTGTTCACCGTCGCTGTGCAACGCGTGAAACAAGAGCGTGAXGCGCACCTTCGGCGGTATGAAGAACGATT
L G A V G P S C G M G H G G V R L I  D K  
A E K P C T A S A E F S V T W G G G S E L R Y G S R R R A S Y - Q  
C R K T V H G V G R V F R D L G R W V R A A V W V T A A C V L L T K  
GCAGAAAAACCGTGCACGGCGTCGGCAGAGTTTTCCGTGACTTGGGGCGGTGGGTCCGAGCTGCGGTATGGGTCACGGCGGCGTGCGTCTTATTGACAAA 
‘V  G27
D A D V - L K N V P A P E R C V S I K I M - Y H I M R V L V F H F  
R C R C V T K K R P S P R A M C F N K N Y V V S Y Y A C P G F S F F  
M P M C D - K T S Q P Q S D V F  Q -  K L C S I I L C V S W F F I F  
GATGCCGATGTGTGACTAAAAAACGTCCCAGCCCCAGAGCGATGTGTTTC|H||B||AATTATGTAGTATCiTATTATGCGTGTCCTGGTTTTTCATTTTT
Figure 5.10. Three-fram e translation of co-terminal RNAs US33A and US34.
Yellow shows transcribed sequence. At the 3’-end of the co-terminal RNAs, red 
shows the poly(A) signal (AATAAA) and the downstream RNA cleavage site. At the 
5’-ends, sky blue shows the residue mapped at the 5’-end of each ORF and the 
upstream TATA boxes (CATAA) of each. The five different 5’-ends determined for 
US34A are also shown in blue. Green shows the amino acid sequences of the proteins 
encoded by US33A and US34. Purple shows the protein predicted to be encoded by 
US34A and blue shows the different residues mapped for the 5’-end of this ORF. 
Also shown are primers used for RACE-PCR.
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Figure 5.11. Three-fram e translation of co-terminal RNAs US31 and US32.
Yellow shows transcribed sequence. At the 3’-end of the co-terminal RNAs, red 
shows the poly(A) signal (AATAAA) and the downstream RNA cleavage site. At the 
5’-ends, sky blue shows the residue mapped at the 5’-end of each ORF and the 
upstream TATA box for US31. Green shows the amino acid sequences of the 
proteins encoded by US31 and US32. Also shown are primers used for RACE-PCR.
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The amino acid sequences encoded by these co-terminal transcripts are shown in 
Figure 5.10. From the RACE analysis, US34 was predicted to encode a 163 aa 
protein, as predicted by Chee et al. (1990). This protein is conserved in CCMV 
(Davison et al., 2003a). RACE analysis also mapped the ends of US33A, which was 
predicted to encode a small protein (57 aa). BLAST analysis of the US33A protein 
did not show significant similarities to other proteins in the NCBI database. 
However, a counterpart of US33A was identified in CCMV. The CCMV ORF is of 
similar size and position and contains a CATAA motif upstream of the potential 5’- 
end (Figure 5.12). These represent novel ORFs in HCMV and CCMV.
RACE analysis determined multiple 5’-ends for US34A, a novel ORF in region G 
proposed by Davison et al. (2003a). However, each 5’-end was determined from a 
single clone, and consequently a definitive 5’-end could not be identified. 
Furthermore, none of these candidate 5’-ends was associated with TATA elements. 
Therefore, although HCMV US34A has a counterpart in CCMV has been identified 
(Davison et al., 2003a), transcript mapping did not yield evidence for its expression.
US31 and US32 were also predicted to encode co-terminal messages and these genes 
encode related proteins in the US 1 family. Primers G23 and G6 were used to amplify 
3’-RACE products, and primers G1R and G15 were used to amplify 5’-RACE 
products (Table 5.2 and Figure 5.8). Again, each RACE-PCR product was gel 
purified and cloned to ensure that an accurate 3’- or 5’-end was obtained. The two 3’- 
RACE amplification products for these ORFs mapped to a T residue at nucleotide 
position 224,901 in AD 169, 17 bp downstream of a poly(A) signal at position 
235,675. The 5’-end of US31 mapped to an A residue at position 223,634, 35 bp 
downstream from a consensus TATA box. However, only one plasmid clone was 
generated from the 5’-RACE products for US32, mapping to an A residue at position 
224,252. This site is not associated with a TATA box and is therefore not a 
convincing 5’-end. The reading frames of these co-terminal transcripts are shown in 
Figure 5.11. From the RACE analysis, US31 was predicted to encode a 162 aa 
protein, as predicted for the revised form of the ORF (Davison et al., 2003).
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Figure 5.12. DNA and amino acid sequence alignments of HCMV 
and CCMV US33A.
(A) DNA sequence alignment. Yellow shows the protein-coding regions in each 
genome. Blue shows the 5’-end of US33A in HCMV and the conserved TATA box 




The original analysis of HCMV strain AD 169 assigned four ORFs to region G: US33- 
US36 (Chee et al., 1990). Comparisons with the CCMV genome led to the 
discounting of US33, US35 and US36 (Davison et al., 2003a). This study also 
introduced a new ORF to the region: US34A. Of the ORFs flanking region G, only 
TRS1 has been functionally characterised (Romanowski and Shenk, 1997).
Sequence analysis of region G and the flanking ORFs showed that US31-US34A and 
TRS1 are well conserved and not disrupted by frameshifts. However, US35 and 
US36 are not intact in all HCMV strains, being disrupted by frameshifts in certain 
strains in comparison with A D I69 (Figure 5.3). Neither of these ORFs commence 
with ATG codons, and are instead preceded by termination codons, containing 
initiation codons internally. A high level of variation between strains was observed in 
US35-US36, and frameshifts were identified throughout. Moreover, no novel ORFs 
emerged in the region between US34A and TRS1 as potentially encoding proteins. 
Also, RNAs specified by these ORFs were not detected in previous transcript 
mapping studies of the region, or in the current study. Therefore, it is very unlikely 
that ORFs US3 5 and US36 actually encode proteins.
A region corresponding to region G can be identified in CCMV, the closest known 
relative of HCMV. Corresponding regions cannot be identified in more distantly 
related CMV genomes. These genomes are more diverged and contain a single 
unique region in contrast to the U l and Us regions o f HCMV and CCMV, which are 
divided by repeat regions. CCMV is only moderately diverged and is essentially 
collinear to HCMV, and the corresponding region in CCMV is similar in size and 
position (Davison et al., 2003a). DNA sequence comparisons between HCMV and 
CCMV sequences in region G are shown as a two-dimensional comparison on a 
matrix plot in Figure 5.11 A. CCMV shares significant sequence similarity with 
HCMV in the corresponding genes, but not in US35-36.
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Figure 5.11. Sequence comparisons and nucleotide composition of region G in 
HCMV and CCMV.
(A) The sequence comparison is displayed in a matrix plot computed using Compare 
(a window of 21 nucleotides with a minimum match of 17 nucleotides) and displayed 
using Dotplot. (B) G+C plots computed using Window (100 nucleotides shifted by 3 
nucleotide increments) and displayed using Statplot.
The G+C content of US31-US34A and TRS1 is similar to the rest of the HCMV 
genome. However, in the region between US34A and TRS1, the G+C content is very 
low (Figure 5.1 IB). The G+C content is also very low in the additional sequence in 
strain 6397. Within this area of low G+C content lie three G:C polynucleotide tracts 
of eight or more residues (four in strain 6397). The only other G:C tracts of eight or 
more residues in the HCMV genome are found in a group within oriLyt (Chapter 4). 




US33 was discounted by the analysis of Davison et al. (2003a). However, in contrast 
to US35 and US36, US33 is well conserved (Figure 5.3), and has a G+C content 
similar to other HCMV genes. Although US33 does not have a counterpart in 
CCMV, much of the sequence in this region is conserved between the two genomes 
(Figure 5.11 A). Transcript analysis identified a 1.2 kb RNA on the opposite strand 
from UL33. The 3’-end of this transcript (US33A) was mapped, showing the RNA to 
be 3’-co-terminal with US34. The 5’-end was mapped approximately 340 bp 
upstream from the start site of US34, and 31 bp downstream from a TATA box 
(CATAA). The predicted US33A protein did not show strong similarities to other 
proteins in the NCBI database. Significantly, a counterpart was identified in CCMV, 
where the ORF is of similar size. US33A is therefore a candidate for a novel HCMV 
protein-coding ORF.
US34A was incorporated previously because a counterpart was identified in CCMV 
(Davison et al., 2003a). Sequence comparisons show that this ORF is not 
frameshifted in seven HCMV strains. However, a definitive transcript corresponding 
to U34A was not determined by northern blot. Also, although a 5’-RACE product 
corresponding to the ORF was amplified, five 5’ -ends were identified from five 
clones, none associated with TATA elements. Despite the presence of a US34A 
homologue in CCMV, the lack of convincing evidence from transcript analysis for 
transcription of HCMV US34A casts doubt on this ORF as protein-coding. This 
leaves US34 as 3’-co-terminal with US33A.
US31 and US32 were mapped in the current study as 3’-co-terminal genes that belong 
to the US 1 gene family. The 5’-end of the US31 mRNA agreed with the revised form 
of the ORF (Davison et al., 2003a). Although a definitive 5’-end was not identified 
for US32, its relationship to US1 and US31 and the northern blot analysis indicate 




The original genome analysis of HCMV strain AD 169 was carried out by Chee et al. 
(1990). Subsequent studies have characterised many HCMV genes, modifying the 
interpretation of some and identifying novel genes. This has led to a more detailed 
and accurate picture of the genetic content of HCMV. Comparative genomics is one 
of the most useful ways of annotating genes, on the basis that authentic protein-coding 
regions will have been conserved during evolution whereas spurious features, such as 
non-functional ORFs, will not. The aim of the present study was to investigate the 
protein-coding potential o f three regions in the HCMV genome, each of which 
contains ORFs identified originally by Chee et al. (1990) that were subsequently 
discounted by a comparative analysis with CCMV (Davison et al., 2003a). Region X 
(Chapter 3) is located between UL105 and UL112, region O (Chapter 4) between 
UL57 and UL69, and region G (Chapter 5), between US32 and TRS1. The genes 
flanking these regions are accepted as encoding functional proteins. In addition to 
containing ORFs discounted by the CCMV analysis, all three regions have been 
predicted to contain novel, small ORFs potentially encoding proteins (Murphy et al., 
2003a, 2003b; Davison et al., 2003a). Only US34A in region G has a counterpart in 
CCMV (Davison et al., 2003a).
Table 6.1 summarises the results of sequence comparisons and transcript mapping of 
the ORFs in regions X, O and G, and gives an evaluation of whether the ORFs are 
likely to encode functional proteins. In regions X and O, frameshifts affect most of 
the small ORFs identified by Chee et al. (1990) and Murphy et al. (2003a, 2003b). 
Only four ORFs (UL66, UL108, C-ORF16 and C-ORF18) are unaffected by 
frameshifts. None of these are conserved in CCMV. In regions X and O, sequence 
analysis of regions not affected by frameshift mutations revealed no novel ORFs 
potentially encoding proteins. Although the presence of highly spliced mRNAs with 
small exons cannot be completely ruled out, careful inspection of the sequence did not 
reveal candidate splice donor and acceptor sites. Furthermore, no transcripts were 
identified in region X other than the 1.1 and 4.6 kb RNAs, representing the two 




Conserved in: Transcript Likelihood of
Region ORF___________ HCMV CCMV_____ identified______ protein-coding
UL106 X X X X
UL107 X X X X
C-ORF16 ✓ X X X
UL108 ✓ X X X
UL109 X X X X
UL110 X X X X
C-ORF17 X X X X
UL111 X X X X
C-ORF18 ✓ X X X
UL58 X X X X
UL59 X X X X
UL60 X X X X
UL61 X X X X
UL62 X X X X
ORFS X X X X
ORF4 X X X X
UL63 X X X X
ORF5 X X X X
UL64 X X X X
UL65 X X X X
UL66 X X X
UL67 X X X X
UL68 X X X X
US31 V V V
US32 ✓ V V V
US33 X X X
US33A V
US34 V V
US34A s X 7
US35 X X X X
US36 X X X X
Table 6.1. Evaluation of the protein-coding potential of 
ORFs in regions X, O and G.
S  is yes, X is no, ? is marginal.
163
Discussion
If regions X and O, which are approximately 4.9 and 8 kbp in size respectively, do not 
contain protein-coding genes, what are their functions? In region X, the splice sites 
for generating the equivalent of the 1.1 and 4.6 kb RNAs are conserved in CCMV, 
and large transcripts in the corresponding region were reported in RhCMV and 
MCMV by Kulesza and Shenk (2004) during the course of the present study. As it is 
unlikely that a functional protein is encoded by the 1.1 kb RNA (Section 3.6), it seems 
probable that one of these RNAs has a non-translated role. This role is unlikely to be 
essential to viral replication in vitro, as a mutant lacking the splice donor site was 
shown to replicate efficiently in cultured fibroblasts (Kulesza and Shenk, 2004). The 
conclusion of Kulesza and Shenk (2004), that the 4.6 kb RNA represents a stable 
intron has parallels with the latency-associated transcripts (LATs) o f HSV-1. The 
most abundant LAT is a stable 2 kb intron, spliced from an 8.5 kb transcript present in 
the long repeats of HSV-1, although alternative splicing produces further transcripts 
o f 1.4 kb and 1.5 kb (Farrell et al., 1991; Krummenacher et al., 1997; Mador et al., 
1995). The 2 kb LAT does not encode a protein (Lock et al., 2001). LAT is the 
major viral transcript detected by in situ hybridisation of latently infected neurons 
(Croen et al. 1987; Stevens et al. 1988; Krause et al. 1988, 1991). LAT is reported to 
have a number o f functions, one o f which is promoting latency by protecting neuronal 
cells from apoptosis (Perng et al., 2000; Thompson and Sawtell, 2001; Ahmed et al., 
2002). Roles in regulating translation and splicing have also been suggested (Ahmed 
et al., 2001). It is possible that the 4.6 kb intron in HCMV region X has a function 
similar to one of those of the LAT transcript. A study by Goodrum et al. (2002) 
suggested that the 4.6 kb RNA (detected using a ULllO-specific probe) may be 
expressed during latency (in CD34+ cells). However, this study detected gene 
expression from many ORFs throughout the HCMV genome, in contrast to other 
studies of HCMV latency. Therefore, investigating the expression of the 1.1 kb or the 
4.6 kb RNA during HCMV latency would be a useful direction in determining their 
function.
A non-coding viral function is also likely to be employed by pp67, a transcript 
originating from region O. Sequence comparisons in the present study suggest that 
pp67 does not encode a protein, in contrast to the conclusions o f Davis et al. (1984, 
1985). Sequence analysis indicates that it is unlikely that any protein-coding ORFs
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are present in the region, but this does not rule out the possibly of other transcripts in 
this part of region O, which could be investigated by transcript mapping.
The last few years have seen a large increase in the number of RNA transcripts 
detected that have no apparent protein-coding potential. These noncoding RNAs 
(ncRNAs) have roles in a variety of biological processes, including transcriptional 
regulation, chromosome replication, RNA processing and modification, mRNA 
stability (Eddy, 1999, 2002; Huttenhofer et al., 2002, 2005; Storz, 2002). 
Consequently, RNAs that do not function via translation may be far more abundant 
than previously predicted. At least four mammalian genes have been identified as 
carrying a number of intron-encoded ncRNA genes: gas5, UHG, U17HG and U19H 
(Eddy, 1999). It is possible the 5 kb RNA could have a similar role, although 
ncRNAs associated with region X were not identified in studies o f HCMV 
microRNAs. Pfeffer et al. (2005) identified nine HCMV miRNAs, spread across the 
viral genome. Grey et al. (2005) characterised three of these by northern blot 
analysis, and identified a further ten HCMV-encoded miRNAs. None of the miRNAs 
identified map to regions X, O or G. Clearly, much work is still to be done to 
elucidate the functions, if  any, o f HCMV miRNAs.
Unusual nucleotide composition and a high prevalence o f homopolymeric tracts are 
characteristic features of regions X, O and G. Table 6.2 shows the distribution of the 
polynucleotide tracts in the Merlin genome. Although there are relatively few G:C 
tracts in the genome, all are found in apparently non-protein coding regions. A:T 
tracts, especially those of nine or more residues, are also found predominantly in non­
protein coding regions of the genome. Therefore, it would appear that there is a form 
of evolutionary selection against long homopolymeric tracts in protein-coding genes, 
since slippage during DNA replication could promote length instability. Region X 
consists of local regions of high G+C content embedded in sequences of low G+C 
content (Figure 3.12), and region O consists of high G+C content in the oriLyt region 
and lower G+C content elsewhere (Figure 4.7). In addition, the two ORFs discounted 
in region G, US35 and US36, are found in a highly variable region of approximately 1 
kb which also exhibits low G+C content (Figure 5.11).
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Polynucleotide tract Number of polynucleotide tracts in:
Minimum
length










A:T 11 10 1 5 36
G:C 0 3 3 0 1
9
A:T 8 6 0 1 26
G:C 0 2 3 0 0
10
A:T 4 2 0 0 10
G:C 0 1 3 0 0
Table 6.2. Distribution of polynucleotide tracts in the Merlin genome.
Sequence comparisons of seven HCMV strains in three regions of the genome have 
confirmed and extended the view of the genetic content o f HCMV from comparisons 
with CCMV, by indicating that many ORFs are unlikely to encode proteins. As 
discussed in Chapter 4, sequencing across region O is incomplete due to difficulties 
caused by high G+C content and highly repetitive and palindromic sequence. 
However, to extend this part of the current study, transcript analysis of region O 
should be carried out, using northern blot and RACE analysis to identify and map any 
further transcripts in the region. Outwith the minimum oriLyt region, one other 
transcript (pp67, discussed in Chapter 4) has been detected in region O. Transcript 
mapping in this region may identify further transcripts in this region, identifying it a 
source of important non-coding, functional RNAs in HCMV.
A novel, spliced transcript from region X was characterised and most likely has a role 
as a non-coding functional RNA. As previously discussed, the spliced transcript has 
parallels with the LATs of HSV-1 and further work would be required to ascertain if 
this spliced RNA has a role in HCMV latency. Alternatively, this RNA, and the pp67 
RNA detected in region O, may have other roles. Functions such as transcriptional 
activation, regulation of gene expression, RNA processing, gene silencing, and even
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genomic imprinting have been described for non-coding RNAs in eukaryotes and one 
of these functions could be performed by the RNAs transcribed in regions X and O.
Alternatively, it is possible that regions X and O may have a cw-acting function in 
HCMV, as both regions are well conserved between strains. To date, one origin of 
replication has been identified in HCMV (orz'Lyt, discussed in Section 4). In contrast, 
three origins have been identified in HSV-1. It is possible that within region X, or 
within the right half of region O (outwith the HCMV oriLyt region), there could be 
important czs-acting sequences which have a function in an alternative origin of 
replication. This role could be investigated using replication assays.
The non-coding area of region G is different to the non-coding areas of regions X and 
O in both size and sequence conservation. The non-coding area of region G is 
smaller, at only 1 kbp, and is not nearly as well conserved between different strains of 
HCMV as regions X and O are. In addition, no transcripts have been detected across 
this area o f region G in the current analyses, whereas transcripts have been detected in 
regions X (1.1 kb and 5 kb RNAs) and O (pp67). Although the lack of transcripts 
across this region may suggest a cis-acting function, the lack of sequence conservation 
casts doubt on this assumption. It is possible that this 1 kbp region may harbour 
micro-RNAs previously unidentified in HCMV, or perhaps it is simply non­
functional, and an example of ‘junk’ DNA in herpesvirus genomes.
In the case o f US33A in region G, further experiments, such as western blotting, are 
required to detect and characterise any encoded protein. This would complement the 
transcript mapping data of the current study, which has detected this novel transcript 
by northern blot analysis, and mapped the 5’- and 3’-ends. Like most other genes in 
the Us region of the HCMV genome, US33A is unlikely to be an essential or core 
gene, and BLAST analysis of the US33A protein did not show significant similarities 
to other proteins in the NCBI database. Although no function is therefore suggested 
from the protein sequence, US33A is detected as an E transcript and may have a 
similar role to other E proteins, such as a glycoprotein or an enzyme involved in DNA 
replication or nucleotide metabolism.
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The position refers to the AD 169 genome (accession number NC_001347).
Region X.
Region X was amplified in three major fragments (Section 3.3). Also included in this 
list are internal sequencing primers (italics), primers used to generate ssRNA probes 
(Table 3.3) and primers used for 5’- and 3’-RACE (Section 3.5).
Primer Sequences Position Strand
XI GATGAGCCACATCTACGTGGCCAT 1 5 5 , 5 7 1 +
X2 GATGAACGTTAACCCGTTGCG 1 5 5 , 6 2 5 +
X5 GCCGAAGCCTCGCCGTGCTGCATA 1 6 1 , 7 3 1 -
X6 AGAAGTCTACCGAGTCGAGTTACA 1 5 7 , 5 3 7 +
X7 CGTTGGGAGGTAGCTTCGTCATGT 1 5 7 , 6 6 0 -
X8 C G C AC G AAAT C G AT C C T AAG T GAG 1 5 9 , 4 7 1 +
X9 ACACGCAAACGCGAATGTACACGA 1 5 9 , 6 7 1 -
XI 0 TCTTCGTAAACTTATCCGTT 155,967 +
XI1 AGACCATAATGTTGACTACT 157,333 -
XI2 TCAGTTGACAGCGAAGAGAC 157,899 +
XI3 TTACTTTCACGGAAGATGCA 159,409 -
XI4 ATCGAGAGCGGCTCGAACCT 159,877 +
XI5 TTTCCAGCCCGCCTAGCAAC 161,409 -
XI 6 CCTGCATCACGGTGGCTCGA 155,872 +
X18 AGAGCCAGCCCTTGTTGAGGT 1 6 1 , 6 9 7 -
XI9 GACGACGATTCTAAGAATTG 156,897 -
X20 CTATGGCTTCATCTATCGTG . 158,317 +
X21 CTTCTCCTTCGTCCCAGACG 159,037 -
X22 TTCGTCTTGATCTCCAGCCG 160,351 +
X23 TTGACCACCGTACCGTCGAG 160,911 -
X25 ATGTGTTGTTGTCGTCGAGG 156,192 +
X28 GATTAGTCGGCTGTCTCAGG 161,178 +
X29 TCTGGTATCTACTGCCTGAC 160,170 -
X30 TCGTTCTCATGATCGCGGAG 159,238 +
X32 CCTCTCTCTAATTCCCTGGA 156,465 -
X34 GTGTGGCAGAGAGGATGCCTT 156,329 +
X35 GTGATGTGGTGGTACATTGA 156,667 +
X36 TCATGGCGGTATTTCTCTTCC 158,786 +
199
Appendix
X37 CTGACGGGTTATCGTCACCA 160,465 -
X38 CCTACGTTGGTAGGTCACGT 160, 780 +
X40 AACAAC CAAAGG ACGACC 1 5 6 , 1 9 2 -
X41 AACAACCAAAGGACGACC 156,192 -
X43 CTTAGGAGGAACGATGAATC 158,258 -
X48 CCACCCGGGTTTCTTCTCTTGCAG 1 5 6 , 0 5 8 -
X50 CAAGACGCAGCAGGGCTTCATGTC 1 6 1 , 7 3 8 +
X53 CCACGTTGCGTCGTGACGTTG 1 6 1 , 3 6 0 +
X54 GCAAAGCGCGAGCGCAAC 1 6 1 , 5 0 8 -
X57 ATGCTGTCGGTGATGGTCTCTTCC 1 6 0 , 6 0 9 +
X59 ACATTGCCGCATGTCTTTGTAG 1 6 1 , 0 6 5 -
X61 CCTCGCGAGGCTGACAGTCGACGG 1 5 6 , 0 0 4 +
X66 GGAGGCGAAGCCGGCGACGACGAC 1 6 0 , 6 7 3 +
Region O.
Region O was amplified in 12 fragments (Table 4.1). Also included in this list are 
internal sequencing primers {italics).
Primer Seauences Position Strand
03 TCCAATGGGACGGCGTTTCC 9 3 , 4 7 9 +
0 6 TTGATGACGCCGTCGCCTTC 9 9 , 3 6 6 -
07 CCAGAATCTCCTGCGTTTCTG 9 1 , 1 1 9 +
0 1 3 CTCGTTGACCAGGAAAGCTGTC 9 2 , 4 9 8 -
0 1 6 CCCGTCGTACGAGGAACAAG 9 8 , 2 2 4 -
0 1 7 CCGTATCCTTCCCTGTTGTAC 9 6 , 8 4 5 +
0 1 8 TGGTGGTCATGGCGGTGGTGGTCA 9 7 , 0 0 7 -
0 1 9 GAGAAAATGGCGTCGAGAGCCTAG 9 5 , 5 8 4 +
0 2 0 CTCGTCGAGATTTTCAGGGCTATC 9 5 , 7 3 4 -
0 2 1 AGTCGTGACCGGGGGTCCCT 9 4 , 7 4 8 +
024 TCTCGCAGCCAGACCGCTA 91,420 +
025 GTGTTTCATGGCAATGGG 92,193 -
026 CTGACGTCAAACCATCTC 95,896 +
02 7 GTCCGCCCGTCCTTCGTA 97,227 +
0 2 8 CAACGATCGTGAAACTGGAGACTG 9 8 , 0 9 0 +
029 GACGGTGATTCTTCAGAGAATC 97,941 -
030 ATAGGTGCCGGACGCCGGCTAC 96,688 -
031 GTAACATGATCAACCACGTCTG 97,739 +






0 4  6





















0 8  6
0 8 8
0 9 0





CACCGTGATGGGGAACGGTGTT 92, 191 +
GGTAGGCGATTTGCATCTG 96 390 +
CCAAGAATAAAACTCTAGCTC 96 724 +
GGTTTCCCGAACACGTAC 92 003 +
CCTCGGCACGACCGTATTTG 97 372 -
CACGGTTTGTTAGCTGATGTG 91 742 -
CCATAAGCTGTGTACTGTTC 98 948 -
CCTCAAATGTTGTACATGTG 98 443 +
TGGGACGGTCGTGGTCTCCTC 95 2 6 0 -
CATCATCGGATATCTCACCAC 99 008 +
GATGCGAATTGGTGGCTATGGTG 98 384 -
GTTCCGCCAGTCCGTTTTCGTAG 93 387 -
CAGCACACACGCCACAGCCT 94 973 -
CTCCACGCGTTTTCCACCCT 95 165 +
GTTCTCTCGCTCGTCATG 95 538 +
TGAACAGAGAAAGGTGGG 95 466 -
CTACCAATCACAGAAACGG 92 781 +
CAGGGGTCACGTGAGAAG 93 083 -
TGGGTGTGGCTTCACTAGG 92 722 -
GGTGCCAGATGCCAACGT 92 620 +
GACGCATGCGCACTGACCGCCTC 93 7 6 2 -
GAGCGGTAATTTTCCACCGCC 93 8 8 3 -
GGTATTTTTCCACTGGGCGG 93 8 0 1 +
GAAGCGAGCTACGTCATCAGTC 93 2 3 8 +
CTTCCCGGTCCACCCGCC 94 3 2 5 +
TCGCCCCGACTGCGCATG 93 5 2 1 -
CTGCGCATGCGCCGGTAAAATTCC 93 67 6 +
CACCTAGGGAGCGCGAG 93 824 +
GACCCGAGCGGGGGCTTC 94 2 3 8 +
GGAAGGGGAGCTGGGTGG 94 468 -
CTGGAGCACCATCCGGGG 94 077 +
GACCACGCCCAGGGCCAGCA 94 8 9 6 -
GGGGAGGGTGGGGGGTAG 94 03 1 -
CTACCCCCCACCCTCCCC 94 014 +




Region G was amplified in two major fragments (Section 5.2). Also included in this 
list are internal sequencing primers (italics), primers used to generate ssRNA probes 
(Table 5.1) and primers used for 5’- and 3’-RACE (Table 5.2). Primers labelled .1, .2, 
etc. are strain-specific.
Primer Sequences Position Strand
G1 C CAGAG TAG C G G T GAC GAGAG TAAC 1 5 5 , 5 7 1 +
G1R GTTACTCTCGTCACCGCTACTCTGG 1 5 5 , 5 9 4 -
G2 CAACGACGTTGGAAGAAAACGGTG 2 2 7 , 3 5 0 -
G3R GAAT C G C G GCACAAC GAC T G GAC 2 2 5 , 9 5 7 -
G4R GTCGGTGATTTTCACGGAGCGTC 2 2 5 , 8 3 6 +
G5 CCAATTGGCGGCGACAGA 224f 418 +
G6 GACAGC CAT T T T CAGCGAC 2 2 4 , 4 2 9 +
G7 CTCTCCAGGTCCGGACTG 225,599 -
G8 GCGTGTCCTGGTTTTTCA 226,231 +
G9 TGCGACGCGTCACGTTTTC 227,100 -
G10 GTCCCCATCATCAGCGTC 224,942 +
Gil CTCCTGTGGGAACCCGCTC 225,051 -
G12.1 CAAGCCGTGGTGCGTGTT 226,676 +
G12.2 CAACATCAGTGTAGCGTG 226, 676 +
G12.3 CAAATCGTCGGGTGCGAC 226,676 +
G12. 4 CAAACTGCGGGGCGTGTC 226,676 +
G13.1 CCACTGTTTTATTCTTGGCG 226,596 -
G13.2 CACCGTTTTACCCATGAC 226,596 -
G13.3 CACCGCTTTACCCATGAC 226,596 -
G14 GACGGCGATGAACTTAGAG 225,406 +
G15 GAGGAAGACGCCGACGAC 224,604 -
G16.1 CTTATCACTGGCGTCGTT 226,971 +
G16.2 CTTATCCGTGGCGTTGTG 226,971 +
G16. 3 CTCATTCGTGGCGTTGTT 226,971 +
G1 7 GAAAAACCAGGACACGCA 226,247 +
G21 GTTCTTCATACCGCCGAAGG 2 2 6 , 0 4 8 -
G22 GTGGAACTGTTGCGACAATAC 2 2 6 , 9 4 6 -
G23 CTCTGCAACGCCTGGCGTGATC 2 2 3 , 9 1 9 +
G24 GTCCCATGCCAACGGTCCCCAAG 2 2 7 , 3 0 1 -
G27 CACGGAAAAGACTGCCGACGCCGTG 2 2 6 , 0 9 1 -
G28 GAGGCGCTGCTCTGAAGCCAAGTG 2 2 5 , 3 9 5 -
G29 GAGAGGGTGGGTTACGAGAAACTG 2 2 5 , 0 8 9 +
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A. Dolan and others
10 15 20 25 30
CD a a D D D D f l  d d l z q x d z d d d ^d d d d d j d d c  id c u e
RL1 RL5A
RL6
RL10 RL12 1 2 4  5 6 7 8 9 10 11 13 14 16 18 20 22A 24
RL11 RL13 15A 17 19 21A 23
30 35 40 45 50 55 60
]D C  DDC □ a a a e ]  aaaa
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41A
44 45
60 65 70 75 80 85 90
46 47 48 48A 49 50 51 52 53 54 55 56 57
90 95 100 105 1 1 0 115 120
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80.5
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180 185 190 195 200 205 210
muQG  n a c a  a c o a a o D i a a n a a a
147 A 145 142 141 140 138 135 148A 148D 150
146 144 139 1 36 148B
147 133 148C
IRS1 1 2 3 6 7 8 9 10 11 12 13 14 15
210 2"5 220 225 230 235 kbp
~k in nnnn( k k— i cd □> D D
16 17 18 19 20 21 22 23 24 26 27 28 29 30 31 32 34 TRS1
34A
RL 11 family 
~ ~ | UL2i> family 
1 1  US1 family 
I I GPCR family
|  ULI4 family 
m  UL82 family 
_] US2 family 
_  other non-core
~l UL18 family 
F jjj i  UL120 family 
U US6 family 
sub-core
J  US22 family 
| j  UL146 family 
I US 12 family
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